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Phagocytic clearance of apoptotic granulocytes is required for the successful
resolution of inflammation, preventing the progression to a chronic state associated
with development of fibrotic repair mechanisms and/or autoimmune responses.
Macrophage capacity for phagocytosis of apoptotic cells can be modulated by a
number of factors including cytokines and adhesion to extracellular matrix. We have
hypothesised that alteration of macrophage phagocytosis could provide a strategy for
increasing the rate of clearance in inflammatory disease. The aim of this thesis was
to investigate the molecular mechanisms underlying control of macrophage
phagocytosis of apoptotic cells. We have demonstrated that exposure of peripheral
blood monocytes to the synthetic glucocorticoid dexamethasone "reprograms"
monocyte/macrophage differentiation resulting in a macrophage phenotype with a
marked augmentation in the phagocytosis of both apoptotic granulocytes and
particles opsonized with low levels of IgG. Increase in phagocytic potential was not
mediated by increased expression of putative "phagocytic receptors" proposed to be
involved in apoptotic cell clearance. In addition, dexamethasone augmentation of
apoptotic cell uptake could not be inhibited by blockade of receptor function with
either soluble competitive ligands or monoclonal antibodies. Dexamethasone-treated
macrophages were found to have altered morphology and actin organisation. In
particular, loss of "podosome" structures was observed, possibly due to decreased
recruitment of adhesion signalling molecules pyk2 and paxillin to focal contacts, and
decreased expression of pl30cas, a key adaptor molecule in integrin signalling. In
addition, glucocorticoid treated cells showed increased activity of the Rho-family
GTPase Rac, which has been previously shown to be important for phagocytosis and
lamellipodia formation. Expression of pl30cas and activation of the mitogen
activated protein kinase, ERK are required for migration in a number of different cell
types. Basal ERK activity was reduced in dexamethasone-treated
monocyte/macrophages. We developed an in vitro "wounding" assay and found that
despite the absence of basal ERK activity or pl30cas expression in dexamethasone-
treated macrophages, these cells were able to migrate.
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To test the novel hypothesis that pl30cas plays a pivotal role in regulation of
macrophage phagocytic capacity, we generated a pl30cas-HIV-TAT fusion protein.
Full length pl30cas sequence was subcloned and inserted into a TAT containing
vector and then expressed in E.coli. Following purification of the fusion protein,
preliminary studies were undertaken to investigate the effects of the protein on
macrophage behaviour.
The morphological and functional changes induced by dexamethasone exposure were
found to be influenced by the cytokine environment during monocyte-macrophage
differentiation. Treatment of monocytes with the Thi cytokine IFNy or the Th2
cytokine IL-4 induced a multinucleated giant cell and dendritic cell like phenotype
respectively. These macrophage phenotypes were characterised by increased
podosome formation and decreased phagocytic capacity for apoptotic granulocytes.
Whereas dexamethasone was found to prevent morphological changes induced by
cytokine exposure, the increase in phagocytic capacity induced by dexamethasone
was inhibited by differentiation in the presence of IFNy and IL-4. Additionally,
phenotypic analysis of cell surface markers differentially regulated by IFNy and IL-4:
CD64, CD 14, ICAM-1 and the mannose receptor, revealed the generation of a
distinct subset of monocyte/macrophages in the presence of dexamethasone plus
cytokine as opposed to cytokine or dexamethasone alone. These studies have
provided novel insight into the control ofmacrophage phagocytosis and will form the
foundation for further studies investigating underlying molecular mechanisms.
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The inflammatory response has evolved as a defence mechanism against microbial
infection or tissue injury. Immune cell recognition of "foreign" material induces the
release of chemokines and other inflammatory mediators that increase local blood
flow and vessel permeability, and promote the recruitment of immune cells to the site
of injury. Accumulation of fluid and inflammatory cells within tissues produces the
characteristic calor, dolor, rubor, and tumor (heat, pain, redness and swelling) of an
inflammatory response (Gallin et al., 1992).
Neutrophils are the most abundant white blood cell in the circulation and the earliest
to be recruited to inflammatory sites in response to chemoattractants such as IL-8
released by monocytes, macrophages and fibroblasts (Follin et al., 1991; Kunkel et
al., 1991; Smith et al., 1991) (figure 1). Their primary function is phagocytosis and
destruction of "foreign" material, by the release of pre-formed enzymes and proteins
from intracellular granules into intracellular compartments containing phagocytosed
material, or extracellularly onto the pathogen, such as cationic proteins, lysozme and
acid hydrolases. Additionally, neutrophils are able to generate highly microbicidal
reactive oxygen species (Gudmundsson and Agerberth, 1999). Neutrophils also have
the capacity to synthesise a number of cytokines which have systemic effects,
increasing temperature (Netea et al., 2000) and inducing the further recruitment of
inflammatory cells (Doherty et al., 1988). The importance of neutrophil function in
mediating acute inflammation is emphasised by the recurrent bacterial infections
suffered by patients with deficiencies in either neutrophil number: neutropaenia
(Bodey et al., 1966), or neutrophil function: leukocyte adhesion deficiency
(Anderson and Springer, 1987), Chediak-Higashi syndrome (Rausch et al., 1978) and






















Figure 1. Recruitment of inflammatory cells. Chemokines induce extravasation of
leukocytes from the blood stream into tissues. Sialyl-Lewisx moieties on neutrophils
bind to P-selectin and E-selectin on the surface of endothelial cells, externalised in
response to inflammatory mediators such as leukotriene B4, C5a, histamine, LPS and
TNFa. This mediates weak adhesion and rolling of the granulocyte along the surface
of the endothelial wall. Rolling is inhibited by the induction of strong adhesion from
the interaction of LFA-1 and complement receptor 3 (CR3) on the leukocyte to
ICAM-1 on the surface of endothelial cells which is also externalised in response to
TNFa. Normally the LFA-1 and CR3 interactions are low affinity, however IL-8
induces changes in the conformation and distribution of these integrins promoting
binding. Leukocytes then undergo extravasation through the endothelial wall via
further LFA-1 and CR3 interactions, plus homotypic binding of PECAM (CD31)
present on both leukocytes and the intracellular junctions of endothelial cells.
Finally the cell penetrates the basement membrane by the release of proteolytic
enzymes in a process known as diapedesis. Monocyte migration follows a similar
pattern except VLA-4 and VCAM-1 appear to be important for binding. Tissue
macrophages also migrate to the inflammatory stimulus in response to chemokines,
and are often initiators of the inflammatory cascade after engulfment of particulate
matter.
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Macrophages represent the sentinels of the immune system with the capacity to
ingest and destroy infectious agents, by the release of enzymes and toxic metabolites,
extracellularly and into intracellular compartments. These include nitric oxide,
superoxide radicals, lysozyme and acid hydrolases (MacMicking et al., 1997;
Nathan, 1987; Nathan and Hibbs, 1991). Macrophages initiate T-cell responses by
antigen presentation, and act as effector cells for both humoral and cell-mediated
immune responses (Uanue and Allen, 1987). They arise from blood monocytes
recruited into tissues in response to a wide variety of chemotactic agents for example
MCP-1 (Monocyte Chemotactic Protein), RANTES (Regulated on Activation,
Normal T cell Expressed and Secreted) and C5a, a component of the complement
cascade. Macrophages are located throughout the different organs and tissues of the
body and the connective tissue around the basement membrane of small blood
vessels. They are particularly concentrated in the lung (alveolar macrophages), liver
(Kupffer cells) and the lining of spleen sinusoids and lymph node medullary sinuses,
where they are strategically placed to "filter" foreign antigen. Other cells of the
monocyte/macrophage lineage include mesangial cells in the kidney glomerulus,
brain microglia and osteoclasts in bone. The early inflammatory response enables
either complete clearance of the pathogen or containment of the infection before the
induction of adaptive immunity. Cytokines produced during this period help
determine the subsequent development of the adaptive immune response and can
determine if this is predominantly T cell mediated or humoral (Mills et al., 2000;
Mosmann and Sad, 1996).
Whilst the inflammatory response has the capacity to clear a large proportion of
infections, the cellular functions of neutrophils and macrophages have the potential
to inflict "bystander" damage on neighbouring cells, thereby exacerbating
inflammation and inducing tissue damage and scarring, characteristic of chronic
inflammatory conditions such as asthma, emphysema and rheumatoid arthritis
(Gadek, 1992; Haslett et al., 1994; Robinson et al., 1992; Weiss, 1989; Woolley et
al., 1996). Inflammatory responses must therefore be highly regulated, at both the
level of the recruitment of cells to the tissue and also their activation state. Priming
of granulocytes with inflammatory mediators such as LPS induces a heightened
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parasiticidal/microbicidal activity in response to fMLP (Guthrie et al., 1984).
Similarly activation ofmacrophages by IFNy prior to TNFa exposure increases nitric
oxide production (Erwig et al., 1998; Lake et al., 1994). Although it is often
assumed that chronic inflammation occurs as a result of uncontrolled pro¬
inflammatory events, there is much evidence to suggest that failure or inefficient
resolution processes are responsible for tipping the balance toward persistent
inflammation (Akbar and Salmon, 1997; Haslett et al., 1994).
Resolution of inflammation
In order for resolution of inflammation to occur with the return to normal tissue
homeostasis, all the processes involved in the initiation of inflammation must be
reversed. This includes removal of stimuli responsible for initiating and maintaining
the inflammatory response such as bacterial and cellular debris and pro-inflammatory
cytokines, a cessation of granulocyte and monocyte migration into the tissue, plus an
active clearance of extravasated cells. Deletion of granulocytes is thought to be
mediated by the induction of a specific form of cell death, apoptosis, followed by
phagocytosis of the cell corpse by macrophages (Haslett, 1992; Newman, 1982;
Savill et al., 1989b), (figure 2). Dysregulation in the induction of granulocyte
apoptosis has been implicated in the pathogenesis of adult respiratory distress
syndrome (ARDS), idiopathic pulmonary fibrosis, ulcerative colitis, rheumatoid
arthritis, asthma, and other allergic diseases (Haslett et al., 1994; Meagher et al.,
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Figure 2. Clearance of inflammatory cells.
Resolution of inflammation requires the "safe" removal of extravasated cells. This is
mediated by induction of granulocyte apoptosis, followed by phagocytosis by
macrophages. During apoptotic cell death, membrane integrity is maintained,
preventing the release of granule contents onto surrounding tissues. Phagocytosis of
apoptotic cells, unlike uptake of other particles, is non-phlogistic, and actually induces
the release of anti-inflammatory mediators that further promote resolution. In contrast,
necrotic cell death results in the release of the formidable array of granulocyte cytotoxic
contents, inducing tissue damage and further recruitment of inflammatory cells.
Furthermore, uptake of necrotic debris potentiates the inflammatory response inducing
release of pro-inflammatory cytokines by the macrophage. Residual apoptotic cells not




Apoptosis is an evolutionarily conserved mechanism executed by a family of
proteases called caspases that cleave targets at specific aspartic acid motifs (for
review see Wolf and Green, 1999). Caspases function either as upstream initiators of
the apoptotic program or as its downstream effectors. In non-apoptotic cells caspases
are present in an inactive pro-form which requires cleavage by an active caspase for
activity, the active protease can then cleave down stream caspases creating a
proteolytic cascade which functions to amplify the initial apoptotic stimulus. Initial
caspase cleavage is thought to occur via " proximity mechanisms" (Salvesen and
Dixit, 1998). Ligation of cell surface "death" receptors induces receptor clustering
and recruitment of intracellular proteins and caspases into a "death inducing
complex". In their inactive form, caspases have a low basal activity, which is not
normally sufficient for induction of the proteolytic cascade, however within the
proximity of the death-inducing complex, full caspase activation occurs. The second
mechanism thought to mediate caspase activation involves release of cytochrome c
from the mitochondrion, regulated by members of the Bcl-2 family of proteins
(Kroemer and Reed, 2000). Cytosolic cytochrome c binds and activates Apafl,
forming the apoptosome and subsequent caspase activation. The caspase cascade
then executes the apoptotic program resulting in cleavage of a number of cytosolic
proteins such as the structural proteins laminin, keratin, pl30cas, actin, FAK, and
PARP (Kook et al., 2000). In addition caspases are able to further activate or
inactivate pro and anti-apoptotic proteins such as Bcl-2, other pro-caspases, and
ICAD, responsible for induction of DNA fragmentation. A number of apoptosis
regulators exist (for review see Reed, 2001), these include protein kinases such as
Akt and IkB kinase which both function to maintain transcription of anti-apoptotic
genes, the IAP family of proteins, which inhibit caspase activation, and the Bcl-2
family of proteins. The Bcl-2 family consist ofboth pro and anti apoptotic molecules
which form homodimers; the relative amounts of these molecules determines the
resistance of cells to apoptotic stimuli such as growth factor deprivation, hypoxia,
radiation, oxidants, and elevated [Ca]2+. Thus caspase cleavage of cytosolic proteins
during apoptosis terminates many cellular activities, inducing the down regulation of
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granulocyte cell function observed during apoptosis and the resolution of
inflammation, but maintains membrane integrity (Savill et al., 1989b; Whyte et al.,
1993). Stimulated granule release and phagocytosis are inhibited due to an inhibition
of membrane trafficking, and specific changes in the expression of cell surface
molecules occur which prevent further stimulation of the granulocyte by
inflammatory mediators. In the neutrophil, fMLP receptors are partially lost and
there is an almost complete depletion of the cell surface IgG receptor FcRylll
(CD 16), in addition to L-selectin, TNF receptors p55 and p75, and CD43 (Dransfield
et al., 1994; Dransfield et al., 1995; Meagher et al., 1992). Receptor shedding occurs
during granulocyte activation suggesting that pathways engaged during activation (of
the neutrophil) also function during its death throes. Induction of a cell that is
functionally "isolated" may be important to limit local tissue injury before apoptotic
cell clearance by macrophages. A number of stimuli have been characterised as
regulators of granulocyte viability (table 1) (for review see Ward et al., 1999). These
include inflammatory agents such as LPS and GM-CSF, which inhibit neutrophil
apoptosis (Colotta et al., 1992; Cox et al., 1992; Haslett et al., 1991; Lee et al., 1993;
Yamamoto et al., 1993), TNFa, nitric oxide donors, and ligation of Fas which
promote granulocyte cell death (Matsumoto et al., 1995; Murray et al., 1997; Ward
et al., 2000). Interestingly work by Brown and colleagues have described how
exposure of macrophages to non-particulate stimuli can induce the induction of
apoptosis in bystander leukocytes via the Fas death pathway (Brown and Savill,
1999), initiating the "safe" clearance of infiltrated neutrophils.
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Granulocyte Apoptosis delaying agents
Neutrophil Agents that increase cytosolic cAMP
Agents that increase [Ca2+]j
Glucocorticoids
Neutrophils agonists (LPS, FMLP, PAF, LTB4, C5a, GM-CSF, IL-6, IL-8)
Hypoxia
Eosinophil Agents that increase cytosolic cAMP
Eosinophil agonists (IL-5, GM-CSF)
Apoptosis accelerating agents
Neutrophil NO donors




Eosinophil Activating Fas antibodies, FasL
Agents that increase [Ca2+];
Glucocorticoids
NF-kB inhibitors
Table 1. Regulation of granulocyte survival.
7+
Abbreviations: [Ca ]i, intracellular free calcium concentration; C5a, complement
fragment C5a; Fas, Fas ligand; FMLP, formyl-methionylleucylphenylalanine; GM-CSF,
granulocyte/macrophage colony-stimulating factor; IL, interleukin; LPS,
lipopolysaccharide; LTB4, leukotriene B4, NF-kB, nuclear factor kB; NO, nitric oxide;




Phagocytosis of the "inert" apoptotic particle can itself promote resolution. Unlike
ingestion of IgG opsonized particles which promote the release of pro-inflammatory
cytokines, uptake of apoptotic cells is non-phlogistic, and actually induces the release
of anti-inflammatory mediators such as TGF(3 and PGE2, and inhibits subsequent
TNFa release in response to inflammatory stimuli (Fadok et al., 1998a; Voll et al.,
1998). This "re-setting" of macrophage activation can be mimicked by ligation of
macrophage receptors thought to mediate uptake of apoptotic cells (table 2). For
example CD36, its bridging molecule thrombospondin (Fadok et al., 1998b), and the
recently identified receptor for phosphatidylserine exposed on the surface of
apoptotic cells (Fadok et al., 2000). IFNy and LPS are the major mediators of
classical macrophage activation inducing production of pro-inflammatory cytokines,
whereas IL-4, -10, and -13, TGF(3 and glucocorticoids have been shown to
"alternatively" activate macrophages inhibiting the production of pro-inflammatory
cytokines, NO and reactive oxygen species (Goerdt and Orfanos, 1999; Mills et al.,
2000; Stein et al., 1992). Alternatively-activated macrophages are thought to
metabolise arginine to ornithine, as opposed to NO (Mills et al., 2000; Munder et al.,
1998; Munder et al., 1999). As a precursor of polyamines, ornithine promotes cell
replication, facilitating cell renewal during wound healing (Williams-Ashman and
Canellakis, 1979). Thus, changes in the cytokine environment mediated by clearance
of apoptotic cells can therefore program infiltrating monocyte/macrophages and
further influence the inflammatory outcome.
In contrast to the induction of apoptotic cell death and subsequent clearance by
macrophages, necrotic cell death and clearance of necrotic cells evokes pro¬
inflammatory responses (Cocco and Ucker, 2001; Fadok et al., 2001a; Stern et al.,
1996). Cell membrane integrity is not maintained, resulting in the leakage of the
cell's toxic contents, and in addition phagocytosis induces macrophage production of
inflammatory mediators. Inflammatory diseases are therefore likely to arise from
failure or inefficiency of normal resolution mechanisms. There are a number of steps
in the clearance pathway where dysregulation could promote chronic inflammation,
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by altering the balance between apoptotic and necrotic cell death. Necrotic cells are
present even in resolving inflammation. Whether these arise from failure to induce
apoptosis or due to the induction of secondary necrosis in non-cleared apoptotic cells
is not known, or how many necrotic cells are required to be present to switch the
balance from resolving to non-resolving inflammation. This is illustrated by in vivo
triggering of Fas which induces massive apoptotic cell death in the liver of mice,
overwhelming macrophage clearance mechanisms and resulting in secondary
necrosis, tissue damage and ultimately organ failure (Ogasawara et al., 1993).
Similarly, induction of bronchial and epithelial cell apoptosis in the rat lung by
inhalation of Fas mAb results in a necrotic lesion, inflammation and scarring
(Hagimoto et al., 1997). The efficiency of clearance of apoptotic cells is likely to
influence the number of necrotic cells present in tissues in addition to modulation of
the death program itself. Much work has been undertaken to understand the
mechanisms modulating inflammatory cell survival, however, unless increased
apoptosis is paralleled by an augmentation of macrophage clearance it is possible
that beneficial effects may be reduced. Recent work has described how the act of
engulfment can trigger the final death throes of a cell (Hoeppner et al., 2001;
Reddien et al., 2001). Thus, engagement of the full apoptotic program would be
delayed until phagocyte engulfment begins, reducing the possibility of secondary
necrosis. Modulation of macrophage phagocytic capacity therefore represents a
major therapeutic target for the treatment of inflammatory disease.
Macrophage clearance of apoptotic cells
Clearance of apoptotic cells by macrophages is regulated at a number of levels.
Firstly, the exposure of "eat-me" signals on the apoptotic cell surface and interaction
of specialised receptors expressed by macrophages and other phagocytic cells
function to identify and "tether" the particle prior to engulfment. "Tethering" may
be enhanced by substances that opsonize apoptotic cells, providing additional cell-
cell interactions. Secondly, engagement of the apoptotic particle evokes intracellular
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signalling pathways that induce cytoskeletal changes mediating the internalisation of
the apoptotic cell and its subsequent processing.
Apoptotic cell ligands
The absence of internalised viable cells within phagocytic populations suggests that
uptake of apoptotic cells is mediated in response to an "eat me" signal induced by the
progressing apoptotic program. However, the observation that macrophages
internalise inert particles could argue that phagocytosis of apoptotic cells proceeds in
response to the loss of a viable cell markers. Earlier I have described the decrease in
expression of certain neutrophil cell surface molecules during apoptosis (Dransfield
et al., 1994; Dransfield et al., 1995) implying that mechanisms for maintenance of
receptor numbers are compromised or proteolytic shedding is employed. Such
protease activity would be required to be specific for apoptotic or necrotic cell death.
Proteolytic shedding of surface receptors during apoptosis has been observed in
myeloid cell lines (Brown et al., 1996), but whether this represents a fundamental
feature of apoptosis in different cell types remains to be determined. One possibility
is that the presence of proteolytic "stubs" of shed receptors could contribute to a
"signal" for phagocytosis. Differences in the apoptotic cell ligand may determine the
cellular response to ingestion, for example the release of pro-inflammatory cytokines
after necrotic cell or latex bead uptake, or release of anti-inflammatory mediators as
described during apoptotic cell phagocytosis (Fadok et al., 1998a; Voll et al., 1998).
Ligation of apoptotic cell receptors on phagocytes during clearance of necrotic cells
could "fool" the macrophage into eliciting anti-inflammatory responses promoting
resolution of the necrotic lesion.
A number of potential apoptotic cell markers have been identified, most of which
depend on specific modification of cell surface molecules by proteolysis, oxidation,
or changes in glycosylation. Non-enzymatic glycosylation of surface proteins to
form advanced glycosylation end products (AGE) induces binding of specific
receptors termed RAGE (Schmidt et al., 1994). RAGE is also able to bind (3-
amyloid fibrils associated with the neuropathology of Alzheimer's disease (Schmidt
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et al., 2000). Failure to clear these modified proteins may provoke inflammatory
responses observed in neurological tissue from Alzheimer's sufferers. However,
inhibition of macrophage phagocytosis with specific polyanionic ligands does not
support a potential role for AGE in the clearance of apoptotic cells (Savill et al.,
1989a), additionally the kinetics of appearance ofAGE on senescent cells is likely to
be too slow for recognition of apoptotic cells by phagocytes.
Other modifications of cell surface molecules thought to induce phagocytosis include
desialylation of lectins (Duvall et al., 1985; Pradhan et al., 1997) and the alteration
of the adhesion molecule ICAM-3 (Gregory et al., 1998; Moffatt et al., 1999). Early
studies indicated that cellular microelectrophoretic mobility was reduced on
apoptotic mouse thymocytes, suggestive of changes in the net negative charge of cell
membranes from changes in surface proteins (Morris et al., 1984). This
corresponded to reduced binding of lectins and mAb observed in flow cytometric
analysis (Morris et al., 1984). High levels of mannose, N-acetylgalactosamine, and
galactose can be detected on apoptotic human peripheral blood lymphocytes using
fluoresceinated lectins as probes and have been implicated in clearance of apoptotic
cells (Dini et al., 1992). Flow cytometric analysis of binding of a panel of
conjugated lectins to apoptotic neutrophils suggests that exposure of these
carbohydrate moieties may not be a general feature of apoptosis on all cell types
(Hart et al., 2000). Screening of the effects on apoptotic cell uptake of a large panel
ofmAb revealed that blockade of certain epitopes of ICAM-3 (CD50) on apoptotic B
cells prevented uptake. One possibility is that ICAM-3 is modified following
induction of apoptosis in a manner that confers binding to CD14, a cell surface
protein previously implicated in the uptake of apoptotic cells (Devitt et al., 1998;
Moffatt et al., 1999).
The most extensively characterised apoptotic cell marker is the externalisation of
amino phospholipids including phosphatidylserine (PS) (Martin et al., 1995) and
phosphatidyl ethanolamine (Emoto et al., 1997). In viable cells, PS is located on the
cytoplasmic face of the cell membrane (Op den Kamp, 1979; Schroit and Zwaal,
1991; Zwaal and Schroit, 1997). During induction of the apoptotic program "flip
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flop" of PS occurs exposing it on the surface of the cell (Bratton et al., 1997; Martin
et al., 1996). This is mediated by specific scramblases, intracellular proteases such
as calpains and caspases, and transglutaminases (Bratton et al., 1999, and references
therein), plus the ABC1 transporter (see below) (Hamon et al., 2000).
Pharmacological inhibition of scramblase function prevents uptake of apoptotic cells
(Fadok et al., 2001b) suggesting that although other apoptotic ligands may promote
phagocytosis by either tethering or acting in a co-stimulatory fashion, PS exposure is
obligatory. Identification of the only phagocytic receptor in C. elegans as a possible
receptor for modified lipid (Zhou et al., 2001) suggests that membrane asymmetry
represents a conserved signal for cell death. Interestingly, PS exposure has been
described to be a specific marker for apoptotic cell death and has been proposed to be
a molecular "switch" for the release of anti-inflammatory cytokines associated with
their engulfment (Henson et al., 2001). However, a number of reports have
demonstrated its involvement during clearance of necrotic particles (Cocco and
Ucker, 2001) and additionally during caspase-independent cell death (Brown et al.,
2000; Hirt et al., 2000). CD36, an alternative PS receptor, has been shown to bind
PS in addition to other oxidised lipids associated with apoptosis (Fadok et al., 1998b;
Tait and Smith, 1999). Co-operation between the PS receptor and additional
stimulatory molecules may be required for the induction of the specific responses
described by Fadok and colleagues (Fadok et al., 1998b).
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Surface molecule Phagocyte Apoptotic particle
avpj/CD36/thrombospondin











Human monocyte-derived macrophage (Savill et al., 1990; Savill et al., 1992)
Human fibroblast (Hall et al., 1994)
Mouse bone marrow-derived macrophage (Ren et al., 2001)
Human glomerular mesangial cell (Hughes et al., 1997)
Mouse bone marrow-derived macrophage (Fadok et al., 1992a)
J774 mouse macrophage (Pradhan et al., 1997)
Human dendritic cell (Rubartelli et al., 1997)
Human THP-1 macrophage
House J774 macrophage (Tait and Smith, 1999)
Microglia (Witting et al., 2000)
COS-7 cell (ectopic expression) (Ren et al., 1995)
Small airway epithelial cell (Walsh et al., 1999)
Human dendritic cell (Albert et al., 1998)
Rat retinol pigment epithelium cell (Finnemann and Rodriguez-Boulan, 1999)
Mouse peritoneal macrophage (Fadok et al., 1992b)
Stimulated bone marrow-derived macrophage (Fadok et al., 1992a)
Human PMA-stimulated THP-1 cell (Fadok et al., 1992b)
J774 mouse macrophage (Pradhan et al., 1997)
Rat vascular smooth muscle cell (Bennett et al., 1995)
Rat Sertoli cell (Shiratsuchi et al., 1997)
Kupffer cells (Shi et al., 2001)
Microglia (Witting et al., 2000)
Stimulated human monocyte derived macrophages (Fadok et al., 2000)

































Thymic macrophage (Piatt et al., 1996)
Human monocyte-derived macrophage (Brown et al., 2000)
Rat Sertoli cell (Shiratsuchi et al., 1999)
Rat thecal cell (Svensson et al., 1999)
Mouse peritoneal macrophage (Chang et al., 1999)
Endothelial cell (Oka et al., 1998)













Human monocyte-derived macrophage (Devitt et al., 1998; Flora and Gregory,
1994; Moffatt et al., 1999)
J774 mouse macrophage (Pradhan et al., 1997)
Peritoneal macrophage (Pradhan et al., 1997)
Human fibroblast (Hall et al., 1994)
Mouse peritoneal macrophage (Duvall etal., 1985; Pradhan et al., 1997)
Endothelial cell (Dini and Carla, 1998)
Small airway endothelial cell (Walsh et al., 1999)
Rat liver cell (Dini et al., 1992)
Liver endothelial cells (Dini et al., 1995)
Kupffer cell (Falasca et al., 1996)
















U937 monocytes (Schwartz et al., 1999)





A TP-binding cassette transporter
(ABC1)
Mouse bone marrow derived macrophage (Scott et al., 2001)








Surfactant protein A (CD91 ?)
(^-glycoprotein ((^-glycoprotein R)
Gas6 (Mer)
Human retinoic acid differentiated THP-1 cell (Takizawa et al., 1996) Jurkat
Human monocyte derived macrophage (Mevorach et al., 1998) Thymocyte
Cells in renal glomeruli (Botto et al., 1998) Cells in renal
glomeruli
Human monocyte derived macrophages (Ogden et al., 2001) Jurkat
Rat alveolar macrophage (Schagat et al., 2001) Rat neutrophil,
Mouse peritoneal macrophage (Balasubramanian et al., 1997) Jurkat
Mouse peritoneal macrophages (Ishimoto et al., 2000) Thymocyte
Table 2. Receptors mediating uptake of apoptotic cells
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Opsonins
A growing number of soluble molecules have been shown to promote apoptotic cell
uptake by opsonization of apoptotic particles (table 2). The complement components
Clq and iC3b bind to the surface of apoptotic cells promoting uptake via Clq
receptors or CR3/CR4 (Korb and Ahearn, 1997; Mevorach et al., 1998; Takizawa et
al., 1996). Susceptibility to the autoimmune disease systemic lupus erythematosus
has been linked to Clq deficiency. An excess of free non-ingested apoptotic cells are
found in the inflamed glomeruli seen in mice deficient in Clq (Botto et al., 1998).
Self antigens which are targets for autoimmune disease have been shown to be
present on the surface of late stage apoptotic cells, and apoptotic blebs (Gilligan et
al., 1996; Kalden, 1997). In addition immature dendritic cells have recently been
shown to present peptides derived from apoptotic cells ingested via ay[3 5 integrins in
both MHC Class I and MHC Class II (Albert et al., 1998a; Inaba et al., 1998).
However, in the absence of co-stimulatory molecule expression presentation of
peptides is thought to induce a toleragenic response to self-antigens. Macrophages
were shown not to be able to present material from apoptotic particles upon
phagocytosis via CD36 and ctvP3. Failure of efficient clearance by Clq deficiency
may result in uptake of particles at the late apoptotic or necrotic stage. This may
represent a "danger" signal inducing differential processing and presentation of
particle fragments resulting in autoimmunity. CD 14 functions as a receptor for LPS
as well as apoptotic cells (see below), uptake of bacterial products at the same time
as apoptotic cells may also result in presentation of bacterial and self antigens via
class II. As macrophages are proficient at stimulating T cell mediated immunity to
pathogens, transient autoimmune responses may also occur which contribute to the
tissue damage acquired during the course of certain inflammatory responses.
Receptors for recognition ofapoptotic cells
Much information on the intracellular mechanisms required for the uptake of
apoptotic cells have arisen from the study of phagocytosis in the nematode worm C.
elegans. However, study of this model organism has not enabled the elucidation of
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the extracellular mechanisms required for recognition and initiation of phagocytosis
of apoptotic particles by mammalian cells. Whilst the genetic approach can identify
molecules involved in global uptake mechanisms it does not address functional
associations or distribution of phagocytic receptors, or the contribution of post-
translational modifications such as phosphorylation and glycosylation on apoptotic
cell uptake. A putative nematode phagocytic receptor has recently been identified as
a transmembrane protein thought to recognise altered lipid products with homology
to the mammalian protein SREC (Scavenger Receptor of Endothelial Cells) a
member of the scavenger receptor family (Zhou et al., 2001). Genetic screens have
not suggested the presence of other receptors. In contrast to the worm at least seven
distinct families of cell surface proteins have been implicated in the recognition of
apoptotic cells in mammalian systems (table 2). The putative receptors range from
integrin molecules previously described for their role in adhesion signalling,
receptors which mediate recognition of pathogens in innate immunity, to proteins
which mediate the uptake and processing of lipid products. Mammalian
"recognition" receptors appear to have dual roles in both clearance of apoptotic cells
and other cellular functions required to maintain tissue homeostasis. Although
multiple receptors and subsequent redundancy complicate investigation into uptake
mechanisms, the duality of their function enables study of these receptors outwith
their phagocytic capacities to help understand their cellular regulation.
The first demonstration of an uptake pathway for apoptotic cells in mammalian
systems was reported as a charge "sensitive" mechanism, inhibited by specific
carbohydrates, and altered pH (Savill et al., 1989a). Further investigation revealed
this to be mediated by the integrin ayp3 (Savill et al., 1990), and the class B
scavenger receptor, CD36, in human monocyte-derived macrophages (Savill et al.,
1992). avp3 and CD36 mediated binding of cell associated thrombospondin which
was thought to act as a bridge or opsonin between the apoptotic cell and the
phagocyte (Savill et al., 1992). This mechanism was also found to function in
murine bone marrow-derived macrophages (Fadok et al., 1992b). In contrast murine
peritoneal macrophages were demonstrated to predominantly use a novel receptor
mediating recognition of externalised phosphatidylserine (Fadok et al., 1992a), and it
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was therefore proposed that macrophages from different tissues use distinct
phagocytic pathways. In addition to the examples discussed above, Kupffer cells
recognise altered carbohydrate residues on apoptotic particles (Dini et al., 1995),
whereas mouse thymic macrophages use class A scavenger receptors (Piatt et al.,
1996). However murine bone marrow-derived macrophages were shown to switch to
the utilisation of the PS system after stimulation, for example with digestible
particles (Fadok et al., 1993; Pradhan et al., 1997). This suggests that the
environmental stimuli a monocyte/macrophage receives at its origin may determine
the molecular mechanism of uptake. Modulation of environmental stimuli are
therefore likely to enable the promotion of specific phagocytic mechanisms.
Understanding the influence of environmental factors on defective clearance in
chronic inflammatory conditions may provide further opportunities for therapy.
Other putative receptors for macrophage clearance of apoptotic cells include those
that also function as receptors of the innate immune system, CD14 and the mannose
receptor. CD 14 has been suggested to recognise an altered conformation of the
adhesion molecule ICAM-3 (Devitt et al., 1998; Flora and Gregory, 1994; Moffatt et
al., 1999), and the mannose receptor is thought to bind altered carbohydrate residues
on the apoptotic cell surface (Dini, 1998; Hall et al., 1994; Linehan et al., 2000).
Members of the scavenger receptor family also function in the innate immune
system. They recognise a number of molecules including carbohydrate residues,
lipids and bacterial LPS, and are able to mediate the uptake of particulate matter in
addition to apoptotic cells. As the scavenger receptor family share homology with
the only apoptotic cell receptor described in C. elegans, SREC (Zhou et al., 2001),
evolutionarily they may represent the oldest family of recognition receptors. During
the development of the inflammatory response, other uptake mechanisms may have
arisen from adaptation of pre-existing pathways in order to fulfil the huge
requirement for clearance of inflammatory cells.
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Intracellular mechanisms of phagocytosis
Inhibition studies using antibodies or competitive ligands to block specific receptor
uptake never results in the complete ablation of apoptotic cell phagocytosis. For
example, pharmacological inhibition of PS exposure cannot not reduce phagocytosis
to that of control non-apoptotic populations (where limited phagocytosis and uptake
still occurs) (Fadok et al., 2001b). Furthermore, deletion of the class A scavenger
receptor prevented phagocytosis of apoptotic cells in vitro, but had no effect on the
cellular architecture of the thymus (Piatt et al., 1999; Piatt et al., 2000). The
redundancy of receptor usage suggests that targeting the intracellular machinery
mediating phagocytosis of apoptotic cells may provide an alternative focus for
therapeutic intervention. The signalling pathways linking the extracellular receptor
with the intracellular uptake machinery have not been fully explored, as research in
this area is problematic. Primary cultures are the preferred choice of model system,
however this restricts the ability to utilise molecular biology techniques for the
expression of constitutively active or dominant negative mutants to assess the role of
kinases, adaptor proteins or cytoskeletal components in phagocytosis. Additionally
the apoptotic "meal" is highly heterogeneous due to the asynchronous progression of
the apoptotic program within a cell population, and may present multiple
"recognition" signals as discussed above. Furthermore engagement of each receptor
type may activate a distinct intracellular pathway. The pathways thought to
physically mediate apoptotic cell uptake share many common components not only
with Fc- and complement phagocytosis mechanisms, but also regulation of adhesion.
For example, cytoskeletal re-organisation during extension of membrane processes
around the particle is thought to be regulated in a manner similar to that described
during cell adhesion and migration. Work within the last few years has identified a
major role for RJho-family GTPases in cytoskeletal organisation during cell adhesion
and migration, and opsonized particle engulfment, providing a model for the
intracellular regulation of apoptotic cell uptake (fig. 3).
18
Cytoskeletal regulation during adhesion andmigration: Regulation ofRho GTPases
Rho GTPase proteins, a subgroup of the Ras superfamily, regulate a number of
cellular functions including actin organisation and cell shape, cell adhesion and
motility, membrane trafficking and gene expression (for review see Bishop and Hall,
2000). Rho GTPases are activated by ligation of cell surface adhesion receptors as
well as by soluble mediators and chemokines. Rho proteins cycle between an
inactive conformation when bound to GDP, and an active GTP-bound form. The
GDP/GTP state is regulated by guanine-nucleotide exchange factors (GEFs) that
promote dissociation of GDP and facilitate GTP binding. In contrast, guanine
nucleotide dissociation inhibitors negatively regulate Rho protein signalling by
preventing GDP/GTP exchange. A third level of regulation is mediated by GTPase
activating proteins (GAPs) which stimulate the intrinsic GTPase activity of Rho
proteins attenuating down stream signalling. A number of GTPase regulating
proteins specific for Rho GTPases exist (Scita et ah, 2000). This redundancy may
facilitate the differential localisation of Rho-GTPases within the cell for example
lipid rafts (Tosello-Trampont et al., 2001), in response to different extracellular
stimuli allowing the induction of specific functional outcomes from a common signal
(Zhou et al., 1998).
Function ofRho-family GTPases during adhesion
Integrin ligation during adhesion to matrix activates src family kinases which
mediate a number of intracellular signalling pathways culminating in the localisation
and activation of Rho-family GTPases (fig 3) (for review see Schoenwaelder and
Burridge, 1999) which regulate the formation of adhesion processes (Allen et al.,
1997; Rottner et al., 1999). Podosomes are highly dynamic specialised adhesion
structures found in cells of the monocyte lineage and in migratory cells where they
are thought to play a role in maintaining cellular polarisation (see below).
Podosomes are morphologically distinct from focal complexes characterised in
immunofluorescence microscopy as punctate staining of integrins, structural proteins
such as vimentin, vinculin, talin, adaptors including paxillin and pl30cas, other
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tyrosine phosphorylated proteins and substrates for protein kinase Cot (PKCa),
assembled around an actin core (Marchisio et al., 1984; Marchisio et al., 1987;
Nakamura et al., 1993). Rho, Rac and Cdc42 have all been linked to the regulation
of podosome formation and turnover (Burns et al., 2001; Chellaiah et al., 2000;
Linder et al., 1999; Ory et al., 2000). The mechanisms governing this regulation
have been most extensively characterised for Cdc42. Cdc42 is linked to the
cytoskeleton via interaction with WASp (Wiskott-Aldrich Syndrome protein)
(Aspenstrom et al., 1996; Kolluri et al., 1996; Symons et al., 1996). WASp was first
identified from Wiskott-Aldrich Syndrome patients where mutations in WASp
resulted in severe immunodeficiency due to defects in leukocyte phagocytosis and
migration (Kirchhausen, 1998; Kirchhausen and Rosen, 1996). Since its discovery a
number of homologous proteins have been identified which also interact with Rho
family GTPases mediating cytoskeletal rearrangement during adhesion and migration
(for review see Takenawa and Miki, 2001). WASp interacts with the Arp2/3
complex of small G-proteins promoting actin polymerisation (Burns et al., 2001;
Linder et al., 2000; Linder et al., 1999; Machesky and Insall, 1998; Machesky et al.,
1999). Cells of the monocyte lineage derived from WAS patients lack podosomes.
Additionally overexpression of inhibitory fragments of WASp disrupts podosome
formation (Linder et al., 2000; Linder et al., 1999).
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Function ofRho GTPases during migration
During cell movement Cdc42 initiates the extension of short cellular protrusions,
termed filopodia, supported by a core of bundled actin filaments (microfilaments).
Filopodia have been observed in a number of cell types including macrophages and
fibroblasts. Suspended between filopodia, are sheets of membrane enclosed
cytoplasm, termed lamellipodia. These processes contain a network of myosin II-
associated microfilaments required for cellular contraction during movement.
Extension of filopodia and lamellipodia processes is mediated by actin
polymerisation under the control of Cdc42 and Rac respectively. (Allen et al., 1997;
Kozma et al., 1995; Nobes and Hall, 1995). Several different mechanisms for the
initiation of actin polymerisation have been proposed (for review see Borisy and
Svitkina, 2000). Severing and uncapping actin filaments exposes free barbed ends to
which new actin subunits can be added. Alternately forward movement may be
propelled by the de novo nucleation of actin polymerisation induced by the Arp2/3
complex and WASp family members. In filopodia, actin filaments are polymerised
in a parallel fashion, in contrast to lamellipodia where the actin filament network is
branched with Arp2/3 initiating formation of new filaments from the side of old ones
(Borisy and Svitkina, 2000; Machesky and Gould, 1999). Branching is thought to
contribute to the contractile capacity of lamellipodia during cell movement. During
extension of adhesive processes, adhesive contacts and podosomes are formed at the
leading edge of the cell to stabilise the membrane structures. These cell-ECM
contacts also function as a base for contraction of cytoplasmic actomyosin filaments
assembled in response to myosin light chain phosphorylation (Adelstein, 1983;
Burridge and Chrzanowska-Wodnicka, 1996; Yoshioka et al., 1998). Then with the
release of contact sites in the trailing edge of the cell, mediated by RhoA (Alblas et
al., 2001; Worthylake et al., 2001), forward movement occurs.
Fc Receptor-mediatedphagocytosis
Particles opsonized by immunoglobulin G (IgG) are recognised by the Fey Receptor
family. Particle binding for both IgG- and complement- opsonized particles does not
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require cytoskeletal integrity, as attachment in the absence of intact microtubules and
microfilaments has been observed (Caron and Hall, 1998; Newman et al., 1991), and
can occur at 4°C. Binding induces receptor aggregation, and intracellular signalling
leading to the accumulation of a number of enzymes and adaptor proteins around the
engaged particle. Actin, talin, paxillin and a-actinin, tyrosine phosphorylated
proteins, and PKCa are enriched near to the phagosome membrane in a diffuse
manner (Allen and Aderem, 1996; Allen and Aderem, 1995; Greenberg et al., 1990;
May et al., 2000; Zheleznyak and Brown, 1992). Additionally a tyrosine kinase of
the src family is thought to be activated upon FcR-aggregation, which
phosphorylates residues in the FcyR cytoplasmic tail, termed ITAMs
(immunoreceptor tyrosine based activation motifs) (Cox et al., 1996). This allows
the recruitment of the tyrosine kinase syk which triggers multiple pathways leading
to inflammatory mediator release, gene expression and actin cytoskeleton
rearrangement (Daeron, 1997; Daeron et al., 1995). Macrophages from syk -/- mice
show defects in particle ingestion but are still able to extend membrane processes,
suggesting that syk may not be directly involved in actin polymerisation but in the
completion of internalisation (Crowley et al., 1997). FcR-mediated phagocytosis is
unsurprisingly inhibited by compounds that perturb actin polymerisation dynamics,
and tyrosine phosphorylation (Allen and Aderem, 1996; Greenberg et al., 1993).
PI-3 kinase activity has also been shown to be required for FcR-mediated
phagocytosis. Blockade of kinase function with pharmacological agents prevents
phagosome closure and intemalisation of IgG opsonized erythrocytes, without
disturbing actin polymerisation at the point of particle attachment (Araki et al., 1996;
Cox et al., 1999). The lipid products of PI-3 kinase are thought to regulate
membrane recycling at the leading edge of cells during migration (Bretscher and
Aguado-Velasco, 1998). Additionally, inhibition of recycling endosomes with
tetanus toxin, an inhibitor of PI-3 kinase, inhibits phagocytosis (Araki et al., 1996;
Bajno et al., 2000; Cox et al., 1999; Ninomiya et al., 1994).
Actin polymerisation and membrane extension allow the formation of cellular
processes around the particle in a "zipper"-like fashion. Blockade of surface
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receptors after particle attachment prevents engulfment (Griffin et al., 1975). As
discussed for cell migration above, co-ordination of actin polymerisation is thought
to be mediated by Rho family GTPases that co-localise with the nascent phagosome
(Caron and Hall, 1998). Treatment of phagocytic cells with toxin B from
Clostridium difficile, an inhibitor of all Rho family members inhibits FcR-mediated
phagocytosis without affecting particle recognition (Caron and Hall, 1998; Massol et
al., 1998). Specific inhibition of Rho with C3 transferase, another Clostridium toxin
which ADP-ribosylates RhoA, suggests a role in receptor clustering required for the
initiation of uptake (Caron and Hall, 1998). However, RhoA has been shown not to
have a direct role in mediating cytoskeletal organisation during FcR-mediated
phagocytosis (Massol et al., 1998; May et al., 2000). Microinjection of proteins, or
protein expression constructs encoding dominant negative or constitutively active
forms of Rac and Cdc42 have identified a role for these GTPases in FcR-mediated
phagocytosis (Cox et al., 1997; Massol et al., 1998). Inhibition of Cdc42 appears to
prevent pseudopod extension, whilst Racl is required for pseudopod fusion and
phagosome closure. Recent work has also demonstrated a potential role for the Rho
GEF Vav in mediating activation ofRac and Cdc24. Vav is tyrosine phosphorylated
upon FcR clustering (Crespo et al., 1997), and can be further activated by the lipid
products ofPI-3 kinase (Han et al., 1998).
Rac and Cdc42 are thought to mediate actin rearrangement by engagement ofWASp
family members and the Arp2/3 complex, similar to the mechanisms employed
during migration. Macrophages from WAS patients show deficiencies in
phagocytosis, and GFP-tagged N-WASp has been shown to localise at the nascent
phagosome (Zhang et al., 1999). Furthermore, inhibition of Arp2/3 complex
activation also abrogates engulfment (May et al., 2000). Therefore we can describe a
model whereby the zipper-like interactions of opsonins and FcRs, combined with a
branched network of nucleating actin filaments, provides the force for pseudopod
extension as for lamellipodia. Localised contractility has also been detected in the
phagosome (Evans et al., 1993). Both contractility and phagosome closure are
sensitive to inhibitors ofmyosins which have also been detected associated with the
nascent phagosome (Swanson et al., 1999). Interestingly PAK-1, a serine/threonine
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kinase activated by Cdc42 and Rac is also localised with the phagosome
Dharmawardhane et al., 1999). PAK-1 regulates contractility by inhibition of
myosin light chain kinase (MLCK) (Sanders et al., 1999). Closure of the phagosome
is thought to require removal of the pre-assembled cellular scaffolding. Cytoskeletal
and tyrosine phosphorylated proteins clustered at the site of ingestion rapidly
dissociate as internalisation occurs (Greenberg et al., 1991). This may be triggered
by a negative feedback mechanism whereby phosphorylated proteins recruit tyrosine
phosphatases via SH2 domain interactions, promoting de-phosphorylation and
dispersion of localised proteins. Candidates include SHP-1 (Hunter and Avalos,
1998), and PSTPIP which associates with the PEST family of PTPases (Spencer et
al., 1997; Wu et al., 1998).
Complement Receptor-mediatedphagocytosis
Uptake of complement opsonized particles, although also dependent on cytoskeletal
integrity, appears to proceed by an alternative mechanism. Particles sink into a
phagocytic pit and are engulfed without the extension of pseudopodia (Kaplan,
1977). Cytoskeletal proteins such as paxillin, actin, vinculin and a-actinin are
recruited to the membrane around the point of particle contact. Unlike Fc-mediated
phagocytosis, these proteins are localised in a punctate fashion (Allen and Aderem,
1995; May et al., 2000), and phagocytosis is not sensitive to inhibitors of tyrosine
kinase activity, but do require PKC function (Allen and Aderem, 1995). PKC is
thought to target the cytoplasmic portion of the p2-integrin subunit, which may
trigger receptor clustering observed upon particle engagement (Kwiatkowska and
Sobota, 1999). Internalisation is thought to be induced by activation of RhoA with
reorganisation of the actin cytoskeleton mediated by the Arp2/3 complex as found
for Fc-mediated phagocytosis (Caron and Hall, 1998; May et al., 2000). Introduction
of dominant negative forms of Cdc42 or Rac have no effect on uptake by
complement receptors (Caron and Hall, 1998; May et al., 2000) and the link between
RhoA and activation of Arp2/3 is not yet clear. The actin rich foci observed around
complement opsonized particles are reminiscent of focal adhesions. During CR3-
mediated uptake, RhoA signalling may promote clustering of integrins at the site of
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ingestion (Dib et al., 2001), in a manner that is analogous to its role during adhesion.
Contractility generated against these sites of contact allow the particle to "sink"
inside the macrophage.
Uptake ofapoptotic cells
Studies to date demonstrate both similarities and differences between uptake of
apoptotic cells, and FcR and CR-mediated phagocytosis. Engulfment of apoptotic
cells requires actin polymerisation and cytoskeletal reorganisation, as for uptake of
opsonized particles, and is likely to be more sensitive to cytoskeletal disruption due
to the size differences between opsonized bacteria and apoptotic cells. Apoptotic cell
binding requires intact cytoskeletal elements and our unpublished observations
demonstrate tethering does not occur at low temperature. Studies of scavenger
receptor function demonstrate binding of lipid microspheres is temperature
insensitive (Bird et al., 1999), such discrepancies are likely to be due to size
constraints. Ingestion does not promote the release of pro-inflammatory cytokines as
seen upon Fc-receptor mediated uptake, and actively down-regulates inflammatory
processes by the release of anti-inflammatory cytokines (Fadok et al., 1998a; Voll et
al., 1998). Immunofluorescent staining of macrophage-particle interactions revealed
localisation of actin and tyrosine phosphorylated proteins in a diffuse manner similar
to the Fc phagosome (Leverrier et al., 2001; Leverrier and Ridley, 2001).
Furthermore scanning electron microscopy revealed that engulfment proceeds by the
extension ofmembrane processes around the particle similar to the "zipper" model of
FcR uptake (Giles et al., 2000; Leverrier and Ridley, 2001). Phagocytosis of
apoptotic cells is predictably inhibited by agents that disrupt actin polymerisation and
dynamics, but also pharmacological inhibitors of tyrosine kinases and PI-3 kinase
(Leverrier and Ridley, 2001).
Prior to the initiation of this study an involvement ofRho-GTPases in phagocytic cell
uptake was only hypothesised. However, experimental evidence within the last few
years has unequivocally demonstrated a role for Rac in regulation of this cellular
process. Elucidation of a putative uptake pathway was approached by two distinct
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angles. The first was exploitation of the nematode worm C.elegans as a model
system, the second was studies utilising molecular biology techniques for the
overexpression or reconstitution of components of the hypothesised pathway using
cell lines.
Phagocytosis in the nematode worm
During the development of the nematode worm, 131 of the 1090 somatic cells
generated undergo programmed cell death (Sulston and Horvitz, 1977). Fourteen
genes have been identified to be employed at various points of the apoptotic
program, at least six of these function during engulfment and have homologues in the
mammalian genome (for review see Hengartner, 2001). Genetic analysis of mutant
worms has shown that the six engulfment genes are organised into two parallel
pathways defined by the epistatic groups ced-1, -7, and -8, and ced-2, -5, -10 and -
12 (Chung et al., 2000; Ellis et al., 1991). The former pathway is less well
characterised in both the worm and mammals. Cloning of C.elegans ced-1 revealed
it encoded a protein with homology to SREC a member of the scavenger receptor
pathway (Zhou et al., 2001), and is thought to bind apoptotic cells via exposed
phosphatidylserine residues. The mammalian CED-7 counterpart is ABC1 (Wu and
Horvitz, 1998a), a membrane protein of the ATP-binding cassette transporter family
(for review see Broccardo et al., 1999). Blockade of ABC1 function by
pharmacological agents prevents phagocytosis (Luciani and Chimini., 1996), and its
function has recently been reported to be required on both phagocyte and target due
to its proposed ability for regulation ofmembrane phospholipid turnover (Hamon et
al., 2000; Marguet et al., 1999). The C.elegans gene ced-6 encodes an adaptor
protein (Liu and Hengartner, 1998), its human homologue hCED-6 is also a cytosolic
adaptor protein required for phagocytosis. It contains a number of protein interaction
motifs, a phosphotyrosine binding (PTB) domain, a leucine zipper motif, and a
proline rich region (Smits et al., 1999; Su et al., 2000). Overexpression of ced-6
rescues ced-1 and -7 mutant worms placing the adaptor downstream in the pathway
(Liu and Hengartner, 1998). Similarly overexpression of the mammalian homologue
rescues the phenotype in the worm, and promotes engulfment in transfected J774
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cells, a murine macrophage cell line (Liu and Hengartner, 1998; Smits et al., 1999).
Putative tyrosine phosphorylation motifs on the cytoplasmic tail of the newly
characterised mammalian "CED-1" suggests that CED-l/CED-6 coupling may
mediate the downstream signalling of this phagocytosis receptor.
Ced-2, -5, and -10 encode proteins homologous to the adaptor proteins Crk and
DOCK180, and the Rho family GTPase Rac (Reddien et al., 2001; Wu and Horvitz,
1998b). Formation of this complex is induced by integrin ligation. Interaction of
Crk/CED-2 with DOCK180/CED-5 induced membrane localisation and activation of
Rac/CED-10, resulting in actin polymerisation during membrane ruffling, adhesion
and migration (Albert et al., 2000; Kiyokawa et al., 1998; Reddien et al., 2001;
Tosello-Trampont et al., 2001). Human DOCK180 is able to rescue defects in cell
migration in ced-5 mutants, but not altered phagocytosis (Wu and Horvitz, 1998b),
suggesting more components of this pathway in the mammalian system remain to be
identified. Albert and co-workers and Tosello-Trampont and colleagues
independently demonstrated a direct function for the crk/DOCK180/Rac pathway for
phagocytosis in mammalian cells. Dendritic cells were found to utilise av(3s
integrins for the recognition of apoptotic proteins, which engaged the
crk/DOCK180/Rac complex via the adaptor protein pl30cas (Albert et al., 2000).
Tosello-Trampont and colleagues similarly demonstrated the formation of the
crk/DOCK180/rac complex upon particle engulfment (Tosello-Trampont et al.,
2001). The link between Rho-GTPase activation and actin polymerisation is thought
to be identical to that instigated during cell migration and adhesion, as macrophages
from WAS patients show defects in phagocytosis of apoptotic cells (Leverrier et al.,
2001).
Regulation ofmacrophage phagocytosis of apoptotic cells
The redundancy in receptor usage for phagocytosis of apoptotic cells demonstrated
by in vitro and in vivo studies suggests that therapeutic intervention at this level
would be unlikely to promote engulfment further within macrophage populations.
Targeted expression of phagocytic receptors in "non-professional" phagocytes could
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augment the phagocytic capacity of specific tissues. However, this approach may be
limited to the cytoskeletal components required for uptake of large particles.
Opsonization of apoptotic cells in a tissue-specific manner may allow the
upregulation of individual pathways in organs that show defective clearance. One
potential problem is that the full extent of redundancy within this system is not yet
fully clear. Regulation of the intracellular mechanisms that represent rate limiting
events for phagocytosis are likely to have important therapeutic potential, but may
represent a difficult target in terms of specificity. A number of exogenous factors
have been shown to augment phagocytic clearance, including soluble mediators such
as cytokines, ligation of adhesion receptors, and glucocorticoids, which may mediate
their effects via modulation of intracellular pathways. Investigation into the
mechanism of their action may allow the manipulation of phagocytic capacity.
Soluble mediators
During inflammation the tissue microenvironment contains elevated levels of
specific cytokine and inflammatory mediators, that regulate apoptotic pathways in
leukocytes (Lee et al., 1993). It might be expected that these substances also affect
phagocytic capacity. Incubation of human monocyte-derived macrophages with
granulocyte-macrophage colony stimulating factor (GM-CSF), IL-1(3, IFNy, TNFa
or TGF(3l for four hours was found to augment macrophage phagocytosis of
apoptotic neutrophils (Ren and Savill, 1995). However phagocytic capacity in other
macrophage models has demonstrated an inhibitory effect of IFNy upon uptake of
apoptotic neutrophils (Erwig et al., 1998), although this study corroborated the
increase in phagocytosis following TNFa exposure. Such discrepancies may be due
to the tissue origin or species of phagocytes used for the studies, the differentiation
state of macrophages, or whether these cells have been exposed to cytokines and
inflammatory mediators. Prior exposure of rat bone marrow derived macrophages to
IFNy prevented subsequent stimulation of apoptotic cell uptake by TNFa (Erwig et
al., 1998). More recently, glucocorticoids have been demonstrated to augment
phagocytosis of apoptotic neutrophils by peripheral blood monocyte-derived
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macrophages and murine bone-marrow derived macrophages. Endogenous
glucocorticoids are released during inflammatory "stress" (Chrousos, 1995) and have
been shown to have a number of immunomodulatory functions discussed further in
the next section.
Adhesion signalling
Substances that elevate intracellular cyclic AMP (cAMP) and activation ofPKA such
as the inflammatory mediator prostaglandin E2, have been shown to modulate
granulocyte apoptosis (Chang et al., 2000; Ottonello et al., 1998; Peacock et al.,
1999; Rossi et al., 1995) and macrophage phagocytic function (Rossi et al., 1998).
The disruption in particle uptake was attributed to the disruption of cytoskeletal
elements and cell detachment that accompanied prostaglandin treatment. We have
described how the components of the phagocytic machinery are common to those
required for cytoskeletal organisation during migration and adhesion, therefore it is
likely that the adhesion status of the cell may contribute to its phagocytic potential,
directly by signals arising from integrin ligation (Albert et al., 2000; Erwig et al.,
1999), or indirectly by adhesion modulating the response to cytokines and other
soluble mediators (Nathan and Sporn, 1991). During the inflammatory response
there is likely to be extensive remodelling of ECM which could function as a
temporal stimulus for augmented phagocytosis (Gailit and Clark, 1994).
Furthermore, with increased characterisation of macrophage-ECM interactions a
growing number of specific examples of adhesion modulation of phagocytic
potential may become obvious.
Cross-linking of the cell surface glycoprotein CD44 rapidly augments the
phagocytosis of apoptotic neutrophils by human peripheral blood monocyte-derived
macrophages (Hart et al., 1997). CD44 is proposed to bind a number of ECM
ligands including hyaluronan and fibronectin, and has been implicated in cell
motility during metastasis (Lesley et al., 1997; Lesley et al., 1993). The intracellular
region of CD44 is thought to interact with the Ezrin/radixin/moesin (ERM) family of
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proteins which are able to mediate cytoskeletal organisation and signalling (Tsukita
et al., 1994). Previously identified inhibitors of apoptotic cell recognition were
unable to block neutrophil uptake in response to CD44 ligation, suggesting either
redundancy of receptor usage or the engagement of unique receptors. The latter
represents an exciting possibility as CD44 ligation was unable to promote
phagocytosis of other apoptotic particles (Hart et al., 1997).
Integrin ligation has been strongly linked to both a positive and negative regulation
of phagocytosis. Ligation of avP3, oci p2 or c^Pi during apoptotic cell uptake, or by
mAb has been reported to inhibit subsequent phagocytosis when macrophages were
re-challenged with apoptotic cells, 48 hrs later (Erwig et al., 1999). The mechanism
for this "programming" is not clear, integrins are able to activate a number of
intracellular pathways leading to cytoskeletal rearrangement, release of soluble
mediators and changes in gene expression (Aplin et al., 1998), which could have
effects on the subsequent phagocytic capacity. In contrast to studies by Erwig and
co-workers, other research groups have demonstrated a positive function of Pi and P3
-integrins during phagocytosis. They have been described to mediate both apoptotic
cell recognition (Albert et al., 2000; Savill et al., 1990; Schwartz et al., 1999), and
modulation of capacity when bound to ECM components such as fibronectin
(McCutcheon et al., 1998). Additionally the ocvPs integrin complex has recently
been shown to be linked to activation of Rac, required for phagocytosis of apoptotic
cells by dendritic cells (Albert et al., 2000).
In addition to integrins, several macrophage "phagocytic receptors" have also been
described to function during cell adhesion. The scavenger receptor-A has been
shown to be involved in divalent cation-independent adhesion to serum-coated cell
culture plastic (Fraser et al., 1993). The adhesive role of scavenger receptors appears
to be augmented following macrophage activation, suggesting SR-A may play a role
in the retention ofmacrophages at the site of inflammation (van Velzen et al., 1999),
which may indirectly promote clearance of apoptotic cells. Furthermore,
characterisation of an involvement of scavengers receptors in the formation of
atherosclerotic plaques suggests a potential role for scavenger receptors in
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phagocyte-endothelial interactions (Maxeiner et al., 1998). CD36, a class B
scavenger receptor can mediate adherence to surfaces coated in collagen, and certain
anti-CD36 mAbs mimic the anti-adhesive effects of the ECM molecule
thrombospondin (Dawson et al., 1997). CD36 may also associate with the tyrosine
kinases fyn, yes, and lyn (Huang et al., 1991) to enable mediation of adhesion
signalling. Interestingly activation of src family kinases fgr, hck and lck upon
integrin ligation has been linked to the modulation of cytoskeletal organisation.
Peritoneal exudate macrophages from fgr'1', hck'' and Ick'' mice show defects in
migration and phagocytosis of IgG opsonized particles (Suen et al., 1999).
Glucocorticoid modulation of inflammation
Glucocorticoids have been widely used for the treatment of immune and
inflammatory diseases due to their immunomodulatory effects affecting T cell
activation, adhesion molecule expression, cell migration, effector cell activation and
cytokine production (table 3) (Schleimer, 1993; Wilckens and De Rijk, 1997).
Endogenous glucocorticoids are secreted by the adrenal glands in response to stress
including inflammation (Chrousos, 1995). Circulating cytokines including IL-1, IL-
6 and TNFa directly stimulate the hypothalamus and/or the pituitary, resulting
ultimately in the release of Cortisol, which in turn is inhibitory to the expression of
these cytokines (Chrousos, 1995). Endogenous glucocorticoids are therefore thought
to function in this capacity to promote the down-regulation and resolution of
inflammatory processes.
Glucocorticoids exert their effects by binding to glucocorticoid receptors localised in
the cytoplasm of target cells. Two isoforms of the glucocorticoid receptor exist, a
and (3, with the signalling defective (3-form acting as an antagonist to glucocorticoid
stimulation (Bamberger et al., 1995; Oakley et al., 1999; Strickland et al., 2001).
The glucocorticoid receptor consists of a ligand binding domain at its C-terminus, a
central DNA binding region composed of two zinc finger motifs, plus an N-terminal
domain involved in the transcriptional trans-activation of genes and interaction with
other transcription factors (for review see Whitfield, 1999). The unoccupied receptor
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is bound to a multi-protein complex composed of two molecules of hsp90, a
heatshock protein, in addition to immunophilin, a chaperone molecule, which
prevents unoccupied GR localising to the nuclear compartment. Upon glucocorticoid
binding, hsp90 dissociates revealing two nuclear localisation signals at the C-
terminus of the receptor promoting translocation to the nucleus and DNA binding. In
the nucleus the receptor usually binds as a homodimer to glucocorticoid response
elements (GREs) (Dahlman-Wright et al., 1991; Luisi et al., 1991), although
dimerisation has been shown not to be required for all trans-repressional activity
(Reichardt et al., 1998). GREs are composed of highly conserved palindromic 15
base pair DNA elements. Negative GREs (nGREs) which confer GC-dependent
repression upon target genes display a more variable DNA sequence (Drouin et al.,
1993). Transcriptional effects of the glucocorticoid receptor are not confined to
activation via GREs. The receptor/hormone complex is able to affect transcription of
genes which contain no GREs or nGREs via repression of other transcription factors
such as API, STAT5, and NF-kB, with the resulting inhibition of a number of genes
(table 4) (Jenkins et al., 2001).
Recently glucocorticoids have been shown to specifically augment phagocytosis of
apoptotic cells, but not opsonized particles (Liu et al., 1999). The augmented
ingestion was non-phlogistic and suggests another mechanism whereby
glucocorticoids exert their anti-inflammatory functions. However, long term steroid
use is associated with a number of undesirable side effects which include retention of
sodium and water, excretion of potassium, osteoporosis, hypertension, diabetes,
gastric ulcers and skin atrophy (Boumpas, 1993). Elucidation of the mechanism of
glucocorticoid-augmented phagocytosis would allow the development of dissociated
steroids that may limit the induction of side effects. The previous studies
characterised the effect of short term (24hr) glucocorticoid exposure of
monocyte/macrophages. Preliminary studies suggested that longer term treatment
(up to 5 days) further increased phagocytic capacity, and would be more analogous





i release from bone marrow and recruitment to tissues
i inflammatory mediator production
Neutrophil t viability
Mast Cell t Apoptosis
T lymphocyte i cytokine releases
I recruitment
Dendritic cell ■I maturation
Macrophage X cytokine production
X recruitment
Table 3. Effect of glucocorticoids on inflammatory cells.
Adapted from Barnes, 1997.
Increased transcription Decreased Transcription
Lipcortin-1 Cytokines: IL-1, -2, -3, -4, -5,-6,-8,-11,-12,-13, TNFoc,
(T-adrenoreceptor GM-CSF, RANTES, MIP1 a)
Secretory leukocyte inhibitory protein Inducible nitric oxide (iNOS)
IkB-(x Inducible cyclooxygenase (COX-2)
Inducible phospholipase A2 (PLA2)
Endothelin-1
NK]-receptors
Adhesion molecules (ICAM-1, VCAM-1)
Table 4 Effects of glucocorticoids on gene transcription in inflammation
Adapted from Barnes, 1997.
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Aims
The primary aims of this study were to investigate the mechanism of phagocytosis of
apoptotic cells, principally by characterising pathways involved in augmented
clearance of apoptotic cells elicited by long-term glucocorticoid treatment of
peripheral blood monocyte-derived macrophages during in vitro culture. When these
studies were initiated, the regulation of cytoplasmic modulators of phagocytosis of
apoptotic cells was largely uncharacterised. Experimental evidence concerning the
uptake of IgG and complement opsonized particles suggested a role for adhesion and
adhesion signalling components in the regulation of these processes. Glucocorticoids
have been shown to alter dendritic cell maturation, and exert immunomodulatory
effects on macrophage function, including induction of alternatively activated cells.
Considering the central role of apoptotic cell clearance in resolution processes we
also sought to assess the effect of glucocorticoids on macrophage differentiation and
the potential wider ranging effects on immune function. Specifically we asked:
1. What were the effects of glucocorticoid treatment on putative phagocytic
receptor expression and function?
2. What were the effects of glucocorticoid treatment on macrophage adhesion and
cytoskeletal organisation?
3. How do glucocorticoids influence monocyte differentiation in vitro and the
responses to polarising immune cytokines.
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CHAPTER 2: MATERIALS AND METHODS
Antibodies and other reagents
Reagents were obtained from Sigma (Poole, UK) unless otherwise stated. Iscove's
DMEM (IDMEM) was from Gibco BRL (Paisley, UK). Dextran and Percoll™ were
from Amersham Pharmacia Biotech, (Buckingham, UK). Dexamethasone was
obtained from David Bull Laboratories (Warwick, UK). Primary antibodies were
from the following sources: pl30cas, paxillin, Pyk2, Rac and RC-20 (anti-
phosphotyrosine) mAb were from Transduction Laboratories (supplied by Becton-
Dickinson, Oxford, UK). Mannose receptor was from Pharmingen (supplied by
Becton-Dickinson, Oxford, UK). HA monoclonal, CrkL and C3G rabbit polyclonal
antibodies were from Santa Cruz (supplied by Insight Biotechnology, Wembley,
UK). mAb specific for CD44v3 (3G5), (31 (12G10) and class II (WR18) were from
Serotec (Oxford, UK). Control mouse immunoglobulins (IgGland IgG2a), BerMac3
(CD 163) and rabbit immunoglobulins, and F(ab')2 goat anti-mouse immunoglobulin
FITC and HRP conjugates were from DAKO (Cambridge, UK). The following
monoclonals were generously provided as gifts: 5A4 (CD44 - Dr. Graeme
Dougherty, UCSF, CA), sm(j) and 15.2 (CD36 and CD54 respectively - Dr. Nancy
Hogg, ICRF, London), 23C6 (CD51/61 - Dr. Mike Horton, UCL, London), PM6/13
(CD61 - Dr. Mike Wilkinson, Wellcome Trust, UK), 3G8 (CD16 - Dr. Jay Unkeless,
Mount Sinai Medical School, New York), UCHM1 (CD 14 - Dr Peter Beverley,
UCL, London), 61D3 (CD 14 - Prof. Chris Gregory, Nottingham, UK). Secondary
anti-rabbit HRP was from Amersham Pharmacia Biotech. Goat anti-mouse and goat
anti-rabbit-Alexa™ conjugated secondary antibodies were supplied by Molecular
Probes (Oregon, USA).
Cell Isolation
Mononuclear and polymorphonuclear leukocytes were isolated as previously
described (Hart et al., 1997). In brief, freshly drawn peripheral blood from healthy
volunteers (typically 160ml) was collected into sodium citrate (Phoenix
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Pharmaceuticals Ltd., Gloucester, UK) (final concentration 0.38%) into 50ml Falcon
tubes, and centrifuged at 350 x g, for 20 min, resulting in an upper fraction (platelet-
rich plasma) which was removed for preparation of autologous serum (see Cell
culture) and a lower cell pellet. Erythrocytes were removed by sedimentation with
0.6% (w/v) dextran T500 (2.5ml dextran/lOml cell pellet, made up to 50ml total
volume with saline) for approximately 30 minutes at room temperature. The upper
leukocyte rich layer was then removed, made up to 50 ml with saline to remove
excess dextran and centrifuged at 350 x g, for 6 min. Leukocytes were then
fractionated on a discontinuous Percoll™ gradient (two gradients sufficient to
separate up to 160ml of blood). Percoll was made isotonic with 10X PBS (90%
solution) and gradients prepared by overlaying 2.5ml of each Percoll 73%/63%/50%
gradient. Bottom layer 73%: 4.05ml 90% Percoll, 0.95ml PBS (w/o Ca2+/Mg2+);
middle layer 63%: 3.5ml 90% Percoll, 1.5ml PBS (w/o Ca2+/Mg2+); bottom layer:
pelleted cells resuspended in 2.5ml 50%: 2.75ml 90% Percoll, 2.25ml PBS (w/o
94- 9+
Ca /Mg ), then centrifugation at 720 x g for 20 min at room temperature. MNC
were aspirated from the 50/63% interface, and PMN from the 63/73% interface, with
residual erythrocytes pelleted at the bottom. Leukocytes were washed three times in
PBS (w/o Ca2+/Mg2+) before culture, and assessment of purity and neutrophil
activation status (see Quality control)
Cell Culture
Neutrophils were resuspended at 4xl06cells/ml in IDMEM containing 10%
autologous serum (prepared by re-calcification of platelet rich plasma, 220pl of 1M
CaCL/lOml plasma, final concentration 22mM) and cultured at 37°C in a 5% CO2
atmosphere for 20h in Falcon tissue culture flasks. Alternatively neutrophils were
resuspended in IDMEM at 20xl06/ml and incubated with 2pg/ml (final
concentration) CellTracker™ Green 5-chloromethylfluorescein diacetate (Molecular
Probes, Oregon, USA), 20 min, 37°C; then incubated for 20h in autologous serum as
before.
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MNC were plated at 4xl06/ml in IDMEM and incubated for 30-60 min, at 37°C, 5%
CO2, after which non adherent lymphocytes were removed by washing 3-4 times
with HBSS (without Ca2+/Mg2+). The resulting monocyte monolayer was cultured
for a period of five days in IDMEM plus 10% autologous serum, ± ljiM
dexamethasone. The resulting cells showed increased expression of CD 14, CD 16,
and the otvP3 integrin, and were negative for myeloperoxidase activity, characteristic
of a macrophage phenotype.
Quality control
Mononuclear cell and polymorphonuclear cell preparations were assessed for purity
by flow cytometry. Figure 1 shows the light scatter profiles of mononuclear, and
polymorphonuclear cell preparations using either an EPICS Profile II (Beckman-
Coulter, High Wycombe, UK) or a FACScaliber (Becton-Dickinson, Oxford, UK)
flow cytometer. Mononuclear and polymorphonuclear cell preperations were
routinely above 95% purity.
Characterisation of neutrophils apoptosis
After culture for 20h in autologous serum, neutrophil populations were >50%
apoptotic as determined by morphological analysis and Annexin V binding, and <5%
necrotic as defined by propidium iodide exclusion (fig. 2). Neutrophils (4xl06/ml)
were cytocentrifuged at 300rpm, 3min, fixed with 100% methanol and visualised
with Diff-Quick™ staining and lOOx oil immersion light microscopy. Viable cells
contained the characteristic neutrophil multi-lobed nuclear morphology compared to





Figure 1. Purity of leukocyte preparations
Mononuclear and polymorphonuclear cells were isolated from peripheral blood via
dextran sedimentation followed by separation on a discontinuous Percoll™ gradient.
Laser scatter properties of cell populations were assessed by flow cytometry.
A mononuclear cell fraction. B Polymorphonuclear fraction. Purity ratios for panel
A, monocytes: 32.6%, lymphocytes: 62.9%, neutrophils: 1.1%; for panel B,
monocytes 0.5%, lymphocytes 1.4%, neutrophils 94.8%.
39
Annexin V binding andPIstaining
190pl of a 1:500 dilution of Annexin V-FITC was added to lOjal of neutrophil
suspension, incubated for 10 min, room temperature, lpl of lmg/ml PI was added to
the cell/Annexin V mix and immediately analysed by flow cytometry for Annexin V
binding on FL-1 and PI exclusion on FL-2.
Macrophage Phagocytosis assay
Monocyte-derived macrophages were cultured in 48 well tissue culture plates as
described above for five days in the presence or absence of DX, or lOpM RU38486
for varying periods of time. Apoptotic neutrophils were washed once in IDMEM to
remove serum and resuspended in IDMEM at 4xl06/ml. Macrophage monolayers
were washed once in IDMEM then overlaid with a "lawn" of apoptotic neutrophils,
and incubated at 37°C, 5% C02, for 20 minutes.
Plate based assay
After the incubation at 37°C, ingested neutrophils were removed by washing 2-3
times with IDMEM. Monolayers were then fixed in 2.5% glutaraldehyde (in PBS),
20 min, room temperature, after which ingested neutrophils were visualised by
staining for myeloperoxidase activity with 0.lmg/ml dimethoxybenzidine (in H2O)
and 0.03% (v/v) hydrogen peroxide (20 min, room temperature). The percentage of
macrophage phagocytosis was quantified microscopically by counting at least 500
cells per well from randomly selected fields, and an average between the duplicate
wells calculated (fig 3). Phagocytic index was calculated as (average number of
neutrophils phagocytosed per macrophage) x (% macrophages that had phagocytosed



















Figure 2. Assessment ofNeutrophil apoptosis
Peripheral blood neutrophils were cultured for 20 hr in IDMEM containing 10%
autologous serum. Neutrophil viability was determined by assessment of
morphological characteristics in cytocentrifuge preparations, and flow cytometric
analysis of Annexin V binding and propidium iodide exclusion. A Freshly isolated
neutrophils, note the high percentage of viable cells containing multi-lobed nuclei. B
Aged neutrophils, apoptotic cells are characterised by the presence of pyknotic nuclei
(condensed rounded), indicated by *. Flow cytometric profiles of Annexin V
binding. C Viable cells demonstrate low AnnexinV binding. D Aged neutrophils,
approximately 55% Annexin V positive. E Necrotic neutrophils generated by
incubation at 70°C, 10 minutes, populations were 98% positive for propidium iodide
inclusion. F Aged, non-necrotic neutrophils, 97% propidium iodide negative.
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Figure 3. Quantitation ofmacrophage phagocytosis of apoptotic neutrophils
Following incubation with apoptotic neutrophils the percentage of cells ingesting
apoptotic particles was assessed. A Ingested neutrophils were visualised by staining
for myeloperoxidase activity, followed by microscopic analysis (Panel shows
phagocytosis after glucocorticoid stimulation). B Cytocentrifuge preparation
demonstrating intemalisation of apoptotic cells. C Flow cytometric analysis of cell-
tracker green™ fluorescently labelled aged neutrophils. D Macrophages ingesting
cell-tracker green™ labelled neutrophils. Gate R1 corresponds to macrophages
demonstrating high fluorescence and therefore uptake of neutrophils. Note the
population of macrophages with intermediate levels of fluorescence, which is




After incubation at 37°C, media was aspirated from wells directly and replaced with
500pl of Trypsin-EDTA. Cells were then incubated at 37°C for 20 min, then 4°C for
30min, followed by rigorous pipetting on ice to ensure removal of all adherent cells.
The percentage macrophages phagocytosing apoptotic particles was assessed by flow
cytometry. Macrophage populations were gated on forward and side scatter
characteristics, and the percentage of cells within this population demonstrating
green fluorescence due to the uptake of labelled neutrophils was calculated (fig 3).
Double staining for neutrophil markers prior to flow cytometric analysis
demonstrated that trypsinisation was sufficient to remove neutrophils bound to
macrophages and the green fluorescence corresponded solely to uptake of fluorescent
particles (H. Jersmann et al., manuscript in preparation).
Assessment ofCD44 augmentedphagocytosis ofapoptotic neutrophils
Macrophages were washed once with IDMEM, then incubated for 15 min at 37°C,
5% CO2 with CD44 mAb 5A4 (1:5 dilution of hybridoma supernatant). Cells were
washed twice to remove antibody prior to addition of apoptotic cells as described
above.
Inhibition ofmacrophage phagocytosis
Macrophages were washed once with IDMEM, then incubated for 15 min at 37°C,
5% CO2 with phagocytosis inhibitors (RGDS/RADS, 0.5mM; sm(j), 1:50 ascites;
glucosamine, lOmM; mannan, 200pg/ml; My4, lOpg/ml; phospho-L-serine, 2mM;
dextran sulfate, 200pg/ml; fucoidan, 500pg/ml; glyburide, 100pM). Apoptotic cells
were then added to a final concentration of 4xl06/ml without removal of inhibitor
(except for sm(|) and My4 antibodies), and assessed as for the plate based assay.
Controlsfor inhibitors
All mAb used have previously been shown to inhibit apoptotic cell phagocytosis and
were used at concentrations that were deemed to be saturating by flow cytometry.
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The following inhibitors were found to be functionally active at concentrations used
in this study. RGDS (integrin inhibition peptide) was shown to inhibit a5pi integrin
mediated adhesion of T lymphocytes to fibronectin. Phospho-L-serine was shown to
inhibit binding of FITC-conjugated Annexin V to apoptotic neutrophils in flow
cytometric analysis. Concentrations required to inhibit Annexin V binding were
higher than that used for inhibition of apoptotic cell uptake due to the high binding
affinity of Annexin V for PS residues compared to macrophage cell surface
receptors, (fig. 4a). Dextran sulfate and fucoidan inhibited uptake of acetylated-
LDL by monocyte-derived macrophages (fig. 4b). Other reagents (glyburide,
mannan, and glucosamine) were used at concentrations that have previously been
shown to exert inhibitory effects.
Flow cytometry
Flow cytometry was performed essentially as described (Dransfield et al., 1994).
Monocyte-derived macrophages were cultured for 5 days ± 1 pM DX in 6-well tissue
culture plates as described above. Cells were washed once in PBS (w/o Ca2+/Mg2+)
then incubated on ice in 2.5mM EDTA plus 0.5% serum (v/v) in PBS (w/o
2+ / ?+Ca /Mg ) for 30-40 min, followed by pipetting to dislodge adherent cells. Cells
were then washed with ice cold PBS containing 0.2% (w/v) bovine serum albumin
and 0.1% (w/v) sodium azide (PBN), to remove EDTA, and 105/cells/assay pelleted
in 96-well flexiwell plates by spinning at 300 x g for 3 min at 4°C. All subsequent
incubations were carried out on ice to prevent internalisation of antibody. Cells were
resuspended and pre-incubated for 10 minutes with 20% (v/v) normal rabbit serum to
block non-specific binding to Fey receptors. Cells were then incubated with
saturating concentrations of mAb for 30 minutes and washed twice in PBN prior to
incubation with FITC-conjugated F(ab')2 goat anti-mouse immunoglobulin (DAKO)
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(1:40), for 30 min and washed twice more before analysis using either an EPICS
Profile II (Beckman-Coulter, High Wycombe, UK) or a FACScaliber (Becton-
Dickinson, Oxford, UK) flow cytometer.
Electron Microscopy
Macrophages cultured on glass coverslips in the presence or absence of lpM
dexamethasone for 5 days were fixed with 3% gluteraldehyde in 0.1M sodium
cacodylate buffer pH7.4 for 3h, and post fixed with 1% osmium tetroxide in 0.1M
cacodylate buffer for 2h. After dehydration in an ascending acetone series, and
critical point drying with CO2, samples were sputter coated with 20nm
gold/palladium and examined using a Phillips 505 scanning electron microscope.
Immunofluorescence
Monocyte-derived macrophages were cultured on glass cover slips, in 12-well tissue
culture plates for 5 days ± lpM DX as described above. Cells were washed once
with IDMEM to remove serum proteins, then fixed in 3% paraformaldehyde (PFA)
in PBS, for a minimum of 20 min at room temperature. PFA was removed by
washing twice in TBS (lOmM Tris, lOOmM NaCl pH 7.5), then permeabilised by
incubation with TBS containing 0.1% NP-40, for 4 min, detergent was then promptly
removed by washing twice with TBS. Non specific binding was blocked by
incubation with TBS containing 10% pooled human AB, 15 min, room temperature,
after which the primary antibody was applied in TBS plus 1% human AB for lhr,
gently rocking. Non-bound primary antibody was removed by washing 3 times with
TBS plus 1% human AB serum, 5 min rocking, before application of Alexa™ dye-
conjugated secondary antibody, in TBS plus 1% human AB, lhr, rocking. Cells
were again washed x3 in TBS plus 1% human AB, before mounting in either 50%
glycerol, or AntiFade™ reagent (Molecular Probes, Oregon, USA), protocol as
manufacturers instructions. Slides were then examined by fluorescence microscopy,
and images captured using AppleMac OpenLab image capture system.
45
control -



















~i—i i ffnii 1—i i 11 rniA—i—i i 1111







I I I I MTU I I I I I I 11! I I TTT




11 in i—i i i 11 in 1—i m









'V i ii M 111 1—i i i 11
10 100 1000
LFL1
Figure 4. Validation of inhibitors
To demonstrate the functionality of inhibitors of phosphatidylserine receptor and
scavenger receptors we assessed the inhibition of FITC-conjugated Annexin V
binding to apoptotic neutrophils with phospho-L-serine, and inhibition of
macrophage uptake of dil labelled-acetylated LDL with dextran sulfate and fucoidan
by flow cytometry. A Profile of Annexin V binding (at sub-saturating concentration,
1:2500) to apoptotic neutrophils in the presence of 2-20mM phospho-L-serine. B
Macrophage uptake of dil-acLDL (lpg/ml) in the presence of 200pg/ml dextran
sulfate, and 500pg/ml fucoidan.
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Immunoprecipitation and western blotting
Monocyte-derived macrophages were cultured for 5 days ± 1 pM DX in 6-well tissue
culture plates as described above. Cells were washed with TBS containing O.lmM
NaVC>3 plus protease inhibitor cocktail (Boehringer Mannheim, Germany), and lysed
by incubation with 150pl/well of lysis buffer (TBS:10mM Tris, lOOmM NaCl pH
7.5; 1% NP-40 (v/v), O.lmM NaVCb, and protease inhibitor cocktail), or 120pl RIPA
buffer (for composition see Rac assay), 10 minutes on ice. Membrane and nuclear
material was removed by centrifugation at 14,000 x g, 4°C, for 30 minutes, and
supernatants were "pre-cleared" of macrophage Fc receptors by incubation with
protein-A agarose-coupled rabbit anti-mouse IgG, 4°C, 30 min, followed by
centrifugation at 15,000 x g, 3 min, 4°C (immunoprecipitations only). lOpl of lysate
was removed and protein concentration estimated using a detergent compatible
protein estimation kit (Pierce, Illinois, USA) (protocol as manufacturers
instructions). Lysates were equilibrated to contain equivalent levels of protein by
dilution with additional lysis buffer, and lOOpl of lysate (100-150pg total protein)
was incubated with 1 pg of either mouse IgG control, anti-paxillin or pyk2 mAb, at
4°C, for 30 minutes, shaking. Immune complexes were precipitated by incubation
with 15pl of protein-A coupled rabbit anti-mouse IgG (Sigma), 30 min, 4°C,
shaking. Immunoprecipitates were washed twice in TBS pH7.5 plus 0.1% Triton X-
100, for removal of proteins non-specifically bound, and once in 25mM Tris pH 8.0
plus 0.05% SDS, to remove salt. Samples were then boiled for 5 min in 15pl of 2x
reducing buffer (0.5M Tris pH6.8, 4% w/v SDS, 30% v/v glycerol, 0.1% w/v
bromophenol blue, 1% P-mercapthoethanol), resolved on a 9% polyacrylamide gel
(37.5mM Tris pH8.8, 0.1% w/v SDS, 0.2% w/v TEMED, 0.04% w/v APS) under
reducing conditions (0.1 % (3-mercaptoethanol), and transferred electrophoretically
(50V for 1 hour) onto nitrocellulose (Amersham Pharmacia Biotech) in 25mM Tris,
192mM glycine pH8.3, 20% w/v methanol. For detection of phosphotyrosine,
membranes were blocked with TBS plus 0.05% Tween-20 (TBS-T) all other blots
with TBS-T plus 10% non-fat dried milk powder (w/v).
For antibody concentrations see individual figure legends.
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Assay for detection of activated Rac
Adherent macrophage cultures were lysed in RIPA buffer (50mM Tris pH 7.2,
500mM NaCl, lOmM MgCh, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1%
SDS) containing protease inhibitor cocktail (Boehringer Mannheim, Germany) plus
ImM PMSF. Lysates were cleared of membrane and nuclear material by
centrifugation, total protein was estimated and levels equilibrated as described for
immunoprecipitation. 20pl of lysate was removed for estimation of total Rac protein
and the remaining protein (approximately300p,g) was incubated with GST-PAK
(CRIB) fusion protein coupled to Sepharose beads, 4°C, lhr, shaking. Beads were
washed 4 times in ice-cold Tris buffer (50mM Tris pH7.2, 150mM NaCl, lOmM
MgCh, 1% Triton X-100, protease inhibitor cocktail, ImM PMSF), and the amount
of active Rac bound to PAK CRIB domain quantified by SDS PAGE and western
blotting as described for immunoprecipitation.
RNA isolation and RT-PCR
Macrophages were washed once in ice-cold PBS, lysed and RNA extracted using
Trizol (Gibco BRL, Paisley, UK) (protocol as manufacturer's instructions). RNA
was DNAse treated to remove genomic DNA for lh, 37°C, and the resulting RNA
used in RT-PCR reactions using Gibco One step™ RT-PCR kit (protocol as
manufacturers instructions). Reactions proceeded for 35 cycles, with annealing at
53°C for M-DOCK, DOCK180 and hABCl, 54°C for hCed6; and 53/54°C for Actin.













A 2.7kb transcript corresponding to the coding region of pl30cas was amplified from
pUNI-V5-His-pl30cas plasmid using Proofsprinter™ DNA polymerase (Hybaid-
AGS, UK), protocol as manufacturers instructions. In brief, reaction mix (50pl total)
contained 5pl lOx buffer, 0.1% Tween-20, 2% DMSO, 400nM 5' primer, 400nM 3'
primer, lOng template, dNTP-Mix (200pM each nucleotide, final concentration), 2.5
units Taq/Pwo Mix, ddfUO as required. The following cycling conditions were





PCR fragments were purified either directly from the reaction mixture or run on a
TAE (Tris-acetic acid-EDTA) buffered 1% agarose gel to separate bands, the specific
bands excised using a clean scalpel blade, then purified using QIAquick spin
columns (Qiagen, Crawley, UK), protocol as manufacturer's instructions.
Restriction Digest
DNA was digested in a total volume of 30-50pl, depending on the amount of
material, using 0.5-1 pi of restriction enzyme per reaction(Promega, Southampton,
UK), in addition to 3-5pl lOx reaction buffer, for 2hr, at 37°C.
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A Tailing
Volumes for one reaction, but may be scaled up depending on the concentration of
the PCR product. 7pl of PCR fragment, 1 jul lOx Taq DNA Polymerase buffer
containing MgCh (final concentration 2.5mM), lpl dATP (final concentration
0.2mM), lpl (5 units) Taq DNA polymerase, were incubated for 30 min at 70°C.
Tailed PCR product was then purified using a PCR spin column to remove Taq, and
dNTPs that may inhibit consequent ligation reactions.
Ligation Reaction
Plasmid-insert ligations were carried out in a total volume of lOpl, in 0.5 ml
eppendorf tubes to minimise adsorbance of DNA to the tube. "Sticky-ended"
reactions were incubated as a 3:1 insert:vector ratio, "blunt-ended" ligations as a 4:1
ratio, calculated using the equation below, in a reaction mix containing 1 pi lOx
ligation buffer, lpl (5 units) ofDNA ligase, overnight at 4°C.
(ng of vector x kb size of insert)/ (kb size of vector) x (insert:vector ratio) = ng of
insert
Preparation ofcompetent cells
A single colony of the E.coli strain, TOP 10 was picked and incubated O/N in 10 ml
of antibiotic free LB media (1% w/v bacto-tryptone, 0.5% w/v bacto-yeast extract,
1% w/v NaCl, pH 7.0), at 37°C, 220rpm. 100ml of LB medium was inoculated with
lml of the overnight culture, and shaken at 37°C until an OD600 of between 0.6-0.8
was reached. Cells were pelleted by centrifugation at 5,000 xg, 5 min, at 4°C,
supernatant discarded, and the pellet resuspended on ice, in ~50ml of ice cold
lOOmM CaCh. Cells were pelleted again at 4°C, then resuspended in 4mls of
lOOmM CaCb, on ice. Competent cells retained activity for approximately 10 days
when stored at 4°C.
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Bacterial Transformation
Transformation of BL-21s (Stratagene, La Jolla, USA). A 50pl aliquot of cells was
incubated with p-mercaptoethanol (final cone 25mM), for 10 min on ice, with gentle
mixing every two minutes. 1 pi of plasmid DNA was then added, and cells incubated
for a further 30mins on ice. Cells were then heat-shocked by incubation at 42°C for
50 sec, followed by incubation on ice for a further 2 min. 450pl of SOC medium
(Stock: 2% w/v bacto-tryptone, 0.5% w/v bacto-yeast extract, 0.05% w/v NaCl,
2.5mM KC1, immediately prior to use add MgCh (lOmM final cone) and glucose
(20mM final cone)) was then added to the transformation, and cells shaken at
220rpm, 37°C for 1.5 hours. Cells were then pelleted and resuspended in 200pl
SOC, andlOOpl of the culture was plated on LB agar containing lOOpg/ml ampicillin,
and incubated O/N at 37°C. BL-21 have a poor transformation efficiency, therefore
TOP10 E.coli strain was used for cloning. Transformation of TOP10 was carried out
as described above except P-mercaptoethanol was not included, 5-lOp.l of ligation
reaction was incubated with cells, and TOPlOs heat shocked for 60-90 sec. To
enable blue/white selection for vector insert during cloning of PCR products,
ampicillin plates were spread with 20pl of IPTG (lOOpg/ml), plates incubated for 30
min at 37°C to allow absorption, then 35pl of X-gal (50mg/ml), and plates incubated
for 30mins prior to plating of bacteria.
Mini prep ofplasmid DNA
Single colonies were picked and incubated in 2mls LB broth containing lOOpg/ml
ampicillin, O/N, 37°C, 220rpm. Cells from 2mls of culture were pelleted by
centrifugation at 5,000 x g, 5 min, in 2ml eppendorfs, and plasmid DNA extracted
using Promega Wizard™ mini-prep kit (protocol as manufacturers instructions).
Midi prep ofplasmid DNA
A single bacterial colony from freshly streaked plates was picked and a starter
culture grown in 3mls of LB broth plus antibiotics, for ~8 hrs or O/N in lOmls of LB
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plus antibiotics, 37°C, 220rpm. Approximately lOOpl of the starter culture was then
used to inoculate 25mls of LB broth containing ampicillin, cells were grown O/N,
37°C, 220 rpm. Bacteria were harvested by centrifugation at 5,000 x g for 10 min at
4°C, and DNA extracted using Qiagen Plasmid Midi purification kit (protocol as
manufacturers instructions). In brief, cells were resuspended in a Tris-EDTA buffer
containing RNase A, and lysed by the addition ofNaOH and SDS. Genomic DNA,
protein, other cell debris and SDS was removed by precipitation with potassium
acetate pH5.5, and centrifugation at 10,000 x g, 15min. The resulting supernatant
was applied to a column pre-equilibrated with a low salt buffer at neutral pH, which
allowed binding of plasmid DNA to anion exchange resin. Plasmid DNA was then
eluted with a high salt buffer, and isopropanol precipitated.
Primer Design
Primers were designed either with Primer3 program http://www-
genome.wi.mit.edu/cgi-bin/primer/primer3 www.cgi or by eye using the following
considerations. Primers were -20 nucleotides in length for sequencing, and RT-
PCR, and -25 nucleotides for insertion of cloning sites, with a GC content of 40-
50%, and melting temperature (Tm) of around 60°C, calculated by the formula: Tm =
69.3 + (0.41 x GC%) - (650 / length). Primers were checked for homology to other
sequences by BLAST analysis of nucleotide sequence database
http://www.ncbi.nlm.nih.gov/BLASTA and scanned by eye to ensure no intra or
inter-primer annealing would occur.
Sequencing: pl30cas construct was sequenced using an ABI sequencer by Nina










Production of Fusion Proteins
Isolation ofhigh expressing clones
pTAT-HA-pl30cas and pTAT-HA-Pgal were transformed into E.coli strain BL21 as
described above, and plated onto LB agar containing 100pg/ml ampicillin. Six
colonies from each transformation was selected and grown in 2 ml LB broth plus
lOOpg/ml ampicillin, O/N. The following day 5mls of LB broth plus ampicillin was
inoculated with 500pl of O/N cultures, and incubated at 37°C, 220 rpm until
OD6oo=0.5. Protein expression was induced by the addition of IPTG to a final
concentration of ImM (stock lpM in dimethylformamide), followed by incubation at
37°C, 220 rpm, for 5hrs. Cells were harvested by centrifugation at 4,000 x g, 20min,
4°C. Cell pellets were resuspended in 400pl of lysis buffer (lOOmM NaH2P04,
lOmM Tris, 8M urea, pH 8.0) by vortexing at room temperature, until solutions were
translucent, and clarified by centrifugation at 10,000 x g, 30 min. Supernatants were
then incubated with 10pl ofNi-NTA slurry (Qiagen, Crawley, UK), pre-equilibrated
with lysis buffer, shaking for lhr at room temperature. Ni-NTA beads were pelleted
at 15,000 x g for 3 min, and washed twice with buffer C (lOOmM NafBPCL, lOmM
Tris, 8M urea, pH 6.3), followed by resuspension in SDS-PAGE loading buffer.
Samples (plus aliquots of whole cell lysates prior to purification and buffer C wash
for comparison) were then analysed by SDS-PAGE and either western blotting with
mAb specific for pl30cas and the HA epitope, or direct staining of acrylamide gels
with Coomassie-brilliant blue dye.
Bulkproduction ofTAT-fusion proteins: His-Tagpurification
A single colony from freshly streaked plates was picked and grown O/N in 10 ml LB
broth plus ampicillin for both pl30cas and P-gal fusion proteins. 500ml and 1L of
LB-broth containing ampicillin was inoculated with 5ml and 10 ml of P-gal and
pl30cas starter cultures respectively. Cultures were incubated at 37°C, 220 rpm,
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until an OD600 of 0.5 was obtained. Cultures were then induced to express protein
with IPTG (final concentration ImM) for 5 hours, after which cells were harvested
by centrifugation at 4,000 x g, 20min, 4°C, supernatants removed, and pellets stored
O/N at -20°C. Pellets were thawed on ice, resuspended in lysis buffer plus lOmM
imidazole (to minimise non specific binding), at 5ml per gram wet weight for (3-gal
expressing cultures, and 2.5ml per gram for pl30cas cultures, as this fusion protein
did not appear to be expressed as efficiently as [3-gal. To ensure complete lysis, cells
were stirred for 60 min at room temperature, or until the solution became translucent,
before clarification of lysates by centrifugation at 10,000 x g for 30 min. Cleared
lysates were then incubated with 1ml of the Ni-NTA slurry (pre-washed with lysis
buffer) per 4ml of lysate for lhr, room temperature, shaking. After fusion protein
binding, the resin/lysate mix was decanted into a disposable syringe barrel pre¬
packed with 0.5-1 cm of nylon wool. Lysate was allowed to pass through by gravity
flow, such that the Ni-NTA beads sedimented with fluid flow, creating a resin
column. The column was washed with lysis buffer until the OD280 of the elutant was
<0.01, followed by buffer C, until OD2so= <0.01. Fusion protein was then eluted 4
times with 2ml of buffer D (lOOmM NaFLPCL, lOmM Tris, 8M urea, pH 5.9) which
elutes monomeric proteins, followed by 4 x 2ml elutions with buffer E (lOOmM
NalLPCL, lOmM Tris, 8M urea, pH 4.5) which elutes multimers. Samples from
each step were analysed by SDS-PAGE together with western blotting, or
Coomassie-blue staining of acrylamide gels.
Purification offusion proteins by ion-exchange
Pooled fractions of fusion proteins from the Ni-NTA column were diluted with
HEPES buffer and NaCl to a final concentration of 4M urea, and 50mM NaCl.
Samples were applied to a 10ml Q-sepharose column pre-equilibrated with 40ml of
low salt buffer (50mM NaCl, 20mM HEPES, pH 8.0), and allowed to pass through
by gravity flow. The column was washed once with 40ml low salt buffer, and
protein eluted into 1ml fractions with 20ml high salt buffer (1M NaCl, 20mM
HEPES), in twenty 1ml fractions. 2 jil of each fraction was spotted onto nitro¬




Pooled fractions from the Q-Sepharose column were concentrated using Centricon®
centrifugation filter columns (Millipore, Massachusetts) (protocol as manufacturer's
instructions), to a volume of 2.5ml. Protein samples were then applied to a
disposable PD-10 desalting column (Amersham Pharmacia Biotech. (Buckingham,
UK)), pre equilibrated with PBS, eluted in PBS and flash frozen in 15% glycerol.
Proteins were stored at -80°C before application to cells
Protein Transduction into macrophages
Peripheral blood monocyte derived macrophages were matured by adherent culture
for five days ± lpJVf dexamethasone in 48 well culture dishes, as described in cell
culture. Macrophages were washed once in IDMEM before incubation with
lOOpl/well of pure fusion protein for 15-60 min at 37°C, 5% CCF. For assessment of
protein transduction, supernatants were removed and retained, macrophages washed
once in IDMEM, lysed with RIPA buffer and protein transduction assessed by SDS-
PAGE and western blotting with mAb specific for pl30cas and HA as described
previously. Alternatively to assess the effect of fusion proteins on macrophage
phagocytic capability, after removal of protein supernatants, macrophages were
incubated directly with apoptotic neutrophils without washing to limit cell loss in
DX-treated cultures. Phagocytosis was then assessed using the flow cytometric
assay as described above.
Statistical analysis
Data were analysed using the GraphPad Instat statistical analysis package. Tests
were chosen on the assumption that data were paired, as control and treatment groups
were obtained from the same donor, and were from a non-Gaussian distibution.
Figure 2, chapter 3 demonstrates the variability of phagocytosis between individual
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donors, which we did not regard as being from a normal distribution. For
comparison of two data sets a Mann-Whitney test was used and for comparison of
multiple data sets a Freidman Test with post test (a repeated measures ANOVA) was
chosen. Data describing the cell surface phenotype of DX-treated macrophages was
normalised and presented as a percentage of control. For analysis of this data we
used a students T-test for analysis, as the data was paired and we assumed were from
a population with normal distribution.
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CHAPTER 3: CHARACTERISATION OF THE EFFECT OF
GLUCOCORTICOIDS ON MACROPHAGE PHAGOCYTOSIS OF
APOPTOTIC NEUTROPHILS
Introduction
The normal resolution of inflammation requires both the induction of apoptosis of
extravasated cells and the swift removal of cellular corpses by macrophages or other
resident phagocytes in a non-phlogistic manner (Akbar et al., 1994; Fadok et al., 1998a;
Meagher et al., 1992; Newman et al., 1982; Savill et al., 1989). However The
pathogenesis of a number of diseases such as asthma, emphysema, and rheumatoid
arthritis are characterised by the persistence of inflammatory cells (Haslett et al., 1994;
Weiss, 1989). Dysregulation in either apoptosis or phagocytic clearance may result in
the accumulation of inflammatory cells, or secondary necrosis of non-ingested apoptotic
cells, potentiating the initial inflammatory insult. Modulation of cell apoptosis programs
or macrophage phagocytic capacity for clearance would therefore be of great therapeutic
benefit. Cytokines such as TNF, GM-CSF, TGF-(3 or IL-1 have been demonstrated to
augment phagocytosis of apoptotic cells (Ren and Savill, 1995). However the effects of
these cytokines on uptake were small and the pleiotropic consequences of some of these
agents may restrict their potential therapeutic value. Glucocorticoids are often used for
the treatment of many inflammatory conditions due to their capacity for inhibition of
inflammatory cell recruitment, and down-regulation of the production and
responsiveness of cells to pro-inflammatory cytokines (Schleimer, 1993). In addition
they have been shown to differentially modulate granulocyte cell fate (Cox et al., 1995;
Meagher et al., 1992). Glucocorticoids reduce the number of circulating eosinophils in
patients with hypereosinophilia, and induce eosinophil apoptosis in vitro (Meagher et
al., 1992). In contrast dexamethasone prolongs neutrophil survival in vivo and in vitro
(Cox et al., 1995; Meagher et al., 1992). The induction of eosinophil cell death would
account for the profound resolving properties of glucocorticoids, however we would
predict that inhibition of neutrophil cell death would not promote resolution, but may
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exacerbate an inflammatory response. Death induction must be accompanied by swift
clearance by phagocytes, a large induction of apoptotic particles may overwhelm a
tissue's phagocytic capacity as seen in mice treated with anti-Fas mAb (Ogasawara et
al., 1993). Recent research in C.elegans suggests that engulfment promotes cell death
(Hoeppner et al., 2001; Reddien et al., 2001), and uptake of apoptotic neutrophils by
human macrophages can induce cell death in bystander leukocytes (Brown and Savill,
1999). A delay in neutrophil phagocytosis may allow further recruitment of peripheral
blood monocyte/macrophages that can then facilitate the triggering of final death
pathways, resulting in efficient removal of extravasated granulocytes before induction of
secondary necrosis. Glucocorticoids can alter gene transcription, either by
transactivation at glucocorticoid response elements, or transrepression of other
transcription factors such as AP-1, and therefore have the capacity to affect expression
and function of potential phagocytic uptake mechanisms. A number of cell surface
molecules have been proposed to mediate the uptake of apoptotic cells (for review see
Giles et al., 2000), these include lectins (Duvall et al., 1985), ocv()3
integrin/CD36/thrombospondin complex (Savill et al., 1990; Savill et al., 1992),
phosphatidylserine receptors (Fadok et al., 2000), scavenger receptors (Piatt et al.,
1996), receptors for oxidised lipids (Chang et al., 1999), CD14 (Devitt et al., 1998),
CD29 (Schwartz et al., 1999), the ABC1 transporter (Luciani and Chimini., 1996) and
receptors for complement components C3bi (CR3/CR4) (Mevorach et al., 1998), and
Clq (Botto et al., 1998). Lui et al. (1999) demonstrated that treatment of human
peripheral blood monocyte derived macrophages, mouse bone marrow-derived, or
thioglycolate-elicited peritoneal macrophages with glucocorticoids for 24 hours
significantly augmented the uptake of apoptotic cells, an effect which was mediated via
the glucocorticoid receptor, and was protein synthesis dependent. More strikingly, their
preliminary evidence showed that the increase in phagocytosis could be further
potentiated by treatment of peripheral blood monocyte derived macrophages for a
prolonged period, up to 4 days. In this chapter we describe the further characterisation
of the effects in phagocyte function elicited by long term glucocorticoid treatment of
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monocyte derived macrophages using the synthetic glucocorticoid dexamethasone, and
assessment of the involvement of previously described phagocytic uptake mechanisms.
Results
Glucocorticoids augment phagocytosis of apoptotic neutrophils in a time and dose
dependent manner
Peripheral blood monocyte-derived macrophages were matured by adherent culture in
the presence of lpM dexamethasone (DX) for varying periods up to 5 days.
Phagocytosis of apoptotic neutrophils by the resulting macrophage population was
assessed (see Materials and Methods for macrophage characterisation). Preliminary
experiments showed that monocyte/macrophages treated for greater than 24 hr detached
from culture plastic during the phagocytosis assay preventing accurate assessment of
phagocytosis. Careful observation revealed that the detachment appeared to be due to
the highly phagocytic nature of glucocorticoid-treated cells. We therefore reduced the
duration of the assay from the previously characterised 30 minute (Liu et al., 1999), to a
20 minute assay (Giles et al., 2001). In agreement with the observations of Lui et al.
phagocytosis was found to increase with duration of steroid treatment (fig. la), with
maximal effect after early inclusion of steroid into the culture medium (untreated:
9.9+0.8%; DX 5d: 39.2+2.7% (mean percent of cells phagocytosing ±SEM, n=68). To
further characterise the effect of early glucocorticoid exposure on macrophage
phagocytic capacity, peripheral blood monocyte derived macrophages were incubated
with 1 pM DX for 24 hr periods, beginning at time zero of initial culture, followed by
removal of steroid and incubation with media only for the remaining duration of
maturation (fig. lb). Exposure to DX during the first 24 h produced a significant
increase in phagocytosis of apoptotic cells, similar to that observed in cultures incubated
with DX for the full 5 days of maturation. Interestingly, the induction in phagocytic
capacity observed with DX treatment from 0-24 hrs was not always as consistent as DX
exposure for 5-days. This observation suggests that although glucocorticoid treatment
of monocytes was able to "program" subsequent macrophage phagocytic capacity, the
59
presence of serum factors also influence macrophage programming in the absence of
glucocorticoids. Analysis of the phagocytic index (a function of the number of cells
phagocytosing within the population, and the number of particles ingested) for cells
incubated with DX for 5 days, demonstrated a seven-fold increase (untreated: 14.1 ±9.3
(SEM), DX: 99.3±14.9 (SEM) n=ll) (fig. lc). We therefore focused our investigation
on five-day DX-treated monocyte/macrophages populations.
Five-day DX treatment consistently augmented macrophage phagocytic capacity above
that of control in each experiment. However, the absolute levels of phagocytosis proved
to be highly variable between experiments and donors (fig 2). Between 1.7 and 37.7%
of cells in untreated populations scored for phagocytosis, whereas in DX treated cultures
these values ranged from 7.4 to 85.6%. Despite such different levels of phagocytosis,
the relative response to varying concentrations of DX was correlative (fig 3), with
maximal phagocytosis reached after ~500nM. Previous observations indicated that the
percentage of apoptotic cells in the phagocytic "meal" (typically 50-80% positive by
AnnexinV staining) did not significantly alter the phagocytic potential of the
macrophage population (S.Hart, personal communication). Furthermore, comparisons
between uptake of apoptotic cells which were syngeneic or allogeneic to the macrophage
population did not appear to account for this variation. For example donor KG recorded
10.2% (control) and 25.7% (DX) phagocytosis of allogeneic targets compared to 8.9%
(control) and 29.1% (DX) uptake of syngeneic cells.
DX augmentation ofphagocytosis of apoptotic neutrophils acts via the glucocorticoid
receptor
In order to investigate if 5-day DX augmented phagocytosis was acting via the classical
glucocorticoid receptor pathway we incubated peripheral blood monocytes with lpM
DX for five days (as previously described) with the addition of 10pM RU38486, a
synthetic antagonist of glucocorticoid receptor signalling. RU38486 inhibited DX
augmented phagocytosis to levels comparable with untreated cultures (fig. 4) (DX:
60
42.9+5.8%; DX+RU38486: 8.1+0.5%, untreated 7.6+1.1 (mean +SEM n=5)),
confirming that the effect of DX was mediated via the glucocorticoid receptor.
Interestingly, RU38486 attenuated baseline phagocytosis in non-DX treated cultures
from 7.6±1.1% to 5.2+1.2% (mean ±SEM). This trend suggested an influence of
endogenous glucocorticoids from autologous serum in the culture medium, possibly
contributing to the variation in phagocytosis observed between donors when monocytes
are cultured in autologous serum alone. As the 5-day DX effect was mediated through
the glucocorticoid receptor it was probable that changes in protein expression elicited
the phagocytic phenotype. We were unable to test this hypothesis by the addition of
inhibitors of translation during the culture period as this prevented normal monocyte to
macrophage differentiation (data not shown). However, the use of synthetic steroids
with predominately transactivating or transrepressing activity allowed us to investigate
this possibility further.
Dexamethasone augmentedphagocytosis ofapoptotic cells requires both transactivation
and transrepression activity ofthe glucocorticoid receptor
DX induces both transactivation and transrepression of gene transcription. In order to
investigate if DX augmented phagocytosis was protein synthesis-dependent we utilised
synthetic glucocorticoids which had previously been characterised to have
predominately transactivational (ZK57740 and ZK77945) or transrepressional
(RU24782 and RU24858) activity (Heck et al., 1997; Vayssiere et al., 1997).
Monocyte/macrophages were cultured for five days (as described above) ± synthetic
steroids, and the effects on phagocytosis of apoptotic neutrophils assessed. At low
concentrations (10-lOOnM) synthetic steroids did not significantly alter phagocytosis of
apoptotic neutrophils (fig. 5). However at lpM both transrepressors and one
transactivator (ZK77945) augmented phagocytosis above control levels, but not to the
same extent as DX, with values for ZK77945 and RU24858 showing statistical
significance. This suggests both glucocorticoid transactivating and transrepressing
activity is required for augmented phagocytosis.
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Dexamethasone treatment (hours)
Figure 1. Effects of dexamethasone on macrophage phagocytosis of apoptotic
neutrophils.
Adherent peripheral blood monocyte-derived macrophages were cultured in the
presence or absence of lpM dexamethasone (DX) for varying periods of time. The
capacity for phagocytosis of apoptotic neutrophils was determined in a 20 minute
assay by microscopic visualisation of myeloperoxidase activity. A
Monocyte/macrophages were incubated with the addition of lpM DX for up to 5
days. Data shown as mean phagocytosis +SEM for 6 separate experiments. B
Monocyte/macrophages were exposed to a 24hr window of glucocorticoid treatment
over a 5-day period. After DX treatment medium was replaced and macrophages
cultured in the absence of steroid. Mean phagocytosis ±SEM, n - 5. C Phagocytic
index (calculated as [average number of neutrophils phagocytosed / macrophage] x
[% macrophages phagocytosing one or more neutrophils] for untreated and 5 day
DX-treated monocyte/macrophages (values taken from mean of a minimum of 500
cells, per well, in duplicate wells ±SEM, n = 5). (*, p < 0.05; **,p < 0.01; <




Figure 2. Phagocytosis levels of untreated and DX-treated macrophages are highly
variable
Adherent peripheral blood monocyte-derived macrophages were cultured in the
presence or absence of lpM DX for 5 days prior to assessment of phagocytic
capacity as described in figure 1. Data distribution of all untreated vs 5-day DX
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Figure 3. Dexamethasone concentration response
Monocyte-derived macrophages were incubated for 5 days in the presence of
different concentrations of DX, and phagocytic capacity for apoptotic neutrophils
assessed as for figure 1. Data shown as mean phagocytosis +SEM, n = 5. (*, p <
0.05; **,p< 0.01; ***,p < 0.001 vs control values, Friedman Test with post test.
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control control + DX DX +
RU38486 RU38486
Figure 4. DX functions through the classical glucocorticoid receptor pathway
Adherent peripheral blood monocyte-derived macrophages were cultured in the
presence or absence of lpM dexamethasone, and lOpM RU38486 for 5 days, and
phagocytosis of apoptotic neutrophils assessed as for figure 1. Data shown as mean
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Figure 5. Effect of synthetic glucocorticoid analogues with predominately
transactivating or transrepressing activity on macrophage phagocytosis of apoptotic
neutrophils.
Adherent peripheral blood monocyte-derived macrophages were cultured in the
presence or absence of varying concentrations of DX or the transactivating
glucocorticoids: ZK57740 and ZK77945, and transrepressing glucocorticoids
RU24782 and RU24858, for 5 days, and phagocytosis of apoptotic neutrophils
assessed as before. Data shown as mean phagocytosis +SEM, n = 3-6 (*, p < 0.05;
**, p < 0.01 vs control values, Friedman Test with post test)
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Increased phenotypic and morphological homogeneity in dexamethasone treated
cultures
A number ofmacrophage cell surface molecules have been implicated in the recognition
of apoptotic cells (see Giles et al, 2000 for review, and chapter 1, table 3). To determine
whether glucocorticoids augmented phagocytosis via an upregulation of previously
described systems, we first assessed the effects of DX upon receptor expression of a
panel of molecules through mAb binding and flow cytometry. Monocyte/macrophages
were cultured for 5-days in the presence or absence of DX as previously described.
Flow cytometric analysis revealed no change in the percentage of cells within the
population expressing phagocytic receptors following DX treatment. However,
expression profiles for several molecules including CD 14 and HLA-DR, appeared more
homogenous after treatment with DX (fig. 6). Analysis of the coefficient of variation for
the fluorescence peaks of each mAb staining confirmed this impression with decreases
in the range of expression of CD14 (108±14; 60±5, n=13), CD16 (96±8; 62±4, n=ll)
HLA-DR (122±11; 96±6, n=10), CD44 (99±15; 66±7, n=6) and CD51 (81±5; 53±4,
n=l 1) (untreated versus DX-treated ±SEM). Additionally, analysis of forward and side
scatter profiles suggested DX-treatment also produced a morphologically more
homogenous population of cells (fig. 6). This effect of glucocorticoid treatment on
macrophage morphology will be explored in chapter 4.
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Figure 6. Increased phenotypic and morphological homogeneity of DX-treated
monocyte/macrophage cultures
Adherent peripheral blood monocyte-derived macrophages were cultured in the
presence or absence of lpM DX for 5 days. Monocyte/macrophage were removed
from culture plastic by incubation with EDTA on ice, and surface phenotype was
examined by indirect immunofluorescence using isotype control, CD44 mAb (5A4)
or CD14 mAb (UCHM1) together with flow cytometry. The profiles (from one of at
least 4 separate determinations) shown here illustrate the more homogeneous laser
scatter properties of DX-treated macrophages . The fluorescence histograms (FL1-H)
for cells within the gates shown illustrate the more uniform cell surface expression of
CD 14 and CD44 following DX treatment. Dotted lines show binding of relevant
isotype controls, solid lines: mAb binding to untreated macrophages, and bold lines:
mAb binding to DX-treated macrophages.
68
Dexamethasone augmented phagocytosis of apoptotic neutrophils utilises multiple
pathways
Comparison of mean fluorescence intensity of mAb binding demonstrated DX-induced
alterations in the levels of cell surface expression of several molecules (table 1).
Changes were not accountable by increased uniformity of expression, as cell surface
markers which exhibited decreases in the coefficient of variation had both augmented
and attenuated mean fluorescence after DX administration. HLA-DR and the
macrophage marker CD16 were slightly elevated after DX treatment, whereas CD44
expression was decreased. CD163, which has homology to the scavenger receptor
family of proteins and previously described as a glucocorticoid-inducible protein, was
considerably increased after DX treatment (189.9±43.4% of control). In contrast,
adhesion molecules ICAM-1 and Pi integrin subunit CD29 were significantly attenuated
by DX treatment to 51.6±5.4% and 44.4±6.3% of control ±SEM (p value, <0.05 using
students t-test). To our surprise considering their well documented role in phagocytic
processes, DX treatment reduced expression of the mannose receptor, CD44, CD44v3
and the P3 integrin subunit CD61 to 38.1±6.8%, 58.8±6.4% and 82.7±7.7% of control
±SEM respectively (p value, <0.05 using students t-test). Furthermore, analysis of
expression of CD36 using the monoclonal antibodies IVC7 and smcj) suggested a steroid-
induced decrease. The mAb IVC7 consistently demonstrated elevated binding when
compared with smcj) in untreated cultures (results not shown), suggesting the epitope
recognised by smcj) is not present on all CD36 molecules. After DX treatment, mean
fluorescence intensity for smcj) binding was not decreased (86.6±20% of control ±SEM),
however binding of the pan CD36 mAb was consistently reduced to 58.1+8.1 % of
control ±SEM. Expression of CD14, and the av integrin subunit CD51 was not affected
by steroid treatment. Together these results suggest that DX augmented phagocytic
capacity was not due to an increase in expression of putative "phagocytosis receptors".
However, as surface expression is not an indicator of receptor function, we next used
specific mAb/soluble ligand inhibitors of apoptotic recognition pathways, in the
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phagocytosis assay, to determine a role of different receptors in DX-treated macrophage
phagocytosis.
Monocyte/macrophages cultured for 5-days in the presence of DX as previously
described were pre-incubated with soluble inhibitors for 15 min before addition of
apoptotic cells, and assessment of phagocytosis was made in the presence of the
inhibitor, except mAb which were removed (table 1). Inhibitors of CD36 (sm(() mAb
(1:50 ascites) and avp3 (0.5mM RGDS peptide) did not prevent phagocytosis of
apoptotic neutrophils by DX-treated macrophages (table 1). Sm(|) was used at
concentrations shown to be saturating by flow cytometry, and RGDS was demonstrated
to be functionally active by inhibition of a5pi-mediated T cell adhesion to fibronectin
(results not shown). The lack of inhibition by RGDS in DX treated cultures mirrored
that for non-DX treated cells in a 30 min assay (percent phagocytosis untreated control
28.5 ± 4%, RGDS 27.5 ± 4%; mean ±SEM n=7 (I. Dransfield personal
communication)), suggesting that this pathway does not play a major role in DX-
augmented phagocytosis. In addition, lOmM glucosamine (thought to inhibit a charge
sensitive mechanism employing avp3/CD36/TSP) partially attenuated uptake to
63.8±10% of control DX-treated cells, further suggesting that integrin-mediated
recognition is not the dominant pathway utilised.
Inhibition of CD14 ligand binding activity with mAb 61D3 (data not shown) and My4
(table 1) also failed to inhibit DX-treated macrophage phagocytosis of apoptotic
neutrophils, despite previous reports demonstrating its involvement in peripheral blood
monocyte derived macrophage phagocytosis of apoptotic neutrophils (Devitt et al.,
1998; Flora and Gregory, 1994; Moffatt et al., 1999). We observed a small inhibitory
effect of 2mM phospho-L-serine upon DX-induced phagocytosis of apoptotic
neutrophils. Phospho-L-serine exerted a greater inhibition of binding of FITC-labelled
Annexin V to apoptotic neutrophils in flow cytometric analysis, demonstrating the
compound was functionally active (see Materials and Methods for validation of
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inhibitors). However, phospho-L-serine may not be the most effective inhibitor of
phosphatidylserine receptor function. Tait and Smith (1999) demonstrated that
monomelic phospho-L-serine could not prevent binding of labelled phosphatidylserine
vesicles to the monocytic cell line THP-1. Instead, binding could be out-competed by
unlabelled phospholipid vesicles containing multiple PS moieties. At the time these
studies were performed no blocking mAb to human PS-receptor was available and a role
for PS receptor-mediated phagocytosis after DX treatment cannot be discounted.
Glucocorticoid treatment has been reported to increase mannose receptor expression by
macrophages (Piemonti et al., 1999). In contrast, our data indicates a decreased
expression of the mannose receptor after macrophage exposure to glucocorticoids (table
1), and we were unable to significantly block uptake by inclusion of mannan in the
phagocytosis assay (81.5%±5.8% of control ±SEM). Since the mannose receptor was
first identified to be involved in uptake of apoptotic cells in fibroblasts (Hall et al.,
1994), it may play a more significant role in clearance by non-professional phagocytes.
Phagocytosis was markedly inhibited in the presence of 500|ig/ml fucoidan (31.3+12.4%
of control, p <0.01 using students t-test) implicating scavenger receptor involvement.
Another scavenger receptor ligand, dextran sulphate, partially inhibited phagocytosis
(table 1). Both compounds inhibit the recognition ofmultiple scavenger receptor ligands
including oxidised-low density lipoprotein (oxLDL) and acetylated-LDL. Fucoidan
inhibited macrophage uptake of dil-labelled acetylated LDL at ljig/ml to 11.5% and
13.4% of control (untreated and DX-treated respectively). Dextran sulfate was not as
potent an inhibitor suggesting it is either a weaker ligand of scavenger receptors, or
alternatively has greater specificity. In the latter case, inhibition by fucoidan may reflect
the blockade ofmultiple pathways, including effects on other carbohydrate recognition
molecules (for example selectins) (Rosen and Bertozzi, 1994).
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Table 1. Effect of dexamethasone on the expression and function of macrophage
"phagocytic receptors"
Monocytes were treated for 5 days with lpM dexamethasone and the effects upon
surface receptor expression and apoptotic cell recognition pathways using previously
defined inhibitors ofphagocytosis was assessed.
* Note: In this table, "control" receptor expression represents expression on 5 day
DX-treated monocyte-derived macrophages relative to untreated 5 day monocyte-
derived macrophages. "Control" phagocytosis represents phagocytosis of apoptotic
neutrophils by 5 day DX-treated monocyte-derived macrophages in the absence of
inhibitor.
References: 1) Savill et al., 1990; 2) Savill et ah, 1992; 3) Savill et ah, 1989; 4) Hall
et ah, 1994; 5) Devitt et ah, 1998; 6) Hart et ah, 1997; 7) Fadok et ah, 2000; 8) Piatt
et ah, 1996; 9) Luciani and Chimini, 1996; 10) Schwartz et ah, 1999; 11) Erwig et
ah,1999
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CD44 crosslinking further augments phagocytosis of apoptotic neutrophils in DX
treated macrophages.
Crosslinking of the cell surface glycoprotein CD44 specifically increases phagocytosis
of apoptotic neutrophils (Hart et al., 1997). The molecular mechanism of CD44
augmentation remains to be determined, and its potential contribution to elevation of
phagocytosis by DX is therefore difficult to assess. However, if macrophage
phagocytosis after glucocorticoid treatment were independent of a CD44 pathway, CD44
crosslinking would be expected to produce an additive effect on uptake. Additionally, as
DX was found to decrease CD44 expression after 5 days treatment, the additive effect
might be expected to be more pronounced with decreased exposure to steroid. To test
this possibility, monocyte/macrophages were cultured for 5-days with varying exposure
to DX (as described for figure 1). Cells were then incubated with the anti-CD44 mAb,
5A4 for 15 minutes, non-bound antibody removed by washing once, and phagocytic
capability assessed. CD44 crosslinking was found to augment phagocytosis in both
untreated and DX treated cultures (fig. 7a). These results indicate that the level to which
CD44 crosslinking was able to elevate phagocytosis did not correlate with the duration
of DX exposure, but to the magnitude of the DX response. In assays where 5-day DX
macrophages had relatively low phagocytic capacities (33.2% and 50.5%), CD44
crosslinking was able to further augment phagocytosis to 57.2% and 68.3% respectively.
However, in one experiment, although CD44 crosslinking was able to elevate
phagocytosis in untreated cells (7.6% to 34.4%) and in macrophages treated with DX for
24 hours prior to the assay (31.3% to 51.5%), phagocytosis by 5-day DX treated cells
was not augmented (85.6% to 84.3%) probably representing the "phagocytic limit" of
the population/assay.
The ATP binding cassette transporter ABC1 is homologous to the C.elegans protein
CED-7, and is required on the surface of both the phagocyte and the apoptotic particle
for uptake (Hamon et al., 2000). ABC1 is thought to mediate the flip-flop of
phosphatidylserine in the membrane of the apoptotic cell, although its role in the
phagocyte is as yet uncharacterised, its ability to regulate membrane lipids may be
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important. Exposure of PS on the surface of macrophages has been reported to be
required for uptake of apoptotic thymocytes(Callahan et al., 2000). lOOpM glyburide
markedly inhibited the uptake of apoptotic neutrophils in both untreated and DX treated
cells (untreated + glyburide 41.5±11.0%; DX + glyburide 44.5±6.1% (of control ±SEM
n=4-7)) (fig. 7 and table 1). However to our surprise, glyburide treatment only partially
inhibited phagocytosis by untreated cells crosslinked with CD44 to 79.2+5.0% of control
(SEM) (fig. 7b), suggesting a fundamentally different mechanism of augmentation
between DX and CD44 cross-linking.
One interpretation of the data presented is that is that DX-augmented phagocytosis may
involve multiple receptor pathways acting co-operatively, or the engagement of a novel
receptor pathway which promotes more efficient apoptotic cell recognition.
Alternatively, DX may increase overall phagocytic capacity of the cell by altering the
intracellular machinery required for the uptake of apoptotic cells.
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Figure 7. CD44 crosslinking augments phagocytosis of apoptotic neutrophils by DX
treated macrophages
A Adherent peripheral blood monocyte-derived macrophages were cultured in the
presence of lpM dexamethasone for the periods shown. Macrophages were
incubated with media alone or anti-CD44 mAb 5A4 for 15 min, washed to remove
non-bound antibody, and phagocytosis of apoptotic neutrophils assessed as for figure
1. Data shown as mean phagocytosis ±SEM, n= 4. B Monocyte derived
macrophages were incubated in the absence of DX for 5 days. Macrophages were
exposed to 1 OOpM glyburide for 15 min prior to CD44 mAb binding and assessment
of phagocytosis as for panel A. Data shown as mean phagocytosis ±SEM, n = 3.
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Discussion
Glucocorticoids augment phagocytosis ofapoptotic neutrophils
Lui et al (1999) described short-term exposure ofmonocyte-derived macrophages to the
glucocorticoid, methylprednisolone (24hours prior to the assay) increased phagocytosis
of apoptotic neutrophils. In this chapter I have expanded the preliminary observation
that the elevation in phagocytic capacity can be further augmented by an increased
exposure to glucocorticoids, and characterised the augmentation of macrophage
phagocytosis of apoptotic neutrophils after 5-day DX-treatment. The greatest effect on
uptake of apoptotic neutrophils occurred when steroid was added to the culture medium
immediately following isolation, suggesting an early event during monocyte to
macrophage differentiation promotes the development of a pro-phagocytic macrophage
phenotype. This hypothesis will be further explored later in this thesis. Monocyte
functional plasticity allows the formation of diverse macrophage phenotypes in response
to stimuli encountered in different tissue types or during the course of an inflammatory
response. For example, culture in the presence of IL-4 and GM-CSF promotes the
formation of an "immature" dendritic cell phenotype (Chapuis et al., 1997; Sallusto and
Lanzavecchia, 1994). Autologous serum used for the culture ofmonocyte/macrophages
is likely to contain a number of cytokines including GM-CSF. Assessment of the
influence of glucocorticoids on macrophage maturation has not been extensively studied.
It is unlikely that the highly phagocytic phenotype induced by DX treatment is a result
of an inhibition of monocyte to macrophage differentiation, as macrophages matured in
the presence of DX expressed avp.3 and CD 16, and in our experience monocytes
phagocytose apoptotic cells poorly (data not shown). Previous reports have documented
an induction ofmonocyte cell death by dexamethasone (Schmidt et al., 2001; Schmidt et
al., 1999). We found no difference in the number of cells recovered after 5 days
between DX-treated and untreated cultures (control: 152±16 cells/field, DX: 140+16
cells/field; (mean +SEM, n=10). These apparently discrepant results may be accounted
for by the higher percentage of autologous serum used in this study favouring monocyte
to macrophage differentiation (Musson, 1983), compared to 1% heat inactivated pooled
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human AB serum used in the Schmidt study. Together, this data indicates that it is
unlikely that selection of cells highly phagocytic but resistant to steroid induced death
can account for the phagocytic phenotype.
Levels ofphagocytosis are highly variable
Throughout the study we encountered a large variability in both baseline phagocytosis of
untreated cultures and DX treated populations. After isolation from peripheral blood,
monocytes are selected by adherence to tissue culture plastic for 1 hr, after which the
non-adherent lymphocyte population was removed by washing. A residual number of
lymphocytes will persist in the culture for 2-3 days. During this period lymphocytes
may secrete a number of cytokines including IL-10, IFNy and IL-4, which can affect
both monocyte viability (Estaquier and Ameisen, 1997), and macrophage phagocytic
capacity (Erwig et al., 1998; Ren and Savill, 1995, plus our own unpublished
observations). More importantly, a recent report suggested that the initial cytokine
exposure monocyte/macrophages receive "programs" subsequent responses to further
stimuli such as nitric oxide production and uptake of apoptotic cells (Erwig et al., 1998).
DX-treatment from 0-24 hrs following isolation induced a significant phagocytic
response, which with certain donors was equivalent to levels of engulfment obtained
with 5-days DX-treatment. However in other experiments induction of increased
phagocytic capacity was not as evident after removal of glucocorticoids from culture
medium As stated previously it is likely that autologous serum contains a number of
cytokines and endogenous glucocorticoids which could be variable between donors
depending on their immunological status, stress levels, and hormonal balance, and in the
absence of glucocorticoids, may alter the macrophage phagocytic response (see also
chapter 7).
Erwig et al. (1999) demonstrated that uptake of apoptotic neutrophils by rat bone
marrow derived macrophages, attenuated further phagocytosis of apoptotic cells on
repeated challenge up to 48hrs later, via a mechanism involving otv(33, a^Pi and ai(32..
The number of apoptotic particles cleared by macrophages during the culture period
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could also potentially alter the final phagocytic readout. Interestingly 5-day DX
treatment significantly decreased the expression of pi-integrin subunits, in addition to a
small decrease in expression of P3 and avp3. Decrease in integrin expression levels may
partially attenuate intracellular signalling in response to integrin engagement which
prevent phagocytosis of apoptotic cells on re-challenge. Uptake of apoptotic cells
present in the culture during monocyte/macrophage differentiation may influence
phagocytic capability in untreated but not DX-treated cultures, contributing to
glucocorticoid augmented phagocytosis. More importantly, the capacity to phagocytose
particles on repeated rechallenge implies that the consequences of DX modulation of
macrophage phagocytosis in vivo would be far more profound.
In order to reduce intra-experimental variability it would be desirable to reduce
lymphocyte contamination by isolation of pure monocyte cultures, normalising serum
supplements or employing serum replacements. Highly pure monocytes can be prepared
by negative selection using magnetically tagged haptenated anti-lymphocyte mAb and
anti-hapten magnetic particles (Macs system, Mitenyi Biotech and Dynabead kits).
These techniques are now routinely used for the preparation ofmonocytes for cell death
studies. However Macs isolated monocytes display a slightly altered phenotype after
monocyte/macrophage differentiation compared to monocytes isolated by adherent
culture, with increased macrophage cell loss after five days in culture. This suggests
that although the presence of lymphocytes and lymphocyte cytokines may affect the
phagocytic readout, they also facilitate monocyte/macrophage differentiation and
survival (Lopez et al., 1993). Alternative serum supplements such as pooled human AB
or FCS, have also been explored, but result in reduced viability when compared to
autologous serum. An alternative culture system employed in the laboratory is the use
of a serum free culture medium, X-vivo, that has recently been made commercially
available. Preliminary experiments suggest culture in X-vivo induces macrophage
differentiation resulting in a similar phenotype to that obtained by culture with
autologous serum, and may therefore be advantageous for further characterisation of the
influence of cytokines and other mediators on macrophage phagocytosis.
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Dexamethasone acts via the glucocorticoid receptor and requires both transactivation
and transrepressionfunctions
Although inclusion of the glucocorticoid receptor antagonist RU38486 confirmed that
dexamethasone augmented phagocytosis was mediated via the classical glucocorticoid
receptor mediated pathway, we were unable to directly test whether this effect was
protein synthesis dependent. Glucocorticoids can both activate and repress gene
expression. The acquisition of phagocytic capability for apoptotic cells during
monocyte to macrophage differentiation may be due to the expression of cell surface
molecules or intracellular components that facilitate the uptake of apoptotic particles.
Conversely loss of negative regulators of phagocytosis may occur during monocyte-
macrophage maturation. Time course experiments demonstrated that steroid exposure
during the first 24hrs of maturation was sufficient to generate a highly phagocytic
macrophage phenotype, however inclusion of 5(iM cycloheximide (CHX) in the culture
media during this period resulted in the death of monocyte populations, as assessed by
Hoechst staining (results not shown). Inclusion of CHX later during culture resulted in
reduced growth, maturation and viability of both control and DX-treated populations,
which was reflected in decreased levels of phagocytosis, compared with non CHX
treated macrophages (results not shown). We therefore employed the use of synthetic
glucocorticoid analogues, previously characterised to have a predominately
transactivational (ZK57740, ZK77945) or transrepressional (RU24782, RU24858)
activity (Heck et al., 1997; Vayssiere et al., 1997), in order to characterise the
phenomenon at the level of the glucocorticoid receptor. As detailed in figure 5 both
transrepressors, and one transactivator (ZK77945) were able to augment phagocytosis
consistently above control at lfiM, but never to the same extent as DX. In previous
studies the transrepressing compounds RU24782 and RU24858 retained a residual
transactivating capacity at higher concentrations. At l|iM RU24782 and RU24858
retained 37% and 25% the transactivating capacity of DX (as measured by the
transactivation of a GRE coupled CAT reporter construct in transfected HeLa cells), but
have similar transrepressing activity as DX (Vayssiere et al., 1997). Similarly the
transactivating ZK- compounds retained residual transrepressing activity. Northern
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analysis of collagenase I mRNA expression in TPA treated HeLa cells after treatment
with lOOnM of the ZK compounds demonstrated that ZK57740 and ZK77945 retained
repressional activity of about 50% that of DX (Heck et al., 1997). Northern blots
demonstrating the induction of metallothionein Ha mRNA expression after steroid
treatment of HeLa cells showed ZK77945 to be a more potent transactivator than
ZK57740 (approximately75% compared to 30% of DX activity) (Heck et al., 1997).
The failure to augment phagocytosis with ZK57740 could therefore be accountable by a
weaker transactivating activity and low transrepressing activity. Interestingly, ABC
transporters such as MDR1A can expel synthetic glucocorticoids from within leukocytes
with the resulting intracellular concentration lower than that applied in the culture
medium (Schinkel et al., 1994; Ueda et al., 1992). Therefore in our culture system
extracellular concentrations of ZK57740 may be required to be in excess of 10p.M to
induce an effect similar to ZK77945. A number of transcription factors implicated in
monocyte/macrophage maturation can also be modulated by glucocorticoids, for
example C/EBPp and AP-1 (Gotoh et al., 1997; Herrlich, 2001). Taken together this
data may indicate a requirement for both the activation and repression of specific
proteins for the induction of a highly phagocytic phenotype. In the advent of new
molecular techniques such as array analysis, gene profiling may allow a full description
of the molecular changes occurring during monocyte/macrophage differentiation in the
presence of glucocorticoids. If we were able to determine if the pro-phagocytic effects
were due to the transactivational, or transrepressional activity of glucocorticoids, it may
be possible with the use of synthetic steroids to reduce some of the negative side effects
of corticosteroids without compromising the beneficial actions.
DX augmentedphagocytosis employs multiple receptors
The predominance for utilisation of a specific molecular pathway for uptake of apoptotic
cells is not constant between different cell types and can be influenced by certain
stimuli. Previous reports have demonstrated that stimulation of human monocyte
derived macrophages and murine bone marrow derived macrophages with digestible
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particles such as (5-glucan, induces a switch from uptake via the avP3/CD36/TSP
pathway, inhibitable with RGDS and anti-avP3 and antiCD36 mAb, to PS receptor
uptake, inhibitable by phospho-L-serine and PS-containing liposomes. DX has been
reported to upregulate p-glucan receptor expression, and may further facilitate a switch
between uptake pathways on stimulation. In human monocyte/macrophages the switch
between phagocytosis mechanisms is accompanied by a down regulation in avp3
expression, but maintenance ofCD36 expression. It is proposed that CD36 either binds
PS or facilitates PS-receptor function (Fadok et al., 1998b; Tait and Smith, 1999). In
DX treated monocyte/macrophages there was a small decrease in expression of P3 and
avp3 moieties, and a decrease in binding of the pan CD36 recognising mAb IVC7
(58.1±8.1% of control). However, only a slight change in the CD36 epitope recognised
by sm(() (86.6±20% of control) was observed following DX treatment. DX has been well
characterised to down modulate pro-inflammatory responses elicited by stimulated
immune cells, and it was recently demonstrated that engagement ofCD36 by oxLDL but
not apoptotic cells induced the release of H2O2. The domain of CD36 which mediates
PS binding has not been characterised, however it would be intriguing to speculate that it
corresponded to the sm(j) epitope, and that changes in CD36 conformation, glycosylation
or isoform expression could induce a switch between av(33/CD36/TSP, and PS-receptor
mediated uptake pathways.
Assessment of the role of several pathways in glucocorticoid-treated
monocyte/macrophages by analysis of receptor expression and functional inhibitor
studies failed to define one single pathway as being dominant, suggesting redundancy
within the system. This is most likely due to DX "programming" the utilisation of
multiple pathways. However, we must consider the validity of the reagents used for
receptor blocking studies. Function of competitive ligands such as PLS and fucoidan
has been verified in our systems by blocking Annexin V binding to apoptotic neutrophils
and inhibition ofmacrophage uptake of acetylated-LDL. Although the binding affinities
may be high enough to validate their function in these assays, it may not be sufficient to
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compete with multivalent ligands present on the apoptotic cell surface. The use of
higher concentrations may overcome this but would lead to undesirable non-specific
effects. One approach to address this problem would be to use multivalent soluble
ligands such as lipid microspheres for the blockade of PS-receptor function (Fadok et
al., 2000; Tait and Smith, 1999). Another consideration relating to antibody studies
would be that crosslinking of receptors (including Fc) by "blocking" mAb or F(ab')2
may induce a number of intracellular signalling pathways which may inhibit
phagocytosis independently of the receptor engaged. Use of Fab' fragments, for
example as employed in studies on the role of CD 14 in phagocytosis of apoptotic cells
(Flora and Gregory, 1994) would confirm this.
An alternative approach would be to exploit the specific genetic knockout of phagocytic
receptors. Flowever, these studies may also provide equivocal results due to redundancy
for clearance of apoptotic cells in healthy pathogen-free animals. For example
thrombospondin-1 (TSP-1) knockout mice showed increased susceptibility to
pneumonia and changes in lung homeostasis which were due to the broader effects of
TSP-1, its ability to activate the latent form of transforming growth factor-P (TGF-P),
rather than a specific fault in clearance of apoptotic cells from the absence of TSP-1
(Crawford et al., 1998). Deletion of the class A scavenger receptor produced profound
effects on phagocytosis of apoptotic thymocytes in vitro, but did not significantly alter
the structure of the thymus or the frequency of apoptotic cells present (Piatt et al., 1999;
Piatt et al., 2000). In contrast, studies of patients with systemic lupus erythmematosus
(SLE), demonstrated high levels of circulating auto-antibodies, and an increase in the
number of apoptotic cells in the skin and blood, due to deficiencies in complement
proteins. This prompted the subsequent generation of a Clq deficient mouse which
defined a role for complement opsonization in the uptake of apoptotic cells via the Clq
receptor. Clq-/- mice develop glomerulonephritis associated with the increased
incidence ofmultiple apoptotic cells in the kidney and a lupus-like disease (Botto et al.,
1998). Deposition of C3bi on apoptotic cells has also been implicated in apoptotic cell
uptake in vitro, however CD1 lb '* and CD 18"'" mice which lack the CR3 receptor do not
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appear to have a defect in clearance of apoptotic cells (Ren et al., 2001). Furthermore
macrophages prepared from patients with leukocyte adhesion deficiency (LAD) a
condition caused by CD18 deficiency, does not effect apoptotic cell uptake (Davies et
al., 1991). A role for the Clq and CR3/CR4 receptors in DX augmented phagocytosis
was not specifically assessed in this study. However, macrophages and aged neutrophils
are washed out of serum containing medium before assessment of phagocytosis in the
absence of serum. Given the short half-life of complement components, participation in
the uptake of apoptotic cells by DX treated macrophages may not be apparent in our
model. Interestingly analysis ofmice with defective Mer, a receptor tyrosine kinase, not
previously linked to phagocytosis of apoptotic cells, revealed a role for this protein in
the uptake of effete cells. Mice demonstrated an increased number of nuclear
autoantibodies, further linking defective clearance with induction of autoimmunity
(Scott et al., 2001).
Masking or preventing the disclosure of uptake cues on the apoptotic cell surface could
alternately offer a system to define target/phagocyte interactions. Fadok and colleagues,
recently demonstrated that depletion of polyamines with difluoromethylornithine
(DMFO) in HL-60 cells prior to induction of apoptosis by UV irradiation inhibited
uptake by macrophages (Bratton et al., 1999), suggesting a definitive role for PS in the
recognition of apoptotic cells. However Cocco and Ucker (2001) showed that PS
exposure was not a specific marker of apoptotic cell death as it could also mediate the
uptake of necrotic cells. Further cell surface changes may be vital not only for
successful engulfment but also for the release of anti- as opposed to pro-inflammatory
mediators associated with apoptotic particle engulfment. Therefore redundancy not only
at the level of the phagocytic receptor, but also in apoptotic cell motifs must be
considered when interpreting data from inhibition studies.
An alternative to specific genetic deletion of putative receptors to define a role in
phagocytosis, is their specific over-expression in cell lines previously deficient as
phagocytes. Such studies have included transfection of CD36 into Bowes melanoma
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cells and COS-7 cell line cells, which conferred a phagocytic phenotype (Ren et al.,
1995). However, such studies may be limited to quantifying binding of apoptotic
particles due to the lack of other phagocytic machinery required for uptake. Such
studies are valuable, but care must be taken not to over-interpret data which does not
distinguish between a receptor facilitating uptake by specifically tethering the apoptotic
particle, as opposed to engagement of receptors initiating engulfment.
Taken together these results suggest that human peripheral blood
monocyte/macrophages employ a number of phagocytic uptake mechanisms, including
the PS-receptor without the requirement for stimulation with digestible particles. I
would suggest that the utilisation of multiple pathways may contribute to the highly
phagocytic phenotype generated after exposure to DX.
DX treatment alters macrophage phagocytic machinery
Cross-linking of CD44 on the macrophage cell surface induces an increase in phagocytic
capacity, which is specific for apoptotic neutrophils, and was able to further augment
phagocytosis in DX treated monocyte/macrophages. Although uptake of other apoptotic
targets after 5-day DX treatment was not assessed in this study, short-term
glucocorticoid treatment (24hrs prior to the phagocytosis assay) potentiated
phagocytosis of apoptotic eosinophils and lymphocytes (Liu et al., 1999). We would
therefore predict that glucocorticoids induce an increase in phagocytic capability for
multiple targets, in a manner distinct from the selective mechanisms employed by CD44
cross-linking. Little is known about how CD44 cross-linking induces phagocytosis.
Preliminary evidence suggests that bone marrow derived macrophages from CD44-/-
mice have higher basal phagocytosis levels than their wild type counterparts (I
Dransfield personal communication), suggesting that CD44 may act as a negative
regulator of apoptotic cell uptake, possibly due to its highly glycosylated (and therefore
charged) nature. Crosslinking would sequester CD44 allowing areas of the cell
membrane to participate in particle engulfment. Downregulation ofCD44 in response to
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DX treatment, measured by pan CD44 mAb, and the v3 epitope, could therefore
contribute to glucocorticoid-augmentation of macrophage phagocytosis. However after
CD44 crosslinking a similar relative augmentation of phagocytosis of apoptotic
neutrophils was seen in 5-day DX treated macrophages compared to untreated
macrophages. Additionally, the effect ofDX on expression of individual splice variants,
which may be specific for the induction of phagocytosis on crosslinking has not been
addressed. Assessment of the phagocytic capability of CD44-/- macrophages exposed to
glucocorticoids may provide a clearer insight. Intracellularly, CD44 has been shown to
interact with ERM (ezrin/radixin/moesin) proteins, important mediators of cortical actin
structure and Tiaml a GEF for Rac, promoting extension of cellular processes
(Oliferenko et al., 2000). Research in our laboratory has previously demonstrated the
importance of adhesion and cytoskeletal dynamics in modulating macrophage
phagocytic capacity (McCutcheon et al., 1998; Rossi et al., 1998). For example,
blockade of actin or tubulin dynamics with cytochalasin or nocodazole prevent
phagocytosis of apoptotic cells and opsonized particles, as do inhibitors of tyrosine
kinase activity (e.g. genestein), which prevent the turnover of podosomes and other focal
contacts. Conversely, disruption of adhesive contacts by elevation of cellular cAMP
inhibits phagocytosis of apoptotic cells. Analysis of potential changes in adhesion
signalling and cytoskeletal organisation after DX treatment may provide further clues to
establish how glucocorticoids promote a highly phagocytic macrophage phenotype.
85
CHAPTER 4: CHANGES IN MACROPHAGE ADHESION
SIGNALLING IN RESPONSE TO GLUCOCORTICOIDS
Introduction
Phagocytosis requires the local rearrangement of the actin cytoskeleton. Therefore it
is not surprising that cell adhesion and adhesion signalling molecules which are able
to modulate actin dynamics have been strongly implicated as regulators of
macrophage phagocytic capability. Disruption of cytoskeletal and adhesion contacts
in monocyte-derived macrophages by elevation of intracellular cAMP inhibits
phagocytosis of apoptotic cells (Rossi et al., 1998). In contrast, ligation of CD44
(Hart et al., 1997) or adhesion to fibronectin (McCutcheon et al., 1998) results in a
rapid and dramatic augmentation of apoptotic cell uptake. The mechanisms
underlying this association remain to be determined, however it is notable that many
of the structural components and regulators of adhesive contacts are also associated
with phagocytic machinery, for example WASp and the Rho family of GTPases
(Allen and Aderem, 1996; Bums et al., 2001; Caron and Hall, 1998; Leverrier et al.,
2001; Linder et al., 1999; Ory et al., 2000). Substances which perturb actin
dynamics induce the disassembly of podosomes and other adhesive contacts within
macrophages, and prevent phagocytosis per se (Allen and Aderem, 1996; Newman et
al., 1991). Additionally tyrosine kinase inhibitors that also alter adhesive contacts,
prevent phagocytosis of apoptotic cells and IgG-opsonized particles. Complement
receptor-mediated uptake however, appears insensitive to tyrosine kinase inhibition
(Allen and Aderem, 1996; Newman et al., 1991), suggesting that certain cytoskeletal
components may be selectively involved in the control of phagocytic processes.
Similarities between phagocytosis and adhesion/migration have been further
demonstrated at an ultrastructural level using electron microscopy. FcR-
phagocytosis and apoptotic cell uptake appears to be mediated by extension of
membrane processes similar to lamellipodia, around the particle (Giles et al., 2000;
Griffin et al., 1975b; Leverrier et al., 2001), whereas complement-opsonized
particles appear to sink into the phagocyte surface (Griffin et al., 1975a; Kaplan,
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1977). Recycling of membrane in lamellipodia at the leading edge of the cell, is
thought to be vital for cell migration (Bretscher and Aguado-Velasco, 1998).
Likewise inhibition of recycling endosomes with tetanus toxin or by blockade of PI
3-Kinase activity, prevents phagocytosis of IgG opsonized particles, and apoptotic
cells (Araki et al., 1996; Bajno et al., 2000; Cox et al., 1999; Leverrier and Ridley,
2001; Ninomiya et al., 1994).
Integrin ligation induces the formation of a multi-protein complex involving the
adapter proteins Crk, pl30Cas, and DOCK180, and the guanine nucleotide exchange
factor C3G (Hasegawa et al., 1996; Kirsch et al., 1998; O'Neill et al., 2000; Sakai et
al., 1994). Assembly and membrane localisation of this complex activates the
GTPases Rac (Kiyokawa et al., 1998a; Kiyokawa et al., 1998b) and Rho (Altun-
Gultekin et al., 1998), inducing membrane ruffling and lamellipodia formation
(Allen et al., 1997). Studies in mammalian cells by Albert et al. suggest that
ligation of avp5 on the surface of dendritic cells by adhesion to ECM, or engagement
of an apoptotic particle, induces formation of the DOCK180/Crk/pl30cas complex,
subsequent Rac activation and uptake of apoptotic cells. Additionally Ravichandran
and colleagues have described a close correlation between Crk and DOCK180
association, Rac activation and apoptotic cell engulfment (Tosello-Trampont et al.,
2001). The lack of complete inhibition of phagocytosis by soluble ligands or
blocking mAb in DX-treated monocyte/macrophages points to functional redundancy
at the level of engagement of the apoptotic particle, and raises the possibility that
glucocorticoids modulate phagocytic potential through regulation of these
intracellular signalling pathways. Several reports suggest that short term (48hr)
glucocorticoid treatment of monocyte/macrophages can augment the uptake of a
number of particles including myelin and Staphylococcus aureous (van der Goes et
al., 2000). 5-day DX treated monocyte/macrophages appear to employ multiple
pathways to ingest apoptotic cells, however the effect of DX-treatment on general
phagocytic function has not been addressed. Lui et al. (2000) demonstrated that
short term DX treatment (24hrs) did not augment FcR-mediated uptake of opsonized
erythrocytes. Assessment of phagocytosis of alternative particles, analysis of
cytoskeletal organisation and the formation of adhesion processes after DX treatment
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may provide further clues as to the key molecules regulating the phagocytosis of
apoptotic cells.
Results
DX augments phagocytic capacityper se
In order to investigate whether long term DX-treatment altered macrophage
phagocytic capacity generally we assessed uptake of erythrocytes after high and low
density opsonization with IgG. Erythrocytes were pre-incubated with polyclonal
anti-erythrocyte surface membrane antibody to give either a 1:100 (high), or a 1:2000
(low) opsonization density. In a 20 minute assay we found an increase in uptake of
highly opsonized (1:100) RBC after DX treatment from 48.2±6.7% (control) to
61.0+9.4 (DX) (mean ±SEM, n = 6) (Figla). However, when erythrocytes were
opsonized at lower concentrations (1:2000) a significant effect of glucocorticoids on
FcR-mediated phagocytosis became apparent, with 27.9±4.9% of control populations
ingesting particles compared to 57.5+9.4% after DX treatment (mean ±SEM, n = 7, p
< 0.05). Although low opsonization represented a limiting factor for the uptake of
particles by untreated macrophages, phagocytosis by DX-treated
monocyte/macrophages was comparable between high and low opsonization (fig la).
Uptake of whole zymosan or complement opsonized zymosan particles, ingested via
[E-glucan and complement receptors respectively also appeared to exhibit differential
trends for untreated and DX-treated cells. Interestingly uptake of whole zymosan
appeared to be slightly elevated with DX treatment: 61.9±3.1%, compared to
54.7±5.1% by untreated populations (mean±SEM, n = 4). In contrast, preliminary
data suggested that 5-day DX treatment produced a slight inhibition of phagocytosis
of complement opsonized zymosan (untreated: 72.5%, DX-treated: 65.3%, mean,
n=2). However, further experiments are required in order to see if these trends are
statistically significant. Interestingly, although DX-treated cells were more
proficient at phagocytosing opsonized particles, expression of the high affinity Fc-
receptor CD64 (FcRyl) was decreased after steroid treatment (See chapter 7). The
lower affinity receptors FcyRII (CD32) and FcyRIII (CD16) also contribute to the
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phagocytic capacity for IgG opsonized particles. Expression of CD32 was not
assessed, however expression of CD16 was slightly elevated after DX treatment.
Surface expression does not always reflect function, suggesting that glucocorticoid
treatment may affect intracellular components common to the ingestion of both
opsonized particles and apoptotic cells.
Inhibitors ofphosphatidyl-3-kinase block DX-treated macrophage phagocytosis of
IgG-opsonizedparticles, and apoptotic cells
PI 3-kinase is required for membrane recycling during extension of cellular processes
(Cox et al., 1999). Inhibition of PI 3-kinase activity with either wortmannin or the
specific inhibitor LY294002 has been previously shown to inhibit the uptake of both
IgG-opsonized particles and apoptotic cells (Araki et al., 1996; Cox et al., 1999;
Leverrier and Ridley, 2001). To assess whether 5-day DX treated
monocyte/macrophages employed a similar signalling mechanism for the uptake of
apoptotic cells as untreated macrophages, we assessed phagocytosis in the presence
of the PI 3-Kinase inhibitor LY294002 (fig. 2a). Pre-treatment of
monocyte/macrophages with up to 100|lM LY294002 for lhr prior to the
phagocytosis assay, inhibited uptake of apoptotic neutrophils in both untreated and
DX-treated cultures from 10.7+2.0% and 41.3+11.7% to 2.0+0.5% and 7.9+3.8%
respectively (mean ±SEM, n=4). Preliminary experiments suggested that LY294002
also produced a slight inhibition of opsonized erythrocyte phagocytosis (fig. 2b). In
preliminary experiments lOOpM LY294002 reduced ingestion of low opsonized
erythrocytes (as described for figure 1), from 17.5% to 12.6% (untreated) and 39.9%
to 27.1%, (DX-treated) (n=2). Failure to produce such a profound inhibition as seen
with apoptotic cells may reflect the strength of signal mediating phagocytosis, or
alternatively an effect relating to particle size. In support of the latter suggestion, PI
3-kinase activity did not appear to be required for phagocytosis of whole or
complement-opsonized zymosan particles (data not shown), which are ingested via a
phagocytic pit rather than extension of membrane processes as in FcR-mediated
uptake. Together these data suggest that DX-treated monocyte/macrophages employ
the same fundamental PI 3-kinase dependent pathways for engulfment as untreated
monocyte/macrophages, however the efficiency of either recognition by cell surface
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receptors, or recruitment of intracellular components is augmented with
glucocorticoids.
DX alters macrophage morphology
Examination of monocyte/macrophage cultures by phase contrast revealed distinct
morphological changes after maturation in the presence of glucocorticoids.
Untreated macrophages were composed of a morphologically heterogeneous
population of cells, with multinucleated giant cells (MNGCs), "spread", apparently
motile cells with evidence ofmembrane ruffling, "rounded" less spread cells and the
occasional dendritic cell-like morphologies (fig. 3a). In contrast treatment of freshly
isolated monocytes with DX for 5 days induced a homogenous population of cells, as
described in chapter 3, with increased numbers of small "rounded" cells, reduced
numbers of "spread" macrophages and an absence of multinuclear cells (fig. 3b).
Examination ofmacrophage morphology using scanning electron microscopy further
illustrated the decreased cell spreading in DX-treated cultures compared to control
(fig. 3d,e). However the "rounded" DX-treated macrophages were attached, with
ruffled membranes and filopodial processes. Interestingly in untreated macrophage
cultures it was apparent that the phagocytic capacity was related to the
morphological appearance of macrophages. MNGC were consistently poor
phagocytes, with less that 1% of cells phagocytosing, whereas smaller, more rounded
monocyte/macrophages were more phagocytic (data not shown). The observation
would be consistent with DX treatment "re-programming" monocyte/macrophage
morphology and adhesion in concert with augmented phagocytic capability. The
concept of re-programming of monocyte-macrophage differentiation and behaviour
will be further explored in chapters 7 and 5 respectively.
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Figure 1. DX augments phagocytosis of IgG but not complement opsonized particles
Adherent peripheral blood monocyte-derived macrophages were cultured in the
presence or absence of 1 |lM dexamethasone for 5 days, and macrophage phagocytic
capacity assessed. A Macrophage monolayers were overlaid with erythrocytes
opsonized by either high or low mAb concentration, and levels of uptake, assessed
microscopically after a 20 minute assay, as previously described. Mean phagocytosis
±SEM, n— 6. B Macrophage monolayers were exposed to boiled zymosan, (mean
phagocytosis ±SEM, n - 4), or C complement opsonized zymosan (mean
phagocytosis n = 2) over a twenty minute period. Zymosan uptake was quantified
by removal of monocyte/macrophages with trypsin EDTA, and analysis of cytospin
preparations. (*, p < 0.05 vs. control values, Wilcoxon matched pairs test).
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Figure 2. Inhibitors of PI-3 Kinase block phagocytosis of apoptotic cells and IgG-
opsonized particles
Adherent peripheral blood monocyte-derived macrophages were cultured in the
presence or absence of l(iM dexamethasone for 5 days. Macrophages were pre-
incubated with varying concentrations of LY294002 for 1 hr, prior to assessment of
phagocytosis of A apoptotic cells, mean phagocytosis ±SEM, n = 4, and B IgG-
opsonized erythrocytes, mean phagocytosis, n = 2. Levels of phagocytosis were
assessed as previously described (*, p < 0.05; **, p < 0.01 vs. non-LY294002
treated values, Friedman Test with post test).
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Figure 3. Effect ofDX on macrophage morphology
Adherent peripheral blood monocytes were cultured for 5 days in the presence or
absence of 1 pM DX on either tissue culture treated plastic (A, B) or glass coverslips
(C, D). Morphology of untreated (A, C), and DX treated (B, D) were assessed by
phase contrast microscopy (A, B) (x40 objective), and scanning electron microscopy
(C, D) (bar equals 10pm). Note the uniform appearance ofDX-treated cells by phase
contrast microscopy, which is also observed in electron micrographs.
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Glucocorticoids alter macrophage cytoskeletal organisation
The distinct morphological appearance of DX-treated macrophages shown in figure
3, suggested that control of adhesion was altered following DX-treatment. In order
to assess the effect of DX programming on the formation of macrophage adhesive
processes, we examined the extent of focal contact and podosome formation in
untreated and DX treated cells by immunofluorescent staining of actin and paxillin,
proteins also recruited to phagocytic cups during FcR-mediated, and apoptotic cell
phagocytosis. Monocyte/macrophages were matured for 5-days +/- IjjM DX on
glass coverslips. Culture on glass did not appear to alter macrophage morphology
and enabled examination of cells at higher magnification. Cells were fixed in
paraformaladehyde, permeabilised using NP-40, actin visualised by binding of
rhodamine-coupled phalloidin, and paxillin localised with an anti-paxillin mAb.
Untreated cells showed punctate (podosome-like) staining of actin (fig. 4d) with
concentric association of paxillin, representing sites of cell-substratum contact (fig
4e). Paxillin was also observed towards the cell periphery coincident with the
localisation of other proteins associated with adhesion (vinculin and tyrosine
phosphorylated proteins) previously demonstrated in the laboratory (Rossi et al.,
1998) and consistent with the adherent phenotype of macrophages observed under
phase microscopy. In contrast, DX-treated cells showed an absence of podosomes
and a reduction of focal contacts at the cell extremity. Paxillin was distributed
diffusely throughout the cytoplasm, and actin organised irregularly around the
periphery of the cell. Interestingly MNGCs present in untreated cultures contained
an extensive number of adhesive contacts. We could speculate that this might hinder
membrane extension and recycling of proteins required for the engulfment of




Figure 4. Effects of dexamethasone on localisation of actin and paxillin in macrophages.
Adherent peripheral blood monocyte-derived macrophages were cultured for 5 days in
the presence or absence of lpM DX. Localisation of paxillin and actin was determined
using either anti-paxillin mAb (C, D) or rhodamine phalloidin (E, F) together with
fluorescence microscopy. Staining observed with control mAb is shown in panels A and
B. These representative micrographs (n=3) illustrate typical punctate actin staining of
"contact sites" similar to podosomes in control macrophages that are absent in DX-
treated macrophages. Paxillin is also localised to smaller "focal adhesion-like" structures
near the cell periphery in control macrophages, that are less well-defined in
dexamethasone-treated macrophages. Scale bar equals 20pm
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DX disrupts components ofmonocyte/macrophage adhesion signalling:
Changes in phosphorylation ofpaxillin andPyk2
Formation of podosomes and focal contacts is a very dynamic process (Chellaiah et
al., 2000; Ory et al., 2000). Disassembly and turnover of podosomes and focal
contacts is thought to occur after changes in phosphorylation of adhesion
components or disassembly of actin structures (Fincham and Frame, 1998). To
investigate how DX treatment may prevent podosome formation we assessed the
phosphorylation state of paxillin and pyk2 by western blot analysis of
immunoprecipitated proteins. Monocyte/macrophages were cultured for 5-days +/-
1 pM DX in 6-well culture plates as previously described. Monolayers were lysed on
the plate (to prevent changes in adhesion signalling components during removal of
cells) using an NP-40 based lysis buffer, and paxillin and Pyk2 immunoprecipitated
using specific mAb. The resulting protein/antibody complex was separated using
SDS-PAGE and analysed by western blotting with either anti-paxillin or Pyk2 mAb,
to ensure equal loading, plus an anti-phosphotyrosine mAb, RC-20. Both paxillin
and Pyk2 were expressed at equivalent levels in untreated and DX treated
populations, however tyrosine phosphorylation of both paxillin and Pyk2 was
markedly decreased after DX-maturation (fig. 5a). This correlated directly with loss
of podosome structures, as monocyte/macrophages exposed to DX for 24hrs after 4-
days maturation, did not show changes in adhesion, or a decrease in paxillin and
Pyk2 phosphorylation (fig. 5b).
As recruitment ofpaxillin to focal contacts is thought to require phosphorylation, it is
likely that localisation to nascent phagosomes is also dependent on the production of
phosphorylated paxillin. Failure of DX treatment to block paxillin phosphorylation
in 4 day differentiated monocyte/macrophages, suggests that DX does not alter
kinase/phosphatase activity directly, and we would therefore predict that 5-day DX-
matured macrophages would phosphorylate paxillin on stimulation. To assess kinase
function, we stimulated DX-treated monocyte/macrophages by re-adherence to
plastic, and ligation of (fi-integrins with an activating mAb 12G10. Mononuclear
cells were isolated from peripheral blood as previously described, and monocytes
purified by MACs isolation. Monocytes were then cultured either in suspension
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using Teflon pots, or by adherence to tissue culture plastic for 5-days +/- lpM DX.
After maturation in suspension, monocyte/macrophages were adhered to tissue
culture plastic for lhr, or pelleted, prior to lysis, and paxillin immunoprecipitation
analysis as before. Non adherent (pelleted) cells showed no detectable paxillin
phosphorylation, and macrophages matured for 5 days by adherent culture
demonstrated phosphorylation of paxillin in untreated but not DX treated cultures as
shown previously. However, in contrast phosphorylated paxillin was present in both
untreated and DX-treated cells cultured in suspension and then re-plated (fig. 6a),
suggesting functional kinase activity in the presence of DX. A full phenotypic
analysis of suspension cells was not undertaken to ensure DX-programming occurred
in non-adherent cells, however DX-treated suspension cells did appear to have
reduced expression of pl30cas (data not shown), and had increased phagocytic
function (I. Dransfield, personal communication).
Ligation of Pi-integrins by cross-linking with monoclonal antibodies or adherence to
ECM induces the phosphorylation and localisation of paxillin and Pyk2 to sites of
focal contact. Flow cytometric analysis of macrophage phenotype after DX
treatment revealed a significant decrease in Pi-integrin expression (chapter 3), which
may contribute to the altered adhesive state observed. The induction of
phosphorylation of paxillin after macrophage "replating" may reflect the repertoire
of receptors employed for initial adhesion, with altered receptor usage during long
term culture. In an attempt to directly assess the contribution of Pi-integrins in
phosphorylation of both paxillin and Pyk2 after DX treatment, we stimulated cell
surface Pi-integrins, with the activating mAb 12G10. Monocyte/macrophages were
matured by adherent culture +/- DX as before. Monolayers were incubated with
normal rabbit immunoglobulin for 15 min, to block mAb binding to endogenous Fc-
receptors, cells were then washed, and incubated with 12G10 for a further 20 min
prior to lysis and immunoprecipitation of paxillin and Pyk2 as described before.
Ligation of pi-integrins with 12G10 had no effect on phosphorylation of Pyk2 in
either untreated or DX-treated cells, however the mAb induced a small increase of
paxillin phosphorylation in untreated monocyte/macrophages (fig 6b). 12G10 was
unable however to stimulate paxillin phosphorylation in DX-treated cells, inferring
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that changes in adhesion in DX-treated monocyte/macrophages may involve defects
in Pi-integrin signalling. Repetition of this experiment using suspension cultured
monocyte/macrophages which have reduced integrin ligation and subsequently
paxillin phosphorylation, would confirm the effect was due to defective signalling
rather than a sequestration of Pi-integrins by adhesion of the cell to its substratum.
Ligation of integrins, including via apoptotic cell engagement or monoclonal
antibodies has been reported to inhibit subsequent phagocytosis of apoptotic cells
(Erwig et al., 1999). Conversely components of Pi-integrin signalling have been
shown to be involved in the engulfment of apoptotic particles (Albert et al., 2000;
Tosello-Trampont et al., 2001). Considering the highly phagocytic nature of DX-
treated macrophages, we next considered possible modulation of Pi-integrin
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Figure 5. Dexamethasone downregulates phosphorylation of pyk2 and paxillin.
Monocyte-derived macrophages were cultured for 5 days in the presence or absence of
1 pM DX, or were exposed to DX for 24 hr after 4 days maturation. Pyk2 and paxillin
were immunoprecipitated from cell lysates and protein phosphorylation of
immunoprecipitated proteins analysed by SDS PAGE together with Western blotting
using the anti-phosphotyrosine mAb RC-20 (1:5000) and enhanced chemiluminescence
detection. In this gel, IgG denotes protein phosphorylation patterns associated with a
non-binding IgGl control mAb. The band at ~85kDa, present to some extent in all
immunoprecipitates probably represents a "non-specific" component. Lanes labelled (C)
are from untreated control macrophages and (D) are from DX-treated macrophages. A
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Figure 6. Stimulation of paxillin phosphorylation in DX-treated macrophages
Monocyte/macrophages treated with DX were assessed for phosphorylation of
paxillin under various conditions. A Peripheral blood monocytes were MACs
purified from blood mononuclear cell fraction, and cultured for 5 days in the
presence or absence of l|iM DX by either adhesion to tissue culture plastic as
described previously, or by suspension in Teflon coated wells. Lysates of adherent
cultured macrophages, suspension cultured macrophages adhered to virgin plastic for
1 hr, or pelleted suspension cultured macrophages were assessed for paxillin
phosphorylation by immunoprecipitation, SDS-PAGE, and western blotting analysis,
as for figure 5. B Adherent peripheral blood monocyte-derived macrophages were
cultured for 5 days in the presence or absence of lpM dexamethasone as described
previously. Monolayers were incubated with normal rabbit IgG for 15 min to block
non specific FcR binding, washed, and incubated with either a control IgG, or Pi-
activating mAb 12G10, for 30 min, and paxillin and pyk2 phosphorylation assessed
as for figure 5. Lanes labelled (C) are from untreated control macrophages and (D)
are from DX-treated macrophages. IgG and (3i denote cells stimulated with control
mAb and activating 12G10 mAb respectively.
paxillin pyk2
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DX alters components of fl/-integrin signalling
The pl30/cas/crk/DOCK180 complex is a major mediator of adhesion signalling, and
is recruited to sites of membrane-ECM contact after integrin ligation inducing actin
organisation, stress fibre formation, and membrane ruffling via activation of Rho-
family GTPases (Altun-Gultekin et al., 1998; Kiyokawa et al., 1998a; Kiyokawa et
al., 1998b). Formation of the complex requires phosphorylation of pl30cas which
then functions as a molecular scaffold, recruiting Crk and DOCK180.
Monocyte/macrophages matured for 5 days +/- DX were lysed and pl30cas
phosphorylation assessed by immunoprecipitation analysis as for paxillin. In these
experiments DX treatment appeared to inhibit pl30cas phosphorylation (data not
shown). However, analysis of whole cell lysates (WCLs) with a mAb specific for
pl30cas demonstrated that the apparent attenuated phosphorylation was the result of
a down-regulation of pl30cas expression (fig 7c). A time course of pl30cas
expression during monocyte-macrophage differentiation in the presence of
glucocorticoids revealed that down-regulation was initiated early, after 24-48hrs of
DX treatment (results not shown), suggesting changes in pl30cas expression are
initiated within the "time window" of DX exposure required to induce a highly
phagocytic macrophage phenotype (chapter 3). Furthermore, exposure of
monocyte/macrophages to DX for 24 hrs after 4 days maturation in the absence of
steroids failed to alter pl30cas expression (fig 7c), as was seen with paxillin
phosphorylation (fig. 5b). Protein levels of Crkll or the haematopoietic cell specific
homologue CrkL were unchanged after 5 day DX treatment (fig 7a,b). Technical
difficulties prevented us reproducibly immunoblotting DOCK180 (data not shown);
therefore semi-quantitative RT-PCR was used to analyse the levels ofDOCK180 and
the haematopoietic cell specific M-DOCK mRNA transcripts. No differences in
mRNA levels were detected after DX treatment, although this does not exclude the
possibility that differences may be apparent at the protein level (fig 7d).
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Figure 7. DX alters components of fti-integrin adhesion signalling
Adherent peripheral blood monocyte-derived macrophages were cultured in the
absence (lanes labelled C) or presence of lpM dexamethasone for 5 days (D5), or
24hrs after 4 days maturation (D24). Macrophage cell lysates were assessed for
expression of A CrkL (36 kDa) B Crkll (40/42 kDa) and C pl30Cas (130 kDa) by
SDS-PAGE and Western blotting. Antibodies used at 1:500, CrkL, Crkll; 1:5000,
pl30cas. D Total RNA from untreated and dexamethasone-treated macrophages
were assessed for expression of actin, DOCK180, and M-DOCK/DOCK2 transcripts
using RT-PCR with primers described in Materials and Methods.
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DX augments Rac activity
The pl30cas/crk/DOCK180 complex is required for Rac activation during the
formation of adhesion processes in a number of cell types, and phagocytosis of
apoptotic particles by dendritic cells and cell lines reconstituted with phagocytic
machinery (Albert et al., 2000; Tosello-Trampont et al., 2001). We would predict
that the down regulation of pl30cas expression may disrupt formation of the
crk/DOCK180 complex, compromising Rac activity, and thus correlate with the
altered adhesion and cytoskeletal organisation of DX treated cells. However, the
highly phagocytic nature ofDX-matured cells suggests that Rac is highly active. We
therefore evaluated Rac activity directly using a pull-down assay utilising the CRIB
domain of PAK (p21 activated kinase) which binds GTP-bound (active) Rac.
Monocyte/macrophages matured +/- DX as described previously were lysed and the
resulting lysates probed with GST-CRIB fusion protein coupled to Sepharose beads.
Levels of active Rac were then quantified by SDS PAGE and western blotting. Both
untreated and DX-treated cultures expressed equal amounts of total Rac (quantified
by probing whole cell lysates with an anti-Rac mAb), however, untreated control
macrophage populations showed little detectable active Rac compared to high levels
in DX-treated cultures (fig. 8). Furthermore localisation of total Rac by
immunofluorescence demonstrated distinct staining patterns between untreated, and
DX-treated macrophages. In untreated cells Rac was localised to membrane ruffles
(fig 9c), whereas membrane ruffling was decreased in DX-treated macrophages, with
Rac distributed in a polarised manner around certain parts of the cell membrane (fig.
9d).
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Figure 8. Augmented Rac activity in monocyte/macrophages treated with DX
Adherent peripheral blood monocyte-derived macrophages were cultured in the
absence (lanes labelled C) or presence of 1 (iM dexamethasone for 5 days (D5).
Activity of the GTPase Rac in macrophage lysates was assessed using "pull down"
assays employing Sepharose coupled with GST-PAK protein. SDS PAGE and
Western blotting with a Rac-specific mAb (1:1000) was used to determine levels of
Rac in "pull-downs" (Active Rac) and Rac expression levels in whole cell lysates
(Total Rac).
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Figure 9. Altered Rac localisation in DX treated macrophages
Adherent peripheral blood monocyte-derived macrophages were cultured for 5 days
in the presence or absence of 1 pM DX. Localisation of Rac was determined using
anti-Rac mAb along with fluorescence microscopy. For staining with control mAb
see figure 4. A control untreated macrophages. B DX-treated macrophages. These
micrographs demonstrate characteristic Rac localisation to membrane ruffles present
in untreated macrophages, indicated by the arrow head. Ruffles are not apparent in
DX treated cells, however Rac localisation is polarised across the cell.
DX alters expression of the Rac GEF, Tiaml
The high levels of detectable active Rac would suggest GEF activity may be elevated
in DX treated cells. A number of GEFs for Rac have been identified. These include
Vav (Crespo et al., 1996; Crespo et a!., 1997; Olson et al., 1996), and Tiaml
(Leeuwen et al., 1997; Michiels et al., 1995; Michiels et al., 1997). Increased
expression or activity of alternative GEFs could account for the increased Rac
activity in DX treated cells. We therefore assessed the expression ofVav, and Tiaml
in macrophage lysates by SDS-PAGE and western blotting. Surprisingly 5-day DX
treatment down regulated the expression of Tiaml, but maintained the expression of
Vav (fig. 10). Activation of Vav by phosphorylation of specific tyrosine residues
promotes Rac binding. Although preliminary immunoprecipitation experiments
suggested that DX-treatment decreased Vav phosphorylation and therefore its GEF
activity, further work would be required to determine the role of Vav in DX-
augmented Rac activity.
Recruitment of alternative adaptor proteins may compensate for loss of pl30cas
expression and promote DOCK180 function. Changes in cellular localisation of
DOCK180 by the engagement of alternative adaptor molecules may also promote
Rac activity at membrane sites involved in phagocytosis as opposed to the formation
of adhesive contacts. The altered cellular localisation of Rac in DX-treated cells
would support this. HEFl/Cas-L (Human Enhancer of Filamentation/cas-like) was
isolated in a screen for human proteins that confer morphoregulatory changes leading
to filamentous budding in yeast, and independently due to its homology with pl30cas
(Law et al., 1996; Minegishi et al., 1996). Analysis ofmacrophage lysates revealed
no change in expression ofHEF1 between untreated and DX-treated cells (results not
shown). Interestingly, we were only able to detect the 55kDa form of the protein that
arises from cleavage of the full length 105kDa protein at G2-M (Law et al., 1998).
As macrophages are terminally differentiated cells, the significance of the possible
presence of mitotic proteins is not known. Expression of the third member of the
pl30cas family of adaptor proteins, Efs/Sin (embryonal Fyn substrate/src interacting)
was not assessed as only the murine form has so far been cloned (Ishino et al., 1995).
Homologues of Crk, DOCK180, and Rac are present in the nematode worm, (CED-
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2, -5, and -10), however as yet no homologue of pl30cas has been identified, despite
cloning the entire C.elegans genome. C.elegans encodes a potential adaptor protein
CED-6, which contains phosphotyrosine binding domains, however the gene
encoding CED-6 does not belong to the same complementation group of
phagocytosis mutations as ced-2, -5, -10 and -12, and is thought to interact with the
intracellular domain of CED-1, a putative membrane receptor. Mutations in both
gene groups are required for full inhibition of engulffnent (Ellis et al., 1991). It is
therefore possible that CED-6 may interact with CED-2/CED-5/CED-10 in the worm
or the human homologue with Crk/DOCK180/Rac or the newly identified ELMO in
mammalian cells. Such interaction may compensate for pl30cas loss in DX-treated
macrophages. As no mAb for CED-6 was available, we looked for mRNA
expression of ced-6 and ced-7 by RT-PCR. In preliminary experiments both
transcripts appeared to be present in untreated and DX-treated





Figure 10. Altered Rac GEF expression in DX treated macrophages
Adherent peripheral blood monocyte-derived macrophages were cultured in the
presence or absence of l(iM DX for 5 days. Macrophage cell lysates were assessed
for expression of A Tiam 1 (202 kDa), and B Vav (95kDa) by SDS-PAGE and
Western blotting. Lanes labelled (C) are from untreated control macrophages and
(D) are from DX-treated macrophages. Antibody dilutions Tiaml, 1:250; Vav,
1:1000.
Discussion
Glucocorticoids alter macrophage morphology
The previous chapter documented how exposure of monocytes to glucocorticoids
during the early phase of monocyte-macrophage differentiation resulted in a highly
phagocytic macrophage phenotype. Here we demonstrate that the increase in
phagocytosis is accompanied by a profound alteration of monocyte/macrophage
morphology. No morphological changes were apparent if monocyte/macrophages
were treated with glucocorticoids late during differentiation. DX treatment after 4
days maturation in the absence of glucocorticoids did not alter cell morphology, and
only resulted in a modest increase in phagocytosis. This suggests that DX does not
alter cytoskeletal organisation directly, but induces morphological changes via
induction of regulatory genes. Glucocorticoids have been reported to induce and
stabilise actin polymerisation in human endometrial cells via a rapid non-genomic
action involving the down regulation of cellular cAMP (Koukouritaki et al., 1997;
Koukouritaki et al., 1996), and paxillin (Koukouritaki et al., 1999). Additionally,
Luini and colleagues demonstrated the remodelling of the actin cytoskeleton and
formation of stress fibres in a number of cell types due to an enhancement of
caldesmon expression, a ubiquitous actin- and calmodulin binding protein which
synergizes with tropomyosin to stabilise microfilaments (Castellino et al., 1992;
Castellino et al., 1995). We have not investigated a role for caldesmon in our system
as we do not observe stress fibre formation in either DX-treated or untreated
monocyte/macrophages. Furthermore, the highly phagocytic nature of DX-treated
cells would require a dynamic regulation of cytoskeletal structure suggesting a
decrease in actin filament stabilisation. Visualisation of cytoskeletal components
with immunofluorescent staining demonstrated altered actin organisation in DX-
treated monocyte/macrophages with localisation around the periphery of the cell
similar to actin arrangement in pl30cas -/- fibroblasts (Honda et al., 1998). In
addition to the downregulation of pl30cas expression, inhibition of Pyk2 and paxillin
phosphorylation is likely to contribute to the "rounded" morphology of DX-treated
macrophages. Inhibitors of Pyk2 phosphorylation abrogate monocyte cell spreading
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and motility (Watson et al., 2001), and fibroblasts which lack Pyk2 expression
demonstrate a more rounded phenotype (Sieg et al., 1998).
Paxillin interacts with a number of proteins able to regulate cytoskeletal organisation
(for review see Turner, 2000). Paxillin contains a number of protein-protein
interaction domains including alpha-helical LD motifs, zinc finger containing LIM
(Lin-11, Isl-1, Mec-3) domains, a proline rich region, plus binding motifs created by
phosphorylation of tyrosine or serine residues. Decrease in paxillin phosphorylation
may disrupt paxillin/Crk interactions in addition to other signalling mediators
pertaining to cytoskeletal organisation. Interestingly, mutations in PP2A a serine
phosphatase, increase serine phosphorylation of paxillin and promote cell spreading
(Ito et al., 2000). Assessment of serine phosphorylation of paxillin and its possible
modulation by glucocorticoids was not undertaken in this study but presents an
attractive target for future investigation. Paxillin has recently been shown to interact
directly with the 0(4 integrin tail, which inhibits cell spreading and reduces the
formation of focal adhesions in Jurkat T cells and mouse embryonic fibroblasts (Liu
et al., 1999). 0(4 integrins are largely restricted to mononuclear leukocyte lineages
(Giancotti, 2000) and may therefore be a cell-specific candidate for paxillin
regulation in macrophages. It would be an intriguing possibility if paxillin/(X4
interactions were independent of paxillin tyrosine phosphorylation, and may
therefore be potentiated in DX-treated cells. Two homologues of paxillin have been
identified in mammalian cells, Hic-5 (Matsuya et al., 1998; Thomas et al., 1999) and
leupaxin (Lipsky et al., 1998). Both are also able to bind 04 integrins, Pyk2 and
FAK (Hic-5 only) in vitro. Recent work described Hic-5 as a negative regulator of
integrin mediated cell spreading. Overexpression of Hic-5 in NIH 3T3 cells
sequestered FAK from paxillin, decreased paxillin phosphorylation, and prevented
interaction ofpaxillin and Crk (Nishiya et al., 2001). Src activity was also decreased
in Hic-5 overexpressing cells suggestive that expression of this paxillin homologue
may alter adhesion signalling by preventing phosphorylation of components such as
pl30cas by Src family kinases. Changes induced by Hic-5 overexpression were
dependent on the presence of FAK as decreased paxillin phosphorylation was not
apparent in FAK -/- fibroblasts. We do not detect FAK expression in our monocyte-
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derived macrophages, however Pyk2 has been shown to compensate for certain FAK
functions when overexpressed in FAK -/- cells (Klingbeil et al., 2001). Increased
Hic-5 (and possibly leupaxin) expression after DX-treatment could therefore promote
a reduction in paxillin phosphorylation by competition for Pyk2 binding resulting in
increased cell rounding characteristic of DX-treated macrophage morphology. These
possibilities could be tested when specific reagents are available.
Changes in kinase/phosphatase activity after DX-reprogramming
Src and src-family kinases mediate phosphorylation of cytoskeletal components in
response to integrin ligation. Src has been show to directly phosphorylate and
activate Pyk2 in addition to pl30cas in fibroblasts (Sakai et al., 1994; Sieg et al.,
1998). In monocytes and macrophages, the major src-family kinases expressed are
p59/61AcA (Hck), p58c"-^'r (Fgr), and p53/56/v" (Lyn) (Tsygankov and Bolen, 1993).
Peritoneal exudate macrophages from hck-/-fgr-/- mice showed reduced
phosphorylation of a number of cytoskeletal associated proteins, including paxillin
and Pyk2, and a dysregulation of paxillin and actin localisation on adhesion to
fibronectin (Suen et al., 1999). Additionally pl30cas promotes Hck
autophosphorylation and activation in an in vitro cell free assay system (Pellicena
and Miller, 2001). Hck and Fgr may therefore be targets for DX modulation directly
by changes in expression or indirectly through reduced activation in the absence of
pl30cas.
Decreased phosphorylation of paxillin and Pyk2 may be mediated by an increased
activity/expression of specific phosphatases. SHP-1 (SHPTP1) dephosphorylates
Pyk2 (Kumar et al., 1999), and is expressed primarily by haematopoietic cells.
Mutation of murine SHP-1 results in the "motheaten" phenotype, characterised by
accumulation of macrophages and neutrophils in the lung (Shultz et al., 1984), and
increased aMfh integrin-mediated macrophage cell adherence and spreading (Roach
et al., 1998). However, examination of macrophage lysates for SHP-1 expression
revealed an actual decrease in expression after DX treatment (data not shown).
Another possible candidate for DX modulation is PTP-PEST. PTP-PEST inhibits
phosphorylation of Pyk2, pl30cas and paxillin (Davidson and Veillette, 2001; Lyons
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et al., 2001; Shen et al., 1998). Analysis of PTP-PEST activity after DX treatment
may present a possible mechanism for the altered phosphorylation of adhesion
signalling proteins observed.
Podosome formation andDX-reprogramming
In addition to regulating cell spreading and morphology, Pyk2, paxillin and pl30cas
have also been shown to regulate the formation of podosomes, specialised adhesion
structures, in response to ligation of 0CmP2, otvfh, and pi-integrins (Duong and Rodan,
2000; Nakamura et al., 1998). Osteoclasts from pl30cas -/- mice show deficiencies
in actin ring formation and podosome assembly (Nakamura et al., 1998). We would
predict that the dysregulation of podosome formation by changes in pl30cas
expression, or Pyk2 and paxillin phosphorylation would affect cellular localisation
and changes in activation of the downstream effectors of actin organisation,
principally Rho family GTPases, and the Wiskott-Aldrich Syndrome protein (WASp)
family. RhoA, Rac, and cdc42 are required for podosome formation in osteoclasts
(Zhang et al., 1995) and MNGCs (Ory et al., 2000), and dendritic cells (Burns et al.,
2001). Changes in of Rho or Rac activity induce the dissociation and turnover of
podosome structures (Ory et al., 2000), and WASp deficient macrophages fail to
form podosomes, exhibit compromised motility and show defective phagocytosis of
apoptotic cells. This demonstrates a direct link between Rho family GTPases, actin
organisation, and phagocytosis. Whether WASp functions in a similar signalling
pathway during phagocytosis as adhesion is not yet known. Analysis of protein
levels in macrophage lysates revealed that WASp is expressed at equivalent levels in
both untreated and DX-treated cells (data not shown), therefore glucocorticoid
programmed monocyte/macrophages may provide a useful model to study WASp
function where expression permits phagocytosis but not podosome formation.
Adhesion andphagocytosis, two opposingfunctions?
Considering adhesion signalling can modulate macrophage phagocytosis, and many
of the components of adhesive contacts are also involved in engulfment, could the
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absence of podosomes facilitate phagocytosis in DX treated macrophages? MNGCs
present only in untreated cell populations contain numerous podosomes and other
adhesion structures (for detailed analysis of the effect of DX programming on giant
cell formation see chapter 7). In our phagocytosis assay these cells are poorly
phagocytic. Phenotypic analysis showed no alteration in the number of cells
expressing cell surface receptors implicated in uptake of apoptotic particles in DX-
treated vs. untreated monocyte/macrophages (where the proportion of MNGCs is
higher) (see chapter 1). Low phagocytic potential may therefore be reflected in the
limiting availability of membrane or cytoskeletal components in highly spread cells
and is reflected in time-lapse video microscopy of macrophage cultures. MNGCs
and large spread monocyte/macrophages showed ruffling membranes, but little
extension of membrane processes. In contrast DX-treated cells were very active in
extending cellular processes and capturing apoptotic cells.
In order to test this hypothesis we would be required to induce podosome formation
in DX-treated cells. Replating DX-treated cells on "virgin" plastic induced strong
adhesion as quantified by paxillin phosphorylation. Microscopic analysis has not yet
been undertaken to assess whether this correlates with podosome formation, or if
replating inhibits phagocytic capacity, but provides a potential model for such an
analysis. As phosphorylation of paxillin can be induced in DX-treated macrophages
the absence of phospho-paxillin in resting DX-cells may be due to a rapid turnover of
weak, transient adhesion structures, where only a small percentage of available
cytoskeletal components are involved. Such components including paxillin and actin
could then be readily mobilised to areas of membrane in contact with an apoptotic
cell without the need for de novo synthesis, or a dismantling of existing cytoskeletal
structures. We would therefore predict an induction of phospho-paxillin after
engagement of apoptotic particles. Technical difficulties precluded us investigating
this directly. The average phagocytic signal in DX treated cultures is approximately
40% which is likely to be sufficient to detect changes after particle engagement.
However phosphorylation may be transient and as phagocytosis is not synchronised
during the assay the actual percentage of cells engulfing particles and consequently
the paxillin phosphorylation signal at any one time may be far lower. The
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contribution of paxillin present in the apoptotic neutrophil may also mask detection
of phosphorylation. Assessment of the time course of paxillin phosphorylation after
replating in conjunction with phagocytic capacity would present further evidence
linking or divorcing adhesion and paxillin phosphorylation status with phagocytic
capability. A time course may also enable assessment of the role ofmatrix laid down
by monocyte/macrophages during differentiation on the phenotype and phagocytic
capacity induced by DX. IfDX programmed morphology was independent ofmatrix
ligation of cell surface receptors, we would expect a recovery of the original
phenotype shortly after initial adherence. Alternatively if the DX treated
macrophage phenotype were influenced by the matrix laid down during culture, we
would not expect recovery for a much longer period. Potential differences in matrix
production after DX treatment raises further questions as to the effect of
glucocorticoids during wound healing and fibrotic repair.
DXpromotes cytoskeletal rearrangement
Increases in phagocytic capability conferred by glucocorticoids was not confined to
the uptake of apoptotic cells. However the phagocytic advantage conferred by DX
diminished with decreasing particle size. DX promoted the uptake of IgG-opsonized
erthyrocytes, but showed little advantage for the uptake of either boiled zymosan or
complement opsonized zymosan. This suggests that under conditions where less
cytoskeletal and membrane organisation was required to physically engulf a particle,
untreated cells would be able to perform with similar efficiency as DX treated
macrophages. Furthermore blockade of PI3 kinase activity did not produce such a
profound inhibition of opsonized erythrocyte phagocytosis when compared with
apoptotic cell uptake in DX treated cells and did not alter uptake of whole zymosan
or complement opsonized zymosan. As different receptor mechanisms are employed
for the uptake of each particle a direct comparison between different phagocytosis
pathways is difficult, however preliminary evidence suggests that DX does not alter
FcR or complement receptor expression. Assessment of phagocytosis of different
sized latex beads coated with phosphatidylserine, IgG or complement proteins could
directly determine whether the phagocytic advantage of DX treated, compared to
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untreated cells, is dependent on cytoskeletal plasticity for each of the three
phagocytosis mechanisms and not the receptor engaged. Alternatively direct
comparison of engulfment of differentially opsonized apoptotic cells would
determine if increased phagocytic potential of DX-treated cells were receptor
dependent. Augmentation of phagocytic capacity for both IgG-opsonized and
apoptotic particles provides further evidence that apoptotic cell uptake is mediated
via a "modified zippering mechanism". In a similar fashion to FcR-mediated
phagocytosis, a number of cell surface receptors may be required for successful
engulfment of apoptotic bodies. This may consist of any number of phagocytic
receptors so far described. Failure to completely abrogate uptake via blockade of a
single receptor may therefore not be due to functional redundancy but by a
physical/spatial redundancy.
DXaugments Rac activity
Increases in phagocytic activity after DX "programming" correlated with heightened
efficiency for the rearrangement of cytoskeletal components required for physical
uptake of particles. In mammalian systems, work modelling dendritic cell uptake of
apoptotic particles using human epithelial kidney 293T cells transfected with avps
integrins demonstrated that uptake via Crk/DOCK180/Rac was associated with
pl30cas phosphorylation. Additionally Ravichandran and colleagues demonstrated
that overexpression of Crk or DOCK180 in CHO cells promoted phagocytosis
(Tosello-Trampont et al., 2001). We would predict that loss of pl30cas expression
would disrupt formation of the Crk/DOCK180 complex, therefore the high levels of
Rac activity in DX-treated cells presents us with a paradox. Sister proteins such as
HEF-1 or Efs/Sin may compensate in the absence of pl30cas. HEF-1 has been
shown to interact with Crk (Kanda et al., 1997; Law et al., 1996; Manie et al., 1997;
Minegishi et al., 1996). Changes in localisation patterns of alternate binding partners
may concentrate active Rac to areas of the membrane participating in engulfing
particles for example lipid rafts (Tosello-Trampont et al., 2001), and may account for
the altered localisation of whole Rac in DX-treated macrophages. Alternatively
glucocorticoids may augment Rac activity by increased expression of Rac specific
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GEFs. Currently 8 Rac specific GEFs have been identified (for review see Scita et
al., 2000). We examined the expression of two at the protein level. DX down
regulated the expression of Tiaml, and prevented Vav phosphorylation (which is
required for activation of Rac), suggesting that these proteins were not involved in
the increase of Rac activity with DX-treatment. A number of other Rac specific
GEFs remain to be examined in our system including mediators of Rac activation
downstream of Ras and Cdc42. Ras has been shown to activate Rac via PI-3 kinase
and the GEFs Sos-1 or Vav (Han et al., 1998; Ridley et al., 1992; Walsh and Bar-
Sagi, 2001). As Ras activity is not required for the uptake of apoptotic cells or
opsonized particles, DX-treated macrophages may employ a Ras independent PI-3
kinase-Rac pathway (Nobes et al., 1995). Cdc42 is required for phagocytosis of
apoptotic cells and IgG-opsonized particles. One of the mechanisms whereby Cdc42
is thought to mediate activation of Rac is via PAK (also a target for activated Rac),
which forms a complex with PIX (PAK Interacting Exchange Factor), a Cdc42/Rac
GEF. Interestingly paxillin can localise PIX (and possibly therefore Rac activity) at
focal adhesions through an ADP-ribosylation factor GTPase-activating protein
(ARF-GAP) called PKL (Turner, 2000). This interaction is via the LD4 domain of
paxillin and therefore independent of tyrosine phosphorylation. Changes in paxillin
phosphorylation with DX-treatment may promote interaction with alternate binding
partners, and in addition to altered paxillin cellular localisation, provide a mechanism
whereby Rac activity is recruited away from sites of focal contact to areas of
membrane engaging apoptotic particles. We were unable to directly show a role for
Cdc42 in our DX-treated macrophage phenotype. Although reagents used for
detection of Rac activity also allow identification of active Cdc42, technical
difficulties prevented us observing GTP-bound Cdc42 in either untreated or DX-
treated cells.
Work examining the role of the pl30cas/Crk complex and Rho GTPases in Yersinia
spp. infection may provide a useful tool for the further extrapolation of Rho family
signalling during phagocytosis. Yersinia are taken up by epithelial cells via
interaction of the bacteria protein invasin with (3i integrins (Fallman et al., 1995;
Isberg and Leong, 1990). This induces phosphorylation of pl30cas, Crk binding,
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Rac activation and engulfment of bacteria (Weidow et al., 2000). Yersinia however,
inhibit this same machinery to avoid immune detection by myeloid cells via the
secretion of Yops (Yersinia outer proteins) (Cornelis and Wolf-Watz, 1997). YopH
is a phosphatase which targets pl30cas phosphorylation, inhibiting pl30cas/Crk
coupling and Rac activation (Black and Bliska, 1997; Hamid et al., 1999; Persson et
al., 1997; Weidow et al., 2000). Additionally YopE has been recently characterised
as a Rac specific GAP (Black and Bliska, 2000; Von Pawel-Rammingen et al.,
2000). Analysis of human umbilical vein endothelial cell cultures infected with a
Yersinia strain that secreted only YopE demonstrated that direct Rac activation was
not inhibited, although Cdc42 mediated Rac activity was (Andor et al., 2001).
Examination of phagocytosis of apoptotic cells and basal levels of Rac activity in
DX-treated monocyte/macrophages cultures infected with a Yersinia strain secreting
only YopE would provide strong evidence for Cdc42 mediated Rac activation in our
system. In a wider context, patients on long-term glucocorticoid treatment
demonstrate increased susceptibility to bacterial infection. Glucocorticoids have
been shown to increase uptake of Staphylococcus aureus (van der Goes et al., 2000),
however we would predict that downregulation of pl30cas would mimic
dephosphorylation by YopH and prevent Yersinia uptake. DX treatment may
therefore be detrimental for functional immunity towards pathogens that employ
similar mechanisms to avoid immune detection. Finally, considering the profound
effects on gene expression seen during glucocorticoid "programming" ofmonocyte-
macrophage differentiation observed so far, its is likely that DX may induce the
expression of novel GEFs. Utilisation of current "chip" technology would allow the
creation of custom arrays for analysis of untreated vs. DX-treated
monocyte/macrophage mRNA expression, identifying novel glucocorticoid inducible
genes.
The majority of studies assessing Rac activation, with the exception of the dendritic
cell work, are performed in either non-phagocytosing or "non-professional
phagocytes". These cells are very likely to require pl30cas for Rac activation in the
context of adhesion but these cells never or rarely have a requirement for Rac during
phagocytosis. In such studies functional readout for Rac activation is the assessment
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of cell spreading or membrane ruffling. Few investigations measure Rac activity
directly or localise active Rac within the cell. The use of dominant negative or
constitutively active Rac constructs are very useful tools but may not be subtle
enough to activate or inhibit individual Rac functions. Work by Albert et al. (2000)
demonstrated pl30cas phosphorylation after adherence of transfected 293 cells to
vitronectin, and that adherence to vitronectin promoted phagocytosis in both
dendritic cells and 293 cells. If adherence induces pl30cas phosphorylation,
promoting Rac activity in an adhesion context, high levels of active Rac in a non-
phagocytosing cell transfected with a "phagocytic receptor" may promote
phagocytosis by default. In a similar fashion expression of constitutively active Rac
would promote uptake. However these mechanisms are unlikely to be as efficient as
in macrophages and may account for the length of assay required to see significant
levels of phagocytosis (2-4 hr as opposed to our 20-min assay). Interestingly, worms
with defects in the two nematode integrin molecules pat-2 and ina-1 do not show
defects in corpse clearance (Gumienny et al., 2001), although CED-2, -5 and -10 are
required. Ced-6 encodes an adaptor protein with phosphotyrosine binding motifs, a
proline rich region at its C terminus and a possible pTyr motif. Genetically, ced-6 is
not in the same complementation group as ced-2, -5, and -10, and is therefore
unlikely to fulfil a "pl30cas-like" role in the worm. Preliminary experiments
demonstrated the presence ofmRNA transcripts for the human homologues of ced-6
and -7 in both DX treated and untreated macrophages (results not shown).
Furthermore we were able to inhibit phagocytosis of apoptotic neutrophils by DX-
treated and untreated macrophages by 50-90% with the ABC1 (CED-7) antagonist,
glyburide (see chapter 3), suggesting this pathway is functional. Whether human
CED-6 can bind Crk and promote Rac activation in mammalian cells remains to be
determined. Further characterisation of the function of CED-12/ELMO another
putative adaptor protein may allow further elucidation of the pathways involved in
mediating recognition of the apoptotic target which may be mediated by CED-1, -6, -
7 and engulfment requiring CED-2, -5, and 10. Expression and function of ELMO in
DX-treated macrophages presents a very exciting target for future work.
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In higher organisms, phagocytosis of apoptotic cells is likely to be highly regulated
with expression of promoters of phagocytosis, in addition to proteins that may
prevent phagocytosis of apoptotic cells where it would be detrimental to the
organism, for example dendritic cell presentation of self-antigens from phagocytosed
apoptotic cells (Albert et al., 1998a; Albert et al., 1998b; Inaba et al., 1998).
Immature dendritic cells have heightened capacity for the uptake of apoptotic cells
and are able to cross-present antigens from apoptotic cells to cytotoxic T
lymphocytes (Albert et al., 1998a; Albert et al., 1998b). In addition, dendritic cells
have also been shown to process antigen and present epitopes in MHC class II from
necrotic and apoptotic cells. (Inaba et al., 1998). However as immature dendritic
cells have low levels of co-stimulatory molecules, cross-priming and MHCII
presentation results in tolerance. In contrast, mature dendritic cells which have
increased expression of co-stimulatory molecules have decreased capacity for the
uptake of apoptotic cells. This is thought to be due to a down regulation of
phagocytic receptors, tXvPs (Albert et al., 1998a). Uptake of apoptotic cells by
immature dendritic cells in the presence of an inflammatory stimulus, which would
induce co-stimulatory activity, has the potential to successfully activate cytotoxic T
lymphocytes to self-antigen, resulting in the death of the APC. Macrophages have
the potential to express co-stimulatory molecules in response to inflammatory
stimuli, if this is married with a continued phagocytic capacity, activation of self-
responses may occur. Albert et al., found that macrophages were unable to cross-
present, and inclusion of macrophages into dendritic cell cultures containing
apoptotic cells actually decreased the cross-presenting ability of dendritic cells
(Albert et al., 1998a). However this does not exclude the potential for macrophages
to present self-antigens on MHC class II. It is proposed that whereas dendritic cells
phagocytose apoptotic cells via otvPs which engages intracellular processing
pathways leading to presentation, macrophages employ ayp3 for uptake resulting in
the degradation of the apoptotic material (Albert et al., 2000). Albert and colleagues
have proposed a requirement for pl30cas during the uptake of apoptotic cells by
dendritic cells, however our data unequivocally demonstrates no requirement for
pl30cas during macrophage phagocytosis, furthermore its absence may promote
clearance of corpses. It would be interesting to speculate that pl30cas may function
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as a cellular switch governing the intracellular pathways with which ingested
apoptotic material is processed. Recent work describes the horizontal transfer of
oncogenes via uptake of apoptotic tumour cells by fibroblasts (Bergsmedh et al.,
2001). This would presumably require engagement of a third specialised processing
pathway for apoptotic cells distinct from the degradative or antigen presenting paths
currently described. How DX-reprogramming affects the fate of proteins from
phagocytosed particles, and the subsequent effects on macrophage function, for
example antigen presentation or release of anti-inflammatory mediators (Fadok et al.,
1998) must be addressed in order to further understand the potential wide ranging
effects of glucocorticoid therapy.
We could propose a dual role for pl30cas in which it is an important mediator ofRac
activation in adhesion, but a negative regulator of phagocytosis. Which pathway
mediated would be dependent on upstream signalling. For example Tiam-1, a potent
Rac-GEF, poorly induces Jun N-terminal kinase (JNK) activity but strongly
upregulates Pakl (Zhou et al., 1998). Function of both kinases requires Rac activity
therefore the upstream signalling that regulates Rac may also determine the final
cellular response. Phosphorylation of pl30cas after integrin engagement by
macrophage adhesion to fibronectin or dendritic cell engagement of apoptotic cells
may act to transiently sequester pl30cas, mimicking the loss of pl30cas expression
in DX treated cells, enabling activated Rac to be directed towards areas ofmembrane
engaging in phagocytosis. In order to determine whether pl30cas does play such a
pivotal role we sought to re-express the protein in DX-treated macrophages and
determine subsequent phagocytic capability and morphological changes. These
studies will be described in detail in chapter 6.
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CHAPTER 5: THE EFFECT OF GLUCOCORTICOIDS ON MAPK
SIGNALLING
Introduction
Cell migration is a fundamental process required for growth and development, wound
repair, angiogenesis and the inflammatory response. Dysregulation of cell motility
promotes tumour invasion, metastasis, and underlies the pathogenesis of developmental
and immunodeficiency disorders (Keely et al., 1998; Lauffenburger and Horwitz, 1996;
Raff, 1992; Steller, 1995). Directed migration requires the regulation of four cellular
activities: polarization towards chemotactic stimuli, extension of membrane processes,
cell contraction, and formation and turnover of adhesive contacts. Stimuli from
chemokines, or cell-ECM interactions are co-ordinated principally by the Rho family of
GTPases and their down stream effectors which mediate organisation of the actin
cytoskeleton (Keely et al., 1998; Keely et al., 1997; Tapon and Hall, 1997) (for review
see Jones et al., 1998). Initially, polarization of chemokine receptors was thought to
promote directed movement, however it has been subsequently shown that receptors are
distributed diffusely around the cell (van Es and Devreotes, 1999), and accumulation of
lipid products of PI 3-kinase at the leading edge of the cells produces a steep internal
gradient to promote cell polarity and chemotaxis (Hirsch et al., 2000; Li et al., 2000;
Sasaki et al., 2000; Servant et al., 2000). Inhibitors of PI 3-kinase, for example
LY294002, reduce chemoattractant motility in a number of leukocytes: neutrophils
(Knall et al., 1997; Niggli and Keller, 1997), T cells (Vicente-Manzanares et al., 1999)
natural killer cells (al-Aoukaty et al., 1999) and macrophages (Vanhaesebroeck et al.,
1999). As the Rho-family GTPases, Racl and Cdc42 can be regulated by PI 3-kinase
lipid products in leukocytes (Akasaki et al., 1999), and their function is required for
chemotactic movement, it is likely that GTPase function translates the internal gradient
of lipid mediators into directionality. Cdc42 function is not required for random
migration, but is essential for macrophage movement towards CSF-1 (Allen et al.,
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1998), and neutrophils from Rac2 deficient mice cannot chemotax towards fMLP
(Ambruso et al., 2000; Roberts et al., 1999). Lipid products are thought to activate a
cellular tyrosine kinase, which phosphorylates Rho-family specific GEFs. One candidate
is Vav, a substrate for the tyrosine kinases Lck and Syk (Gulbins et al., 1993; Han et al.,
1997). GEF activity is increased on tyrosine phosphorylation, and the presence of the
lipid products of PI 3-kinase (Han et al., 1998). Macrophage movement is initiated by
the extension of filopodia and lamellipodia regulated by Cdc42 and Rac respectively
(Kozma et al., 1995; Nobes and Hall, 1995; Ridley and Hall, 1992). During extension
of processes adhesive contacts and podosomes are formed under the control of
Cdc42/WASp/Arp2/3 complexes, and function to stabilise membrane structures and
maintain cell polarity (Bums et al., 2001; Linder et al., 1999; Zicha et al., 1998).
Podosomes may be important sites of cross talk between cytoskeletal and adhesive
contacts during the regulation of directed migration. Interestingly another effector of
cdc42, PAK, has also been shown to be defective in WAS patients (Haddad et al., 2001).
Contraction of cytoplasmic actomyosin filaments assembled in response to myosin light
chain (MLC) phosphorylation (Adelstein, 1983; Burridge and Chrzanowska-Wodnicka,
1996; Yoshioka et al., 1998), plus the release of contact sites in the trailing edge of the
cell, mediated by RhoA (Alblas et al., 2001; Worthylake et al., 2001) induces forward
movement. Extracellular regulated kinase (ERK) can regulate MLC-kinase, promoting
phosphorylation of MLC, and assembly of myosin fibrils (Klemke et al., 1997).
Phosphorylation of MLC can also be augmented directly by Rho-Kinase (a Rho
GTPases effector) (Amano et al., 1996) or indirectly by phosphorylation and
inactivation ofmyosin phosphatase (Kimura et al., 1996).
The mechanisms modulating random movement or persistent directional movement in
the absence of a chemokine gradient have not been so extensively studied. WASp and
Cdc42 are not required for random movement (Linder et al., 2000; Zicha et al., 1998),
however inhibition of RhoA or Rac does perturb haptotactic movement (Jones et al.,
1998). Additionally the adapter protein She which can mediate sre kinase activation of
122
Ras signalling pathways has been implicated in the regulation of random migration in
carcinoma cells (Collins et al., 1999; Gu et al., 1999).
In addition to Rho family GTPases and PI 3-kinase, multiple signals have been shown to
regulate migration, PLCy (Chen et al., 1994a), FAK (Ilic et al., 1995), c-src and family
kinases (Fincham and Frame, 1998), C3G (Uemura and Griffin, 1999), Pyk2 (Watson et
al., 2001; Williams and Ridley, 2000), Tiaml (Michiels et al., 1995; Sander et al., 1998)
and MAPK (Anand-Apte et al., 1997; Klemke et al., 1997). Functional studies have
described how different regulators modulate distinct aspects of migration in different
cell types. For example Klemke and colleagues demonstrated that during fibroblast
migration pl30cas/crk coupling and Rac activation were required for membrane ruffling
whereas, ERK was required for cell contractility (Cheresh et al., 1999). In addition to
their role in cell migration Mitogen Activated Protein Kinase (MAPK) cascades are
involved in a number of cellular programs including cell differentiation, cell division,
and cell death (for reviews see Ip and Davis, 1998; Lewis et al., 1998; Nebreda and
Porras, 2000). Induction can be triggered by ECM-integrin engagement, or occupancy
of cytokine or growth factor receptors. The MAPK cascade is composed of five
branches or modules: the extracellular-regulated kinase 1 and 2 (ERK1/2) cascade which
regulates growth and differentiation, and more recently has been shown to be an
important regulator of cell migration and survival (Cho and Klemke, 2000); c-Jun N-
terminal kinase (JNK) and p38 MAPK cascades which are activated in response to
stress, for example during inflammation and apoptosis; plus ERK3 and ERK5 cascades
thought also to modulate proliferation (Cheng et al., 1996; English et al., 1999; Robbins
et al., 1993; Zhou et al., 1995). Activation of the terminal kinases, in this case ERK1
and 2, occurs after sequential phosphorylation (and activation) of components of a four
step cascade. This commences on activation of a G-protein, typically Ras, which
activates a MAPKKK (Raf amongst others), followed by activation of a MAPKK
(MEK) before induction ofMAPK (ERK) activity. The cascade enables not only signal
amplification but also cross-talk from stimuli which may modulate the duration and
amplitude of the response, and consequently the biological outcome (Schaeffer and
123
Weber, 1999). DX-treated monocyte/macrophages show a heightened capacity for
reorganisation of cytoskeletal components, and an augmented Rac activity. However
DX induces a downregulation of pl30cas expression and other signalling intermediates
which have been implicated in migration, Tiam 1, C3G, plus a decrease in Pyk2
phosphorylation. We also observe a loss of podosome formation after DX-treatment.
Little work has explored how cell migration contributes to phagocytosis of apoptotic
cells, however we would predict that efficient clearance of apoptotic cells is likely to be
highly dependent on cell motility in vivo. Furthermore cytoskeletal plasticity
accompanying a migratory phenotype would promote the functional rearrangement of
intracellular components required for phagocytosis. In order to investigate the effect of
DX programming on macrophage migration we assessed ERK function, and observed
macrophage migration in vitro.
Results
Glucocorticoids downregulate basal ERK activity
To assess ifDX altered basal activity ofERK 1 and 2 we investigated whether ERK was
phosphorylated by western blotting ofmacrophage cell lysates. Monocyte/macrophages
were matured for 5-days in media containing autologous serum, plus or minus lpM DX.
Cells were lysed in either an NP-40 based lysis buffer or RIPA buffer, whilst adherent to
tissue culture plastic, to prevent any changes in ERK activity during cell detachment.
Whole cell lysates were separated by SDS-PAGE and analysed by western blotting,
firstly with mAbs recognising total ERK2 to ensure equal loading, and secondly with a
mAb corresponding to the active enzyme. This recognises an epitope created by
phosphorylation of a Thr-Glu-Tyr motif in the activation loop of ERK1 and 2. ERK2
was expressed at equivalent levels in untreated and DX-treated cells. Due to cross-
reactivity of the antibody, we were also able to visualise a 44kDa band corresponding to
ERK1, which also showed no change in expression. Assessment of ERK
phosphorylation revealed high levels of basal enzyme activity in untreated macrophages,
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which was significantly inhibited in DX-treated monocyte/macrophages (fig. 1). ERK
activity can be stimulated by serum factors, for example lysophosphatidic acid (Dikic et
al., 1996), and serum starvation of cell lines reduces basal ERK activity. To ensure that
downregulation of ERK activity in DX-treated cells was not due to a premature
depletion of serum factors by increased metabolism or proteolytic activity in the
glucocorticoid treated cultures, we "fed" macrophages with media containing fresh
autologous serum 24hrs prior to analysis of ERK activity. Despite serum replenishment,
levels of ERK activity remained constant in untreated macrophages, with a similar
downregulation in DX-treated cells (results not shown). This suggested that inhibition
of ERK activity might represent a component of DX-programming of monocyte-
macrophage differentiation in concert with the morphological changes and increase in
phagocytosis observed. To examine whether changes in ERK activity followed a similar
pattern to observed morphological changes described in chapter 4, we cultured
monocytes/macrophages for up to 5 days in the presence or absence of lpM DX as
previously described. Lysates were made at 24hr intervals from time 0 to 5 days.
Additionally cells were cultured in the absence of DX for 4 days, then treated with DX
for 24 hrs prior to analysis. The time course ofmonocyte maturation revealed that ERK
activity was reduced after 24 hrs of culture, which might be interpreted as a direct effect
of glucocorticoids on kinase function. However, dexamethasone treatment after cells
had matured in culture for 4 days without glucocorticoid showed no changes in ERK
activity, demonstrating that downregulation of basal ERK function was part of DX
reprogramming ofmacrophage differentiation.
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Figure 1. Effect ofDX on ERK activity
Adherent peripheral blood monocytes were cultured for up to 5 days in the presence
(D) or absence (C) of 1 pm DX, for the periods shown (in hours). Macrophage cell
lysates were assessed for expression of A phospho-ERKl/2 (active) (p44/42 kDa)
and B total ERK2 (42 kDa) by SDS-PAGE and Western blotting. Antibody
concentrations: pERK and ERK, 1:2000.
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Down-regulation of ERK activity does not contribute to glucocorticoid augmented
phagocytic capability
As a reduced ERK activity correlated with the acquisition of phagocytic capacity we
therefore wished to test directly if ERK activity inhibited phagocytosis of apoptotic
cells. Pre-treatment of 5-day monocyte/macrophages with 50nM of the pharmacological
ERK inhibitor PD98059, for 30 min prevented ERK phosphorylation in non-DX-treated
cultures, as assessed by western blotting of control macrophage lysates, see figure 3.
Pre-incubation ofmonocyte/macrophages with PD98059 did not however alter levels of
phagocytosis of apoptotic neutrophils by either non-DX-treated macrophages, or as a
control for potential non-specific effects, DX-treated cells (fig. 2). Analysis was
conducted using both the plate based and flow cytometric phagocytosis assay (see
chapter 1).
Induction ofERK activity in DX-treated macrophages
ERK activity had no effect on phagocytosis in our in vitro assay system, however
reduction in kinase function has implications for migration and phagocytosis in vivo.
Cellular movement at the inflammatory site is likely to be required for the efficient
clearance of apoptotic cells. Time lapse video microscopy of an in vitro phagocytosis
assay showed little movement of either untreated or DX-treated monocyte/macrophages
within a 20-minute assay period, although extension of cytoplasmic processes, sufficient
for phagocytosis was readily observed (I. Dransfield, personal communication). We
may not observe active movement during the phagocytosis assay, as our in vitro system
is likely to lack specific matrix or chemotactic stimuli that would induce movement in
vivo. To investigate if DX-treated monocyte/macrophages were able to activate ERK
signalling cascades in response to classical inflammatory stimuli, we pre-incubated
untreated and 5-day DX-treated monocyte/macrophages with either Ipg/ml LPS,
lOng/ml TNF, InM fMLP or 50nM PD98059 (as a control for the phagocytosis studies),
for 30 minutes, prior to lysis and analysis of ERK phosphorylation by western blotting.
Both LPS and TNF induced ERK phosphorylation in DX-treated macrophages, and LPS
augmented existing activity in control untreated cells (fig. 3). Surprisingly, although
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fMLP induces a calcium spike in monocyte/macrophages, demonstrating the presence of
functional fMLP receptors (K. Ross personal communication), and has been shown to
activate ERK in neutrophils (Avdi et al., 1996; Chang and Wang, 1999; Nick et al.,
1997), the peptide failed to induce ERK activation in either untreated or DX-treated
macrophages (fig. 3).
In addition to inflammatory mediators, MAPK signalling pathways can also be triggered
by engagement of integrin receptors. Macrophages have the capacity to secrete ECM
components in vivo during wound healing and tissue repair and during in vitro
maturation and culture. Differences in matrix production between DX-treated and
untreated monocyte/macrophages could influence the utilisation of a repertoire of
adhesion receptors that fail to maintain basal ERK activity. "Replating" cells onto tissue
culture plastic has been reported to induce a spike ofMAP kinase activity in response to
integrin engagement (Chen et al., 1994b; Clark and Hynes, 1996; Miyamoto et al., 1996;
Morino et al., 1995; Schlaepfer et al., 1994). This may persist at 60-100% of maximal
levels for periods ranging from 15 minutes to 2 hours or more, followed by either a
gradual decline (Chen et al., 1994b; Clark and Hynes, 1996) or a rapid decrease
(Miyamoto et al., 1996; Morino et al., 1995). The kinetics of ERK activation will
depend on the cell type and integrin-ligand interaction involved. As was hypothesised
for paxillin phosphorylation in chapter 4, if the low ERK activity in DX-treated
macrophages were due specifically to "reprogramming", replating would induce an
initial kinase activation, which would diminish rapidly, possibility from engagement of
adhesion receptors employed by the original DX phenotype. Alternately if cell contact
with specific matrices laid down in response to glucocorticoid treatment maintained the
low basal levels of ERK activity, initial induction of kinase function would be likely to
be maintained for a longer period. Analysis of the time course demonstrating
downregulation of ERK activity during monocyte-macrophage differentiation in figure
1, showed ERK activity was decreased after 24hrs but not significantly until day 3-4
which could be interpreted as suggestive of formation of distinct matrix interactions. 5-
day DX-treated monocyte/macrophages were detached from tissue culture plastic by
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incubation with EDTA on ice, washed, resuspended in IDMEM, and allowed to adhere
to virgin plastic for 1, 4 and 6 hrs prior to lysis and assessment of ERK activity.
Western blots demonstrated that ERK activation was induced on initial adhesion but
decreased within 6 hrs to levels equivalent to that seen in 5-day DX treated cells lysed
prior to detachment (fig. 3). This suggests that changes in ERK activity were not due to
differential matrix production by DX-treated cells, but dependent on the repertoire of
adhesion receptors and/or the downstream signalling proteins employed after DX
maturation ofmonocyte/macrophages.
DX attenuation of basal ERK activity is mediated by decreased expression of C3G and
B-Raf
Activation of ERK via soluble mediators, or on engagement of adhesion receptors can
be mediated by Ras/c-Raf and Rap 1/B-Raf signalling. Crosstalk occurs between the two
pathways, as in the absence of B-Raf, Rapl is antagonistic to Ras function inhibiting
ERK activation (Cook and McCormick, 1993). G protein recruitment to
receptors/integrins is mediated via adapter proteins, in the case of Rapl formation of a
Crk/C3G complex is sufficient for Rapl activation during growth factor stimulation and
adhesion to matrix. (Buensuceso and O'Toole, 2000; Kao et al., 2001). DX-treatment
inhibits expression of C3G (fig. 4). Failure to form Crk/C3G complex could account for
the decreased levels of ERK activity after DX-treatment. Analysis of components of
Rapl and other components of this signalling pathway by western blotting of whole cell
lysates demonstrated equal expression of Rapl, but a decreased expression of B-Raf
after DX-treatment (fig 4). Therefore activation of Rapl independent of C3G, for
example via cAMP or PKA would therefore further inhibit ERK activation (Dugan et
al., 1999). This pathway may account for resting levels or ERK activity but is unlikely
to be engaged, and more likely inhibited upon "replating".
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Figure 2. ERK activity is not required for phagocytosis
Adherent peripheral blood monocyte-derived macrophages were cultured in the
presence or absence of lpM DX for 5 days. Macrophages were pre-incubated with
5-50nM PD98059, for 30 min prior to the assessment of phagocytic capacity for
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Figure 3. Stimulation ofERK activity in DX treated macrophages
Adherent peripheral blood monocyte-derived macrophages were cultured in the
presence or absence of lpM DX for 5 days. A Macrophages were incubated for 30
min with either medium alone, fMLP (InM), TNF (lOng/ml), PD98059 (50nM), or
LPS (lfig/ml), before lysis, and assessment of ERK activity as for figure 1. B
Macrophages were removed from culture plastic with EDTA, and replated onto
virgin plastic. Lysates were made over a time course up to 6 hrs, and ERK activity
assessed as for figure 1. C, control untreated cells; D, dexamethasone; F, fMLP; T,




















Figure 4. DX alters components of the Rapl signalling pathway
Peripheral blood monocyte derived macrophages were matured by adherent culture
for 5 days ± lpM DX. Macrophage cell lysates were examined for the expression of
A C3G (121 kDa) B Rapl (21 kDa), and C B-Raf (95 kDa), by SDS-PAGE and
western blotting. C, untreated control cells; D, DX-treated. Antibody concentrations:
C3G, 1:500; Rapl, 1:1000; B-Raf, 1:100.
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DX inhibits macrophage migration in vitro
To determine whether the deficit in basal ERK activity and pl30cas expression in DX-
treated macrophages affected migration in culture, or if activation of ERK with LPS
could rescue the phenotype, we used an in vitro "wound healing" assay. Cell movement
that occurs in response to an artificial "wound" made by scratching a monolayer of cells
with a pipette tip can be assessed by quantification of migration of cells back into the
"wounded" areas. Initially we used 48 or 24 well culture plates, however this gave
equivocal results, particularly in DX-treated cultures as cells appeared to re-seed in the
centre of the wound. We had noted that during culture of monocyte/macrophages in 6
well plates, detached cells, contaminating lymphocytes and cellular debris tended to pool
in the centre of the well, thus wounding towards the periphery of the well would present
a much cleaner assay. Monocyte/macrophages were cultured in 6 well plates for 5 days
± 1 pM DX as described previously. Cells were incubated with either lpg/ml LPS,
50nM PD98059 or culture medium alone for 30 minutes, the monolayer was then
wounded with a pipette tip at intervals over a period of 24hrs, after which cells were
fixed and migration into the empty area of the culture assessed microscopically (fig. 5).
Untreated monocyte/macrophages migrated into the space with significant movement
after 12hrs, and confluency after 24hrs. Incubation of control cultures with LPS which
elevates ERK activity did not appear to augment migration, rather migration at each time
point appeared slightly reduced compared to macrophages incubated with medium
alone. Surprisingly the ERK inhibitor PD98059 had only a very slight effect on
migration in both un-treated and DX-treated cultures. PD98059 has been shown to both
inhibit and not inhibit fibroblast migration (Cary et al., 1998; Cheresh et al., 1999;
Klemke et al., 1997), therefore assessment of the stability of the compound during
culture, and direct quantification of the phosphorylation state of ERK 1 and 2 in
macrophages used in the assay must be addressed before a requirement for ERK activity
for migration in our system is dismissed. Compared to untreated macrophages,
migration of DX-treated monocyte/macrophages was reduced. However, cells were able
to colonise the wound by 24hrs in medium alone and in PD98059-treated cultures. DX-
treated macrophages treated with LPS presented an unusual and unexpected pattern of
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migration. There was little cell movement at 6 hrs, however by 12 hrs cells had
migrated into the wound such that the density of the cells where the monolayer had been
scored was higher than in the surrounding culture. This phenomenon was still apparent
at 24 hrs, but cell density in the strip was reduced. This observation suggests that
wounding may have created a chemotactic signal, possibly through release of cellular
contents of damaged cells. These assays demonstrate that in the presence of an activator
ofERK, DX-treated cells were able to undergo directed migration.
In contrast to untreated control populations where cells migrating into the wound had a
dendritic like, polarized morphology, migrating DX treated macrophages did not appear
polarised, even in LPS treated cultures where migration was more evident. However
some cells appeared slightly more irregular in shape compared to the normal DX
rounded phenotype, even in the LPS treated cultures. Migration of DX-treated cells
suggests that the high levels of active Rac may be sufficient to rescue for the loss of
pl30cas and allow migration. Additionally the assay suggests that with the appropriate
chemotactic stimuli DX-programmed macrophages would migrate as proficiently in vivo
as their unstimulated counterparts.
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Figure 5. Migration of DX-treated monocyte/macrophages
Adherent peripheral blood monocyte-derived macrophages were cultured in
the presence or absence of ljxM DX for 5-days in 6 well culture plates.
Control (A, B, C) and DX-treated (D, E, F) macrophages were pre-incubated
with either medium alone (A, D), 50nM PD98059 (B, E) or lpg/ml LPS (C,
F). Monolayers were wounded with a pipette tip and fixed at 0, 6, 12, and 24
hrs, and migration assessed by phase microscopy (xlO objective).
Discussion
DX downregulates ERK activity but not motility
DX-treatment of monocytes early during monocyte/macrophage differentiation induces
profound morphological and functional changes. DX-treated cells show an increased
ability for the rearrangement of cytoskeletal components, a characteristic "rounded"
phenotype with a heightened capacity for phagocytosis. One prediction would be that
increased cytoskeletal plasticity of DX-treated cells would promote migration.
However, DX macrophages are deficient in two components demonstrated to be
required for migration in several cell types, the adaptor protein pl30cas and activity of
the MAPKs, ERK1 and 2 (Cary et al., 1998; Klemke et al., 1997; Klemke et al., 1998).
Loss of ERK activity correlated with the downregulation of pl30cas expression and the
acquisition of morphological and phagocytic phenotypes. It is unlikely that ERK
directly regulates phagocytic potential since inhibition of ERK activity in untreated
macrophages did not promote phagocytosis. Our inability to detect a role for ERK
activity in phagocytosis may be in part due to the nature of the phagocytosis assay used.
Macrophage monolayers are covered with a "lawn" of apoptotic cells and may therefore
not require active migration, in contrast to the situation in vivo.
We have previously demonstrated that down regulation of Pyk2 and paxillin
phosphorylation was only obtained if cells were exposed to glucocorticoids early during
maturation (see chapter 4). In a similar fashion, we found that ERK activity was
dependent on glucocorticoid programming, as ERK activity in cells matured in the
absence ofDX was refractory to modulation on subsequent steroid challenge. Induction
of ERK activity in DX-treated macrophages remained responsive to inflammatory
mediators, suggesting that DX did not affect kinase function directly, but altered
upstream signalling pathways. Despite a reduction in basal ERK activity, DX-treated
macrophages were able to migrate during an in vitro "wounding" assay. This may be
due to an induction of ERK activity on wounding of the monolayer, compensation of
ERK function by other molecules, or induction of movement via an ERK-independent
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mechanism. Visualisation of active ERK in migrating cells would determine if ERK
were required for DX-treated macrophage migration. Preliminary experiments to
visualise active ERK using anti-phospho-ERK mAb produced a diffuse non-specific
pattern of staining. The difference in migration rate and pattern of migration between
control DX-treated and LPS/DX-treated cultures would suggest that glucocorticoid
programmed cells were able to employ mechanisms resulting in random and directed
migration. Changes in signalling pathways which may account for the down-regulation
of basal ERK activity, or molecules which may compensate for the decrease in kinase
function and pl30cas expression are discussed below.
Changes in adhesion signalling mediate DX-downregulation ofERK activity
Activation of ERK signalling cascade can occur in response to a number of extracellular
stimuli such as growth factors, cytokines, and serum proteins (Schaeffer and Weber,
1999). Many studies have implicated integrins in mediating ERK activation during cell
adhesion, as opposed to adhesion receptors such as cadherins, selectins, and the
immunoglobulin family of cell adhesion molecules (for review see Aplin et al., 1998).
Integrin engagement can potentially induce a number of intracellular signalling
pathways (summarised in fig. 6) many of which are able to activate ERK, and influence
cellular morphology. The kinetics of ERK activity in DX-treated macrophages after
replating onto tissue culture plastic raises a possibility that DX programs a unique
repertoire of adhesion receptors that maintain a low basal ERK activity. ERK activity
following reattachment may be due to the engagement of a specific receptors which then
alters during subsequent culture. Alternatively it has been proposed that ERK can
localise to the cytoskeleton (Reszka et al., 1995), and is activated by cytoskeletal
dynamics during cell spreading on substratum, or during shape changes under fluid shear
stress (Takahashi and Berk, 1996; Tseng et al., 1995). Cytochalasin D, an inhibitor of
actin polymerisation, blocked ERK activation in HUVEC cells (Takahashi and Berk,
1996; Zhu and Assoian, 1995). DX treated macrophages do appear to show increased
cell spreading upon initial adhesion to "virgin" plastic, but regain a rounded morphology
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over time (results not shown), supporting either hypotheses. Determination of the
localisation of ERK activity in adhering cells, to either the cytosol or the cytoskeleton,
by immunofluorescence staining, or western blotting of cell fractions would allow this to
be tested directly. Although we have not investigated the status of all possible activators
of ERK activity during DX-treated monocyte/macrophage adhesion and culture in this
study, the preliminary data presented here are suggestive that several pathways are
compromised by glucocorticoid programming ofmacrophage differentiation.
Rapl activation ofERK
G-proteins, Ras and Rapl can activate similar but distinct pathways leading to ERK
activation (fig 6) (for review see Reuther and Der, 2000; Schaeffer and Weber, 1999).
Upon integrin engagement, src activation ofPyk2 leads to the recruitment of Ras/Raf via
the adaptor protein Grb2, and the Ras-GEF, Sos (Blaukat et al., 1999). Alternatively,
Rapl mediates activation of ERK via B-Raf, and can be linked to adhesion receptors via
the Crk/C3G complex (Gotoh et al., 1995; Okada et al., 1998) in conjunction with other
adaptor proteins. The specific adaptors have not yet been identified, however Crk is
able to bind both paxillin and pl30cas in a phosphorylation dependent manner, and C3G
has been shown to associate with pl30cas in vitro (Kirsch et al., 1998; Sakai et al.,
1994). Interestingly Crk/C3G were also able to activate ERK activity via a Ras
dependent pathway in a haematopoetic cell line 32D, stimulated with soluble mediators
erythropoietin or IL-3 (Nosaka et al., 1999). We would predict that C3G down
regulation in DX-treated cells would inhibit activation of Rapl resulting in decreased
ERK activity, if this pathway were employed during DX-macrophage adhesion.
However, Rapl activity does not potentiate ERK activity in the absence of B-Raf (York
et al., 1998), furthermore association of Rapl with Ras inhibits Ras activation of Raf-1,
decreasing cellular ERK activity (Cook et al., 1993). As B-Raf expression was
downregulated in the presence ofDX, activation ofRapl independent ofC3G would not
be expected to promote ERK activity, and may prevent activation of the kinase by
functional Ras pathways. Buensuceso and O'Toole (2000) have demonstrated the
importance of B-Raf expression in mediating ERK activation in response to adhesion
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signals. Adherent CHO cells had increased ERK activity, low Rapl activity and no
C3G/Crk complex formation. In contrast CHO cells in suspension were shown to have
low levels of active ERK, and high levels of active Rapl from C3G/Crk association.
ERK activity was induced in suspension cells by expression of B-Raf. The observation
of Crk/C3G coupling in suspension cells conflicts with previous findings that formation
of the complex was associated with adhesion in BaF3 cells, a B cell line (Uemura and
Griffin, 1999). Signals mediated by the Crk/C3G complex may be cell type specific, or
dependent on the Crk family member or C3G splice variant employed (Matsuda et al.,
1992; ten Hoeve et al., 1993; Zhai et al., 2001). During cell attachment Crk binds a
number of protein partners including pl30cas and paxillin, which may sequester Crk
from C3G. Loss of pl30cas phosphorylation in suspension would disrupt pl30cas/Crk
complex formation that may promote the interaction of Crk with C3G. The balance of
effector proteins present within the cells would therefore determine the complexes
formed and hence the functional outcomes. It would be intriguing to know how loss of
pl30cas and C3G in DX-treated cells effects the pattern of Crk/protein interactions.
Regulation of B-Raf expression has also been shown to regulate ERK responses to
exogenous stimuli in neighbouring cell types. Central nervous system-derived neurons,
but not astrocytes express B-Raf. Consequently elevation of cAMP induces ERK1/2
activity in neurons, promoting cell survival, but inhibits kinase activation in astrocytes,
reducing proliferation and promoting differentiation (Dugan et al., 1999). Therefore B-
Raf acts as a molecular switch that enables different functional outcomes in cells from a
single soluble messenger.
PKA can modulate the activation ofRaf-1 and B-Raf. High intracellular cAMP prevents
Ras-induced ERK activity by inhibition of Raf-1 function in fibroblasts (Cook and
McCormick, 1993; Sevetson et al., 1993). In contrast, elevated cAMP promotes Rap-1
activity (de Rooij et al., 1998; Vossler et al., 1997; York et al., 1998). We have
previously shown in the laboratory that treatment of monocyte/macrophages with
substances which elevate cellular cAMP, and hence PKA activity, induce rounding and
detachment of macrophages resulting in the inhibition of phagocytosis due to the
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disruption of cytoskeletal components (Rossi et al., 1998). The morphological
appearance and altered actin organisation in DX-treated macrophages is suggestive that
intracellular levels of cAMP may be elevated. However, the highly phagocytic nature of
DX-treated populations argues against this. The absolute levels of intracellular cAMP
and localisation may induce different effects on cell architecture, with a slight elevation
inducing cell rounding such as that observed in DX-treated cultures, whereas higher
levels may induce disruption of cytoskeletal elements as described by Rossi et al.
(1998). Increased levels of cAMP, although potentially activating ERK have an
opposing effect on the principal ERK substrate during cell migration, MLC-kinase
(MLCK). PKA phosphorylates and inhibits MLCK enzymatic activity (Lamb et al.,
1988), and hence MLC phosphorylation. In addition, PKA reduces RhoA activation of
Rho-kinase, which is also able to promote MLC phosphorylation (Dong et al., 1998;
Lang et al., 1996). We would therefore predict that elevated levels of PKA activity
would be inhibitory to migration.
ERK activation via Src-kinases and Pyk2
Although FAK is a major mediator of integrin-induced ERK activity, we do not detect
expression in monocyte/macrophages. Instead, several FAK functions are mediated by
the sister kinase Pyk2. Integrin engagement and src activation induces the recruitment
and phosphorylation of Pyk2 to sites of focal contact and membrane ruffles at the
leading edge ofmigratory cells (Duong and Rodan, 2000; Watson et al., 2001; Williams
and Ridley, 2000). Changes in Pyk2 phosphorylation may be mediated by an increase in
phosphatase activity or decrease in kinase function. Peritoneal exudate macrophages
from Hck'VFgr" double mutants exhibit decreased tyrosine phosphorylation of paxillin
and Pyk2 (Suen et al., 1999). Therefore Src-family kinases represent potential targets
for steroid modulation. Phosphorylation of tyrosine residues on Pyk2 enables Ras-
mediated ERK activity via Grb2 and Sos (Blaukat et al., 1999). Src can also initiate
ERK activation independent of Pyk2 with direct localisation ofGrb2/Sos via the adaptor
protein She, which has been linked to the regulation of random cell migration (Collins et
al., 1999; Gu et al., 1999). Loss of Pyk2 phosphorylation in resting DX-treated cells
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could also potentially compromise ERK activity. Williams and Ridley (2000)
demonstrated that exposure of peripheral blood monocytes and macrophage cell lines to
LPS induced phosphorylation of paxillin and Pyk2. We have not assessed the effect of
LPS treatment on paxillin or Pyk2 phosphorylation in DX-treated cells, but we do
observe augmented ERK phosphorylation. Since replating DX-treated macrophages
induced both ERK and paxillin phosphorylation we would predict increased Pyk2
phosphorylation on reattachment. 1 therefore propose that Pyk2 dephosphorylation
observed during DX-programming may be the principal effector for the decreased ERK
phosphorylation observed in glucocorticoid-treated cells. The use of pharmacological
inhibitors of Pyk2 phosphorylation would provide a useful tool for the investigation of
this pathway.
ERK activation via Rho family GTPases
Cross talk between signalling pathways has revealed induction of ERK activity by Rho
family GTPases. Rho has been proposed to activate ERK activity via interaction with
Raf-1 (Li et al., 2001), additionally Cdc42 and Rac activate the ERK cascade, via PAK1.
PAK1 phosphorylates MEK on ser298 required for the maximal association of MEK
with Raf-1 (Frost et al., 1997). However PAK1 can also phosphorylate and inactivate
MLCK (Sanders et al., 1999; van Leeuwen et al., 1999). Localisation of opposing
signals may allow the inhibition of contraction during cell protrusion at the leading edge,
but allow contraction in the tail. Despite high levels of active Rac in DX-treated cells
we see no resting ERK activity. Potentiation of MAPK signalling pathways by Rho-
family GTPases in DX-treated cells may require further molecular cues not present in
these cells, alternatively Rac may be sequestered away from components of the MAPK
pathway. Interestingly, overexpression of active Rac in either tumour cell lines or
pl30cas deficient fibroblasts was not sufficient to promote migration (Cho and Klemke,
2000). This suggests that additional functions mediated by the pl30cas/Crk complex are
required for cell movement, for example specific localisation of active Rac to the
leading edge of the cell. Localisation of Rac and phosphorylated ERK by
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immunofluorescent staining may suggest if Rac is able to influence ERK activity in
migrating DX-treated macrophages.
PI 3-Kinase andERK activation
PI 3-kinase activity has been shown to be important for cell polarization during directed
migration (Sasaki et al., 2000; Servant et al., 2000). The lipid kinase has also been
shown to activate ERK activity in response to adhesion, via a multi-protein complex
containing the tyrosine kinase syk, adaptor proteins cbl and Grb2, and the GEF Vavl, in
response to anbp3 integrin ligation (Miranti et al., 1998). Additionally, PI 3-kinase
coupling to the adaptor protein cbl, has been shown to maintain basal ERK activity in
HL60 cells (Finkelstein and Shimizu, 2000). Preliminary evidence suggested that
tyrosine phosphorylation of cbl and Vav, required for protein/protein interactions is
downregulated in DX-treated macrophages (results not shown), which could
compromise directed migration. PI 3-kinase can promote movement independent of
ERK activation through Rho-GTPases (Rickert et al., 2000). The catalytic domain of PI
3-kinase facilitates Rac activation, lamellipodia formation, membrane ruffling, and
migration towards a CSF-1 gradient (Vanhaesebroeck et al., 1999). Additionally the
p85 subunit is required for Cdc42 induction of filopodial formation during fibroblast
migration towards PDGF (Meng and Lowell, 1998). In addition to its role in regulating
cytoskeletal organisation, PI3-kinase has been implicated in the regulation of exocytic
insertion of recycling endosomes at the leading edge of the cell, required for the
extension of cellular processes during phagocytosis (Bajno et al., 2000). A similar
requirement for recycling of membrane has been proposed for migration (Mellman,
2000). Recycling receptors have been shown to appear preferentially at forward margins
ofmigrating cells (Pierini et al., 2000).
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Directed verses random migration: Migration ofDX-treatedmacrophages
The "wounding" assay provides a simple assessment of cell motility, and provides an
assay for directed movement. Scoring of the plate may induce the active release of
soluble mediators from damaged cells that could function as a chemoattractant.
Movement after scoring a monolayer of cells may be induced by loss of cell-cell contact,
with movement into the gap, until contact with neighbouring cells occurs again, as
demonstrated by macrophages in untreated cultures. DX treated cells were able to
colonise the gap left by scoring, although movement appeared to be less efficient than
untreated cells, with only a slight polarization of cells during migration, suggestive of
random movement. Interpretation of the "type" of motility induced in either culture
must be made with caution. The cell density of the DX-treated cells was lower than
untreated cells, with very few contacts between neighbouring cells in the culture.
Although apparent to a greater degree in this assay, it is a feature of all DX-treated
macrophage cultures. The lack of cell-cell contact might prevent DX-treated
macrophages "sensing" the wounded area. Direct comparison with untreated cultures
may only be valid with a complete monolayer of DX treated cells. In view of this, re-
colonisation of the wound to a level nearly comparable to original cell density after
24hrs by random movement suggests DX-treated macrophages may in fact be more
motile than their untreated counterparts. Time laspe video microscopy would reveal the
role of directed or random migration in the re-colonisation process.
Migration of cells in the presence of LPS produced some intriguing results. Control
cells appeared to migrate slightly less than non-LPS-treated cultures, despite the
induction of elevated levels of ERK by LPS. Williams and Ridley (2000) demonstrated
that LPS treatment of the macrophage cell line J774 induced phosphorylation of paxillin
and Pyk2 and increased cell spreading. Augmentation of adhesive contacts could
decrease migration. Migration of DX-treated cells in the presence of LPS was
suggestive of a directional response, as the density of cells in the wound was greater
than in the surrounding culture after 12 hours. Cell density in the wound decreased after
24hrs suggesting a resumption of random migration by glucocorticoid programmed
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cells. In the absence of pl30cas, we would not predict an induction of directional
migration (Cary et al., 1998; Cheresh et al., 1999; Klemke et al., 1998; Rigot et al.,
1998; Yenush et al., 1994). However, some groups have demonstrated that pl30cas is
not required for directed migration (Bornfeldt et al., 1995; Coffer et al., 1998). The high
levels of active Rac observed in DX-treated macrophages, which is thought to be
functionally downstream of pl30cas in migration signalling (Cheresh et al., 1999), may
be sufficient for cell movement in the absence of pl30cas expression, and may allow
rapid movement when ERK activity is elevated by LPS. The lack of inhibition of
movement in either untreated or DX-treated cells by PD98059 would suggest ERK
activity is not required for directed or random migration in our system. Analysis ofDX-
treated cell migration in the presence of LPS (and hence a strong ERK response) and
PD98059 may be more informative. Assessment of the activity of PD98059 during the
time course of the assay must be verified before conclusions are drawn. It would be
nai've to expect migration would be regulated by one single pathway across a broad
range of cell types and exogenous stimuli. Cell type and stimuli specific pathways
would ensure that, for example, an inflammatory cytokine, which may be perceived by a
number of inflammatory cells would only be translated into movement by a subset.
Modulation of a number of signalling pathways by DX has been discussed above. It is
unlikely that all the pathways modulated by DX-programming will have a direct
functional effect on DX-treated macrophage movement, but may affect other cellular
processes that also utilise components of that signalling pathway.
Wider implications
Engagement of specific adhesion receptors, or cytokine/growth factor receptor
stimulation, can induce a number of intracellular signalling pathways leading to ERK
activation. The specific pathway employed is able to determine the duration and
amplitude of ERK activity, and subsequently the biological outcome. For example
Epidermal growth factor receptor (EGF-R) stimulation of neuronal PC 12 cells induces
transient activation of ERK 1 and 2 activity inducing a proliferative response whereas
treatment of cells with NGF promotes a sustained activation of ERK 1 and 2 leading to
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neuronal differentiation. The sustained as opposed to transient activation has been
suggested to be due to activation via Rapl-B-raf interaction on NGF R stimulation as
opposed to EGF R recruitment of Ras-c-Raf (York et al., 1998). The duration and
amplitude of the ERK response may determine the functional outcome by activation of
transcription factors such as Elk-1 and Ets. Ets induces the transcription of a number of
proteins required for proliferation, p21, cyclinDl, and Fos. As macrophages are
terminally differentiated cells, decrease in mitogenic signals will have no effect on
proliferation but may affect cell viability. Cho and Klemke (2000) have proposed that
migratory cells suppress their apoptotic pathway during migration and detachment from
matrix via pl30cas/crk and ERK pathways. DX downregulation of both pl30cas and
basal ERK activity may have implications for monocyte/macrophage survival during
migration in vivo. The induction of ERK activity with LPS and TNFa would suggest
that DX-programmed cells are able to respond to some soluble mediators. Flowever,
ERK activity has been shown to be required for the active secretion of TNFa (Barouch
et al., 2001; Kraatz et al., 1999; Means et al., 2000), and some cellular effects of IFNy
are thought to be mediated via the C3G/Rapl signalling pathway in human NB-4 cells.
How DX-programmed macrophages respond and interact with their cytokine

















Figure 6. ERK and Rho-GTPase signalling pathways during migration
Adhesion to matrix or occupancy of chemokine receptors activates a number or
pathways leading to migration. PI 3-kinase and its lipid products induce cellular
polarization, Cdc42/Rac and WASp/Arp2/3 actin polymerisation mediates extension
of membrane processes, and activation of the ERK signalling cascade results in
contraction of the cell through phosphorylation of MLC and formation of
actomyosin fibres. See text for details.
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CHAPTER 6: GENERATION OF AN HIV TAT FUSION
PROTEIN FOR THE TRASNDUCTION OF P130CAS INTO
MACROPAHGES
Introduction
Based upon data presented in chapters 4 and 5, we have proposed that
glucocorticoids "reprogram" macrophage differentiation resulting in a phenotype
characterised by altered cytoskeletal organisation, and augmented phagocytic
capacity. Our results suggest that this is mediated by the changes in expression and
activation of a number of proteins previously shown to regulate cytoskeletal
dynamics and which are also components of the phagocytic machinery. In particular,
DX down regulates the expression of pl30cas, an adapter molecule involved in a
number of cellular functions including migration, adhesion, cell cycle, apoptosis, and
recently phagocytosis (Albert et al., 2000; O'Neill et ah, 2000). We hypothesised
that down regulation of pl30cas expression promotes the reduction of adhesion
structures resulting in an increased availability of cytoskeletal components required
for phagocytosis. Re-expression ofpl30cas in DX-treated macrophages would allow
us to directly assess the importance of this protein in DX-programming. However,
transfection of macrophages with DNA expression constructs is exceedingly
inefficient. Lipid based transfection protocols and electroporation result in only a
low percentage of transfected cells, although some success has been achieved using
adenoviral vectors (Foxwell et al., 1998). One potential problem is that adenoviral
entry is mediated in part via avP3 integrin, a putative "phagocytic receptor". In
addition, pl30cas phosphorylation has been shown to be required for adenoviral
entry into colon carcinoma cells (Li et al., 2000). The use of adenoviral vectors to
study the effects of pl30cas expression on phagocytic processes may therefore
produce equivocal results. Microinjection of plasmid constructs or purified protein
has also been used for expression of proteins in macrophages. Since this procedure
requires the direct physical introduction of material into cells, only a few percent of
cells in a culture can be modified, prohibiting this method for biochemical analysis
or studies which require responses from the cell population as a whole. An
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alternative approach would be the use of cell lines. Treatment of the mouse
macrophage line J774 with DX induced a similar down regulation of pl30cas
expression as is seen in human peripheral blood monocyte derived macrophages.
However, phagocytosis of apoptotic cells in both untreated and DX-treated J774s
was very low (~ 1%), and therefore this does not present as a viable model.
Direct introduction of proteins into a variety of cell types including macrophages has
recently been achieved by utilising peptide domains that enable the direct
transduction of proteins through the cell membrane. Transduction mediated by the
HIV TAT protein was first demonstrated independently by Green and Frankel when
TAT was added to culture media (Frankel and Pabo, 1988; Green and Loewenstein,
1998). The ability of TAT to transduce into cells is dependent on an eleven amino
acid sequence termed the protein-transduction domain (PTD). PTDs have also been
identified in Antennapedia (Antp) (Joliot et al., 1991), a homeotic transcription factor
of Drosophila, and the herpes-simplex-virus-1 DNA binding protein VP22 (Elliott
and O'Hare, 1997). The mechanism of transduction is unknown, however it does not
require a classical receptor, transporter, endosome, or absorptive-endocytosis-
mediated process (Derossi et ah, 1996; Derossi et ah, 1994; Elliott and O'Hare, 1997;
Mann and Frankel, 1991; Vives et ah, 1997), and efficient transduction of Antp and
TAT still occurs at 4°C (Derossi et ah, 1994; Vives et ah, 1997). Sequence analysis
revealed the presence of basic residues within the PTD which may facilitate contact
with negatively charged lipids (Elliott and O'Hare, 1997; Green and Loewenstein,
1998; Joliot et ah, 1991). Secondary structure analysis also offers few clues to the
transduction mechanism. Antp PTD when translated as part of the whole protein
demonstrates a helical formation, however the Antp PTD peptide in isolation is less
structured (Derossi et ah, 1996). Additionally TAT PTD appears structure-less by
circular dichroism and nuclear magnetic resonance spectroscopy (Loret et ah, 1991;
Mabrouk et ah, 1991), but protein-structure predicting algorithms suggest that TAT
PTD can adopt a helical conformation (Schwarze et ah, 2000). It is not known if
VP22, TAT or Antp transduce via a common mechanism. Antp induced transduction
is limited to proteins with less than 100 residues (Derossi et ah, 1998), whereas both
TAT and VP22 PTDs are able to allow entry ofmolecules of over 1000 amino acids
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(Fawell et al., 1994; Schwarze et al., 1999). Moreover superparamagnetic iron
particles up to 40nm in diameter, coated in TAT PTD have been introduced into T
cells (Lewin et al., 2000). A model of Antp transduction involving inverted micelles
has been proposed by Derossi et al. (1998), in contrast Dowdy and colleagues
suggest in the instance of TAT, a mechanism whereby the localised positive charge
of the PTD directly penetrates the lipid bilayer (Schwarze et al., 2000). Whatever the
mechanism of transduction, proteins appear to be partially or totally unfolded during
entry, with refolding inside the cell by HSP90 heat shock proteins (Bonifaci et al.,
1995). This can result in loss ofactivity in certain cases, for example transduction of
TAT-GFP into mammalian cells results in a high intracellular level of TAT-GFP, but
significant loss of GFP fluorescence (Schwarze et al., 2000). The efficiency of
correct refolding is likely to be protein specific, and may be problematic when
transducing proteins across species. In order to test our hypothesis that pl30cas
downregulation is an important factor in mediating DX reprogramming we
constructed a TAT-pl30cas fusion protein, plus a TAT-(3galactosidase fusion as a
control for transduction into DX-treated monocyte-macrophages. The fusion protein
was created by insertion of sequence into the pTAT-HA vector (kindly supplied by
S.F. Dowdy, Washington University School of Medicine, St. Louis, USA). This
construct contains an N-terminal 6-histidine leader, for affinity purification, followed
by the 11 amino acid TAT PTD, flanked by glycine residues (for free bond rotation
of the domain), and a hemagglutinin (HA) tag, under the control of an IPTG
inducible T7 promoter.
Cloning Strategy
Full-length human pl30cas was kindly provided by F. Hildebrant (University
Children's Hospital, Freiburg, Germany), in pUNI-V5-His vector (Invitrogen). The
sequence was identical to accession nm_014567 with the exception of two silent
polymorphisms at position 1384: g=>a, and 2065: a=>g. The pUNI-V5-His/pl30cas
construct was originally generated by T/A cloning ofPCR amplified pl30cas (coding
region nucleotides 122-2734 of nm_014567, no 3' UTR), consequently no restriction
enzyme sites for excision of the coding region were available. Construction of HIV-
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TAT fusion protein requires an in-frame insertion of coding sequence into the Ncol
restriction enzyme site located 5' to the TAT peptide sequence, minimising the
insertion of "junk" amino acids which may compromise the folding or function of the
resulting fusion protein. Our initial strategy was to design a 5' primer corresponding
to sequence encoding the first few amino acids of pl30cas, but with the insertion of
an artificial Ncol site around the ATG initiation codon. Secondly, we would design
a 3' primer for annealing to pUNI-V5-His vector sequence directly after the T/A
cloning site, generating an artificial Xhol restriction site for ligation into the final
TAT vector, removing any 3' UTR from the pUNI-V5-His vector. The resulting
PCR product would be sub-cloned into pGEMT vector (Promega) via A overhangs,
excised via Ncol/Xhol digest, and ligated into the pTAT construct. However
pl30cas contains two Ncol sites (positions 711 and 933 of nm_014567 sequence),
digestion of pGEMT/pl30cas or the pl30cas PCR product directly would result in
fragmentation of the coding sequence, and failure to clone the full length insert. We
therefore employed an alternative strategy whereby pl30cas was amplified by PCR
using the original 3' primer, but with a second 5' oligomer containing an artificial
Kpnl restriction site upstream of the pl30cas coding sequence. This would allow in-
frame ligation of pl30cas into pTAT-HA vector six base-pairs 5' to the original Ncol
cloning site, with insertion of four additional amino acids (alanine, glycine threonine
and methionine) between the TAT and pl30cas sequences.
Results
PCR amplification ofpl30cas
Full-length pl30cas was amplified from pUNI-V5-His/pl30cas vector using the
proofreading Pwo DNA polymerase and the following primers:
Forward: yAAA CCG GGT ACC ATG AAC CAC CTG AAC GT 3'
Reverse: y GGC TTA CCG AGCTCGAGA ATT GCC CT 3'
The inserted Kpnl restriction site GGTACC (underlined) resulted in the substitution
of two base pairs, AC=>GT (bold), 5' to the ATG start (italics). The reverse primer
was designed from vector sequence immediately down stream of the PCR cloning
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site of pUNI-V5-His. This produced a substitution of two base pairs CC=>GA
(bold) creating a Xhol restriction site CTCGAG. A product of ~2.7 kb was
amplified using an annealing temperature of 60°C, corresponding to the 2.62 kb
coding region of pl30cas (Fig la).
Cloningpl30cas PCR product into pGEM-T easy vector
Pwo was used for amplification ofpl30cas due to its proofreading capacity, however
this enzyme does not produce poly-A overhangs at the ends of PCR products, in
contrast to Taq polymerase. PCR product was therefore incubated with dATP and
Taq polymerase, to "tail" the product for ligation into pGEM-T. Concentration of
product was estimated visually by running an aliquot on a 1% agarose gel, and the
remaining product ligated into pGEM-T easy vector (Promega) at a 3:1
(insert:vector) ratio. Ligations were transformed into E.coli (TOP 10 strain), plated
onto agarose containing ampicillin and X-gal/IPTG for blue/white selection of
positive clones. Insertion of PCR product into pGEM-T easy vector disrupts coding
of the p-galactosidase (Pgal) encoding LacZ gene, positive clones are unable to
metabolise the chromogenic substrate X-gal, and colonies remain white. Half a
dozen positive colonies were picked and amplified by growth overnight in liquid
culture plus ampicillin selection. Plasmids were extracted using a Promega Wizard
mini-prep kit, and the resulting plasmid DNA checked for inclusion of the pl30cas
sequence by restriction digest with EcoRI. EcoRI restriction sites flag the PCR
cloning site, "dropping-out" the insert resulting, in two bands of approximately 3.0
kb (pGEM-T), and 2.7 kb (pl30cas) (fig. lb).
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Figure 1. Construction ofpTAT/HA-p!30cas
A PCR amplification of the 2.7 kb coding region of pl30cas from pUNI-V5-
His/pl30cas (gift from F. Hildebrant, University Children's Hospital, Freiburg,
Germany). Forward primer AAA CCG GGT ACC ATG AAC CAC CTG AAC GT,
Reverse primer GGC TTA CCG AGC TCG AGA ATT GCC CT, annealing 60°C. B
Mini-prep DNA of pGEM-T-pl30cas sub-cloning digested with EcoRI. Bands
correspond to insert (2.7 kb), and plasmid (3.0 kb). C Mini-prep DNA of pTAT/HA-
pl30cas sub-cloning digested with Kpnl and KpnI/XhoI. Bands correspond to
linearised vector (5.7 kb), insert (2.7 kb), and plasmid (3 kb). M, marker,
corresponding to 1 kb ladder (10, 8, 6, 5, 4, 3, 2.5, 2, 1.5, 1, 0.75, 0.5, 0.25 kb); W,
water control; C, pl30cas; 1-6, individual transformants.
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Sub-cloningpi30cas into pTAT/pTAT-HA
After creation of pGEM-T-pl30cas, we next subcloned the pl30cas sequence into
pTAT/HA using the artificial restriction sites engineered during PCR amplification.
pGEM-T-pl30cas and pTAT/HA were digested with Kpnl, an aliquot of the digest
visualised on an agarose gel to ensure full linearisation had occurred, and the
remaining DNA purified before digestion with Xhol, as the two enzymes required
different salt buffers for optimal activity. After digestion with Xhol, pGEM-T and
pl30cas fragments were separated on an agarose gel, and the 2.7 kb band
corresponding to pl30cas was excised and purified. As digestion of pTAT vectors
produces only one major product, plasmid was purified directly from the digest. The
pTAT-HA-pl30cas was created by ligation of products in a 3:1 insert:vector ratio
and transformed into TOP 10s. The pTAT vector does not support blue/white
selection therefore in order to estimate the efficiency of the ligation reaction, a
second ligation containing vector only was set up in parallel to pTAT-HA-pl30cas,
and equal amounts of bacterial transformants plated onto agar overnight.
Comparison of the number of colonies between vector only and vector plus insert,
then allowed estimation of the percentage of positive clones. pTAT-HA-pl30cas
produced approximately a 5 fold greater number of colonies than the vector only
plates. Ten clones of the pTAT-ElA-pl30cas transformants were picked, amplified
overnight in liquid culture, plasmid extracted and assessed for presence of insert by
digestion with BamHI and Sphl. This combination of restriction enzymes "dropped
out" the pl30cas insert in 3/12 clones (results not shown). Sequential digestion of
the three positive clones demonstrated insert of the plasmid at Kpnl and Xhol sites as
expected, producing bands of 5.7 kb (linearised vector), 2.7 kb (pl30cas insert) and
3.0 kb (pTAT vector) (fig. lc).
SequencingpTAT-HA-p130cas construct
Although a proofreading polymerase enzyme was used for amplification of pl30cas
from the gift vector, sequence changes may still have occurred. We therefore
designed 8 primers to allow sequencing of the entire 2.65 kb reading frame of
pl30cas in the pTAT-HA-pl30cas construct. Plasmid DNA from clone 1 was
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retransformed into TOP 10s and plated onto agar with ampicillin selection. A single
colony was picked and grown in 50mls of liquid culture for bulk purification of
DNA, using a Qiagen plasmid midi prep kit, resulting in purification of 100(il of
plasmid DNA at 2.1|ig/|il. Plasmid was then sequenced using an automated ABI
sequencer by N. Kotelevtseva (CVRI Molecular Physiology Group, Edinburgh
University). The sequence of the TAT-HA-pl30cas coding region, plus positions of
sequencing primers is shown in Appendix A. Cloning resulted in an in-frame fusion,
however four base pair substitutions had occurred during PCR amplification of the
pl30cas transcript, at positions 390 (A—>G), 476 (A—>G), 1501 (A—>T), and 2364
(T—>A) (corresponding to sequence accession number nm_014567), resulting in
His—>Arg; Thr—>Ala; Gin—>Leu; and Leu—>Gln amino acid substitutions respectively
(see Appendix A).
Construction ofpTAT-HA/LacZ control plasmid
We would predict that transduction of TAT/pl30cas fusion protein would affect cell
morphology, and possibly phagocytic function. In order to determine if changes in
macrophage function are specific for the re-expression of pl30cas and not the
introduction of "foreign protein" per se, we constructed a control vector containing
the LacZ gene which encodes the (3-galactosidase (Pgal) enzyme. (3gal at 119 kDa is
of a comparable size to pl30cas, is non toxic, and has the ability to produce blue
pigmentation when incubated with the chromogenic substrate X-gal, enabling
estimation of transduction efficiency by light microscopy.
A vector containing sequence encoding (3-Gal, pnlacF, kindly supplied by A. Lacy-
Hulbert (CIR, Edinburgh University), was first digested with Bglll , the resulting 5'
overhangs blunted using Klenow DNA polymerase, and further digested with Ncol,
producing a fragment of approximately 3.6 kb. This corresponds to the 3.06 kb
coding region plus downstream sequence from the pnlacF vector. (3gal was then
ligated into pTAT-HA via 5' Ncol, and 3'XhoI (blunted) restriction sites. Ligations
were transformed into TOP 10s as before, plating on ampicillin plates containing X-
Gal/IPTG for blue/white selection. Blue colonies were picked and screened by
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NcoI/SphI digest which "dropped out" the insert in 6/6 clones (fig. 2). The blue
white selection also demonstrated the transcript was cloned "in-frame", producing
functional (3-galactosidase.
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Figure 2 . Construction of pTAT/HA-(3gal
Mini-prep DNA of pTAT/HA-Pgal sub cloning, digested with Ncol/Sphl. Bands
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Production ofTATfusion protein: Selection ofhigh expressing clones
Fusion proteins can be produced in E.coli by transfection of a plasmid construct
containing the gene of choice. The pTAT plasmid contains an IPTG inducible
promoter. However upon induction, not all transformants will synthesise protein at
the same level. This can be due to the copy number maintained by the clone, but can
also be affected by the toxicity of the protein. Additionally, production is likely to
have an inverse correlation with growth and replication, with very high levels of
protein production compromising viability. We therefore assessed the level of
pl30cas and (3gal synthesis from a number of individual colonies.
pTAT-HA-pl30cas and pTAT-HA-(3gal were transformed into E.coli strain BL21,
plated onto ampicillin plates and 6 colonies from each transformation selected and
grown as starter cultures O/N in the presence of antibiotic selection. The following
day starter cultures were used to inoculate media for growth of cells to an OD6oo of
0.5, before induction of protein synthesis for 5hrs with IPTG. Cells were lysed and
protein solubilised using lysis buffer containing 8M urea. Initially samples were
analysed immediately by SDS-PAGE then either Coomassie-blue protein staining of
acrylamide gels, or by western blotting with mAb specific for the HA epitope or
pl30cas. Bands of approximate size could be identified by Coomassie-blue staining,
with 2/6 pTAT-pl30cas transformants, and 3/6 pTAT-pgal transformants appearing
to express fusion protein to a detectable level. To ensure the candidate bands
corresponded to pl30cas and (3gal fusions, samples were assessed by western
blotting. Unfortunately both HA and pl30cas mAb had a high level of cross
reactivity with endogenous bacterial proteins, masking identification of fusion
proteins. To minimise the presence of cross reacting protein, the clones viewed as
high expressers by Coomassie-blue analysis, were grown and induced as before, but
fusion proteins precipitated with a small amount of Ni-NTA resin, prior to analysis
by SDS-PAGE and western blotting. Semi-purification and concentration of the
fusion proteins allowed clearer identification by Coomassie-blue staining and
enabled definite identification when a sample of each fusion protein was assessed by
western blotting (fig. 4).
158
A B
1 2 3 1 2 3
M L W P L W P L W P M L W P L W P L W P
185 185




(kDa) 60 60 10$
49 !! H 49 i,;:■ iiiS







L W P L W P
Figure 4. Identification of clones expressing high levels of TAT/pl30cas and
TAT/pgal fusion protein
E.coli strain BL-21 was transformed with pTAT/HA-pl30cas and pTAT/HA-flgal
constructs. Single colonies were amplified in liquid culture and expression of fusion
constructs assessed by SDS-PAGE and Coomassie blue staining. High expressing
clones were semi-purified by immunoprecipitation of proteins with Ni-NTA resin. A
Coomasie blue staining of SDS-PAGE gel of pl30cas purification. B (3galactosidase
purification. C Western blot of two highly expressing clones probed with mAb
specific for the HA epitope (1:250). Putative fusion proteins are indicated by arrows
in panels (A) and (B), TAT/pl30cas (135 kDa), TAT/pgal (125 kDa). M, molecular
weight marker; L, whole cell lysate; W, wash; P, semi-purified fusion protein.
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Bulkproduction ofTAT-fusion proteins: His-Tagpurification
Starter cultures of G2 and C2, clones highly expressing TAT/(3gal, and TAT/pl30cas
fusions respectively were grown in liquid culture O/N and used to inoculate 500ml
(G2) and 1L (C2) of LB-broth containing lOOjig/ml ampicillin. Cultures were grown
until an OD60o of 0.5 was obtained and then induced with IPTG for 5 hours. Cells
were lysed in denaturing conditions with buffer containing 8M urea, pH 8.0, lysates
clarified by centrifugation and incubated with Ni-NTA resin plus lOmM imadazole
(to minimise non specific binding). After incubation, the resin/lysate mix was loaded
into 50ml syringes containing a nylon wool plug (to prevent loss of resin through the
syringe), and allowed to pass through by gravity flow, with the effect that the Ni-
NTA beads sedimented with fluid flow, creating a resin column. The column was
washed to remove non-specifically bound proteins with urea buffers at pH 8.0, and
pH 6.3, and eluted in denaturing buffer in fractions at pH 5.9 and pH 4.5. Samples
from each step of the column were analysed by SDS-PAGE and western blotting.
Coomasie-blue staining of acrylamide gels revealed the presence of clean bands of
~135 kDa and 125 kDa for pl30cas and p-gal fusions, respectively (fig. 5a,b). This
corresponds to the addition of the TAT leader sequence of ~3.5 kDa, and the HA tag
of ~1.5 kDa. Both proteins eluted at pH 5.9, corresponding to monomeric protein,
but also at pH 4.5 that allows the elution of multimers and aggregates. Western
blotting with anti-pl30cas and anti-HA mAb demonstrated these bands corresponded
specifically to pl30cas and (3gal (fig. 5c,d).
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Figure 5. His-Tag purification of TAT/pl30cas and TAT/ftgal fusion proteins
Bulk cultures of high expressing clones induced with IPTG were lysed with 8M urea
and purified over a Histidine binding Ni-NTA column to isolate tagged proteins
TAT/pl30cas (A, C) and TAT/pgal (B, D). Washes and elutions were assessed for
protein content by SDS-PAGE and together with Coomassie blue staining (A, B) or
western blotting with mAb specific for pl30cas panel C (1:5000), or HA panel D
(1:250). TAT/pl30cas (135 kDa), TAT/pgal (125 kDa). M, molecular weight
marker; L, crude lysate; F, column flow through; B and C, washes with buffers B and
C; D and E, elution fractions with buffers D and E.
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Shock refolding offusion proteins on an ion-exchange column
Efficient transduction ofTAT fusions requires linearisation of the protein in order for
it to traverse the lipid membrane. Correctly folded proteins that are stable with a low
AG are difficult to unfold and are hence poor transducing substrates (Nagahara et al.,
1998). Proteins capable of highly efficient transduction are characterised as being
unstable (high AG), misfolded and aqueous soluble. We can produce proteins in this
state by shock refolding from urea to aqueous solution on an ion exchange column.
Pooled fractions of fusion proteins from the Ni-NTA column were diluted with
HEPES buffer to a urea concentration of 4M, and applied to a ResourceQ column pre
equilibrated with a low salt HEPES buffer, and protein eluted with 1M NaCl in
twenty 1ml fractions. 2 pi of each fraction was spotted onto nitrocellulose
membrane and probed with pl30cas and HA mAb. The dot blots revealed elution in
fraction 2 for both pl30cas and (3gal, with further elution at decreasing levels in the
following 18 fractions (fig. 6a,b). Protein present in these fractions appeared at the
correct molecular weight when subsequently analysed by SDS-PAGE and western
blotting (fig. 6c,d). Fractions containing protein were therefore pooled and
concentrated by centrifugal filtration, then applied to disposable PD-10 columns to
remove salt and allow elution in PBS.
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Figure 6. Purification of fusion proteins by gravity flow ionic exchange
Ni-NTA fractions containing fusion protein were pooled and passed through a
gravity flow monoQ ion exchange column for shock refolding of TAT fusion
proteins. Twenty 1ml fractions were collected and assessed for protein content by
dot blot analysis (A, B) and fractions 1-14 by SDS-PAGE together with western
blotting (C, D) using mAb specific for pl30cas (A, C) or HA (B, D).
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Transduction ofTAT into monocyte/macrophages
Dowdy and colleagues have previously demonstrated transduction of proteins up to
110 kDa into a range of cell types. Before assessment of the potential biological
functions of the TAT/pl30cas fusion protein, we must first demonstrate its cellular
transduction. Reports suggest that TAT fusions are able to transduce into cells
within 15 min of incubation, and reach a steady state (as proteins can theoretically
transduce back out) after lhr (Nagahara et al., 1998). Other reports have suggested
transduction within 15 min, but loss of biological function after 45 min (Alblas et al.,
2001). In preliminary experiments we chose a lhr time point, and assessed
transduction of TAT/pl30cas and TAT/figal into DX-treated macrophages by SDS-
PAGE and western blotting. Macrophage monolayers were washed once to remove
serum, and incubated with TAT fusion proteins. After lhr, supernatants were
removed, and cells lysed. At this time point we could not detect transduction of the
TAT/|3gal fusion, however TAT/pl30cas had appeared to enter the cell. Probing
blots with a pl30cas specific mAb revealed a protein of approximately 100 kDa,
approximately 35 kDa smaller than the predicted TAT-HA/pl30cas product,
suggesting cleavage of the fusion protein. In addition to the 100 kDa band, there
appeared to be extensive lower molecular weight degradation products visualised by
the pl30cas mAb. We therefore repeated the experiment with earlier time points of
15 and 45 min. Monocyte/macrophages matured for 5-days ± lfiM DX in 48 well
plates were incubated with 100p.l of TAT/pl30cas for 15, 45 and 60 min, and 100|Lil
of TAT/pgal for 15 and 60 min intervals. Supernatants were removed and retained
and the cells washed briefly in PBS to remove bound, non transduced protein, before
lysis with RIPA buffer. Analysis of lysates and supernatants by SDS-PAGE and
western blotting with pl30cas, and HA specific mAb, revealed TAT/pl30cas fusion
protein was able to enter macrophages within 15 min of incubation (fig7). Cellular
transduction appeared to protect the protein from non-specific degradation occurring
in the supernatant, however the major species in cell lysates was a band of
approximately 100 kDa. A band of the correct molecular weight (135kDa)
corresponding to the band pattern of whole protein was present in supernatants,
suggesting that cleavage to the 100 kDa form may be a specific cellular event rather
than non-specific proteolytic degradation. Alternatively the 100 kDa species present
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in the supernatant also may transduce more efficiently into the cell, and would
therefore be more concentrated in cell lysates. Transduction did not significantly
increase with increased incubation times, nor was there an increase in cellular
degradation of the pl30cas fusion protein, in contrast to previous experiments. One
possibility was that failure to rinse cells after removal of the supernatant, to prevent
wash out of protein, may have left residue degradation products on the surface of
macrophages. TAT/(3gal could not be detected inside either control or DX
macrophages after 15 or 60 min (fig7), however the fusion protein could be detected
in the supernatants. A band of between 70-75 kDa was present in cell lysates from
cells incubated with the TAT/[3gal fusion. This may represent transduced protein
that has been processed by the cell, or alternatively, a non-specific band. Full length
transduced TAT/(3gal may not be detected due to the reduced sensitivity of the HA














Figure 7. Transduction ofTAT fusion proteins into macrophages
Adherent peripheral blood monocyte-derived macrophages were cultured in the
presence or absence of lpM DX for 5 days in 48 well plates. Cultures were
incubated with lOOjil of TAT/pl30cas or TAT/(3gal for 15-60 min prior to lysis and
assessment of the level of protein transduction by SDS-PAGE and western blotting
using mAb specific for pl30cas: panels A and C, or HA: panels B and D, in either
control non-DX-treated (A, B) or DX-treated (C, D) macrophages. Note the level of
transduced pl30cas compared to endogenous levels present lanes corresponding to
control non-DX-treated macrophages treated with PBS/glycerol and TAT/[3gal. C,
TAT/pl30cas; B, TAT/(3gal; L, lysates; S, supernatants; P, purified protein control.
The putative "100 kDa band" referred to in the text is marked *.
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The effect of TAT fusion proteins on macrophage phagocytosis of apoptotic
neutrophils
The aim of this work was to reintroduce pl30cas back into DX-treated macrophages
to test our hypothesis that pl30cas was a negative regulator of phagocytosis. As cell
loss can occur during the plate based phagocytosis assay we used flow cytometry to
assess phagocytic uptake. Monocyte/macrophages were cultured in 48 well plates
for 5 days in the presence or absence of l(iM DX. Cells were washed once to
remove serum and incubated with 1 OOjllI of either PBS, PBS/glycerol, TAT/pgal or
TAT/pl30cas for 15min. Supernatants were removed and phagocytosis of apoptotic
neutrophils assessed as previously described. Both untreated and DX-treated cells
pre-incubated with PBS only showed average levels of phagocytosis of 7.5% and
48.9% (non-DX-treated and DX-treated respectively). However, incubation of
macrophages in PBS/glycerol appeared inhibitory to phagocytosis. Levels of uptake
in untreated cells were reduced to 4.1%, and in DX-treated cultures just 7.3% of
macrophages were positive for engulfment of particles. In addition samples that had
been incubated with PBS/glycerol appeared to contain fewer macrophages
suggesting cell loss at some point during the assay. Similar findings were obtained
for cultures treated with TAT/Pgal. In DX-treated cultures phagocytosis remained at
7.2%, however phagocytosis by non-DX-treated macrophages appeared to be
improved in the presence of protein (7.7%). Pre-incubation with TAT/pl30cas
demonstrated similar phagocytosis levels in untreated cells as for TAT/pGal (9.1%),
but decreased phagocytosis compared to TAT/pgal in DX-treated cells (2.2%).
167
Figure 8. Effect of fusion proteins on phagocytosis of apoptotic cells
Adherent peripheral blood monocyte-derived macrophages were cultured in the
presence or absence of lpM DX for 5 days in 48 well plates. Cultures were
incubated with lOOfil of TAT/pl30cas or TAT/pgal for 15 min, and macrophage
phagocytic capacity for apoptotic neutrophils assessed by flow cytometry. Results
show one representative experiment of two that were performed.
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Discussion
Glucocorticoids reprogram monocyte to macrophage differentiation resulting in the
alteration of a number of adhesion signalling pathways. In particular, DX down
regulates pl30cas expression. We have hypothesised that the decrease in protein
level of pl30cas contributes to the morphological changes induced by
glucocorticoids and the augmentation of phagocytic capacity. To test our hypothesis
we created a TAT/pl30cas fusion protein for the direct transduction of pl30cas into
DX-treated macrophages. Initial experiments suggested that the pl30cas fusion
protein was able to enter DX-treated and untreated macrophages as assessed by
western blotting of cell lysates. However the control TAT/(3gal protein could only be
detected in supernatants. This may be due to a complete failure of the protein to
transduce, or a lack of sensitivity of the anti-HA mAb, which may not allow the
visualisation of low levels of transduced protein. Despite transduction into the cell
TAT/pl30cas did not alter macrophage morphology as assessed by phase contrast
microscopy (data not shown). An absence of effect in non-DX treated control
macrophages could be due to the presence of endogenous pl30cas. However,
increased cell spreading, membrane ruffling and formation of stress fibres was
observed in cell lines overexpressing pl30cas and pl30cas"~ fibroblasts re-
expressing the protein after transfection using mammalian expression vectors
(Cheresh et al., 1999; Eisenmann et ah, 1999; Honda et ah, 1998; Kiyokawa et ah,
1998). Additionally although TAT/pgal may have been entering cells in these
experiments at a low levels, it was unable to metabolise the chromogenic substance
X-gal, raising questions as to the functionality of the fusion proteins produced.
Sequencing of the pTAT-pl30cas expression construct revealed four polymorphisms
that had arisen during PCR amplification, resulting in four amino acid substitutions.
Only one change Thr—>Ala occurred in a functional domain of pl30cas. This
substitution was proximal to a putative tyrosine phosphorylation motif in the
substrate domain. Whether this affects pl30cas phosphorylation, or if the other
substitutions alter protein folding is not know, but should be addressed if extensive
future work is undertaken using this construct.
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Stability ofTATfusion proteins
The lack of effect on macrophage morphology of pl30cas fusion protein may be due
to failure to reach levels comparable to endogenous expression, although western
blot analysis suggests that pl30cas transduced into control cells is in excess of
normal basal levels. However, the pl30cas species present is not the full-length
protein. Endogenous pl30cas in human macrophage lysates (see chapter 4, fig. 7)
appears as a doublet of protein bands of 130kDa and 120kDa when analysed by
SDS-PAGE and western blotting. The doublet is specific for human pl30cas as it is
not apparent when anti-pl30cas mAbs are used to probe cell lysates generated from
J774s , a mouse macrophage cell line. This may be due to the presence of a cryptic
termination signal, specific cleavage sites, or alternative splicing of human pl30cas
mRNA. pl30cas has been shown to be cleaved by caspases during apoptosis
resulting in the production of a number of fragments ranging between 31 and 74 kDa
(Kook et al., 2000). Over exposure of pl30cas blots of macrophage whole cell
lysates reveal that endogenous pl30cas is susceptible to non-specific protein
degradation, with the generation of a number of lower molecular weight bands
(results not shown). Visualisation of purified pl30cas fusion protein by SDS-PAGE
and western blotting also demonstrates the presence of two major bands plus a
number of degradation products. The upper major band approximately 135kDa is
likely to correspond to pl30cas plus the TAT/HA leader sequence, an extra 5kDa
(although TAT proteins have been shown to migrate up lOkDa larger than their
actual size (Nagahara et al., 1998). In western blot analysis the lower band at
~100kDa is too small to correspond with the lower 120 kDa doublet plus TAT
leader. Additionally the stoichiometry of the two bands in pl30cas fusion protein
samples is different to endogenous pl30cas. The two products of TAT/pl30cas are
present throughout purification, suggesting that either two species are produced in
the bacterial expression system, or that the fusion protein is unstable and prone to
proteolytic degradation from the outset. During initial purification experiments,
protein from the Ni-NTA column was left in urea overnight before further
purification on the monoQ column. Even in 8M urea, residual protease activity was
able to cleave pl30cas, to a protein of approximately the same size as the lower 100
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kDa band. Transduction of proteins from 18-120 kDa have been reported by Dowdy
and colleagues. Although inert particles up to 40nm have been reported to pass into
cells using the HIV-TAT system (Lewin et al., 2000), there may be an upper size
limit for the transduction of highly charged moieties such as proteins, as is seen with
the PTD of Antennapedia (Derossi et al., 1998). The production of two species of
pl30cas, although not intended, may be fortuitous in allowing entry of the lower
molecular weight protein, however size constraints may contribute to the lack of
transduction of the TAT/(3Gal fusion.
Proteolytic degradation of the protein with the generation of lower molecular weight
species occurred in a pattern similar to that seen with endogenous pl30cas, but to a
greater extent. The presence of degradation products was most pronounced in
supernatant fractions, with a reduction in cleavage upon transduction inside the cell.
Cytoplasmic pl30cas appeared to be protected against non-specific cleavage and the
generation of lower molecular weight products. In contrast the (3gal fusion protein
did not appear to be cleaved in the supernatant. This may be due to lower sensitivity
of the anti-HA mAb, failing to detect TAT/(3gal degradation products that would be
present at lower concentrations. Addition of protease inhibitors during purification
would inhibit cleavage, however interpretation of morphological and functional
changes in the presence of protease inhibitors may not be possible. Incubation of
monocyte/macrophages with fusion protein, or just the carrier, PBS/glycerol resulted
in cell loss and a decrease in phagocytosis, suggesting glycerol may compromise
macrophage viability and induce cleavage of pl30cas by the induction of an
apoptotic program. Cell viability could be assessed by either blotting the resulting
lysates for cleavage of pro-caspase 3 or assessing levels of Annexin V binding in
duplicate samples by flow cytometry during the eating assay. Dowdy and colleagues
transduce proteins in the presence of BSA (Nagahara et al., 1998). Although we
undertake our phagocytosis assays in the absence of serum due to its capacity to
opsonize apoptotic cells, the use of heat-inactivated BSA may be a possible means to
stabilise both protein and cells.
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pl30cas contains a number of protein/protein interaction domains required for
activation of its downstream signalling pathways, protein cleavage with the loss of
specific motifs may therefore compromise function. N-terminal degradation would
remove the TAT leader sequence preventing transduction into the cell, although
specific cleavage of the leader sequence once inside the macrophage may still occur.
It is more likely therefore that degradation occurs from the C-terminal end of the
protein. The C-terminal region of pl30cas contains a potential
hetero/homodimerisation motif, plus a signature motif for tyrosine phosphorylation
by src family kinases. pl30cas is a major mediator of src-signalling effecting
changes in cell morphology, adhesion and migration. Disruption of this interaction
may prevent the observation of morphological changes following fusion protein
transduction.
In addition to detection of transduced proteins by western blotting, we attempted to
visualise TAT/pl30cas and TAT/[3gal inside macrophages using immunofluorescent
staining, to enable assessment of localisation patterns, and provide evidence that the
protein was correctly folded and functional. However both pl30cas and HA
antibodies gave a large amount of background immunofluorescence in cytospin
preparations of transduced cells. This is likely to reflect the binding properties of the
specific monoclonal and polyclonal antibodies used. Additionally, the lower
molecular weight degradation products that are faintly apparent in cell lysates may
also contribute to an apparent non-specific staining, therefore the issue of protein
cleavage may need to be addressed before immunofluorescent staining is possible.
Another potential problem with protein transduction, is that in addition to cleavage
compromising fusion protein function, re-folding of both pl30cas and pgal after
transduction may not be correct. Improperly folded proteins would be targeted to the
proteosome, and rapidly degraded. However, as we still detect pl30cas and J3gal
after lhr of incubation this is unlikely to occur. Folding of large complex molecules
may be further compromised when transducing proteins between species. The
bacterial strain BL-21 expressed pgal and was able to metabolise X-gal producing
blue pigmentation, suggesting functionality of the protein, however correct folding in
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mammalian cells of this bacterial protein may be limited. Furthermore the copy
number of correctly folded proteins may be too low for the visualisation of X-gal
metabolism by microscopy.
We purified fusion proteins from the insoluble denatured phase to promote maximal
recovery and production of "transducible" protein. However it has recently been
shown that some fusions with TAT require purification from the soluble or aqueous
fraction to become efficiently refolded in vivo. For example TAT fusion with herpes
simplex virus thymidine kinase requires purification from the soluble phase.
Unfortunately it has also been reported that (Igal can only form the enzymatically
active homotetramer when purified from 0 and 2M urea, but not 8M. Complete
denaturation leaves the TAT-fusion in a highly transducible state, but with a poor
rate of folding. Although loss of Pgal activity does not enable us to graphically
demonstrate protein transduction, its presence inside the cell still functions as a
control for non-specific effects generated by the transduction of a protein in excess of
lOOkDa into monocyte/macrophages. Further production of TAT fusion proteins for
studies in macrophages will require careful tailoring of purification procedures for
each individual protein in order to obtain maximal function.
Although reconstitution of pl30cas itself may not be sufficient to change the gross
appearance of DX-treated cells, we may be able to detect subtle changes.
Immunofluorescent staining of actin organisation or the re-appearance of podosome
structures could potentially reveal functional effects of pl30cas that are
compromised in DX-treated macrophages. Furthermore, assessment of Rac activity,
and pyk2 and paxillin phosphorylation after protein transduction would allow
investigation of the specific signalling pathways altered by the decrease in pl30cas
expression. In the previous chapter we described a crude migration assay, in which
DX-treated cells were able to migrate despite the absence of pl30cas and active
ERK. It would be very interesting to assess macrophage migration after
reconstitution with pi 30cas.
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Effect ofTATfusions on phagocytic capacity
In the functional studies, we found that pre-incubation with PBS/glycerol disrupted
phagocytosis and induced a slight cell loss in control macrophages and a marked
reduction of cell number and phagocytosis in DX-treated cultures. The viscosity of
glycerol may prevent settling of neutrophils onto the macrophage monolayer. In the
first preliminary experiment apoptotic cells were added on top of glycerol/PBS or
fusion protein, to limit potential transduction of fusion protein back out of the cell
when the extracellular concentration of protein was reduced by the addition ofmedia
containing apoptotic cells. This could account for the decrease in phagocytosis, but
not the dramatic cell loss observed in DX-treated cultures. Furthermore, similar
results were obtained when glycerol/PBS was removed before application of the
apoptotic meal in subsequent experiments. Alternatively the viscosity of the glycerol
mix may itself compromise cell adhesion. Alternatively glycerol, even at 10-15%
may be toxic to monocyte/macrophages. Decreased viability would inhibit
phagocytosis as well as causing detachment of cells. Possible apoptotic effects could
be assessed by examination of nuclear morphology by cytospin analysis and
assessment of phosphatidylserine extemalisation with AnnexinV binding.
Phagocytosis rates were improved slightly in the presence of the TAT/pgal fusion
protein, compared to PBS/glycerol, and effect that is unlikely to be specific. Dowdy
and colleagues transduce proteins in the presence of BSA (Nagahara et al., 1998), the
use of heat inactivated serum may promote adhesion and viability, and prevent
possible opsonization of apoptotic particles with complement proteins, that might
complicate interpretation of phagocytosis data.
An alternative approach to the use of glycerol would be to freeze protein in a
different carrier such as sucrose, or to obtain concentrated preparations of fusion
protein that would allow dilution of glycerol when the fusion protein is used in
functional studies. This would require optimisation of protein production and
purification methods. The intracellular location of pl30cas suggests that post-
translational modifications such as glycosylation are not required permitting use of
bacterial expression systems that allow higher yields. Protein solubility can be
compromised if the protein is toxic or expressed in large quantities, resulting in
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sequestration into insoluble inclusion bodies within bacteria. Protein can be accessed
by sonication in the presence of a denaturant such as 8M urea or 6M guanidine
hydrochloride. Although we were able to recover considerable amount of protein
from the bacterial cytoplasm the addition of a sonication step to our purification
procedure may further increase the total yield. Very long recombinant proteins can
also undergo premature termination during translation in bacteria due to differences
in codon usage between prokaryote and mammalian systems. Attachment of the His-
tag to the C-terminus of the protein would select for full-length proteins during
purification. The lower molecular weight band observed in purified TAT/pl30cas
could represent a terminal truncation during translation, data presented in figure 7
suggests it is more likely to be the result of proteolytic degradation. Unlike many
smaller fusion proteins that are degraded by bacterial proteases, the length of both
pl30cas and (3gal fusions preclude them from undergoing cleavage in the bacterial
cytoplasm. Use of different protease inhibitors would limit proteolysis following
lysis and inhibitors would not co-purify with fusion proteins on subsequent affinity
columns, preventing contamination of the final protein solution.
In this chapter I have explored techniques for the transduction of proteins into
macrophages. Further refinement of this technique would allow a more detailed
analysis of the effects of pl30cas expression on macrophage programming. For
example manipulation of the pl30cas protein by deletion of protein domains to
generate dominant negative mutants, or constitutively active protein may also allow
the elucidation of specific signalling pathways mediated by pl30cas in normal
macrophages. Most importantly use of this technology for the introduction of protein
into monocyte derived macrophages will provide opportunities for the study of other
key molecules involved in macrophage adhesion, differentiation and function.
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CHAPTER 7: THE EFECT OF THE CYTOKINE
ENVIRONMENT ON GLUCOCORTICOID "PROGRAMMING"
OF MONOCYTE-MACROPHAGE DIFFERENTIATION
Introduction
The inflammatory response provides a defence mechanism against bacterial
infection, injury and allergy. Recruitment of inflammatory cells and the release of
inflammatory mediators is required for the elimination of the causative agent,
however these processes must be tightly controlled to prevent escalation of the
inflammatory reaction, and actively diminished to allow healing. Cells that mediate
initiation of inflammation also act during the healing or resolution phase.
Macrophages play a central role in innate immunity and the initiation of adaptive
immune responses. Tissue injury is associated with an increased number of
macrophages from the infdtration of circulating peripheral blood monocytes which
differentiate into macrophages (van Furth, 1989). It has also been proposed that
tissue macrophage numbers increase by local cell division (Sawyer et al., 1982). The
role macrophages play during an immune response is dependent on the cytokine
microenvironment which can be influenced by TH1 or TH2 lymphocytes (Jankovic et
al., 2001; Mosmann and Sad, 1996). Infection with Leishmania major is the
prototypical model of TH1/TH2 responses (for reviews see Alexander et al., 1999;
Louis et al., 1998). T lymphocytes from resistant C57BL/6 mice produce a TH1
cytokine, interferon-gamma (IFNy), in response to the infection, resulting in
macrophage activation, production of NO, and parasite killing. In contrast, T
lymphocytes from susceptible BALB/c mice produce IL-4 associated with TH2
responses that suppresses macrophage microbicidal function, and the infection
persists. A large number of cytokines and growth factors have been shown to
modulate macrophage function and "activation state", these arise from both activated
T cells and also via autocrine effects from the macrophage itself. IFNy, LPS and
TNFa have been shown to be important mediators of classical macrophage
activation, associated with the induction of pro-inflammatory responses and the
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propagation of TH1 cytokine production (Goerdt et al., 1999; Mills et al., 2000;
North, 1978). In addition, other cytokines such as IL-2, IL-12 and IL-15 have been
shown to promote macrophage pro-inflammatory actions (Munder et al., 1998b;
Nathan, 1987). In contrast, cytokines such as IL-4, IL-10, IL-13, and glucocorticoid
hormones have been shown to downregulate these responses (Becker and Daniel,
1990; Bogdan and Nathan, 1993; Kourilsky and Truffa-Bachi, 2001).
Downregulation of pro-inflammatory functions was initially thought to be due to a
"deactivation" of macrophage function. However, it has become apparent that
deactivated macrophages are able to actively influence the inflammatory outcome via
the production of TH2 cells and cytokines. The induction of this phenotype has been
termed "alternative activation" (Stein et al., 1992). Furthermore, there is evidence
that cytokine release from macrophages and dendritic cells can act in a paracrine
fashion on T lymphocytes promoting their polarisation into TH1 or TH2 cells, as well
as influencing macrophage or dendritic cell functions. Thus, the TH1/TH2 paradigm
has been expanded to encompass macrophages and dendritic cells with the resulting
classification ofM-l/M-2 (Goerdt et al., 1999; Mills et al., 2000), and DC1 and DC2
cell subtypes (Rissoan et al., 1999; Sallusto et al., 1999). M-l cells are characterised
by upregulation of immunoglobulin receptors, to promote uptake of opsonzied
particles, and increased NO production from an upregulation of expression of
inducible nitric oxide synthetase promoting the destruction of ingested pathogens
(Munder et al., 1998a; Munder et al., 1999). In contrast M-2 or alternatively
activated macrophages express receptors for pathogen associated molecular patterns
such as the macrophage mannose receptor (Stein et al., 1992), the p-glucan receptor
(Mosser and Handman, 1992), scavenger receptor type I (Geng and Hansson, 1992),
and CD 163, a member of the cysteine rich family of scavenger receptors (Hogger et
al., 1998). Recognition of pathogens by these pattern recognition receptors induces
the production of pro-inflammatory cytokines (Gamer et al., 1994), further
emphasising that this macrophage phenotype is not de-activated. Despite an
increased capacity for phagocytosis of pathogens, M-2 macrophages show decreased
production of O2, and NO upon stimulation (Becker and Daniel, 1990; Munder et al.,
1998a; Munder et al., 1999), but express enhanced levels ofMHC class II molecules
such as HLA-DR and HLA-DQ, suggesting increased antigen presentation (Becker
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and Daniel, 1990). Decreased NO production is thought to result from a switch in
metabolism of arginine to ornithine from the induction of expression of arginase
(Munder et al., 1999). Ornithine, as a precursor for polyamines, promotes cell
replication, facilitating cell renewal during wound healing (Williams-Ashman and
Canellakis, 1979). In contrast, NO inhibits proliferation and induces cell death
(Nathan and Hibbs, 1991). In vivo, alternatively activated macrophages are found in
normal healthy placenta and lung, during the healing phase of acute inflammatory
reactions, in chronic inflammatory disease states such as rheumatoid arthritis and
psoriasis, during wound healing and angiogenesis (Djemadji-Oudjiel et ah, 1996;
Gratchev et ah, 2001; Kodelja and Goerdt, 1994; Kodelja et ah, 1997; Mues et ah,
1989; Szekanecz et ah, 1994). Interestingly, macrophage phagocytosis of apoptotic
cells has been suggested to promote alternative activation in the context that uptake
of apoptotic particles downregulate the secretion of inflammatory mediators, and
promote the release of anti-inflammatory cytokines such as TGF(3 (Fadok et ah,
1998). The suppressive function of these macrophages suggests they may be more
akin to a TH3 phenotype characterised by secretion ofTGFf) (Chen et ah, 1994). The
capacity for phagocytosis by M-2 macrophages has not been extensively studied,
however the effect of TH1 type cytokines on uptake has produced equivocal results
(Erwig et ah, 1998; Ren and Savill, 1995). It is worth remembering that the TH1/TH2
paradigm represents two extremes of a spectrum of possible outcomes, and although
it is possible to produce TH1 or TH2 responses in animal models, the real in vivo
situation may represent a mid-point between these two extremes. Similarly the
phenotype of normal tissue macrophage populations is likely to be between
macrophage M-l and M-2 states.
IFNy, thought to induce an M-l phenotype, induces the formation of multinuclear
giant cells (MNGCs) (Fais et ah, 1994; Most et ah, 1990; Weinberg et ah, 1985). In
vivo, MNGCs are found in granulomas during chronic inflammatory disease such as
infection with Mycobacterium tuberculosi, sarcoidosis, Crohn's, and primary bilary
cirrhosis (for review see Fais et ah, 1997). They consist of macrophages and
MNGCs centered around an infectious focus, with lymphocytes aggregating around
the cirumference, providing a possible source of fusion-inducing IFNy. Generation
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of multinucleated cell granulomas is dependent on the recruitment of extravasated
monocytes, as tissue macrophages appear refractory to IFNy induced fusion (Most et
al., 1997). Erwig et al., (1998) have recently shown that in vitro macrophage
programming is dependent on the first stimuli encountered. Monocytes infiltrating to
the inflammatory site at different periods of the immune response may therefore be
pre-programmed to undertake specific functions. We have demonstrated that
glucocorticoids program monocyte/macrophage function and morphology when
monocytes are exposed to DX early during maturation. Maturation of monocyte
derived macrophages in culture induces the formation of a number of phenotypes as
described in chapter 4. These include small "rounded" cells, larger spread cells,
dendritic like migratory phenotypes, and multinucleated giant cells (MNGCs). The
proportion of cell types, especially the number of giant cells present within a
population differs between donors. This may be due either to soluble factors present
in the autologous serum used to culture the cells, or a pre-programmed disposition
for the formation of giant cells. In contrast, maturation of peripheral blood
monocytes in the presence of DX prevents the formation of MNGCs, producing a
culture ofuniformily small, rounded macrophages, no matter how multinucleated the
phenotype of the untreated counterparts. The formation of MNGCs can also be
induced by IL-13 and IL-4 (DeFife et al., 1997; McNally et al., 1996), important
mediators of the M-2/TH2 paradigm. The production of a macrophage phenotype
refractory to cytokine influence through DX-programming may prove detrimental in
vivo. Alternatively cytokine inhibition of the DX-phagocytic phenotype, would have
huge implications for the efficacy of glucocorticoids treatment for the resolution of
certain inflammatory conditions. We therefore assessed the effect of the TH1 and
Th2 cytokines INFyand IL-4 on glucocorticoid maturation of monocyte/macrophage
morphology, phenotype, and phagocytic capacity.
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Results
DX inhibits giant cellformation
In order to assess the effect of cytokines on macrophage morphology induced by DX,
peripheral blood monocytes were matured by adherent culture in 48 well plates for 5
days ±l|jJM DX in addition to lOng/ml IL-4 or lOng/ml IFNy, and examined using
phase contrast microscopy (fig.l). Maturation ofmonocytes in the presence of IFNy
induced a striking formation of MNGCs (fig. le), with cells up to 1 OOjiM in
diameter. In contrast IFNy/DX matured cultures demonstrated a uniform phenotype
of small rounded cells devoid of multinuclear cells of any size (fig. If). In fact the
IFNy/DX treated cells appeared smaller and more rounder than those treated with DX
alone (fig. lb). It was noted that macrophages from IFNy/DX cultures tended to
exhibit increased detachment from culture plastic during cell washing, suggesting
that changes in adhesion induced by DX were amplified by the presence of IFNy.
Although IL-4 has been described to induce the generation of multinucleated giant
cells from peripheral blood monocytes in culture, we observed a dendritic cell-like
phenotype. Furthermore, after 3-4 days maturation, cultures incubated with IL-4
demonstrated a clustering of cells reminiscent of cell aggregation during the
formation of immature dendritic cells from peripheral blood monocytes in response
to GM-CSF and IL-4. Autologous serum that is used to culture
monocyte/macrophages is likely to contain GM-CSF, which may account for the
differences in IL-4 induced morphology that we observe. The morphological
changes during DX-programming were also dominant over the IL-4 induced
phenotype. DX prevented clustering of cells and the resultant polarized morphology
after 5 days maturation, instead producing smaller rounded cells. However the
phenotype induced by maturation in the presence of IL-4 and DX was not as extreme
as observed in DX only cultures. DX/IL-4 macrophages appeared slightly more
irregular in shape with an increased number of cellular processes. Preliminary
evidence suggested that DX-programmed cells were also refractory to the induction
of giant cell formation by ligation of CD98 with the monoclonal antibody 4F2,
preventing both clustering and fusion of cells (results not shown). No significant
changes in 4F2 expression were observed after DX treatment suggesting changes in
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intracellular signalling may inhibit fusion by this mechanism. The changes in
morphology observed after cytokine-treatment was reflected in altered forward and
side scatter properties of each subset of cells to a certain extent (fig.2). IL-4
treatment did not alter scatter properties compared to control, however the increased
homegeneity observed with DX-treatment was maintained in DX/IL-4 treated
cultures. Interestingly, although treatment with IFNy induces formation of a
heterogenous population of MNGCs, this was not reflected in the scatter profile,
which appeared more homogenous than untreated cultures. The scatter profile of
DX/IFNy treated macrophages reflected the adherent morphology of these cells,
showing a compact population of small homogenous cells.
A characteristic feature of giant cells and polarized/dendritic-like cells, as obtained
by incubation with IFNy and IL-4 respectively, is the extensive formation of
podosome structures. In MNGCs podosomes are located in a cortical ring formation
around the periphery of the cell. In osteoclasts, a cell of the monocyte lineage, the
ring structure constitutes the "sealing zone" where resorption of matrix material
occurs. In polarised or migratory cells, podosomes are formed at the leading edge of
the cell, and are thought to contribute to the maintenance of cell polarity (see results
chapter 3). Peripheral blood monocytes were matured by adherent culture on glass
coverslips for 5 days as previously described, in the presence or absence of lpM DX,
lOng/ml IL-4 or lOng/ml IFNy. Immunofluorescent staining of actin with
rhodamine-coupled phalloidin in IFNy treated cells, demonstrated the formation of
punctate podosomal structures in a distinct pattern running around the periphery of
the cell (fig.3). In IL-4 treated cultures, podosomes appeared both in the main body
of the cell, and at the leading edge. Examples of cortical ring formation and cell
polarisation were present in control cell cultures but to a lesser extent than in the
cytokine treated populations. In contrast, the presence of DX completely inhibited
the formation of podosmes in response to IFNy and resulted in decreased actin
organisation, similar to that observed in cells treated with DX only. However, in
DX/IL-4 treated cultures although cells appeared small and rounded by phase
contrast microscopy immunofluorescence revealed a more organised actin
cytoskeleton with some evidence of adhesive contacts.
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Figure 1. Effect of cytokine programming on macrophage morphology
Adherent peripheral blood monocytes were cultured for 5 days in the presence or
absence of l|iM DX, lOng/ml IFNy or lOng/ml IL-4 on tissue culture treated plastic.
Morphology was assessed by phase contrast microscopy (x40 objective). A control
untreated. B DX. C IL-4. D IL-4 plus DX. E IFNy. F IL-4 plus DX.
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Figure 2. Increased homogeneity of macrophage morphology induced by cytokine
programming
Adherent peripheral blood monocytes cultured on tissue culture treated plastic for 5
days in the presence or absence of lpM DX, lOng/ml IL-4 or lOng/ml IFNy. Cells
were detached by incubation with on EDTA ice and laser scatter qualities assessed
by flow cytometry.
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Figure 3. Effect ofcytokine programming on actin organisation
Adherent peripheral blood monocyte-derived macrophages were cultured for 5 days
in the presence or absence of lpM DX, lOng/ml IFNy or lOng/ml IL-4. Localisation
of actin was determined using rhodamine phalloidin together with fluorescence
microscopy, x40 objective. A Media only, B DX, C IL-4, D DX/IL-4, E IFNy, F
DX/IFNy. These representative micrographs illustrate typical punctate actin staining
of "contact sites" and podosomes present in control, IFNy, IL-4 and DX/IL-4 treated
macrophages that are absent in DX-treated, and DX/IFNy treated macrophages.
Cytokine influence on DX-programming ofadhesion signalling
Morphological changes induced by DX correlate strongly with the down regulation of
pl30cas, an important regulator of actin cytoskeletal organisation and podosome
formation (Honda et al., 1998; Nakamura et ah, 1998), and the decrease in ERK
activity, thought to be required for directed migration (Cheresh et ah, 1999; Klemke et
ah, 1998). In order to see ifDX programming was dominant over cytokine effects at a
signalling level, we assessed the status of these two indices ofDX maturation (detailed
in chapters 4 and 5) in cells exposed to the cytokines IFNy and IL-4.
Monocyte/macrophages were matured for 5 days in the presence or absence ofDX plus
lOng/ml IFNy or lOng/ml IL-4. Whole cell lysates were assessed for the presence of
pl30cas expression, or phosphorylated (i.e. active) ERK, by SDS-PAGE and western
blotting (fig.4). Expression of pl30cas and phosphorylation of ERK were decreased in
DX-treated cultures compared to control. Treatment of monocyte/macrophages with
IL-4 had no effect on levels of active ERK compared to untreated control, but caused a
small increase in pl30cas expression (fig. 4). IL-4 inhibted the effect of DX on ERK
activity and pl30cas expression, lysates from DX/IL-4 treated cultures contained both
pl30cas and active ERK. In contrast, IFNy treated cells, although morphologically
very different from DX-treated macrophages showed decreased levels of pl30cas
expression (in some experiments protein levels were below that of DX-treated
macrophages), and a reduction in phosphorylated ERK. Downregulation in pl30cas
expression and ERK activity was also observed in DX/IFNy-treated cultures.
Previous results have demonstrated that DX does not effect the activation of ERK
directly, but via changes in upstream signals. To assess whether changes in ERK
activity with IFN were due to a direct action of cytokine signalling on kinase function,
the six subsets of cells were exposed to LPS to induce ERK activity, as described in
chapter 5. LPS induced ERK phosphorylation in DX treated macrophages, and
increased basal levels in control untreated cells as previously described. ERK activity
was also induced in IFNy and DX/IFNy cultures, and basal levels of ERK activity were
augmented in IL-4 and DX/IL-4, suggesting cytokines had no effect on the activation
of kinase function (fig.5).
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Figure 4. Effect of cytokines on expression of the adaptor protein p!30cas and
activity of the MAPK ERK.
Adherent peripheral blood monocytes were cultured for 5 days in the presence or
absence of 1pm DX, lOng/ml IFNy, or lOng/ml IL-4, and the influence of cytokines
on macrophage reprogramming assessed by analysis of pl30cas expression and ERK
activity in whole cell lysates by SDS-PAGE and Western blotting. A Expression of
pl30cas (130 kDa). B CrkL (36 kDa). C and D Macrophages lysates were
examined for the presence of phophorylated-ERKl/2 (active) (44/42 kDa) (C) and
total ERK2 (42 kDa) (D), prior to and after incubation with lpg/ml LPS as described
in figure 3, chapter 5
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Effect ofcytokine environment on DX-augmentedphagocytosis
Previously we have correlated augmented phagocytosis with loss of podosomes and a
decrease in adhesion structures in DX-treated macrophages. We have proposed that
changes in morphology and the increase in phagocytosis observed in DX-treated
macrophages may in part be mediated by the decrease in pl30cas expression. However
the cellular morphologies ofmonocyte/macrophages generated by incubation in with a
combination of DX and cytokines does not correspond to the cytoskeletal phenotype.
We would have predicted that DX/IFNy-treated macrophages would have a similar
capacity for the engulfment of apoptotic cells as DX only treated cultures. To
determine how morphological and phenotypic programming affected the phagocytic
capacity of macrophages for apoptotic cells, we assessed the uptake of apoptotic
neutrophils by DX and cytokine-matured macrophages. Monocyte/macrophages were
cultured in 48 well plates for 5 days in the presence or absence of l[iM DX and
lOng/ml IFNy, or lOng/ml IL-4. Uptake of apoptotic cells by each subset of cells was
assessed using plate based and flow cytometric assays as previously described. In this
series of experiments the mean phagocytosis for DX-treated cultures was lower than
the overall average, reflecting variability in the assay system as described in chapter 3,
fig. 2. The lower levels of phagocytosis was a result of inclusion of data from two
individuals which demonstrated very low levels of phagocytosis of 5.5 and 7.9% in
untreated macrophages, with an increase to 16.5 and 14% respectively after DX-
treatment. Hoever, treatment of monocyte/macrophages with IFNy and IL-4 clearly
reduced phagocytosis in both control and DX-treated cultures in a dose-dependent
manner (fig.6). lOng/ml IFNy reduced basal phagocytosis in control cells from
12.2±2.3% to 4.9±1.9% respectively, and DX augmented phagocytosis from 28.6±6.3%
to 8.4+2.5% (n=5-6). In a similar fashion lOng/ml IL-4 decreased control phagocytosis
from 12.2.0±2.4% to 7.2±1.0%, and DX-phagocytosis from 27.7±5.2% to 10.2+2.8%
(n=5-7). Together, these findings suggest that the cytokine environment is likely to be
an important factor that determines macrophage responses to corticosteroids and
therefore must be carefully considered when developing strategies for DX





















Figure 5. Effect of cytokine programming on macrophage phagocytosis of apoptotic
neutrophils
Adherent peripheral blood monocyte-derived macrophages were cultured in the
presence or absence of 1|_lM DX, lOng/ml IFNy or lOng/ml IL-4 for 5 days. The
capacity for phagocytosis of apoptotic neutrophils was determined using both the
plate based and flow cytometric assays as described in chapter 1. Data presented as
mean phagocytosis (n=5-7).
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Cytokine downregulation ofDX-augmented phagocytosis is not due to a decrease in
"phagocytic receptors "
The presence of IL-4 and IFNy decreased phagocytic potential in both control and
DX-treated macrophages. The decrease in phagocytosis in IL-4-treated cultures
correlates with the maintenance of pl30cas expression, as we would have predicted
if pl30cas expression represented an important regulatory influence on macrophage
phagocytosis. However despite the similar morphological and cytoskeletal
characteristics of DX and DX/IFNy cells, in the presence of IFNy, DX failed to
augment phagocytosis. Flow cytometric analysis revealed no change in the
percentage of cells within the population expressing phagocytic receptors after
treatment with cytokines. Expression of 0CvP3 remained constant in all six subsets of
cells. In contrast (3i-integrin expression was diminished in all conditions compared
to control untreated cells. Although ligation of Pi-integrins has been reported to
inhibit subsequent uptake of apoptotic cells (Erwig et al., 1999), diminished
expression of pi-integrins in IL-4 and IFNy treated cultures did not promote
phagocytosis. Despite evidence for a role for CD36 in dendritic cell phagocytosis of
apoptotic cells (Albert et al., 1998), and regulation of dendritic cell maturation and
function (Urban et al., 2001), binding of the pan CD36 mAb IVC7 was decreased in
IL-4 and DX/IL-4 cultures. CD36 was also markedly reduced in IFNy and DX/IFNy
treated populations to 44.9±7.8% and 15.5±5.8% mean+SEM, n-4, compared to
control. However, expression of the CD36 epitope recognised by the mAb sm(j) was
slightly diminished in DX and DX/IFNy, compared to control and IFNy only, but
augmented with IL-4 and to a lesser extent, DX/IL4. Expression of the
glucocorticoid responsive scavenger receptor family member CD 163, recognised by
the mAb Ber-mac was increased in all DX-treated cultures, demonstrating
dominance over cytokine influence for the expression of this molecule. Expression
of CD 14 was an interesting example of the balance of programming between
cytokines and glucocorticoids. IL-4 reduced expression of CD 14 even in the
presence of DX. However, the increase in CD 14 expression induced with IFNy was
inhibited by glucocorticoids. Finally, expression of the IL-4 inducible mannose
receptor, was increased as expected by IL-4, but reduced below that of control by
DX. Expression was further decreased in DX only cultures, and almost completely
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reduced with IFNy and DX/IFNy. Overall, DX/IFNy cells did not show significant
differences in the decrease of receptor expression compared to DX only-treated
cultures, therefore it is unlikely that the phagocytic defect observed in the presence
of IFNy can be accounted for by changes in receptor expression. Furthermore,
inhibitor data for the blockade of phagocytosis in untreated and DX-treated
macrophages (chapter 3, table 1), suggested redundancy in receptor function,
indicating that changes in receptor function would also be unlikely to account for the
failure to augment phagocytosis observed after treatment with IL-4 and IFNy in
combination with DX.
DX-programmed macrophages are neither M-l nor M-2
IFNy and IL-4 can induce either classical or alternative macrophage "activation". In
order to assess whether DX matured macrophages follow a M-l or M-2 profile, or if
glucocorticoid programming affects the cytokine-induced development of these two
phenotypes (and visa versa), we next examined the expression of cell surface
markers known to be differentially expressed in the presence of IFNy and IL-4, plus
the expression of arginase, a marker of alternative macrophage activation. As
discussed above DX treatment did not induce surface changes consistent with either
an M-l or M-2 phenotype. Furthermore, expression of ICAM-1 and CD64 is
induced with IFNy, but expression was decreased below untreated control with IL-4
and DX. IFNy maintains CD64 expression in the presence of DX, and
glucocorticoids are able to override the effect of IFNy on ICAM-1 expression,
maintaining the downregulated phenotype.
Expression of arginase and two cysteine-rich proteins, members of the family of
"resistin-like" molecules first identified in fat cells, Fizzl and 2 in the mouse, and
Fizz2 and 3 in humans have been identified as markers of "alternative"
activation.(Holcomb et al., 2000; Steppan et al., 2001). To further investigate if DX-
programmed cells are similar to "alternatively" activated macrophages, we assessed
the level of expression of arginase and Fizz2 and 3 using RT-PCR.
Monocyte/macrophages were cultured for 5 days in the presence or absence of 1 |iM
DX and total RNA was extracted and used for RT-PCR analysis with arginase and
190
Fizz-specific primers. Fizz2 and 3 transcripts were detected at a similar level in
untreated and DX-treated monocyte/macrophages. However arginase expression
could not be detected from either untreated or DX-treated RNA (fig.7). Although the
presence of non-specific bands suggests conditions were not optimal for binding,
manipulation of annealing temperatures and magnesium concentrations failed to
allow us to detect arginase transcripts.
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Expression (% relative to control)



































Pi-integrin P4C10 64.9+1.9 46.5±1.5 37.1±3.3 39.311.1 28.311.4


















Table 1. Effect of cytokine programming on expression macrophage cell surface
molecules
Data presented as mean expression compared to control untreated macrophage
populations for 3-5 experiments.
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actin arginase Fizz2 Fizz3
M C D c~~b c~~b C D
Figure 6. mRNA expression ofmarkers of "alternative" macrophage activation
Adherent peripheral blood monocytes were cultured for 5 days in the presence or
absence of 1 jiM DX. Total RNA from untreated and dexamethasone-treated
macrophages were assessed for expression of actin, arginase, Fizz2 and Fizz3
transcripts using RT-PCR with primers described in Materials and Methods. Note
the bands in arginase reactions represent non-specific products. Marker, 100 bp




A striking feature of DX-programming of monocyte-macrophage differentiation, was
the inhibition of multinucleated giant cell formation. MNGCs are found at sites of
chronic inflammation associated with granuloma formation. Granulomas can be
induced by an infectious agent such as Mycobacterium tuberculosis (Langerhans type
MNGCs), or sterile foreign bodies such as surgical implants (foreign body MNGCs),
and can be initiated by cytokines such as IFNy, IL-4 and IL-13 (for review see
Anderson, 2000). In addition to the cytokine environment, a number ofmolecules have
been proposed to be required for giant cell fusion. These include CD98 (FRP1) and 0C3-
integrin (FRP2) (Higuchi et al., 1998; Ohgimoto et al., 1995), CD44 (Sterling et al.,
1998), the mannose receptor (DeFife et ah, 1999), Macrophage Fusion Receptor (MFR)
identical to P84/SHPS-l/SRPa/BIT and its ligand CD47 (Comu et ah, 1997; Han et ah,
2000; Jiang et ah, 1999; Saginario et ah, 1998; Sano et ah, 1997), ICAM-1 and LFA-1
(Fais et ah, 1994; Kazazi et ah, 1994; Most et ah, 1990), and the purinogenic receptor
P2X7 (Chiozzi et ah, 1997). In addition, cellular filamentous actin organisation (DeFife
et ah, 1999; McNally et ah, 1996), and an acidic extracellular environment are also
thought to contribute to polykaron formation (Franklin, 1958; Hernandez et ah, 1996).
Little is known about the physical mechanism of monocyte fusion. Reports suggest
that interaction of CD44 with an unknown ligand on the opposing cell surface, and a
step wise interaction of the long splice form of MFR with CD47, followed by
engagement of the short splice form of MFR, results in the close apposition of
membranes. Fusion may then be induced by the putative pore-forming ability ofCD47,
or the pore-forming P2X7 ATP transporter (Vignery, 2000). Blockade of P2X7
function with pyridoxalphosphate (PPADS) has been shown to inhibit MNGC
formation (Lambrecht et ah, 1992).
We have assessed the involvement of a number of these molecules and aspects of their
down stream signalling pathways in previous chapters. DX re-programming of
monocyte differentiation appears to alter or inhibit a number of fusion mechanisms.
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We were unable to demonstrate formally a requirement for P2X7 for fusion of
monocyte derived macrophages, as PPADS induced cell death in our system. An
increase in extracellular acidity regulated by H+-ATPases has been suggested to
promote fusion (Franklin, 1958; Hernandez et ah, 1996). Acidity of culture media
can be approximated by inclusion of phenol red which shows a yellow colour at low
pH. We observe that media pH is maintained more stringently in glucocorticoid-
treated cultures compared to control cells, suggesting that ATP-regulated transporters
may be altered by DX-treatment. CD47 or integrin associated protein (IAP) and
CD98 have been shown to regulate integrin affinity (Brown and Frazier, 2001;
Fenczik et al., 1997). CD98 ligation is thought to lead to increased LFA-l/ICAM-1
adhesion in lymphocytes via the activation of Rapl (Suga et al., 2001). In
monocytes it is thought to induce a pathway involving ERK activation (Miyamoto et
al., 2000). Preliminary evidence suggests CD98 expression is slightly elevated with
DX-treatment, although downregulation of ERK activity in DX-treated cells could
potentially compromise CD98 signalling. Occupancy of CD44 by ligands such as
hyaluronan, chondroitin sulfate, osteopontin or recombinant CD44 prevents fusion,
due to an inhibition of CD44 mediated cell-cell interaction (Sterling et al., 1998).
Glucocorticoid treatment downregulates CD44 expression (chapter 3, table 1), that
may mimic the sequestration of CD44 by ligand occupancy, demonstrated to inhibit
giant cell formation. MFR was cloned as a fusion regulating protein by Vignery and
colleagues, and was found to be identical to the scaffolding protein SHPS-1,
involved in adhesion signalling (Timms et al., 1999). Pathways that promote cellular
awareness of the substratum may therefore also be employed to recognise cell-cell
contact. Two of the major SHPS-1 interacting proteins thought to mediate
downstream signalling are Pyk2, and SHP-1, which show reduced phosphorylation
and expression in DX-treated macrophages (chapter 4, fig. 5). Dysregulation of
SHPS-1 signalling may also contribute to the lack of polykaryon formation in DX-
treated monocyte/macrophage cultures.
Polarization and the formation of highly adherent monocyte aggregates is thought to
promote fusion via the mannose receptor (DeFife et al., 1999), however DX-treated
macrophages do not appear polarised, have a disorganised actin cytoskeleton and
195
show decreased mannose receptor expression. Similarly localisation of ICAM-1 on
the monocyte cell surface to uropod-like structures is thought to promote fusion by
interaction with LFA-1 (Fais et al., 1997; Fais et al., 1994; Kazazi et al., 1994; Most
et al., 1990). Although the expression of LFA-1 in response to DX-programming has
not been assessed, glucocorticoids down regulate the expression of ICAM-1 on 5-day
macrophages. The time point during maturation at which this occurs has not been
established, however if it were early during maturation whilst
monocyte/macrophages were at their most fusogenic (Most et al., 1997), it would
provide a further mechanism for glucocorticoid inhibition ofMNGC formation.
The pro-inflammatory cytokine IFNy has been shown to induce MNGC formation in
vitro and in vivo. Crohn's disaese and sarcoidosis, chronic inflammatory conditions
associated with granuloma formation, show increased production of IFNy at the
inflammatory lesion and in the periphery (Fais et al., 1994; Robinson et al., 1985).
Peripheral IFNy is likely to be generated by TH1 type T-cells. Exposure of
monocyte/macrophages to TH1 cytokines would induce an M-l response with the
further release of pro-inflammatory cytokines including IFNy potentiating granuloma
formation. Thus the refractivity ofDX-treated macrophages to IFNy induced fusion,
and possibly aspects of the M-l phenotype could explain the effectiveness of
glucocorticoid therapy for granulomatous conditions such as sarcoidosis (Gibson,
2001). The mechanism of initiation of granuloma formation in conditions such as
sarcoidosis and Crohn's is not known but appears to occur in the absence of any
known antigen (Sheffield, 1990). MNGC have the capacity to present antigen as
they have been reported to express MHCII and B7 (Burgio et al., 1995), however
polykaryons are poorly phagocytic (Mariano and Spector, 1974, plus our own in
vitro observations). It has been proposed that during membrane fusion, exogenous
antigens and membrane molecules such as ICAM-1 may be included into the MNGC
cytoplasm and presented (Fais et al., 1997). MNGCs therefore have a capacity to
present endogenous antigens promoting autoimmune responses.
Infection of monocytes and T cells by the HIV virus induces a similar fusion
mechanism as proposed for IFNy, utilising an ICAM-1 mediated pathway, with the
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formation ofMNGCs and syncitia respectively (Butini et al., 1994; Fais et al., 1996).
MNGCs are able to survive in culture for more than 2 years (Bigi et al., 1990), fusion
of infected monocytes would therefore provide a long-lived reservoir of viral
production. In contrast, syncitia formation occurs by the rapid recruitment and
fusion of hundreds of cells which die shortly after infection (Lifson et al., 1986;
Sodroski et al., 1986). Formation and turnover of syncitia may explain why they are
rarely detected in the organs ofAIDS patients. More importantly the rapid demise of
syncitia proposes a mechanism for the rapid depletion ofCD4+ cells in AIDS patients
(Soil and Kennedy, 1994). Conventional glucocorticoid therapy would be
detrimental to T cell survival, promoting further immune suppression.
Understanding the mechanism of glucocorticoid inhibition of cell fusion may provide
novel approaches for inhibition of long-lived cellular reservoirs for viral production,
and the depletion of T-cells by syncitia formation.
Osteoclasts, cells of the monocyte/macrophage lineage are also formed by the cell
fusion of granulocyte-macrophage progenitors. Osteoclasts are found at bone
surfaces where they mediate bone remodelling. Over-activity of osteoclasts and
increased bone resorption has been implicated in osteoporosis, a complication
observed during long term glucocorticoid therapy. However based upon our in vitro
observations we would predict that DX would inhibit cell fusion and hence decrease
osteoclast formation leading to osteopetrosis characterised by increased bone
deposition. Additionally the disruption of podosomes may decrease the rate of bone
turnover and remodelling following DX-treatment. We have only assessed the affect
of DX on giant cell formation in response to IFNy, and IL-4, and therefore cannot
predict if DX would inhibit fusion in response to other soluble mediators. The role
of IFNy and IL-4 in osteoclast formation is unclear with contradictory findings in
vitro (Anderson, 2000; Vignery et al., 1990). However ICAM-1 and LFA-1 have
been implicated in the fusion process (Kurachi et al., 1993) and TNFa as the soluble
mediator inducing osteoclast formation and bone resorption activity (Merkel et al.,
1999; Takahashi et al., 1999). Our own experiments have demonstrated that DX-
programmed macrophages can respond to TNFa in terms of an induction of a MAPK
response, therefore macrophage TNFa responses may not be compromised by
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glucocorticoid treatment. Interestingly osteoblast viability can be modulated by
glucocorticoids. Corticosterone has been shown to induce mouse osteoblast cell
death (Gohel et al., 1999). Loss of osteoblasts would lead to the development of an
osteopetrotic phenotype. In contrast, DX has been shown to inhibit TNFa mediated
osteoblast apoptosis (Chae et al., 2000). Glucocorticoids therefore appear to
influence a number of important processes involved in bone homeostasis.
DX-inhibits IL-4 programming ofdendritic-like cells
Culture of peripheral blood monocytes in GM-CSF and IL-4 induces the formation
of dendritic cells (Romani et al., 1994; Sallusto and Lanzavecchia, 1994).
Glucocorticoids have been shown to inhibit aspects of dendritic cell maturation and
function. DX-treatment of dendritic cell progenitors during differentiation induces a
subset of CD14+ CD83", and CD14+ CD80" cells distinct from both immature and
mature dendritic cells (Canning et al., 2000; Matasic et al., 1999). Additionally
glucocorticoids have been proposed to promote the formation of macrophages rather
than dendritic cells from common precursosrs (Matasic et al., 1999; van den Heuvel
et al., 1999). Glucocorticoids have been reported to decrease the uptake and
processing of antigen, but not presentation by some groups (Holt and Thomas, 1997).
However, conflicting reports demonstrate an increase in mannose receptor-mediated
endocytosis (Piemonti et al., 1999a), and a down regulation of antigen presentation
and expression of costimulatory molecules CD80 and CD86 (Moser et al., 1995;
Sacedon et al., 1999; Vanderheyde et al., 1999). Differences in the origin and the
maturation status of dendritic cells exposed to steroid may account for these
discrepancies. DX treatment of monocytes retarded their differentiation into an
immature dendritic cell phenotype, whereas DX could not block the subsequent
differentiation from immature to a mature dendritic cell (Piemonti et al., 1999b).
Furthermore, in contrast to the effects of DX on mature dendritic cells treatment of
immature dendritic cells with DX prior to the maturation stimulus LPS, resulted in a
decrease in priming of T lymphocytes for the production of IFNy, and multiple re-
stimulation of lymphocytes with DX/LPS treated dendritic cells resulted in the
production of T regulatory cells (Matyszak et al., 2000).
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Cytokines inhibit DX-augmentedphagocytosis
It might be expected that cytokines associated with resolving inflammation would
potentiate clearance of apoptotic cells. IL-4, IL-10 and IL-13 which antagonise the
effects of IFNy and other type 1 cytokines are associated with the healing phase and
have the capacity to "alternatively" activate macrophages (Goerdt and Orfanos,
1999). Interestingly, glucocorticoids have also been described to induce
"alternative" activation. However, uptake of apoptotic cells was decreased with both
cytokines. Previous conflicting reports relating to the effects of IL-4 and other TH2
cytokines (Erwig et al., 1998; Ren and Savill, 1995) may reflect the species and
tissue origin ofmacrophages used in the studies and the period of cytokine exposure.
Long term exposure to cytokines used in this study will alter monocyte
differentiation pathways making direct comparisons with previous studies difficult.
For example our data indicates that long term and short term steroid exposure
augments phagocytosis in different ways (Giles et al., 2001). Interestingly IL-4 has
recently been shown to induce the expression of 11 (3-hydroxysteroid dehydrogenase
typel (11 (3-HSD1) which metabolises the inactive glucocorticoid cortisone to the
active Cortisol in monocyte/macrophages (Thieringer et al., 2001). This could
potentially promote clearance of apototic cells in vivo. However, our results suggest
that the presence of IL-4 would abrogate any effects of glucocorticoids on
macrophage function. This may be due to the induction of a dendritic cell like
phenotype by IL-4 as described in the previous section. Differences in cross-
presenting capacity between macrophages and immature dendritic cells may be due
to the engagement of different intracellular pathways upon intemalisation, which
may influence the efficiency of particle uptake. Furthermore, the intracellular
pathway engaged might determine the cellular response, such as release of soluble
mediators, which could influence particle processing by an autocrine mechanism.
For example, IL-10 and IL-13 released by macrophages after apoptotic cell ingestion
upregulate class II expression promoting presentation via this pathway. The cytokine
profile generated by dendritic cells after phagocytosis of apoptotic particles has not
been assessed, but may contrast profiles observed in the macrophage. Additionally
the direct effect of glucocorticoids on dendritic cell phagocytosis of apoptotic cells
has not been assessed, glucocorticoid inhibition of dendritic cell maturation may
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prevent expression of co-stimulatory molecules during augmented apoptotic cell
uptake. We are currently assessing the effect of DX and DX/IL-4 programming on
the expression of co-stimulatory molecules CD80 and CD86. Efficient uptake and
presentation of pathogens and opsonized particles is required for a functional
immune response. It would therefore be interesting to assess the capacity of IL-4 or
DX/IL-4 treated macrophages to phagocytose opsonized erythrocytes or complement
opsonized zymosan.
Loss of pl30cas in DX-treated cells was suggested to contribute to podosome loss
and increased phagocytic capacity (chapter 4). Expression of pl30cas was apparent
in DX/IL-4 treated cells, although the adhesions appeared slightly different to
classical posodomes, it correlated with decreased phagocytosis. In contrast DX/ILNy
treated cells had no podosome structures or pl30cas expression, but also had
decreased phagocytic capacity. Comparison of DX/ILNy and DX matured
macrophages provide a strategy for the elimination of genes involved in
morphological changes alone, allowing rapid identification of modulators of
macrophage phagocytosis. During manipulation of cells, for example washing
during phagocytosis assays, or during detachment for phenotyping experiments, it
was evident that DX/IENy macrophages were much less adherent than cells treated
only with DX. Although we hypothesise that the reduction of adhesion processes
observed in DX-treated macrophages potentiates their phagocytic capacity, too little
adhesion, as seen with cells treated with cAMP may inhibit phagocytosis.
Interestingly, ILNy treated macrophages that expressed no pl30cas but had extensive
podosome formation and decreased phagocytosis, may provide a useful model
system for the study of other molecules involved in adhesion and phagocytosis. Lor
example assessment of Rac activity in DX/ILNy and DX/IL-4 treated cells would be
most interesting. Additionally both glucocorticoid and cytokine matured
macrophages expressed WASp, a protein shown to be required for phagocytosis and
podosome formation (Leverrier et al., 2001; Linder et al., 2000; Linder et al., 1999).
Thus ILNymatured cells provide a model system in which function ofWASp may be
assessed, such that its expression is sufficient for podosome formation, but cannot
rescue phagocytosis.
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M-2 or not M-2 ? that is the question
Phenotypically DX-treated monocyte/macrophages are distinct from either IFNy or IL-4
treated cells. IFNy upregulates the expression of CD 14, ICAM-1 and CD64, and
downregulates mannose receptor expression. Conversely IL-4 treatment induces
mannose receptor expression, and down regulates CD 14, ICAM-1 and CD64. The
profile of these molecules after DX-treatment shows similarities to both M-l and M-2
cells, with the decrease in ICAM-1 and CD64 seen after IL-4 treatment, but a decrease in
mannose receptor expression characterised by IFNy. The effect of glucocorticoid
programming is dominant over the cytokine influence in terms of ICAM-1 and mannose
receptor expression, but it is unable to prevent IFNy induced CD64 expression, or IL-4
induced CD 14 downregulation. Based upon these data, I propose that DX-matured
macrophages are clearly not "alternatively" activated. Furthermore, in glucocorticoid-
treated cultures we were unable to detect augmented expression of mRNA encoding
arginase or changes in transcripts encoding the recently identified markers of alternative
activation: Fizz2 and Fizz3. Examination of other specific functions of DX-treated cells
may allow better definition of this phenotype. The effect of early exposure to DX on
monocyte/macrophage differentiation supports the suggestion that initial cytokine
exposure determines macrophage phagocytic function (Erwig et al., 1998). Therefore,
during an inflammatory reaction extravasating monocytes will have already been exposed
to elavated levels of glucocorticoids present in the bloodstream in response to stress
stimuli prior to encountering the cytokine environment at the inflammatory site.
Monocyte/macrophages may therefore be unable to be programmed as M-l or M-2,
producing a third subset of macrophages typified by our DX-treated
monocyte/macrophage phenotype generated during in vitro culture. Such effects may
have profound implications for patients receiving long-term glucocorticoid therapy.
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CHAPTER 8: SUMMARY AND FUTURE DIRECTIONS
The aim of this study was to understand the mechanisms underlying the regulation of
macrophage phagocytosis of apoptotic cells, a possible "rate limiting step" for
resolution of inflammation. Much research work has concentrated on modulation of
granulocyte death programs, however in the absence of clearance, there is a
persistence of inflammatory infiltrate and chronic inflammation occurs. The recent
reports describing how the act of engulfment triggers the final steps of the apoptotic
program in the nematode worm, demonstrate the evolutionary conservation of
clearance mechanisms in the maintenance of tissue homeostasis.
When this work was originally undertaken, little was known of the intracellular
pathways regulating phagocytosis of apoptotic cells and research was centred largely
on understanding the interaction of the phagocyte and prey at the receptor level.
However, the diversity of receptor families involved suggested redundancy in the
system and therefore regulation at this level would not present a target for therapeutic
intervention. We therefore first characterised the effects of a modulator of
macrophage phagocytic capacity for apoptotic cells, glucocorticoids. Although
previous work had demonstrated an upregulation in phagocytosis of apoptotic cells
after 24 hours of glucocorticoid treatment, preliminary experiments suggested that
this increase could be further augmented with longer exposure. We demonstrated
that exposure of monocytes to glucocorticoids immediately following isolation for
the full period of their maturation into macrophages not only increased phagocytosis
but also brought about a number of changes in the resultant monocyte/macrophage.
In summary, long term dexamethasone treatment:
■ Increased phagocytosis of apoptotic cells four-fold
■ Phagocytic index was increased nearly seven fold
■ Augmentation was independent of increases in receptor expression or
function
■ Uptake of opsonized particles was also increased
■ DX-treated macrophages showed a distinct morphology
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■ Increased homogeneity, smaller, rounder
■ Decreased formation of adhesion processes
■ Disordered actin cytoskeleton
■ Biochemical analysis suggested this was linked to changes in adhesion signalling
■ Decrease in Paxillin and Pyk2 phosphorylation
■ Decrease in pi30cas expression
■ Increase in Rac activity
■ Decreased basal ERK activity
■ The distinct morphological, biochemical and functional characteristics of DX-
treated macrophages were influenced by the cytokine environment
■ IFNy and IL-4 inhibited DX-augmented phagocytosis without influencing
morphology
Our hypothesis generated from this data was that the increased cytoskeletal
plasticity, from decreases in adhesive processes involved in cell substratum
interactions, and augmented Rac activity allowed the efficient rearrangement of
cytoskeletal components required for the uptake of apoptotic cells. We proposed that
decrease in pl30cas was pivotal in generating this phenotype due to its role in
podosome formation and interaction with DOCK180 and Crk. The number of
potential binding partners for Crk and DOCK 180, suggest that some of these
cytoskeletal regulators may preferentially be involved in adhesion, whilst others may
be required for phagocytosis. We propose that the balance of expression of these
molecules is pivotal to the overall functional outcome, in a manner analogous to the
balance of pro- and anti-apoptotic Bcl-2 family members determining the sensitivity
of cells to apoptotic stimuli. Thus the balance of adaptor proteins may determine a
cells phagocytic potential. For example the absence of pl30cas in glucocorticoid
treated macrophages may therefore promote interaction of Crk and DOCK180 with
the ELMO family of adaptor proteins recently implicated in phagocytic uptake in C.
elegans (Gumienny et al., 2001).
With the publication of work by Albert et al (2000) and Tosello-Trampont (2001)
there has been a shift in emphasis of research in this field to understanding the role of
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molecules involved in regulating the actin cytoskeleton in the uptake of apoptotic
cells, rather than events on the cell surface. The data presented in this thesis supports
the suggestion that cytoskeletal regulation in the clearance of apoptotic cells, is
important. However, my data suggests also that there are additional complexities.
The cytokine and cytokine/DX maturation experiments generated several interesting
"subsets" of macrophage cytoskeletal phenotypes described in chapter 7. In
summary:
• IFNy, podosomes, no pl30cas
• DX/IFNy, no podosomes, no pi30cas
• IL4; podosomes, pl30cas
• DX/IL-4; no podosomes, pi30cas
The common factor between these four treatments is that unlike DX alone they all
displayed low phagocytic potential for apoptotic cells. These experiments raise
questions as to the validity of our suggested target molecule pl30cas indicating it is
unlikely to be the only key regulator of phagocytic capacity. However, we would be
naive to expect such a complex process to be influenced by a single molecule.
Further development of the TAT fusion protein technology described in chapter 6
will allow us to determine the contribution of pl30cas expression to the DX
phenotype. The generation of the cell subtypes following combinations of DX and
cytokine provides a valuable tool for divorcing adhesion from phagocytosis. Array
technology will allow gene expression profiling that may provide important clues as
to the key regulatory elements involved in phagocytic clearance of apoptotic cells.
However, we must be aware that focussing on single changes might be misleading.
What may be other targets for glucocorticoid modulation? As mentioned above the
recent identification of ELMO, the human homologue of the C. elegans protein
CED-12, and its role in phagocytosis provides a potential target for modulation
during DX-re-programming. Decrease in pl30cas and an increase in ELMO may
promote phagocytosis as opposed to adhesion. Within the context of molecules
evaluated in this study, Pyk2 is worth further investigation. Pyk2 has been shown to
interact with Crk and can influence ERK activity, one "marker" of DX re-
programming, and has been linked to regulation of podosome formation.
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Interestingly, although both IFNy and DX-treated macrophages lack pl30cas and
express WASp, the ability to form podosome adhesions is lost in the presence of
glucocorticoid, suggesting that organisation in these phenotypes is dependent on
signalling upstream of these molecules. Assessment of Pyk2 phosphorylation status
in cytokine-treated macrophages may therefore prove very informative. It was
demonstrated several years ago that tyrosine kinase inhibitors block the uptake of
apoptotic cells. The identification of a new phagocytic receptor, Mer, as a receptor
tyrosine kinase, a putative pTyr motif in the newly cloned human PS receptor, and
the association of syk with CrkL and WASp, suggests that membrane associated or
membrane localised tyrosine kinases may have an important part to play in the
regulation of engulffnent. We tried (unsuccessfully) to immunoprecipitate Crk and
assess its phosphorylation status in DX treated cells. It remains possible that tyrosine
phosphorylation is required for the control of interaction of Crk with a number of
adaptor molecules. My studies also illustrate an important conceptual point.
Documenting altered gene expression patterns in macrophages deficient in
phagocytic function, although informative, cannot identify subtle post-translational
modifications for example phosphorylation or glycosylation, that are critical for
function. Biochemical approaches will therefore be required to fully understand the
mechanisms that regulate phagocytic potential.
The studies in this thesis have been carried out using isolated cells entirely in vitro.
Although this approach allows the intricate dissection of signalling pathways, it
cannot reconstitute the specialised microenvironments that may further influence
phagocytic potential in vivo. For example adhesion to different matrices or ligation
of macrophage cell surface molecules can have a profound effect on macrophage
phagocytic function (McCutcheon et al., 1998, Hart et ah, 1997). Furthermore, work
presented in chapter 7 illustrated the potential effect of the cytokine environment on
phagocytosis. Clearly, glucocorticoid therapy in isolation may not be the most
effective approach for augmenting phagocytosis in many inflammatory conditions.
Combination of glucocorticoid and anti-cytokine treatment may provide a strategy
for more efficient clearance of inflammatory infiltrate. This suggestion would
require testing in models of inflammation using different inflammatory stimuli in
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different tissues. However, such combinations may allow a beneficial reduction in
steroid doses, decreasing the detrimental effects of long-term glucocorticoid therapy.
Finally, one question concerning the effect of glucocorticoid programming on
pl30cas expression not addressed by this study is whether the effects are cell specific
or does downregulation of pl30cas expression occur in other cell types? Sequence
analysis demonstrated that pl30cas was identical to BCAR1 (Breast Cancer Anti-
oestrogen Resistance), identified in tamoxifen-resistant breast carcinoma cells
(Brinkman et al., 2000). Increased expression levels of BCARl/pl30cas in breast
cancer cell cytosols correlated with rapid recurrence of disease (van der Flier et al.,
2001). A high BCARl/pl30Cas level was also associated with a higher likelihood of
resistance to first-line tamoxifen treatment in patients with advanced breast cancer
(van der Flier et al., 2000). Given the close link between adhesion and resistance to
apoptotic stimuli and the potential for secondary metastases,
it may be that pl30cas expression has a pivotal role in controlling tumour cell
growth. Glucocorticoid induced changes in ERK activity that are required for
proliferation and migration in certain cell types could also contribute to the
modulation of tumour growth. Potential targeting of glucocorticoids to cancerous
tissue in combination with anti-oestrogen treatment may provide a novel therapy of
breast carcinoma.
In conclusion, this study has provided a novel insight into the control of monocyte-
macrophage differentiation, adhesion and phagocytosis. The data presented in this
thesis suggests a major impact of long term glucocorticoid treatment on cell type that
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1 gaggcggcag ctgcgcggcg gcaccggggc ggctgcggcg cgctcggagc cccgaggcac
61 gc^cccggg
catgaaccac
cagctcggtg tgcgcccccg cgagagccgg gccccaggcc cgccggacac
121 ctgaacgtgc tggccaaagc gctctatgac aatgtggccg agtccccgga
181 tgagctctcc ttccgcaagg gtgacatcat gacggtgctg gagcaggaca cgcagggcct
241 ggacggctgg tggctctgct cgctgcatgg gcgccagggc atcgtgcctg ggaaccgcct




361 caccccggcc cagcctcagc tgccccagcg cctccggcct cccagtacac
S
tgcccactcc421 gcccatgctc cccaacacct accagcccca gccagacagc gtctacctgg
481 cagcaaggct cagcaaggcc tctaccaagt cccgggtccc agccctcagt tccagtctcc
541 cccagccaag cagacatcca ccttctcgaa gcagacaccc catcacccgt ttcccagccc
601 ggccacagac ctgtaccagg tgcccccagg gcctggaggc cctgcccagg atatttacca
661 ggtgccacct tctgccggga tggggcatga catctaccag gtccccccgt ccatggacac




781 gggctatgta tacgaggccg cccagccgga tacgacatcc cgcgacacct
841 gctggccccg gggccacagg acatctatga tgtgcccccg gttcgggggc tgcttcccag
901 ccagtatggc caggaggtgt atgacacacc ccccatggct gtcaagggtc ccaatggccg
961 agacccgttg ctggaggtgt atgacgtgcc ccccagtgtg gagaagggcc tgccaccgtc
1021 caaccaccac gcagtctacq acgttcctcc
^ Primer 3
atcggtgagc aaggatgtgc ccgatggccc
1081 actgctgcgt gaggagacct acgatgtgcc ccccgccttc gccaaggcca agccctttga














1321 tgatggtggc gtggtcgaca gtggtgtgta tgcggtgcct cccccagctg aacgtgaagc
1381 cccggcagag ggcaagcgcc tgtcggcctc cagcaccggc agcacacgca gcagccagtc




1501 ggaggccctg gcacggctgc gagcgccacc gttgcccacc ttctggacct
1561 ggcaggcagc gccggtgcga ctgggagctg gcgtagcccc tctgagccac aggagccgct
1621 ggtgcaggac ctgcaggctg ctgtggccgc tgtccagagt gccgtccacg agctgttgga
1681 gtttgcccgc agcgcggtgg gcaatgctgc ccacacatct gaccgtgccc tgcatgccaa
1741 gcttagccgg cagctgcaga agatggagga cgtgcaccag acgctggtgg cacatggtca
1801 ggccctcgac gctggccggg gaggctctgg agccaccctt gaggacctgg accggctggt
1861 ggcctgctcg cgggctgtgc ccgaggacgc caagcagctg gcctccttcc tgcacggcaa
1921 tgcctcactg ctcttcagac ggaccaaggc cactgccccg gggcctgagg ggggtggcac
1981 cctgcacccc aaccccactg acaagaccag cagcatccag tcacgacccc tgccctcacc
2041 ccctaagttc acctcccagg actcaccaga tgggcagtac gagaacagcg aggggggctg
2101 gatggaggac tatgactacg tccacctaca ggggaaggag gagtttgaga agacccagaa
2161 ggagctgctg gaaaagggca gcatcacgcg gcagggcaag agccagctgg agttgcagca











^ Primers 6 and 7 ►
gtgtgaggcc aacctgacca cactgaccaa
232
2401 cgccgtggac gccttcttta ccgccgtggc caccaaccag ccgcccaaga tctttgtggc
2461 gcacagcaag ttcgtcatcc tcagcgccca caagctggtg ttcatcgggg acacactgtc
2521 acggcaggcc aaggctgctg acgtgcgcag ccaggtgacc cactacagca acctgctgtg
2581 cgacctcctg cgcggcatcg tggccaccac caaggccgct gccttgcagt acccatcgcc




2701 ccgccgcgtc ctaggccagc tggcagccgc tgaccccagg agggaggcag
2761 gggaggggtg cggcggtccc agctccctgg ctcccatgtc aagagtcgct gtgccacagg
2821 cttagggaca ggaccccagc tctgcgtcgg tcctggtgcc ctggatgccc aggaatctgt
2881 atatatttat ggccgggcag ggtgtggggc catgcctcct caggagccga agcccagggg
2941 ccgcagtggc cttccccagc atgcaccacg ggcccgggtt gggtcaccag acggggctgg
3001 agtgtgaggg tcctgcagcc tgcaggacct cgtgccaccc cgagggctga gcctggtccc
3061 acgagggtgc cgtgtcccct gacagggcca gtgcagtttg gtgtgtcctc cgccttacca
3121 ggagaagaac ctgaagaact atttttcgtt attggttttc caatcatttg actaagagtc
3181 tccatttaaa taaagttttt aaaaggaa
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Sequence shown as original clone with nucleotide and subsequent amino acid
changes shown above the sequence. Putative phosphorylation motifs in the amino
acid sequence are shown in grey font.
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AN APPETITE FOR APOPTOTIC CELLS? CONTROVERSIES AND CHALLENGES
The biochemical pathways involved in programmed cell
death are broadly similar in phylogenetically diverse multi¬
cellular organisms, including the nematode worm Caenor-
habditis elegans, Drosophila and mammals, suggesting that
cell death and subsequent phagocytosis of apoptotic cells
represents an important regulatory mechanism that has
been conserved through evolution (Ellis et al, 1991;
Hengartner, 1996).
During apoptosis. the cell activates intrinsic suicide
mechanisms that lead rapidly (within hours) to the
characteristic macroscopic features of cell shrinkage, chro¬
matin condensation, membrane budding and, eventually,
the formation of one or more apoptotic bodies (Kerr et al,
1972). Phagocytosis of senescent cells had been described in
the late nineteenth century by the Russian biologist Elie
Metchnikoff who observed that 'macrophages' (neutrophil
granulocytes) were 'englobed' by macrophages in injured
tadpole fins, although the significance of these observations
has only become apparent in the last few decades. It has now
been established that apoptotic cells are swiftly recognized
and ingested by neighbouring phagocytes without elicitation
of pro-inflammatory responses from phagocytic cells
(Meagher et al, 1992; Savill et al, 1993; Fadok et al, 1998).
Apoptosis and the subsequent phagocytic clearance of
senescent cells have central roles in many fundamental
biological processes, including normal tissue turnover (Han
et al, 1993), remodelling of embryological tissues (Hopkin-
son-Woolley et al, 1994), development of the immune system
(Cohen. 1991) and the normal resolution processes of
inflammation (Haslett et al, 1994). Macrophages are the
principal phagocytes that are responsible for clearance of
apoptotic cells in mammals, although cells with the potential
for phagocytosis, e.g. endothelial cells (Dini et al. 1995: Hess
et al, 1997). fibroblasts (Hall et al, 1994), glomerular
mesangial cells (Hughes et al, 1997), hepatocytes (Dini
et al, 1992), Sertoli cells (Shiratsuchi et al, 1997) and
vascular smooth muscle cells (Bennett et al, 1995) may
remove apoptotic cells in certain circumstances.
GRANULOCYTE APOPTOSIS AND THE
RESOLUTION OF INFLAMMATION
There is increasing evidence that aberrant apoptosis and/or
phagocytic clearance of apoptotic granulocytes may con¬
tribute to the pathogenesis of inflammatory diseases (Fig 1).
Neutrophil granulocytes play a vital role in the body's
Correspondence: Dr I. Dransfield, The Rayne Laboratory. Respiratory
Medicine Unit, University of Edinburgh Medical School, Teviot Place,
Edinburgh EH8 9AG, UK.
defence against infectious agents, but uncontrolled release of
their formidable array of toxic substances may inflict
'friendly fire' damage on surrounding tissue and propagate
the inflammatory response (Haslett et al, 1994). In contrast
to the potentially harmful effects of necrotic cell death upon
tissue integrity and organ function, deletion of cells by
apoptosis represents a cellular removal pathway that does
not provoke pro-inflammatory phagocyte responses, indeed,
dysregulated neutrophil and eosinophil granulocyte apop¬
tosis has been implicated in the pathogenesis of the adult
respiratory distress syndrome (ARDS), idiopathic pulmonary
fibrosis, ulcerative colitis, rheumatoid arthritis, asthma and
other allergic diseases (Weiss, 1989; Meagher et al, 1992;
Haslett et al, 1994: Stern et al, 1996; Woolley et al, 1996).
Uncoupling of neutrophil effector responses associated with
apoptosis (Whyte et al, 1993). together with 'anti-inflam¬
matory' clearance by phagocytes, provides a mechanism for
the 'safe' disposal of potentially destructive inflammatory
cells. Strategies for manipulation of cellular apoptosis
programmes for therapeutic gain in inflammatory or allergic
disease are likely to fail if the capacity for clearance of
apoptotic cells is exceeded. Data from in vivo experimental
models support this hypothesis. For example, induction of
widespread apoptosis in the liver, after treatment of mice
with intraperitoneal Fas antibody, led to extensive hepatic
necrosis and death of the animals (Ogasawara et al, 1993).
Similarly, induction of bronchial and alveolar epithelial cell
apoptosis in the rat lung by repeated inhalation of
aerosolized Fas antibody culminated in pulmonary inflam¬
mation and scarring (Hagimoto et al, 1997). Although
previous strategies have identified several distinct families of
molecules involved in apoptotic cell recognition, the precise
mechanism of phagocytosis of apoptotic cells is still not
known. Clearly, a detailed understanding of the mechanisms
of phagocytic clearance of apoptotic cells and the underlying
regulatory mechanisms are likely to have important
implications for the design of therapeutic strategies for the
treatment of inflammatory disease. In this review, we will
illustrate some of the problems that need to be resolved and
describe some of the challenges for future research on
phagocyte recognition of apoptotic cells.
PHAGOCYTE RECEPTORS FOR RECOGNITION OF
APOPTOTIC CELLS
At least seven distinct molecular families have been
implicated in the recognition process. Table I summarizes
the experimental data that support the involvement of the
receptor pathways for the clearance of apoptotic cells shown
schematically in Fig 2 (see also Savill et al, 1993; Hart et al,


































Fig 1. Schematic representation illustrating
the proposed role of neutrophil apoptosis and
phagocytic clearance by macrophages in the
process of resolution of inflammation.
1996: Piatt et al, 1998a). The first molecular pathway for
the specific clearance of apoptotic neutrophils by human
macrophages was identified on the basis of distinct patterns
of inhibition by carbohydrates and sensitivity to altered pH
(Savill et al, 1989). Subsequent analyses implicated the
phagocyte integrin, av/33 (Savill et al, 1990) and the class B
scavenger receptor, CD36, as receptors of apoptotic cell-
associated thrombospondin (Savill et al, 1992). Inhibition of
phagocytosis of apoptotic cells after blockade of integrin
function in murine bone marrow-derived macrophages
indicated that similar pathways exist in other species
(Fadok et al. 1992a). However, Fadok et al (1992b) also
demonstrated that murine peritoneal macrophages did not
use this pathway and characterized phosphatidylserine (PS)
as a ligand for a putative PS receptor. In support of the
suggestion that macrophages from different tissue sites use
distinct pathways, Kupffer cells recognize altered carbohy¬
drate present on apoptotic cells via the asialoglycoprotein
receptor (Dini et al, 199 5), whereas mouse thymic macro¬
phages use class A scavenger receptors (Piatt et al, 1998b).
Furthermore, alteration of macrophage phenotype after
stimulation (for example, with digestible particles) may
drive switching of the dominant pathway used for clearance
(Fadok et al. 1993: Pradhan et al, 1997). A number of
alternative pathways for human macrophage clearance of
apoptotic cells have been reported. Detailed characterization
of macrophage recognition of apoptotic B cells (Flora &
Gregory, 1994) pointed to a role for phagocyte CD14 (Devitt
et al, 1998) and apoptotic cell CD50 (Moffatt et al, 1999).
Recent data have also suggested a role for elements of
humoral immunity, specifically, complement components
Clq (Botto et al, 1998) and C3bi (Mevorach et al. 1998).
Specific opsonization of apoptotic cells may serve to
accelerate apoptotic cell clearance. In addition, there are
other receptors that have been identified to have a role in
apoptotic cell clearance, e.g. ATP binding cassette trans¬
porter (Luciani & Chimini. 1996). However, whether these
molecules mediate phagocyte recognition of apoptotic cells
directly is unclear. These data serve to illustrate the
molecular complexity of phagocyte recognition of apoptotic
cells and suggest considerable functional redundancy in
molecular pathways that are used for phagocytic clearance,
perhaps ensuring that clearance of apoptotic cells is not
compromised by genetic mutations in any one pathway.
Altered cell surface molecules Opsonins
Fig 2. Cell surface molecules implicated in the
uptake of apoptotic cells by phagocytes (see
also Table I and text).
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4 Review
Interpretation of results from studies of phagocyte
clearance of apoptotic cells has been complicated by a
number of factors in addition to the existence of tissue-
specific clearance pathways. The use of 'apoptotic' cell
populations that may contain cells at different stages of
apoptosis (Hebert et al, 1996) and variable numbers of
necrotic cells (Vermes et al, 1997) represents an additional,
frequently overlooked variable in the study of phagocytic
clearance. Phagocytosis of 'late' apoptotic and necrotic cells
may be mediated by different mechanisms with distinct
functional consequences. Furthermore, the experimental
approaches that have been used to determine the involve¬
ment of specific molecules in recognition may give rise to
further ambiguity. Identification of the molecular pathways
involved in phagocytosis of apoptotic cells has relied to a
large extent on the use of monoclonal antibodies (mAbs) and
competitive ligands. One of the potential problems of
competitive ligands is that, if the affinity of binding is low,
high concentrations of ligand are necessary to compete with
surface presentation of multivalent ligands on the surface of
apoptotic cells, with the possibility of non-specific effects.
Intact mAb or bivalent F(ab')2 fragments have the potential
for cross-linking macrophage surface receptors (including Fc
receptors via intact mAb) and the initiation of signalling
cascades that may indirectly alter phagocyte function. For
example, we have demonstrated previously that cross-
linking CD44 with bivalent mAb augments phagocytosis of
apoptotic cells (Hart et al, 1997). It is therefore possible that
mAb may exert inhibitory effects without the recognized
receptor necessarily being directly involved in the phagocytic
process. It is notable that, with a few exceptions (Flora &
Gregory, 1994), confirmation of direct receptor involvement
using Fab' fragments has not been made. Specific genetic
deletion of putative apoptotic cell receptors has provided
somewhat equivocal data, perhaps reflecting the functional
redundancy of receptor usage discussed above. For example,
absence of thrombospondin-1 expression resulted in pneu¬
monia, together with marked changes in lung homeostasis,
which might have reflected altered potential for clearance of
apoptotic cells. However, these effects were largely attributed
to the ability of thrombospondin-1 to activate the latent form
of transforming growth factor (TGF)-/31 (Crawford et al,
1998). Similarly, deletion of the .class A scavenger receptor
had profound effects upon phagocytosis of apoptotic
thymocytes in vitro, but did not alter the architecture of
the thymus significantly (Piatt et al, 1998b). However, the
absence of a structural abnormality in vivo may be accounted
for by a large functional reserve for apoptotic cell clearance
capacity in the healthy, 'pathogen-free' animal.
Although gene transfection into cell types lacking putative
apoptotic cell receptors provides evidence suggestive of direct
involvement via a 'gain of function' (Ren et al, 1995). these
experimental approaches may be limited by the requirement
for phagocytic machinery that may not present in the
transfected cell type. Recent studies examining the binding of
phospholipid vesicles have demonstrated a direct role for
CD36 binding to anionic phospholipids (Tait & Smith, 1999),
and uptake of oxidized low-density lipoprotein (LDL) via
scavenger receptor recognition of the lipid moiety rather
than apoprotein B as described previously (Bird et al, 1999).
Similar experimental approaches using binding of apoptotic
cells to purified isolated cell surface receptors would provide
definitive evidence for an apoptotic cell recognition receptor.
For each system described so far. it is also noteworthy that
there is often considerable mismatch between observed levels
of phagocytic responses in macrophage populations or
transfected cells with the percentage of cells that express
putative recognition molecules. For example, human mono¬
cytes express CD36 and CD 14. yet they bind and ingest
apoptotic cells very poorly, implying that these receptors may
be necessary, but not sufficient, for efficient phagocytosis to
occur. This suggestion is supported by the lack of complete
inhibition of phagocytosis of apoptotic cells, even when multiple
pathways are blocked, implying that further molecular path¬
ways for removal of apoptotic cells remain to be identified.
One of the characteristics of apoptotic cell clearance
mechanisms is the lack of induction of pro-inflammatory
macrophage responses, which may be important for the
silent clearance of apoptotic cells in normal physiological
processes (Meagher et al, 1992;SaviIl et al, 1993; Fadok et al,
1998). In contrast, phagocyte clearance of 'post-apoptotic'
or necrotic cells may trigger pro-inflammatory responses
(Stern et al, 1996: Hughes et al, 1997). Fadok et al (1998)
demonstrated that one potential mechanism for the inhibi¬
tion of pro-inflammatory cytokine production after apoptotic
cell phagocytosis might involve the production of TGF-/3 and
prostaglandins to actively suppress pro-inflammatory med¬
iator production. Active modulation of inflammatory or
immune responsiveness by macrophages after apoptotic cell
phagocytosis is further supported by preliminary findings
that interleukin (IL)-IO may be released from monocytes in a
CD36-dependent manner after interaction with apoptotic
cells (Voll et al, 1997). Recent data suggest that macrophage
phagocytosis of apoptotic cells may also lead to the release of
soluble Fas-ligand with the potential to influence inflamma¬
tory cell survival (Brown & Savill. 1999). It is likely that
progression of inflammatory responses and development of
disease is profoundly influenced by the combination of these
factors. Interestingly, analysis of interaction of type A
scavenger receptors and CD 3 6 with oxidized LDL (oxLDL)
suggested that, in contrast to soluble oxLDL. surface-bound
oxLDL induced macrophage secretion of H202. Inhibition
studies indicated that CD36 might play a role in the
promotion of secretion, suggesting that distinct CD36
ligands (apoptotic cells and oxLDL) might exert differential
effects (Maxeiner et al. 1998). Similarly, CD14-mediated
binding of lipopolysaccharide (LPS) has pro-inflammatory
effects on macrophage behaviour, whereas apoptotic cell
recognition via CD14 does not (Devitt et al, 1998). For many
cellular molecular recognition processes (e.g. macrophage-
T cell interactions involved in antigen presentation), co¬
operative receptor interactions are required to ensure
appropriate responses in the interacting cell types. One
possibility is that phagocytes use a number of pathways in
parallel to ensure the rapid identification of membrane
changes of apoptotic cells and that the repertoire of receptor
engagement during apoptotic cell recognition determines the
phagocyte responses initiated. One of the challenges for
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future research on apoptotic cell recognition mechanisms is
to define the pattern of utilization of distinct molecular
pathways in vivo and the issue of functional redundancy or
exclusivity using tissue-specific and temporal gene targeting
strategies or double knock-out animals.
PHAGOCYTOSIS: GENERAL MECHANISMS
Understanding the basic cellular machinery required for
apoptotic cell internalization and comparison with well-
characterized [e.g. FcR- and complement receptor (CR)-
mediated] phagocytic mechanisms may generate useful clues
for understanding the underlying control processes involved
and provide the basis for novel strategies for manipulation of
apoptotic cell clearance for therapeutic gain.
The dissociation of two distinct phases (initial binding to
specific receptors on the phagocyte surface and subsequent
internalization) during phagocytosis of particles that have
been opsonized with immunoglobulin (Ig) or complement
has allowed detailed dissection of the pathways at the
molecular level. Binding of opsonized ligands via FcR or CR
occurs in the absence of intact microfilaments or micro¬
tubules (Newman et al, 1991: Caron & Hall, 1998). In
contrast, attachment of apoptotic neutrophils appears to be
both energy dependent and requires intact cytoskeletal
elements. Little or no binding of apoptotic cells to human
macrophages is observed at 4°C or when cytoskeletal
elements are disrupted (our unpublished observations).
These findings contrast with studies of scavenger receptor
function, which show temperature-insensitive binding of
lipid microspheres (Bird et al 1999).
Particle internalization requires microfilament integrity in
all three forms of phagocytosis. Fc phagocytosis is mediated
by lamellipodia extension around the particle in a 'zipper¬
like' fashion (Griffin et al, 1975). and blockade of surface
receptors after particle attachment inhibited internalization.
Fig 3. Scanning electron micrograph of the interaction between a
human monocyte-derived macrophage and an apoptotic neutrophil
in vitro. The apoptotic neutrophil has been bound to the ruffled
membrane of the macrophage, and membrane projections can be
seen extending around the apoptotic cell (arrowed). Bar= 10 /xm.
Consistent with this model, inhibition of pseudopod exten¬
sion by the PI-3 kinase inhibitor, wortmannin. prevented
phagosome closure (Cox et al, 1999). CR1- and CR3-
mediated ingestion also requires intact microfilaments
but, in contrast to FcR-mediated internalization, bound
complement-opsonized particles appear to 'sink' into the
phagocyte surface, suggesting that internalization may
occur via a 'modified zippering' mechanism involving the
formation of a phagocytic pit (Kaplan. 1977). Further
differences were revealed after stabilization of microtubules
by elevation of cGMP, which enhances CR-mediated phago¬
cytosis (Newman et al, 1991). Examination of macrophages
ingesting apoptotic cells by scanning electron microscopy
suggests that apoptotic cell uptake may be similar to the
zippering mechanism observed for FcR-mediated phago¬
cytosis (Fig 3). In support of this assertion, stabilization of
microtubules via elevation of cGMP did not affect phago¬
cytosis of apoptotic neutrophils, whereas microfilament
disruption after cAMP elevation agents prevented ingestion
(Rossi et al, 1998).
Ultrastructural identification of differences in phagocytic
uptake is supported by recent molecular analysis of the
recruitment of cytoskeletal elements to nascent phagosomes
and regulation of cytoskeletal integrity by the Rho family of
GTPases. These findings suggest intriguing parallels with the
recruitment of proteins to nascent phagosomes and the
formation of actin-rich podosomes containing talin and
tyrosine-phosphorylated proteins that have been described
during macrophage adherence (Marchisio et al, 1987). During
FcR-mediated phagocytosis, cytoskeletal proteins (actin, talin,
paxillin and a-actinin) and tyrosine-phosphorylated proteins
are enriched near to the phagosome membrane in a diffuse
manner, and phagocytosis is sensitive to tyrosine kinase
inhibitors (Allen & Aderem, 1996). In contrast, during CR-
mediated phagocytosis (which is insensitive to tyrosine kinase
inhibition), discrete foci of these proteins are distributed over
the phagosome surface. Consistent with the requirement for
cytoskeletal elements described above, manipulation of Rho
family GTPases does not alter FcR- or CR-mediated binding of
particles. However, inhibition of formation of lamellipodial
and filopodial membrane extensions by microinjection of
dominant negative forms of Rho family GTPases, Rac and
Cdc42, inhibits FcR-mediated phagocytosis (Caron & Hall.
1998). In addition. Rac and Cdc42 control membrane
ruffling in macrophages, causing cell rounding and loss
of integrin-containing focal complexes with co-localized
vinculin. paxillin and FAK (Allen et al, 1997). In contrast,
injection of the Rho inhibitor C3 transferase into macro¬
phages inhibited the assembly of mechanotransducing
actomyosin filaments and prevented CR-mediated phago¬
cytosis (Allen et al, 1997; Caron & Hall. 1998). Distinct
effects of Rho on cytoskeletal organization and adhesion
were also observed with cell rounding after the injection of
constitutively active Rho into macrophages, whereas inhibi¬
tion of Rho led to loss of the presence of fine actin cables
(Allen et al, 1997). These data demonstrate that there are
distinct molecular mechanisms for phagocytosis via FcR and
CR (termed type I and type II respectively), which may
account for the observed differences in pro-inflammatory
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mediator production after particle internalization (Wright &
Silverstein, 1983; Yamamoto & Johnston, 1984; Aderem
et al, 1985; Scholl et al, 1992; Debets et al, 1998).
As yet, there has been no direct demonstration of a role for
Rho or Rac in apoptotic cell uptake. However, recent studies
of C. elegans mutants that display defective phagocytic
removal of cellular 'corpses' have characterized a number
of genes involved in this process (Liu & Hengartner. 1998:
Wu & Horvitz, 1998a,b), which suggest an important role
for cytoskeletal-associated proteins and regulators in apop¬
totic cell uptake. The ced-6 gene product has sequences
similar to phosphotyrosine-binding domains, and it may
therefore act as an adaptor in the signalling pathways
engaged after recognition and binding of apoptotic cells (Liu
& Hengartner, 1998). Our preliminary data indicate that
there is an absolute requirement for tyrosine kinase activity
in apoptotic cell uptake, in keeping with the involvement of
tyrosine phosphorylation and ultrastructural evidence for a
'zippering'-like mechanism (Fig 3).
The protein encoded for by ced-5, a gene that is required
for the orderly engulfment of cell corpses in C. elegans, shows
homology to the human CRK-binding protein DOCK180.
which has been implicated in cytoskeletal function and
extension of cell surfaces (Hasegawa et al. 1996, Wu &
Horvitz, 1998a). We would suggest that phagocytosis of
apoptotic cells shows characteristics that distinguish it from
those involved in the clearance of opsonized particles,
perhaps defining a novel 'type III' phagocytic mechanism.
Further analysis of the basic phagocytic processes involved in
the uptake of apoptotic cells will be required to identify the
underlying control mechanisms.
REGULATION OF PHAGOCYTOSIS OF APOPTOTIC
CELLS
Macrophage capacity for apoptotic cell phagocytosis is likely
to be closely regulated in order that the tissue load of
apoptotic cells is matched by appropriate clearance activity.
Macrophage capacity for phagocytosis of apoptotic cells is
influenced by soluble mediators, such as c3'tokines (Ren &
Savill. 1995), prostaglandins (Rossi et al, 1998) and
glucocorticoids (Lui et al, 1999), and by adhesive inter¬
actions with the extracellular matrix (McCutcheon et al,
1998). After binding of ligand to cell surface receptors,
intracellular signals are transduced that may influence the
capacity of the macrophage to phagocytose apoptotic cells
(Fig 4). The potentially important ligand-receptor inter¬
actions and intracellular signalling pathways that are
involved in the regulation of phagocytosis of apoptotic cells
are beginning to be identified. Furthermore, as mentioned
previously, analysis of the proteins encoded by engulfment
genes in C. elegans has provided additional clues relating
to the role of intracellular signalling pathways and the
cytoskeleton in the phagocytosis of apoptotic cells in
mammals.
SOLUBLE MEDIATORS
Co-ordination of cellular behaviour during the inflammatory
response involves a complex interplay of cytokines. It is
perhaps not surprising that, in addition to the modulation
of apoptotic pathways in leucocytes (Lee et al, 1993),
incubation of human monocyte-derived macrophages with
granulocyte-macrophage colony-stimulating factor (GM-
CSF). IL-l/S. interferon (IFN)-y. tumour necrosis factor
(TNF)-a or TGF-/31 for 4h was found to augment macro¬
phage phagocytosis of apoptotic neutrophils significantly
(Ren & Savill, 1995). However, in rodent models, IFN-y
appears to exert inhibitory effects upon the uptake of
apoptotic neutrophils, suggesting possible species differences
(Erwig et al, 1999). More recently, we have identified a novel
role for glucocorticoids in 'reprogramming' the phagocyte
for enhanced recognition and phagocytosis (Lui et al. 1999).
One implication of these findings is that increased capacity
for disposal of apoptotic cells may contribute to the powerful
anti-inflammatory effects of glucocorticoids.
In contrast to the relatively slow effects of cytokines and
glucocorticoids, transient elevation of cAMP and activation
ofprotein kinase A after exposure to inflammatory mediators
and pharmacological agents that stimulate adenylate
cyclase (e.g. prostaglandins) rapidly and specifically inhibit
macrophage phagocytosis of apoptotic neutrophils (Rossi
Fig 4. Regulation of macrophage phagocytic
potential by soluble mediators, surface
receptors and the concomitant intracellular
signalling pathways (AC. adenylate cyclase;
ABC1, ATP binding cassette transporter 1;
GcR, glucocorticoid receptor; TF, transcription
factor).
© 2000 Blackwell Science Ltd, British Journal of Haematology 109: 1-12
Review 7
et al, 1998). Inhibition of macrophage phagocytic capacity
for apoptotic cells persisted long after the intracellular cAMP
concentration had fallen back to basal levels, implying that
secondary signalling pathways had been initiated that
ultimately determined phagocytic responses. Furthermore,
activation of protein kinase C by phorbol esters enhanced
macrophage phagocytosis of apoptotic neutrophils in vitro,
while inhibition of tyrosine kinases with genestein had an
inhibitory effect (unpublished observations). Together, these
observations suggest that macrophage phagocytic capacity
in the tissue may be dynamically 'fine-tuned' by the balance
between the activity of different protein kinases.
ADHESION MODULATION AND PHAGOCYTOSIS
OF APOPTOTIC CELLS
Phagocytosis shares mechanistic links with adhesion,
spreading and migration, processes that require co-ordinated
cytoskeletal reorganization, suggesting that regulatory
factors may also have a role in the control of phagocytosis
of apoptotic cells. Inhibition of apoptotic cell uptake after
elevation of intracellular cAMP was associated with redis¬
tribution of cytoskeletal proteins, including actin. talin and
paxillin, and profound morphological alterations (Rossi et al,
1998). In contrast, ligation of cell surface adhesion receptors
by extracellularmatrix (ECM) molecules leads to the assembly
of cytoskeletal components and activation of intracellular
signal transduction cascades (Giancotti, 1997), which, in
concert with soluble chemical mediators, allows the behav¬
iour of inflammatory cells to be co-ordinated (Nathan &
Sporn. 1991). Remodelling of the ECM and temporal
alterations in the matrix composition after injury or infection
(Alitalo et al, 1980: Gailit & Clark, 1994) may therefore
modulate the capacity for apoptotic cell phagocytosis during
progression of the inflammatory response.
A precedent for the suggestion that adhesion receptor
ligation may influence phagocyte capacity for clearance of
apoptotic cells was provided by our demonstration that
cross-linking of CD44 by bivalent antibodies rapidly (within
minutes) augmented phagocytosis of apoptotic neutrophils
by human monocyte-derived macrophages (Hart et al,
1997). CD44 is a cell surface glycoprotein that has been
proposed to bind multiple ligands in the ECM (including
hyaluronan and fibronectin) and has been implicated in
cytoskeletal organization and intracellular signalling (Lesley
et al, 1993; Tsukita et al, 1994; Galandrini et al, 1996; Taher
et al, 1996). Previously defined inhibitors of apoptotic cell
recognition did not affect CD44-augmented phagocytosis of
apoptotic neutrophils, suggesting either that several path¬
ways were engaged together or that unique molecular
recognition pathways were involved. This latter possibility
was supported by the finding that CD44 mAb failed to
augment phagocytosis of apoptotic lymphocytes.
Although there is evidence that /31 and (33 integrins
may directly mediate apoptotic cell recognition (Savill et al,
1990; Schwartz et al, 1999). integrins may have a broader
role in the control of phagocytic processes. Generation of
'outside-in' signals via integrins allows 'sensing' of the local
microenvironment and may influence phagocytic function.
In support of this suggestion, we have shown recently that
adhesion of human monocyte-derived macrophages to
fibronectin substantially augmented phagocytosis of apopto¬
tic neutrophils (McCutcheon et al, 1998), an effect that was
partially dependent on macrophage (31 integrins. However,
ligation of av/33i aL/32 or a6/3i, after apoptotic cell uptake or
with mAb, was reported to inhibit subsequent phagocytosis
when macrophages were rechallenged with apoptotic cells
48 h later (Erwig et al, 1999). Association of integrins with
phosphatidylinositol 3-kinase (PI3K) (Lakkakorpi et al,
1997) or induction of tyrosine phosphorylation and activa¬
tion of focal adhesion kinase-related molecule Pyk2 (Duong
et al, 1998) after integrin-mediated binding of osteoclasts
to matrix components illustrates how integrins might exert
indirect effects.
It is interesting to note that other molecules implicated in
apoptotic cell recognition have well-defined roles in adhesion
processes. The macrophage scavenger receptor has a role in
divalent cation-independent adhesion to serum-coated cell
culture plastic (Fraser et al, 1993), and certain anti-CD36
mAbs may mimic many of the anti-adhesive effects of the
ECM molecule thrombospondin (Dawson et al, 1997).
Interestingly, CD36 may associate with tyrosine kinases
Fyn, Yes and Lyn (Huang et al, 1991) and link directly with
signal transduction cascades. Furthermore, ligation of
cell surface molecules from diverse receptor families [e.g.
urokinase-plasminogen activator receptor (CD87), integrin-
associated protein (CD47), CD14, CD16, CD66 and CD31;
Petty & Todd, 1996; Stocks et al, 1996] act to regulate
adhesion (Klemke et al, 1998; Schaffner-Reckinger et al,
1998). Further investigation into the role of indirect effects
(e.g. via adhesion modulation) is required in order to
understand the regulation of apoptotic cell phagocytosis.
One of the challenges for future studies is to distinguish
receptors that may act as accessory molecules (in a manner
analogous to (CDlla/CD18) LFA-1 and ICAM-1 (CD54) in
antigen presentation via the T-cell receptor) from those that
play a direct role in the recognition of apoptotic cells.
APOPTOTIC CELL LIGANDS
The final level of complexity concerning regulation of
apoptotic cell uptake is the role of apoptotic cell ligands.
Although it has been widely assumed that phagocytes are
able to recognize alterations in the plasma membrane that
distinguish apoptotic cells from their viable neighbours, it
remains possible that phagocytes respond to a loss of signals
that characterize interactions between viable cells. For
example, in the absence of 'viable cell' signals, 'non-specific'
phagocytosis mechanisms involved in the internalization of
inert particles, such as latex microspheres or aldehyde-fixed
cells, may be engaged. However, as discussed above, in
contrast to apoptotic cell phagocytosis, uptake of inert
particles elicits pro-inflammatory cytokine release in some
phagocyte populations (Meagher et al, 1992). These data lend
support to the concept that phagocytes have the capacity for
recognition of determinants specific for apoptotic cells.
While a number of distinct phagocyte receptors involved
in the recognition and subsequent internalization of dying
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cells have been identified, the determinants on the surface of
the apoptotic cell that signal phagocyte recognition and
removal remain poorly characterized. For the erythrocyte
(which has an average lifespan of 120 days in the healthy
adult human), post-translational modification of the anion
transport protein band 3 may lead to binding of endogenous
IgG autoantibodies and subsequent Fc receptor-mediated
phagocytosis (Kay, 1981: Kay et al, 1996). In parallel, non-
enzymatic glycosylation of surface proteins to form advanced
glycosylation end-products (AGE) may allow the engage¬
ment of specific receptors (e.g. the immunoglobulin super-
family member RAGE; Schmidt et al, 1994) that trigger
clearance. However, the kinetics of appearance of AGE on
senescent cells is likely to be too slow to serve as a signal for
apoptotic cell recognition by phagocytes. In addition, the
patterns of inhibition of macrophage phagocytosis of
apoptotic neutrophils using polyanionic ligands indicated
that AGE and AGE receptors were unlikely to participate
(Savill et al, 1989).
Recent data indicate that rapid redistribution of amino-
phospholipids. including PS (Martin et al, 1995) and
phosphatidylethanolamine (Emoto et al, 1997). may repre¬
sent a general feature of apoptosis in many cell types. In
viable cells, PS is confined to the cytoplasmic face of the
plasma membrane by the action of a phospholipid trans-
locase and is specifically relocated (possibly via specific
phospholipid scramblases) to the outer surface of the
membrane during apoptosis (Verhoven et al. 1995). PS
exposure has been implicated in the recognition of apoptotic
leucocytes by mouse inflammatory macrophages, but not by
human monocyte-derived macrophages, in vitro (Fadok et al,
1992b). Binding of the serum /^-glycoprotein I to exposed PS
residues on apoptotic thymocytes and lipid symmetric red
blood cell ghosts may 'mark' them for uptake by both
thioglycollate-elicited mouse peritoneal macrophages (Bala-
subramanian et al, 1997) and the human THP-1 macro¬
phage cell line (Balasubramanian & Schroit, 1998). Studies
using the monocyte cell line THP-1 suggest that CD3 6 may
act as a receptor for phosphatidylserine, with little or no
specificity for other anionic phospholipids (phosphatidylino-
sitol and phosphatidylglycerol). This activity appeared to
involve sites in the receptor distinct from those involved in
binding collagen or thrombospondin (Tait & Smith, 1999).
In addition, anti-oxLDL autoantibodies cloned from Apo-E-
deficient mice specifically bound to apoptotic aortic endo¬
thelial cells and prevented phagocytosis by mouse peritoneal
macrophages (Chang et al, 1999). It is therefore possible
that scavenger receptor-mediated recognition of oxidized
phospholipids and oxidized phospholipid protein complexes
may provide a specific signal for phagocyte binding and
recognition of damaged or apoptotic cells.
It has been reported recently that complement compo¬
nents Clq and iC3b bind to the surface of certain apoptotic
cell types, facilitating their uptake by macrophage Clq
receptors or CR3/CR4 (Takizawa et al. 1996; Korb & Ahearn,
1997. Mevorach et al, 1998). These findings contrast with
previous reports that CR3 was not involved in the recognition
of apoptotic neutrophils by human monocyte-derived
macrophages (Savill et al, 1989). Interestingly, cells in the
late stages of apoptosis or blebs derived from apoptotic cells
have been shown to contain self-antigens (Gilligan et al,
1996; Kalden, 1997). which are targets for autoantibodies
found in autoimmune disease. One interpretation of these
findings is that failure of tissue phagocytes to clear apoptotic
cells may result in the development of autoimmune
responses. Susceptibility of patients with Clq deficiency to
the autoimmune disease systemic lupus erythematosus may
be partly explained by the excess of free non-ingested
apoptotic cells in the inflamed glomeruli seen in mice
deficient in Clq (Botto et al, 1998).
Other molecular changes in the membrane of apoptotic
cells have been studied using mAbs and lectins as probes.
Early studies indicated that cellular microelectrophoretic
mobility was reduced on apoptotic mouse thymocytes,
suggestive of changes in the net negative charge of cell
membranes (Morris et al, 1984). Reduced binding of lectins
and mAbs observed in flow cytometric analysis corresponded
closely with the degree of reduction in membrane surface
area after apoptosis (Morris et al, 1984). It has been reported
that high levels of mannose, N-acetylgalactosamine and
galactose can be detected on apoptotic human peripheral
blood lymphocytes using fluoresceinated lectins (Dini et al,
1992). However, flow cytometric analysis of binding of a
panel of conjugated lectins to apoptotic neutrophils suggests
that exposure of these carbohydrate moieties may not be a
general feature of apoptosis on all cell types (unpublished
observations). Screening of a large panel of mAbs revealed
that blockade of certain epitopes of ICAM-3 (CD50) on
apoptotic B cells was found to inhibit their phagocytosis by
macrophages. These epitopes have been suggested as being
associated with apoptotic cell-specific modifications of ICAM-
3 recognized by macrophage CD 14 (Gregory et al, 1998:
Moffatt et al, 1999). There is evidence that specific changes
in surface protein expression accompany apoptosis (Drans-
field et al. 1994, 1995). implying that mechanisms for the
maintenance of receptor numbers are compromised during
programmed cell death. Neutrophil apoptosis is associated
with a marked downregulation ofFc7RIII (CD 16) (Dransfield
et al, 1994). leukosialin (CD43) and L-selectin (CD62L)
(Dransfield et al, 1995), which may provide a mechanism for
functionally isolating apoptotic neutrophils from potentially
pro-inflammatory signals. As these receptors are shed by
proteolytic mechanisms during activation, one possibility is
that there is activation of surface-associated proteases during
apoptosis or, alternatively, release of functional constraints
upon protease activity by as yet undefined mechanisms.
Proteolytic shedding of surface receptors during apoptosis
has been observed in myeloid cell lines (Brown et al, 1996),
but whether this represents a fundamental feature of
apoptosis in different cell types remains to be determined.
One possibility is that the presence of proteolytic 'stubs' of
shed receptors could contribute to a 'signal' for phagocytosis.
CONCLUSION
Phagocytosis of apoptotic cells is a vital process in cellular
homeostasis in a wide range of tissues, but especially so in
the inflammatory response in which apoptotic granulocytes
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have the potential to inflict tissue damage if they are not
removed quickly and efficiently. Further work is required to
identify cell surface molecules present on apoptotic cells that
may trigger phagocyte recognition. Future research must
resolve apparent differences in receptor usage in experi¬
mental models of apoptotic cell clearance in different species
using different phagocyte and apoptotic cell populations. In
addition, the role of macrophage receptors that may act as
'accessory' molecules that indirectly influence the recogni¬
tion process needs to be defined. We would speculate that
modulation of macrophage phagocytic capacity by a variety
of cytokines, prostanoids, hormones, matrix molecules and
possibly neighbouring cells may allow the tissue load of
apoptotic cells to be matched by appropriate phagocyte
clearance capacity, thereby minimizing release of histotoxic
apoptotic cell contents. In contrast, phagocyte clearance
capacity may be exceeded in pathological states. We suggest
that therapeutic induction of cellular apoptosis to ameliorate
tissue damage in inflammatory diseases, such as ARDS or
rheumatoid arthritis, will require concurrent augmentation
of phagocyte clearance capacity. Identification of the surface
receptors involved in phagocyte recognition of apoptotic cells
and definition of the contribution of regulatory influences in
vivo will be important for the development of future
therapeutic strategies for the treatment of inflammatory,
allergic and autoimmune diseases.
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Glucocorticoid Augmentation of Macrophage Capacity for
Phagocytosis of Apoptotic Cells Is Associated with Reduced
pl30Cas Expression, Loss of Paxillin/pyk2 Phosphorylation,
and High Levels of Active Rac1
Katherine M. Giles,* Katherine Ross,* Adriano G. Rossi,* Neil A. Hotchin,T
Christopher Haslett,* and Ian Dransfield2*
Phagocytic clearance of apoptotic granulocytes has a pivotal role in determining an inflammatory outcome, resolution or pro¬
gression to a chronic state associated with development of fibrotic repair mechanisms, and/or autoimmune responses. In this study,
we describe reprogramming of monocyte to macrophage differentiation by glucocorticoids, resulting in a marked augmentation
of their capacity for phagocytosis of apoptotic neutrophils. This monocyte/macrophage phenotype was characterized by decreased
phosphorylation, and therefore recruitment of paxillin and pyk2 to focal contacts and a down-regulation of pl30Cas, a key adaptor
molecule in integrin adhesion signaling. Glucocorticoid-treated cells also displayed higher levels of active Rac and cytoskeletal
activity, which were mirrored by increases in phagocytic capability for apoptotic neutrophils. We propose that changes in the
capacity for reorganization of cytoskeletal elements induced by glucocorticoids are essential for efficient phagocytic uptake of
apoptotic cells. The Journal of Immunology, 2001, 167: 976-986.
The acute inflammatory response provides a defense mech¬anism against microbial infection or tissue injury involv¬ing the rapid and coordinated recruitment of granulocytes
and other inflammatory cells in response to chemokines and other
inflammatory mediators. This response is normally self-resolving,
but the pathogenesis of a number of diseases such as asthma, em¬
physema, and rheumatoid arthritis is characterized by a persistent
accumulation of inflammatory cells presumably as a result of fail¬
ure of the natural resolution process (1-3). During normal inflam¬
matory resolution, clearance of extravasated granulocytes requires
the induction of apoptosis and concomitant uptake by macro¬
phages (4). Apoptotic cell death, in contrast to necrosis, is asso¬
ciated with maintenance of cell membrane integrity (4) and down-
regulation of granulocyte secretory function (5), thereby inhibiting
potential exacerbation of the inflammatory response through the
release of cytotoxic granule contents and proinflammatory cyto¬
kines. Additionally, macrophage ingestion of apoptotic cells, un¬
like phagocytosis of necrotic cells or opsonized particles, does not
induce proinflammatory mediator production (6) and can function¬
ally down-regulate cytokine release induced by LPS or opsonized
cells (7). Failure to clear apoptotic cells may result in secondary
necrosis with predictable consequences in terms of tissue injury
and/or initiation of autoimmune processes when phagocyte clear¬
ance processes in vivo are overwhelmed by excess apoptotic cell
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load (8-10). Clearly, if induction of apoptotic pathways is to be
considered as a potential therapy for cancer or inflammatory dis¬
ease, a parallel strategy to maximize phagocytic clearance is likely
to be required to avoid the deleterious consequences of necrotic
cell death.
A number of cell surface molecules have been proposed to me¬
diate the uptake of apoptotic cells; these include lectins (11), av/33
integrin/CD36/thrombospondin complex (12, 13), phosphatidyl-
serine receptors (14), scavenger receptors (15), receptors for oxi¬
dized lipids (16), CD14 (17), CD29 (18), the ABC1 transporter
(19), and receptors for complement components C3bi (CR3/CR4)
(20) and Clq (21). The lack of complete inhibition of phagocytosis
by soluble ligands or blocking mAb points to functional redun¬
dancy, and we have suggested that a more effective strategy for
altering clearance of apoptotic cells would be manipulation of
macrophage phagocytic potential (22). Although cytokines such as
TNF, GM-CSF, TGF-/3, or IL-1 may be used to augment phago¬
cytic clearance (23), the effects have been small and the pleiotropic
consequences of some of these agents may restrict their potential
therapeutic value. Our previous studies have revealed that disrup¬
tion of cytoskeletal and adhesion contacts in monocyte-derived
macrophages by elevation of intracellular cAMP inhibits phago¬
cytosis of apoptotic cells (24). In contrast, ligation of CD44 (25) or
adhesion to fibronectin (26) results in a rapid and dramatic aug¬
mentation of apoptotic cell uptake. For example, CD44 induces a
400% increase in phagocytic index within a 30-min assay period.
If similar augmentation of phagocytic activity were attainable in
vivo, the potential for clearance of apoptotic cells over the course
of an inflammatory response would be considerable. Recent ge¬
netic studies in Caenorhabditis elegans have further suggested a
role for adhesion signaling in the control of phagocytosis. Ced-5,
-2, and -10, members of a family of genes required for clearance
of cellular corpses during development, are highly homologous to
mammalian proteins DOCK 180 (27) (myoblast city protein in
Drosophila) (28), Crk, and Rac (29), involved in mediating inte¬
grin signaling in mammalian cells. Integrin ligation induces the
Copyright © 2001 by The American Association of Immunologists 0022-1767/01/S02.00
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formation of a multiprotein complex involving DOCK 180 and
Crk, the adapter protein pl30Cas, and the guanine nucleotide ex¬
change factor C3G (30-33). Assembly and membrane localization
of this complex activates the GTPases Rac (34, 35) and Rho (36),
inducing membrane ruffling and lamellipodia formation (37) re¬
quired for spreading, adhesion, and cell migration. Ced-5 and
ced-2 have been shown to interact and activate ced-10 GTPase
activity in vitro (29), and ced-5-, -2-, and -10-deficient animals
have defects in both cell migration and phagocytosis (27, 29).
Glucocorticoids represent a powerful antiinflammatory treat¬
ment due to their capacity for inhibition of inflammatory cell re¬
cruitment and down-regulation of production and responsiveness
of cells to proinflammatory cytokines (38). We have recently de¬
scribed a novel glucocorticoid receptor-dependent promotion of
macrophage capacity for phagocytosis of apoptotic cells following
short-term exposure of macrophages to glucocorticoids (39). In the
present study, we show that long-term exposure of monocytes to
the synthetic glucocorticoid dexamethasone (DX)3 reprograms
monocyte differentiation toward a proresolution phenotype, exhib¬
iting increased phagocytosis of apoptotic cells. Monocytes treated
with DX represented a homogeneous cell population characterized
by a more rounded appearance. Marked down-regulation of ex¬
pression of pl30Cas, which is required for integrin adhesion sig¬
naling through the DOCK180/Crk/C3G complex, together with re¬
duced phosphorylation and recruitment of paxillin and pyk2 to
sites of adhesion, may account for this phenotypic alteration. We
therefore propose that the dramatic increase in phagocytic poten¬
tial in DX-treated monocyte-derived macrophages results from
changes in the capacity for adhesion-dependent reorganization of
cytoskeletal elements that are then available for coordinated
phagocytic uptake of apoptotic cells.
Materials and Methods
Abs and other reagents
Reagents were obtained from Sigma (Poole, U.K.), unless otherwise stated.
Iscove's DMEM (IDMEM) was from Life Technologies (Paisley, U.K.).
Dextran and Percoll were from Amersham Pharmacia Biotech (Bucking¬
ham, U.K.). DX was obtained from David Bull Laboratories (Warwick,
U.K.). Primary Abs were from the following sources: pl30Cas, paxillin.
Pyk2, Rac. and RC-20 (anti-phosphotyrosine) mAb were from Transduc¬
tion Laboratories (supplied by Becton Dickinson, Oxford. U.K.); CrkL and
C3G rabbit polyclonal A'o were from Santa Cruz (supplied by Insight Bio¬
technology. Wembley, U.K.). mAb specific for CD44v3 (3G5), /31
(12G10), and class II (WR18) were from Serotec (Oxford, U.K.). Control
mouse Igs (IgGland IgG2a). BerMac3 (CD 163) and rabbit Igs, and F(ab')2
goat anti-mouse Ig FITC and HRP conjugates were from Dako (Ely, U.K.).
The following monoclonals were generously provided as gifts: 5A4
(CD44: G. Dougherty, University of California, San Francisco, CA), SM(f>
and 15.2 (CD36 and CD54. respectively: N. Hogg. Imperial Cancer Re¬
search Fund (London, U.K.), 23C6 (CD51/61: M. Horton, UCL, London.
U.K.), PM6/13 (CD61; M. Wilkinson, Wellcome Trust, London. U.K.),
3G8 (CD16: J. Unkeless. Mount Sinai Medical School. New York, NY),
UCHM1 (CD 14: P. Beverley, UCL), 61D3 (CD 14; C. Gregory, Notting¬
ham, U.K.). Secondary anti-rabbit HRP was from Amersham Pharmacia
Biotech.
Cell isolation and culture
Mononuclear and polymorphonuclear leukocytes were isolated as previ¬
ously described (25). In brief, erythrocytes were sedimented from freshly
drawn peripheral blood, with 0.6% (w/v) dextran T500. followed by frac¬
tionation of leukocytes on a discontinuous Percoll gradient (prepared in
Ca2+/Mg2+-free PBS with final concentrations of Percoll of 50, 63, and
73%) at 720 X g for 20 min. Mononuclear cells were aspirated from the
50/63 interface, and neutrophils from the 63/73% interface, and washed
three times in PBS (without Ca2+/Mg2+) before culture. Neutrophils (re-
suspended at 4 X 106cells/ml in IDMEM containing 10% autologous se¬
3 Abbreviations used in this paper: DX, dexamethasone; IDMEM, Iscove's DMEM;
PAK, p21-activated kinase.
rum) were cultured at 37°C in a 5% C02 atmosphere for 20 h in Falcon
tissue culture flasks. Cultured populations were >50% apoptotic, as deter¬
mined by morphological analysis and annexin V binding, and <5% pro-
pidium iodide positive. Mononuclear cells were plated at 4 X 106/ml in
IDMEM and incubated for 30-60 min, at 37°C, 5% C02 after which
nonadherent lymphocytes were removed by washing with HBSS (without
Ca2+/Mg2+) and monocytes were cultured for a period of 5 days in
IDMEM plus 10% autologous serum, ±1 gM DX.
Macrophage phagocytosis assay
Monocyte-derived macrophages cultured in 48-well tissue culture plates, as
described above, were cultured in the presence or absence of DX, or 10 p,M
RU38486 for varying periods of time. For experiments using inhibitors of
phagocytosis, macrophages were washed once, then incubated with phago¬
cytosis inhibitors (at the concentrations described in figure legends) for 15
min before the phagocytosis assay. The macrophage monolayer was then
overlaid with apoptotic neutrophils (washed and resuspended at a final
concentration of 4 X 106/ml in IDMEM) and incubated at 37°C, 5% C02
for 20 min. Noningested neutrophils were removed by washing in IDMEM,
and monolayers were then fixed in 2.5% glutaraldehyde. The percentage of
phagocytosis of neutrophils stained for myeloperoxidase activity with 0.1
mg/ml dimethoxybenzidine and 0.03% (v/v) hydrogen peroxide was quan¬
tified microscopically by counting at least 500 cells in randomly selected
fields per well, and an average between the duplicate wells was calculated.
Phagocytic index was calculated as: (average number of neutrophils phago-
cytosed per macrophage) X (% macrophages that had phagocytosed one or
more neutrophil). Controls for inhibitors used were as follows: All mAb
used have previously been shown to inhibit apoptotic cell phagocytosis and
were used at concentrations that were deemed to be saturating by flow
cytometry. The following inhibitors were found to be functionally active at
concentrations used in this study. RGDS (integrin inhibition peptide) was
shown to inhibit a5fil integrin-mediated adhesion of T lymphocytes to
fibronectin. Phospho-L-serine was shown to inhibit binding of FITC an¬
nexin V to apoptotic neutrophils in flow cytometric analysis. Dextran sul¬
fate inhibited uptake of acetylated low density lipoprotein by monocyte-
derived macrophages. Other reagents (glyburide and glucosamine) were
used at concentrations that have previously been shown to exert inhibitory
effects.
Flow cytometry
Flow cytometry was performed essentially as described (25), with all in¬
cubations conducted on ice to prevent internalization of Ah. Macrophages
were detached from tissue culture plastic using PBS containing 2 mM
EDTA and 0.5% serum. After washing with ice-cold PBS containing 0.2%
(w/v) BSA and 0.1% (w/v) sodium azide cells (105/assay) were preincu-
bated for 10 min with 20% (v/v) normal rabbit serum to block nonspecific
binding to Fc-yR. Cells were then incubated with saturating concentrations
of mAb for 30 min, and washed twice in PBS containing 0.2% BSA and
0.1% sodium azide before incubation with FITC-conjugated F(ab')2 goat
anti-mouse Ig (Dako) for 30 min, and washed twice more before analysis
using either an EPICS Profile II (Beckman-Coulter. High Wycombe, U.K.)
or a FACSCalibur (Becton Dickinson) flow cytometer.
Electron microscopy
Macrophages cultured on glass coverslips in the presence or absence of 1
pM DX for 5 days were fixed with 3% gluteraldehyde in 0.1 M sodium
cacodylate buffer, pH 7.4, for 3 h. and postfixed with 1% osmium tetroxide
in 0.1 M cacodylate buffer for 2 h. After dehydration in an ascending
acetone series, and critical point drying with CO,, samples were sputter
coated with 20 nm gold/palladium and examined using a Phillips 505 scan¬
ning electron microscope.
Immunoprecipitation and Western blotting
Adherent macrophage cultures were washed with PBS containing 0.1 mM
NaVO, plus protease inhibitor cocktail (Boehringer Mannheim. Mann¬
heim. Germany), and were lysed by incubation with PBS containing 1%
Nonidet P-40, 0.1 mM NaV03, and protease inhibitor cocktail, 10 min on
ice. Membrane and nuclear material were removed by centrifugation at
14,000 X g, 4°C, 30 min. Lysates were precleared by incubation with
protein A agarose-coupled rabbit anti-mouse IgG, 4°C, 30 min. The re¬
sulting lysates were tested for protein concentration using a detergent-
compatible protein estimation kit (Pierce, Rockford, IL), and equilibrated
to contain equivalent levels of protein. A total of 100 jul lysate (100-150
pg total protein) was incubated with 1 pg of either mouse IgG control,
anti-paxillin, or pyk2 mAb. 4°C, 30 min, shaking. Immunoprecipitation
was achieved by incubation for 30 min with protein A-coupled rabbit anti-
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mouse IgG (Sigma), and washed twice in TBS containing 0.1% Triton
X-100, and once in 25 mM Tris, plus 0.05% SDS. Samples were resolved
using a 9% reducing polyacrylamide gel and transferred electrophoretically
(50 V for 1 h) onto nitrocellulose (Amersham Pharmacia Biotech). For
detection of phosphotyrosine, membranes were blocked with TBS plus
0.05% Tween 20 (TBS-T) and all other blots with TBS-T plus 10% nonfat
dried milk powder (w/v).
Assay for detection of activated Rac
Adherent macrophage cultures were lysed in radioimmunoprecipitation as¬
say buffer containing protease inhibitor cocktail (Boehringer Mannheim)
plus 1 mM PMSF. Lysates were cleared of membrane and nuclear material
by centrifugation, total protein was estimated, and levels were equilibrated
as described for immunoprecipitation. A total of 20 /xl lysate was removed
for estimation of total Rac protein, and the remaining (—300 p,g) was
incubated with GST-p21-activated kinase (PAK) (cdc42 or Rac interacting
binding domain) fusion protein coupled to Sepharose beads, 4°C, 1 h,
shaking. Beads were washed four times in ice-cold Tris buffer (50 mM Tris
(pH 7.2), 150 mM NaCl, 10 mM MgCl2, 1% Triton, protease inhibitor
mixture, 1 mM PMSF), and the amount of active Rac bound to the PAK
cdc or Rac interacting binding domain quantified by SDS PAGE and West¬
ern blotting, as described for immunoprecipitation.
RNA isolation and RT-PCR
Macrophages were washed once in ice-cold PBS, lysed, and RNA ex¬
tracted using TRIzol (Life Technologies; protocol as manufacturer's in¬
structions). RNA was DNase treated to remove genomic DNA for 1 h.
37°C, and the resulting RNA was used in RT-PCR reaction using Life
Technologies One Step RT-PCR kit (protocol as manufacturer's instruc¬
tions). Primers used (35 cycles, annealing 53°C) were as follows:
DOCK 180, 5'-GAGGCAGAGGAGACGAACAG, 3'-AAGCCGATTCG




Glucocorticoids augment phagocytosis of apoptotic cells in a
time-dependent manner
Monocytes isolated from peripheral blood were cultured in vitro
for up to 5 days in the presence of the synthetic glucocorticoid DX,
and macrophage potential for phagocytosis of apoptotic cells was
determined. Preliminary experiments revealed that macrophages
treated with DX for >24 h were highly phagocytic, leading to
some cell detachment during our standard assay (data not shown).
We therefore reduced the assay time from 30 to 20 min to mini¬
mize cell loss and reveal differences between treated cells. DX
treatment consistently increased monocyte-derived macrophage
phagocytosis of apoptotic neutrophils in a manner that was related
to the duration of treatment (Fig. 1A), and blocked by addition of
the steroid receptor antagonist RU38486 (10 p,M), indicating that
a glucocorticoid receptor-dependent process mediated these effects
(results not shown). In particular, we noted a striking effect of
exposure of freshly isolated monocytes to DX for 120 h upon
phagocytic potential. We therefore investigated whether a time
window for steroid exposure early in maturation was sufficient to
generate a highly phagocytic phenotype. Monocytes were incu¬
bated with DX for periods of 24 h (0-24, 24-48, 48-72, 72-96,
and 96-120). To ensure that observed changes were the result of
DX exposure exclusively during the stated time window, the ste¬
roid receptor antagonist RU38486 was added following removal of
DX-containing media. The addition of the antagonist alone had no
significant effect (data not shown). Augmentation of apoptotic cell
phagocytosis was much less pronounced when DX was added later
in the culture period, and that exposure of monocytes to DX within
the first 24 h was sufficient to induce highly phagocytic macro¬
phages (Fig. IS). Comparison of phagocytic indices revealed that
5-day DX-treated monocytes/macrophages had a 9-fold higher ca¬
pacity for apoptotic cell clearance in a 20-min assay (Fig. 1, C-£).
Thus, glucocorticoids represent the most potent stimulus for aug¬
mentation of macrophage capacity for phagocytosis of apoptotic
cells described to date. Moreover, glucocorticoid modulation of
phagocytosis could have profound effects on clearance of apoptotic
cells during the resolution of inflammation.
Glucocorticoids reprogram macrophage phenotype
Examination of macrophages by phase-contrast microscopy re¬
vealed that augmented phagocytic potential following 5-day treat¬
ment with DX was accompanied by distinct morphological
changes consistent with the suggestion that DX influences in vitro
differentiation of monocytes. Under our standard culture condi¬
tions (IDMEM containing 10% autologous serum) at 5 days, mac¬
rophages were composed of a heterogeneous population of cells
with different morphologies: multinucleated giant cells, spread ap¬
parently motile cells with evidence of membrane ruffling, rounded
less spread cells, and occasional dendritic-like cells (Fig. 2A). Mi¬
croscopy-based quantitation revealed that large macrophages (>25
pm diameter) represented 29.5 ± 5.8% of cells present in 5-day
monocyte/macrophage preparations (n = 4 separate experiments).
Treatment of freshly isolated monocytes with DX for 5 days re¬
sulted in consistent morphological changes, with the absence of
large multinucleated cell populations and reduced numbers of
spread macrophages (large macrophages representing less than 2%
of the cells present). In contrast, the proportion of rounded cells
was increased (Fig. 2B). Further examination of macrophage mor¬
phology using scanning electron microscopy demonstrated that the
rounded DX-treated cells were attached, with ruffled membranes
and filopodial processes (Fig. 2D) when compared with untreated
cells (Fig. 2C). An increase in the morphological homogeneity of
DX-treated monocyte-derived macrophages was also reflected in
the laser scatter properties of DX-treated cells and more uniform
expression of a number of surface molecules, including CD 14,
when analyzed by flow cytometry (Fig. 2E). Analysis of the co¬
efficient of variation for the fluorescence peaks (untreated vs DX-
treated ± SEM) for CD 14 (108 ± 14; 60 ± 5, /; = 13), CD16
(96 ± 8; 62 ± 4, n = 1 1), HLA-DR (122 ± 11; 96 ± 6, n = 10),
CD44 (99 ± 15; 66 ± 7, n = 6), and CD51 (81 ± 5; 53 ± 4, n =
11) confirmed this impression and would be consistent with re-
programming of monocyte differentiation by DX during in vitro
culture.
Increased phagocytosis of apoptotic cells involves multiple
phagocytic receptors
Flow cytometric analysis was further used to determine whether
DX augmentation of phagocytosis was associated with increased
expression of receptors previously implicated in the recognition
process (see Ref. 22 for review and Table I). Although most re¬
ceptors examined exhibited more uniform levels of surface expres¬
sion, as described above, we did not observe changes in the per¬
centages of positive cells following DX treatment. However,
comparison of mean fluorescence intensity of binding revealed
some consistent alterations in the levels of surface expression of
certain receptors. HLA-DR and the macrophage differentiation
markers FcyRIII (CD 16) and BerMac (CD 163) were expressed at
slightly elevated levels on DX-treated macrophages (Table I). In
contrast, we found significantly reduced expression of CD44,
CD44v3, ICAM-1 (CD54), and integrin ft subunit (CD61) (p <
0.05 using Student's t test). Binding of the CD36 mAb SMc(> was
always found to be lower than that of the IVC7 CD36 mAb, even
when both Abs are used at saturating concentrations, suggesting
that SM<t> may recognize an epitope that is not present on all CD36
molecules. Interestingly, although overall levels of CD36 expres¬
sion (IVC7 staining) were decreased with DX treatment, binding
of the SM(/> mAb was not reduced. Together these results indicated
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FIGURE 1. Elfects of DX on macrophage
phagocytosis of apoptotic neutrophils. Adher¬
ent peripheral blood monocyte-derived mac¬
rophages were cultured in the presence or ab¬
sence of 1 |U,M DX for different times, as
shown. The capacity for phagocytosis of ap¬
optotic neutrophils was determined in a 20-
min assay by microscopic visualization of
myeloperoxidase activity. A, Monocyte-
derived macrophages were incubated with 1
p,M DX for the time periods shown during 5
days of culture before assessment of phago¬
cytosis. Data shown as mean phagocytosis ±
SEM for three separate experiments. B,
Monocyte-derived macrophages were ex¬
posed to a 24-h pulse of 1 p.M DX for the
time periods shown during 5 days of culture,
before assessment of phagocytosis. Data
shown are one representative experiment of
four that were performed. Representative
photomicrographs showing untreated and
5-day DX-treated monocyte-derived macro¬
phage capacity for phagocytosis are shown in
C and D, respectively. Phagocytic index (cal¬
culated as (average number of neutrophils
phagocytosed/macrophage) X (percentage of
macrophages phagocytosing one or more neu¬
trophils) for untreated and 5-day DX-treated
monocyte-derived macrophages (values taken
from mean of duplicates of a minimum of 500
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that augmented phagocytic capacity was not associated with in¬
creased expression of putative apoptotic cell recognition receptors.
However, since surface expression does not necessarily indicate
the presence of functionally active receptors, we used specific
mAb/soluble ligand inhibitors of apoptotic recognition pathways
to define their contribution to DX-treated macrophage phagocytic
activity. Inhibitors of CD36 (SMt/> rnAb, 1:50 ascites) and fflvj33
(0.5 mM RGDS peptide) did not prevent phagocytosis of apoptotic
neutrophils by DX-treated macrophages (Table I), suggesting that
this pathway does not play a major role in DX-augmented phago¬
cytosis. In addition, 10 mM glucosamine exhibited only partial
inhibition of DX-augmented phagocytosis, further suggesting that
integrin-mediated recognition is not the dominant pathway uti¬
lized. However, it should be noted that although we have validated
that RGDS is functionally active in preventing a^/J,-mediated T
cell adhesion to fibronectin, in our experimental system RGDS
does not inhibit untreated macrophage phagocytosis either (per¬
centage of phagocytosis control 28.5 ± 4%, RGDS 27.5 ± 4%;
mean ± SEM, n = 7). Therefore, these data cannot be taken to
indicate that treatment of monocytes with DX induces a switch to
av/33-independent recognition of apoptotic cells. Inhibition of
CD14 with the 61D3 mAb also failed to inhibit DX-treated mac¬
rophage phagocytosis of apoptotic neutrophils, suggesting that glu¬
cocorticoid up-regulated phagocytosis was not CD 14 dependent
(data not shown). We observed a small inhibitory effect of 2 mM
phospho-L-serine upon DX-induced phagocytosis of apoptotic
neutrophils, implying that the phosphatidylserine receptor does not
play a major role. However, it is possible that phospho-L-serine is
not the most effective inhibitor of phosphatidylserine receptor
function. Phagocytosis was markedly inhibited in the presence of
500 jug/ml fucoidan (31% of control, p < 0.01), implicating scav¬
enger receptor involvement. However, other scavenger receptor
ligands, including dextran sulfate (Table I), only partially inhibited
phagocytosis. These data suggest broader effects of fucoidan,
which may also inhibit other carbohydrate recognition molecules
(for example, selectins). One interpretation of these data is that DX
augmentation may involve multiple receptor pathways acting co¬
operatively. Alternatively, DX might promote engagement of a
novel receptor pathway to provide more efficient apoptotic cell
recognition.
Glucocorticoids alter macrophage cytoskeletal organization
The distinct morphological appearance of DX-treated macro¬
phages shown in Fig. 2 suggested that control of adhesion was
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FIGURE 2. Effects of DX on macrophage phe-
notype. Adherent peripheral blood monocytes
cultured for 5 days in the presence or absence of
1 gM DX on either tissue culture-treated plastic
(A and B) or glass coverslips (C and D). Morphol¬
ogy of untreated (A and C), and DX-treated (B and
D) was assessed by phase-contrast microscopy
(A and B) (X40 objective), and scanning electron
microscopy (C and D) (bar, 10 /am). Note the uni¬
form appearance of DX-treated cells by phase-
contrast microscopy, which is also observed in
electron micrographs. E, Monocyte-derived mac¬
rophage surface phenotype was examined by in¬
direct immunofluorescence using control IgGl
mAb, CD44 mAb (5A4), or CD14 mAb
(UCHM1) together with flow cytometry. The pro¬
files (from one of at least four separate determi¬
nations) shown here illustrate the more homoge¬
neous laser scatter properties of DX-treated
macrophages. The fluorescence histograms
(FL1-H) for cells within the gates shown illustrate
the more uniform cell surface expression of CD 14
and CD44 following DX treatment. Dotted lines
show binding of relevant isotype controls; solid
lines, mAb binding to untreated macrophages; and
bold lines, mAb binding to DX-treated macro¬




altered following DX treatment. In untreated cells, visualization of
focal contacts within macrophages cultured for 5 days on glass
slides showed punctate (podosome-like) staining of actin (Fig. 3C)
with concentric association of talin (Ref. 24 and our unpublished
data) and paxillin (Fig. 3D), probably representing sites of cell-
substratum contact. Paxillin and other proteins associated with ad¬
hesion (vinculin and tyrosine-phosphorylated proteins (data not
shown)) were also observed toward the cell periphery (see Fig.
3D), consistent with the adherent phenotype of macrophages. In
contrast, DX-treated cells showed an absence of actin- and paxil-
lin-containing podosomes (Fig. 3, E and F), suggesting an altered
organization of adhesion structures.
Altered cytoskeletal protein phosphorylation and organization in
DX-treated macrophages
Since paxillin recruitment to sites of adhesion is regulated by phos¬
phorylation, we next examined levels of expression and the ty¬
rosine phosphorylation status of paxillin and pyk2 by Western blot
analysis of immunoprecipitated proteins. Although paxillin and
pyk2 are still expressed at equivalent levels in DX-treated macro¬
phages (not shown), phosphorylation was found to be reduced in
adherent DX-treated macrophages when compared with untreated
macrophages (Fig. 4). The observed decrease in phosphorylation
of paxillin and pyk2 was consistent with the altered distribution of
paxillin in macrophages and raised the possibility that DX treat¬
ment disrupted adhesion-dependent signaling. The pl30Cas/Crk/
DOCK 180 complex is a major mediator of adhesion signaling. We
therefore examined the levels of expression of CrkL, Crkll, and
pl30Cas by Western blot analysis, and since we were unable to
reproducibly immunoblot DOCK 180 (data not shown), we used
RT-PCR to test for mRNA for DOCK 180 and M-DOCK. Al¬
though we did not see changes in levels of CrkL (Fig. 5A) or Crkll
(data not shown), pl30Cas expression was markedly reduced in
DX-treated macrophages (Fig. 5B). No differences in the levels of
mRNA for DOCK 180 or M-DOCK were noted in PCR analysis
(Fig. 5C), although differences may be apparent at the level of
protein. Despite these marked changes in cytoskeletal organization
and phosphorylation, we were surprised to find that DX-treated
cells were extremely active in formation of lamellipodia and cel¬
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Table I. Monocytes treated for 5 days with 1 pM DX, and the effects on surface receptor expression and apoptotic cell recognition pathways using
previously defined inhibitors of phagocytosis
Expression Function
% relative to % phagocytosis relative
mAb control" Inhibitor to control" Ref.
Q:v/33/CD36/thrombospondin
av 13C2 98.7 ± 7.3
03 lm6/13 82.7 ± 7.7
«v03 23C6 83.6 ± 7.0 RGDS (active) 85.7 ± 5.7 (n = 7) 12, 13
RADS (inactive) 101.3 ± 8.6 (« = 3)
CD36 ICV7 58.1 ± 8.1 12, 13
Sm<)> 86.6 ± 20.0 Sm<i> 76.6 ± 7.0 (n = 9)
Charge sensitive Glucosamine IIoo+1oocno
Pattern recognition receptors
Mannose receptor Mannan 81.5 ± 5.8 (n = 8) 57
CD14/ICAM-3 UCHM1 94.9 ± 14.4 17
CD44
CD44 (all isoforms) 5A4 71.6 ± 9.0 25
CD44V3 3G5 58.4 ± 6.4
Phosphatidylserine receptor Phospho-L-serine 80.8 ± 6.3 (n = 8) 14
"Scavenger" receptors
SR-A Dextran sulfate 67.9 ± 8.6 (n = 10) 15
CD 163 BerMac3 189.9 ± 43.3
Other molecules
HLA-DR WR1S 123.6 ± 20.6 NA* NA
CD 16 3G8 130.5 ± 11.5 NA NA
" "Control" receptor expression represents expression on 5-day DX-treated monocyte-derived macrophages relative to untreated 5-day monocyte-derived macrophages.
"Control" phagocytosis represents phagocytosis of apoptotic neutrophils by 5-day DX-treated monocyte-derived macrophages in the absence of inhibitor.
b NA, Not available.
microscopy analysis (data not shown). To test whether the actin-
regulatory machinery remained functional in DX-treated macro¬
phages, we assessed the levels of activity of the Rho family
GTPase Rac. which is involved in membrane ruffling and exten¬
sion of cellular processes. Using pull-down assays with p21-acti-
vated kinase-GST agarose, we found that DX caused a marked
increase in the amount of active Rac detectable within macrophage
lysates (Fig. 5D). The pronounced morphological alteration ob¬
served in DX-treated cells may reflect reprogramming of the ca¬
pacity for adhesion-dependent signal transduction via down-regu¬
lation of pl30Cas, reduced paxillin, and pyk2 phosphorylation, and
failure to form podosome-like adhesion structures. However, DX-
treated macrophages were found to have high levels of active Rac
that might contribute to the increased capacity for cytoskeletal re¬
organization necessary for phagocytosis.
Discussion
In this study, we present evidence that a macrophage phenotype
with augmented phagocytic potential for clearance of apoptotic
cells is induced following exposure to DX. We believe that DX
exerts distinct regulatory mechanisms upon macrophage behavior,
depending upon the stage of monocyte maturation. In our previ¬
ously published work, monocytes/macrophages were treated with
DX from 96 to 120 h. leading to a relatively modest increase in
phagocytic potential (39). In contrast with the morphological
changes described in this work for cells treated with DX immedi¬
ately following isolation, no gross changes in morphology are ob¬
served following exposure of 96-h monocytes/macrophages to DX
(data not shown). Importantly, we demonstrate that treatment of
monocytes with DX for the first 24 h of the 5-day culture period
following isolation from peripheral blood is critical for induction
of this phenotype, suggesting that glucocorticoids, acting via glu¬
cocorticoid receptors, have the potential to reprogram monocyte
differentiation. In support of our suggestion, we observe that DX-
treated monocytes mature into macrophages that exhibit a uniform
morphological appearance consisting of smaller, more rounded
cells with more homogeneous laser scatter properties in flow cy¬
tometric analysis. Although a number of macrophage surface re¬
ceptors are expressed at slightly reduced levels in DX-treated cells
when compared with untreated cells, the range of expression
within the population was found to be less in DX-treated mono¬
cytes/macrophages, indicating that functional homogeneity is
matched by cell surface phenotype. In addition, the specific in¬
crease in BerMac (CD 163) expression following DX treatment
lends further support to the suggestion of a reprogramming event.
However, our analysis failed to reveal any single surface molecular
change that would define a prophagocytic phenotype.
In preliminary experiments, we noted that highly phagocytic
macrophages were prone to detach during washing following a
30-min assay. One speculation would be that internalization of
plasma membrane during phagocytosis of apoptotic cells may
compromise cellular adhesion. In addition, the marked functional
alterations that we observe following glucocorticoid treatment of
monocytes further illustrate a close association between control of
monocyte/macrophage adhesion and clearance of apoptotic cells.
Many of the receptors implicated in phagocytosis also have key
roles in macrophage adhesion and migration (22). In this study, we
demonstrate that augmentation of phagocytic potential is associ¬
ated with decreased tyrosine phosphorylation of paxillin and pyk2,
proteins that represent important components of adhesion contacts
(for review, see Ref. 40), and decreased expression of pl30Cas, a
mediator of adhesion signaling (32). Immunofluorescence analysis
revealed that adhesion structures containing localized paxillin and
actin were altered in DX-treated macrophages. Reduced expres¬
sion of p!30Cas would be predicted to disrupt Crk/DOCK180
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FIGURE 3. Effects of DX on localization of actin
and paxillin in macrophages. Adherent peripheral
blood monocyte-derived macrophages were cultured
for 5 days in the presence or absence of 1 /xM DX.
Localization of actin and paxillin was determined using
either rhodamine phalloidin (C and E) or anti-paxillin
mAb (D and F) together with fluorescence microscopy.
Staining observed with control mAb is shown in .4 and
B. These representative micrographs illustrate typical
punctate actin staining of contact sites similar to podo-
somes in control macrophages (C and D) that are ab¬
sent in DX-treated macrophages (E and F). Paxillin is
also localized to smaller focal adhesion-like structures
near the cell periphery in control macrophages that are
less well defined in DX-treated macrophages.
complexes, which together with reduced phosphorylation of pax¬
illin and pyk2 may have implications for control of the turnover of
adhesion structures in macrophages (shown schematically in Fig.
6). Since decreased pl30Cas expression in DX-treated macro¬
phages is associated with augmentation of phagocytic capacity,
specific recruitment of p 130Cas to focal contacts following adhe¬
sion to matrix may mimic loss of pl30Cas observed in DX-treated
cells and influence the availability of other components to drive
cytoskeletal reorganization necessary for phagocytosis. We have
tried to define whether cytoskeletal components we have examined
contribute directly to phagocytosis. However, these studies are
made difficult by the morphological and functional heterogeneity
of macrophage preparations. Furthermore, cytoskeletal elements
present within internalized apoptotic neutrophils complicate inter¬
pretation of observed staining patterns. Both Crk and pl30Cas
have previously been shown to influence the capacity for actin
reorganization in rat-1 fibroblast cells (41, 42); therefore, down-
regulation of the central signaling molecule p 130Cas is likely to
have important implications for the control of adhesion and mi¬
gration in DX-treated monocytes. We propose that the repertoire of
adhesion receptors that are engaged on the macrophage surface
might control phagocytic potential indirectly by releasing or se¬
questering key regulatory molecules such as pl30Cas from focal
adhesion complexes.
Time-lapse video microscopy reveals that despite the small
rounded appearance of DX monocytes/macrophages, these cells
remain extremely membrane active, rapidly extending and retract¬
ing cellular processes (data not shown). Increased levels of active
Rac in DX-treated macrophages lend support to the suggestion that
although recruitment of proteins such as paxillin to podosome ad¬
hesion-signaling complexes does not occur in the absence of
pl30Cas, Rac may still drive the extension and retraction of pro¬
cesses observed in DX-treated cells. One possibility is that other
pl30Cas-like adapters such as HEF1 and Efts/Sin (Ref. 32 and
pyk2
. paxillin
FIGURE 4. DX down-regulates phosphorylation of pyk2 and paxillin.
Adherent peripheral blood monocyte-derived macrophages were cultured
for 5 days in the presence or absence of 1 /xM DX. Pyk2 and paxillin were
immunoprecipitated from cell lysates, and protein phosphorylation of im-
munoprecipitated proteins was analyzed by SDS-PAGE together with
Western blotting using the anti-phosphotyrosine mAb RC-20 and ECL de¬
tection. In this gel, IgG denotes protein phosphorylation patterns associated
with a nonbinding IgGl control mAb. The band at ~85 kDa, present to
some extent in all immunoprecipitates, probably represents a nonspecific
component. C lanes are from untreated control macrophages, and D lanes
are from DX-treated macrophages.
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FIGURE 5. Specific down-regulation of p 130Cas and increased activation of Rac following DX treatment of macrophages. Adherent peripheral blood
monocyte-derived macrophages were cultured in the absence (C) or presence of 1 /xM DX for 5 days (D5). Macrophage cell lysates were assessed for
expression ofA, CrkL (36 kDa) and B, pl30Cas (130 kDa) by SDS-PAGE and Western blotting. C, Total RNA from untreated and DX-treated macrophages
were assessed for expression of actin, DOCK 180, and M-DOCK/DOCK2 transcripts using RT-PCR with primers described in Materials and Methods. D,
Activity of the GTPase Rac in macrophage lysates was assessed by pull-down assays using Sepharose coupled with GST-PAK protein. SDS-PAGE and
Western blotting with a Rac-specific mAb were used to determine whether Rac was present in pull-downs (Active Rac) or in whole cell lysates (Total Rac)
to test whether Rac was present at similar levels in untreated and DX-treated cells.
references therein), present in macrophages, may allow the recruit¬
ment of Rac/Crk/DOCK180 specifically to membranes in a man¬
ner that facilitates phagocytosis of apoptotic cells and possibly
other particles (43). Indeed, in preliminary experiments using low
density IgG-opsonized particles, we have found that DX-treated
monocytes/macrophages are more efficient phagocytes (untreated,
24.5% phagocytosis; DX treated, 53.5% phagocytosis, n = 4).
Importantly, these data suggest that expression or phosphorylation
of pl30Cas may have a negative regulatory role upon macrophage
phagocytic potential. We would speculate that decreased expres-
sion/phosphorylation of pl30Cas together with augmented Rac ac¬
tivity defines a subpopulation of macrophages highly competent
for phagocytosis of apoptotic cells.
Interestingly, recent data suggest that dendritic cell capacity for
presentation of apoptotic cell-derived material via MHC class I or
class II may depend on av/T,-mediated internalization mechanisms
(44). Our data suggest that in addition to differences in integrin
usage, DX-treated macrophages lack pl30Cas, a molecule that is
recruited following apoptotic cell binding to dendritic cells (45).
One possibility is that pl30Cas expression may determine the cel¬
lular consequences of apoptotic cell handling in macrophages and
other cell types. Recent studies have shown that immature den¬
dritic cells treated with glucocorticoids down-regulate the capacity
for production of IL-12, and consequently induce a regulatory phe-
notype (46-48). Changes in the adhesion status of macrophages
described in this work may also have important consequences for
other macrophage functions that influence the progression of in¬
flammation. Loss of podosome adhesion structures observed in
Wiskott-Aldrich syndrome macrophages leads to defective chemo-
taxis responses as a result of loss of the capacity for polarization
(49). Whether DX-treated macrophages show increased potential
for directed migration necessary for recruitment or emigration of
cells to and from the inflamed site has not been assessed and may
also be dependent on the effects of DX upon expression of che-
mokine receptors and activation of kinases such as extracellular
signal-related kinase 1 and 2. One speculation would be that in
addition to augmented capacity for clearance of apoptotic cells,
emigration of DX-treated macrophages from inflamed sites to
draining lymph nodes might be altered. Formation of podosome
structures in osteoclasts has also been shown to require p!30Cas/





















FIGURE 6. Schematic representation of the effects of DX upon cytoskeletal elements present in macrophages. A. Attachment to matrix activates a
number of adhesion pathways. Integrin ligation induces Src activation and phosphorylation of pyk2 and the scaffolding protein paxillin and pl30Cas. The
resulting phosphotyrosine motifs recruit Crk and downstream Crk effectors, including DOCK 180. The DOCK 180/Crk/p 130Cas complex may facilitate actin
redistribution and podosome formation and may lead to activation of the small GTPases Rac and Rho. B. Following DX treatment, loss of phosphorylation
of paxillin and pyk2 would be expected to disrupt interactions of these molecules with other effectors. Crk and DOCK180 complexes that are required for
formation of adhesion structures may be altered by the reduced levels of pl30Cas. Our data would suggest that activation of Rac is facilitated despite the
reduced levels of pl30Cas in DX-treated cells.
Crk/DOCK180 (50). One interesting possibility is that the detri¬
mental effects of prolonged steroid treatment on bone homeostasis
may be mediated though disruption of important adhesion events
associated with bone homeostasis.
A striking feature of DX-treated macrophage phenotype was the
lack of large multinucleated cells observed in culture when com¬
pared with untreated cells. Preliminary data indicate that formation
of multinucleated macrophages promoted by treatment with IFN-y
(51), or following stimulation with CD98 (52), is inhibited by DX,
consistent with data on alveolar macrophages (53), and suggests a
dominant regulatory effect of glucocorticoids upon macrophage
differentiation. Although previous reports have suggested that glu¬
cocorticoids drive monocyte apoptosis (54), we believe that these
apparently discrepant results are accounted for by differences in
the culture media used. In this present study, monocytes were cul¬
tured in 10% autologous serum with no differences in the numbers
of cells recovered with or without DX (control, 152 ± 16 cells/
field; DX, 140 ± 16 cells/field; average counts ± SEM from 10
separate experiments). Moreover, the phenotype we observe is un¬
likely to represent selection of a subpopulation of monocytes that
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are resistant to glucocorticoid-induced death. The percentage of
monocyte-derived macrophages that phagocytose apoptotic cells is
increased at least 3-fold by DX treatment, requiring that most of
the cells in the initial population be lost if selection of a phagocytic
phenotype occurred. Although production ofmodulatory cytokines
(e.g., TGF/3) following DX treatment might influence monocyte
differentiation and phagocytic potential, exposure of monocytes to
TGF/3 or IL-10 does not induce the prophagocytic functional phe¬
notype described in this study (not shown).
In conclusion, we report the novel finding that early exposure of
monocytes to glucocorticoids induces a proresolution phenotype.
The proportion of monocytes/macrophages capable of phagocyto¬
sis of apoptotic cells and the phagocytic index are increased dra¬
matically following DX treatment. The combined efFect would
give rise to a markedly enhanced potential for clearance of apo¬
ptotic cells from an inflammatory site following DX treatment,
with considerable implications for therapeutic strategies for ma¬
nipulation of inflammatory processes in vivo. The prophagocytic
phenotype of DX-treated monocytes/macrophages was character¬
ized by profound morphological changes, down-regulation of
phosphorylation of paxillin and pyk2, and loss of pl30Cas expres¬
sion. We propose that the increased Rac activity we observe to¬
gether with these changes in cytoskeletal changes may define a
prophagocytic macrophage phenotype. These data further empha¬
size the importance of understanding the contribution of adhesion-
related signaling pathways in the regulation of macrophage
phagocytosis.
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